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ABSTRACT 
 A major objective in Theileria parva subunit vaccine development is to induce 
a vaccine antigen specific response mediated by cytotoxic CD8+ T cells (CTL). 
Therefore it is essential to be able to measure the frequency of the responding CD8+ T 
cells after vaccination and correlate it with a clinical outcome on challenge. Recently 
concluded immunogenicity and efficacy studies of T. parva specific CTL antigens 
showed successful induction of CTL responses in some animals, which correlated 
with reduced disease severity after challenge. To provide correlates of immunity 
antigen-specific CD8+ T cell mediated IFN-γ responses and CTL lytic responses were 
measured over the course of the experiments. Several challenges presented in these 
trials aimed at optimising vaccine efficacy. While the IFN-γ ELISPOT is a sensitive 
and reliable assay widely used in vaccine research, the use of chromium/indium 
release assay remains to be the only assay in use that measures T. parva-specific CTL 
activity. Hence the overall goal of the study was to develop novel reagents and novel 
assays to identify parasite-specific CD8+ T lymphocytes with lytic potential.  
To address this objective, bovine perforin, granzymes A and B, as specific 
effector proteins expressed in activated CTL were cloned and expressed using a 
baculovirus expression system. Sequence analysis of the cloned cDNAs showed the 
isolated cDNA belonged to the perforin and granzyme sub-families respectively. 
Perforin cDNA demonstrated 85% homology to human perforin with presence of 
conserved regions resembling calcium binding motif, membrane attack complex 
component as well complement protein. The sequences encoded by the cloned 
granzyme A and B cDNAs have the features of a trypsin like serine protease and 
demonstrates over 70% homology to the human cDNA over the active enzyme region 
as well catalytic residues characteristic of serine proteases. The expressed 
polypeptides of all three proteins were used to produce specific antibodies for use as 
reagents in immunoassays including ELISpot and intracellular staining for flow 
cytometric analysis. While the antibodies showed reactivity to the recombinant 
proteins, these reagents displayed different functionality in the recognition of the 
native protein.  
Peptide-major histocompatibility complexes (MHC) class I tetrameric 
complexes (tetramers) are proving invaluable as fluorescent reagents for enumeration, 
characterisation and isolation of peptide-specific CD8+ T cells and have afforded 
advantages to phenotype antigen-specific T cells with minimal in vitro manipulation. 
Fluorescent bovine tetramers were shown to specifically stain antigen-specific CTL 
by directly binding the T cell receptor (TCR). Analyses of CD8 T-cell responses in 
live-vaccine immunised cattle also showed that this method is robust and 
demonstrates changes in the kinetics and specificity of the CD8+ T cell response in 
primary and secondary infections with T. parva. On average, results of functional 
assays and tetramer staining followed parallel trends, measured roughly the same 
populations and allowed for surface and intracellular staining for CD8 T cell marker 
and perforin, respectively, demonstrating a method that reliably quantifies the 
frequency, phenotype and function of specific CD8+ T cells. The technical simplicity, 
rapidity and ability of the flow cytometric technique described in this thesis to 
measure low frequency antigen-specific responses suggests that tetramer staining, 
combined with functional assays could be broadly applicable to the valuation of 
vaccination efficacy to determine which protocols are most successful in inducing 
CTL responses. 
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1.1 The history and biology of Theileria parva and East Coast fever 
1.1.1 Historical background of East Coast fever 
East Coast fever was first reported in southern Africa in 1902. The origin of 
this virulent disease, initially diagnosed as Rhodesian red water, was traced to 
importations of cattle from the eastern Africa coastline and it was given the name East 
Coast fever (ECF). A devastating rinderpest epidemic in southern Africa in 1896 had 
led to the importation of cattle from a number of sources including eastern Africa to 
rebuild the cattle population. It appears that the disease was known to the inhabitants 
of eastern Africa long before it was reported in southern Africa but nothing was 
known of its aetiology. Koch (1897) (cited by Neitz, 1957) while investigating red 
water in cattle in German East Africa (now Tanzania) found erythrocytes of affected 
animals that were parasitized by minute rod-shaped, oval and round organisms which 
he considered to be young forms of Babesia. The importation of cattle coupled with 
the widespread use of transport oxen and the existence of common grazing grounds 
and outspans in the region proved major factors in the spread of ECF. Following the 
early outbreak and subsequent spread of the disease after the introduction of affected 
cattle from German East Africa (Tanzania), Koch, Theiler and others investigated the 
aetiology and transmission of the disease. The causal agent, which is now known as 
Theileria parva (Bettencourt et al., 1907), was originally named Piroplasma kochi 
(Stephens and Christophers 1903) and Piroplasma parvum (Theiler, 1904). Schizonts, 
commonly known as Koch blue bodies, were described by Koch (1905, 1906), but it 
was Gonder (1910, 1911) who conclusively showed that the Koch bodies represented 
the schizogonous phase of the developmental cycle of the parasite. Pioneering studies 
by Theiler and Lounsbury further identified Rhipicephalus appendiculatus (the brown 
ear tick) (Neumann, 1901) as the principal vector (Lounsbury, 1904; Theiler, 1908), 
which was already widespread in the region. The history of bovine theileriosis has 
been extensively reviewed in Norval, Perry and Young (1992).  
1.1.2 Classification and life cycle of Theileria parva 
1.1.2.1 Taxonomy 
Theileria are tick-borne, intracellular protozoan parasites which infect wild 
and domestic ruminants although one species, Theileria equi is found in horses 
(Norval, Perry and Young, 1992; Mehlhorn and Schein, 1998; Bishop et al., 2004). 
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The taxonomy of Theileria has been a subject of review for many years. Theileria are 
currently classified in the class Sporozoa together with human pathogens, including 
Plasmodium and Toxoplasma. Along with other Sporozoa, Theileria has been 
included within the phylum, Apicomplexa based on the possession of an apical 
complex containing secretory organelles involved in invasion, or establishment, in the 
cells of their mammalian hosts. Analysis of the 18S ribosomal RNA gene sequences 
shows that the genus Theileria is phylogenetically most closely related to Babesia, a 
genus of tick-borne protozoans infective to the red cells of mammals including 
domestic livestock, and more distantly to the genus Plasmodium which cause malaria 
in humans and other species of vertebrates (Allsopp et al., 1994). The classification 
scheme originally suggested by Levine et al., 1980, is as follows: 
Sub-kingdom: Protozoa 
Phylum: Apicomplexa 
Class:  Sporozoea  
Sub-class: Piroplasmia  
Order:  Piroplasmorida 
Family: Theileridae  
Genus:  Theileria 
Species: Theileria parva 
At least thirty nine Theileria species have been described (Levine, 1988). 
Economically important Theileria species that infect cattle and small ruminants are 
transmitted by ixodid ticks of genera Rhipicephalus, Amblyomma, Hyalomma and 
Haemaphysalis. Table 1 summarizes the major Theileria species of economic 
importance in ruminants.  
1.1.2.2 Life cycle 
 Theileria parva life cycle stages in the tick vector and bovine host have been 
described previously (Mehlhorn and Schein, 1984; Norval, Perry and Young, 1992; 
Bishop et al., 2004) and are summarised schematically in Figure 1. T. parva has a 
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Table 1: Theileria species infective to domestic ruminants, their tick vectors, disease and distribution 
Species Vector Disease Distribution 
T. parva R. appendiculatus 
 R. zambesiensis 
 R. duttoni 
East Coast fever, January disease,  
Corridor disease 
Eastern, central and southern Africa 
T. taurotragi R. appendiculatus 
 R. zambesiensis 
 R. pulchellus 
Benign theileriosis Eastern, central and southern Africa 
T. mutans Amblyomma spp. Benign theileriosis Western, eastern, central and southern Africa,  
Caribbean Islands 
T. velifera Amblyomma spp. Theileriosis Western, eastern, central and southern Africa 
T. annulata Hyalomma spp. Tropical theileriosis Southern Europe, western, southern and eastern Asia 
T. orientalis Haemaphysalis longicornis Oriental theileriosis Japan, Korea 
T. lestoquardi* Hyalomma spp. Malignant ovine theileriosis Asia and northern Africa 
T. ovis* Hyalomma spp. Benign ovine theileriosis Asia 
Adapted from Brown et al., (1990) and Bishop et al., (2004). * Indicates Theileria species infective to small ruminants (sheep and goats). Other 
species are infective to cattle. 
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Figure 1: Life cycle of Theileria parva in cattle and the ixodid tick, 
Rhipicephalus appendiculatus 
Figure prepared by A.S. Young. Adapted from Norval et al., (1992). 
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typical apicomplexan life cycle that is predominantly haploid, with only a brief 
diploid phase in the tick. T. parva is transmitted by the three-host tick Rhipicephalus 
appendiculatus. Transmission occurs transtadially i.e. infection acquired by the larvae 
or nymph is subsequently transmitted, following moulting, by the nymph or adult 
stages of the tick, respectively (Lounsbury, 1904; Theiler, 1905, 1908). Larvae or 
nymphs get infected during feeding on infected cattle when they ingest piroplasm-
infected erythrocytes. Lysis of infected erythrocytes within the tick gut releases 
piroplasms which differentiate into micro- (male) or macro- (female) gametes. These 
undergo syngamy to form diploid zygotes, which invade gut epithelial cells and 
differentiate to motile kinetes, a process that appears to be synchronised with the 
moulting of the tick (Young and Leitch, 1980). There is evidence that this process 
also entails a meiotic reduction division involving interchromosomal cross-events 
(Gauer et al., 1995; Morzaria et al., 1993; Katzer et al., 2006). The existence of 
sexual cycle in T. parva has been demonstrated in direct measurements of DNA 
content of single cells by fluorescence microscopy (Gauer et al., 1995) and analysis of 
laboratory crosses of Muguga and Marikebuni or Uganda isolates (Bishop et al., 
2002). Evidence for genetic cross-over of T. parva in the tick has been obtained by 
tracking the segregation of several polymorphic sequences (Morzaria et al., 1992; 
1993; 1995). Following tick moulting, kinetes are released into the haemocoele of the 
tick and migrate to the developing salivary gland, where they specifically invade E-
cells of type III acini (Mehlhorn and Schein, 1984; Fawcett et al., 1982a). Parasites 
then remain quiescent or undergo limited development, until activated by the stimulus 
of tick feeding or ambient high temperature. As an infected adult tick or nymph feeds 
on its next host, the kinete undergoes further development within the infected cell to 
form a large synctial structure known as the sporoblast (Fawcett et al., 1982a; 1985). 
Each sporoblast has been estimated to give rise to 104 – 105 uninucleate haploid 
sporozoites, which are released from about the fourth day of feeding (Fawcett et al., 
1982a).  
Once sporozoites are inoculated, infection in the mammalian host is initiated 
when they gain entry into lymphocytes. In vitro observations indicate that sporozoites 
rapidly gain entry into host lymphocytes by receptor-mediated endocytosis which is 
completed within 10 min of cell contact (Fawcett et al., 1982b). The host cell 
membrane enveloping the parasite is then lysed and the parasite then comes to lie free 
in the cytosol. The intracellular sporozoite rapidly differentiates into a trophozoite 
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which continues to grow and by 48 – 72 hr it has undergone nuclear division to form a 
multi-nucleate schizont (Fawcett et al., 1984). At this time, the host cell is 
transformed to a state of uncontrolled proliferation. At each cell division, the parasite 
also divides so that both daughter cells are infected (Hulliger et al., 1964; Brown et 
al., 1973). Thus infection is established and becomes disseminated by clonal 
expansion of the small population of lymphocytes initially infected by the parasite. As 
the infection progresses, the mean number of nuclei per schizont increases and a 
proportion of the schizonts undergo merogony to form merozoites (Schein et al., 
1978). The latter, upon release through cell lysis, infect erythrocytes and develop into 
piroplasms which are infective for the tick. Susceptible cattle die within three weeks 
of infection as a result of pathological changes associated with the invasion of tissues 
by the rapidly dividing infected lymphoblasts.  
1.1.3 Epidemiological features of Theileria parva 
Pathogenic Theileria are found worldwide but the economically important 
species are in the tropics and sub-tropics (Uilenberg, 1995). The emergence of the 
disease complex due to T. parva followed the introduction of T. parva-infected cattle 
into southern Africa where the disease had not previously been reported and where a 
large population of cattle was markedly susceptible. The extensive introduction of 
European breeds into ECF-endemic regions to improve livestock productivity was 
also a precipitating factor in the spread of the disease. ECF is enzootic in a large part 
of eastern and central Africa where it causes considerable economic losses in the 
cattle industry. The presence of disease closely follows the distribution of the tick 
vector, R. appendiculatus. However, in South Africa and Zimbabwe, the tick exists 
but the disease was eradicated early in the 20th century by rigorous quarantine 
measures, systematic dipping and slaughter of infected and contact cattle as well as 
fencing to prevent contact of cattle with buffalo (Lawrence, 1981). In some areas, the 
tick population is maintained throughout the year while in other areas there is 
seasonal variation in the number of ticks following temperature and rainfall patterns, 
further affecting the epidemiological state. Theileria species may also affect wild or 
feral ungulates (Burridge, 1975; Young et al., 1977; Uilenberg et al., 1982; Stagg et 
al., 1994) but are rarely associated with disease. Buffaloes are considered the 
definitive hosts of T. parva. The presence of the African buffalo (Syncerus caffer) acts 
as a constant reservoir of parasites from which infection can be maintained in the 
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resident tick population. In addition, the carrier state engendered in cattle following 
natural or experimental infections with Theileria provides an important reservoir of 
parasites that can be transmitted to susceptible animals (Young et al., 1978; 1986; 
Kariuki et al., 1995). The extent to which transmission of infection occurs from 
carrier cattle in the field remains to be determined. However, studies by Oura and 
colleagues (2004, 2007) have shown that some of the strains present in live vaccines 
can establish a persistent carrier state in immunised cattle that is accessible to the 
local tick population and is transmissible to unvaccinated cattle. 
1.1.4 Genome characteristics of Theileria parva 
 In order to underpin studies of the biology of T. parva, its genome sequence 
was determined. The haploid T. parva nuclear genome is 8.3x106 base pairs (bp) in 
length and consists of four chromosomes (Gardner et al., 2005). T. parva 
chromosomes contain one extremely A+T rich region (>97%), about 3000 bp in 
length, that is suggested to be the centromere. The regions between the telomeric 
repeats and the first protein-encoding gene are short, about 2900 bp on average, and 
do not contain other repeats; constituting much less structural complexity than that in 
Plasmodium falciparum where arrays of repeats extend up to 30000 bp. The T. parva 
nuclear genome contains about 4035 protein coding genes, which is fewer than that 
(5268) of P. falciparum but exhibits higher gene density, a greater proportion of genes 
with introns and shorter intergenic regions. Putative functions have been assigned to 
approximately 38% of the predicted proteins. Massively parallel signature sequencing 
(MPSS) analysis of the transcriptome suggests a low level of baseline transcription 
from most of the protein coding genes (Bishop et al., 2005). Like other apicomplexan 
organisms, T. parva contains two extrachromosomal DNAs, a mitochondrial DNA 
and a plastid DNA molecule (Kairo et al., 1994; Gardner et al., 2005). The complete 
sequencing and significant annotation of the T. parva genome has aided vaccine 
development efforts by contributing to the identification of schizont stage antigens 
that are targets of cell-mediated immunity (Graham et al., 2006). The genome 
sequence data has also facilitated efforts toward identification of parasite molecules 
involved in inducing reversible host leukocyte transformation and tumour-like 
behaviour of transformed parasitized cells (Shiels et al., 2006). 
 10
1.1.5 Parasite strain diversity 
Reports from field observations and cross-immunity experiments have 
indicated that different strains of T. parva exist (Cunningham et al., 1974; Irvin et al., 
1983). Indeed, early literature quotes three sub-types of Theileria parva namely, T. 
parva parva, T. parva bovis and T. parva lawrencei (Uilenberg, 1976, 1981; 
Lawrence, 1979; Uilenberg et al., 1982) as causative agents of classical East Coast 
fever, January disease and Corridor disease, respectively. Sub-type classification was 
based on the apparent epidemiological distinction and clinical differences of the 
diseases they produce; their morphological features and serological characteristics 
being indistinguishable. T. p. bovis and T. p. parva are primarily transmitted between 
cattle but the disease caused by T. p. bovis is less virulent. T. p. lawrencei is 
transmitted mainly from buffalo to cattle. Although T. p. parva and T. p. lawrencei 
both produce acute fatal diseases in cattle, the infections differ in the lower level of 
schizont parasitosis and much lower piroplasm parasitemia but higher virulence 
caused by T. p. lawrencei compared to T. p .parva. However, it is noteworthy that 
monoclonal antibodies and DNA probes which detect heterogeneity between isolates 
of the parasite do not reveal a clear distinction between the subtypes (Conrad et al., 
1987a and b).  
The diversity of parasite populations in the field is evident at both the 
antigenic and molecular levels. Studies using monoclonal antibodies (mAb) that react 
with polymorphic determinants on schizont antigens (Irvin et al., 1983; Minami et al., 
1983; Conrad et al., 1987b) and parasite-specific DNA probes demonstrating 
restriction fragment length polymorphism in DNA from different parasite populations 
(Conrad et al., 1987a; Bishop, Sohanpal and Morzaria, 1993;  Bishop et al., 1993; 
1996) have corroborated reports of a lack of protection between distinct isolates of the 
parasite (Cunningham et al., 1974; Irvin et al., 1983). The heterogeneity of T. parva 
parasites is also reflected in their virulence with some isolates being highly 
pathogenic whereas others give rise to only mild infections (Koch et al., 1988). In 
addition, the duration of the carrier state varies following infection with different 
isolates (Skilton et al., 2002).  
It is presumed that sexual recombination in T. parva contributes to the 
extensive polymorphism observed in field isolates (Morzaria et al., 1990; Katzer et 
al., 2006). Using a genome-wide panel of polymorphic markers, Katzer et al. (2006) 
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recently provided evidence for extensive genotypic diversity in a T. parva population 
derived from ticks fed on cattle infected with Marikebuni stock and Patel et al., 
(2011) have recently shown the presence of at least eight genotypes in a live T. parva 
sporozoite vaccine stabilate that is derived from three T. parva stocks. To what extent 
recombination occurs in T. parva in field populations is currently unknown. However 
the use of DNA satellite markers (Oura et al., 2003) in population studies of T. parva 
reveal a high level of diversity and frequency of infection of cattle with mixed 
genotypes (Oura et al., 2005; Odongo et al., 2006). 
Little is known about the influence of host immunity on the genotypic 
diversity of T. parva. It has been reported that protective immunity against T. parva 
has considerable impact on the emergence of targeted parasites following challenge 
but fails to prevent their differentiation into transmissible forms (McKeever et al., 
2006; Katzer et al., 2007). This suggests that in addition to the tick, the host and/or 
parasite factors may also play a role in the emergence of dominant genotypes. 
1.1.6 The disease 
1.1.6.1 Clinical features 
Clinical aspects of ECF have been discussed in several papers including 
Shannon (1977), Jura and Losos (1980), Maxie et al., (1982) and Irvin and 
Mwamachi (1983). After a natural exposure to infestation by infected ticks, there is an 
incubation period of between eight and twenty five days, with an average of thirteen 
days, before clinical disease is observed (Theiler, 1904; Neitz, 1957; Irvin and 
Morrison, 1987). Clinical disease arises from invasion of lymphoid and non-lymphoid 
tissues by parasitized cells (Irvin and Morrison, 1987). The disease presents as a 
generalized lymphoproliferative disorder characterised by enlargement of lymph 
nodes and sustained high fever. In terminal cases, the animals develop severe 
pulmonary oedema seen clinically as acute dyspnea and frothing at the nostrils. The 
course and severity of the disease may vary depending on factors such as the 
virulence of the parasite strain, sporozoite infection rates in ticks and genetic 
background of infected animals. In general, indigenous cattle (Bos indicus) develop 
less severe disease and suffer lower levels of mortality than European breeds (Bos 
taurus) which are highly susceptible.  
The pathology and pathogenesis of the disease was extensively reviewed in 
 12
Irvin and Morrison (1987). The major pathology of ECF is caused by invasion of 
tissues with parasitized cells, lysis of infected lymphoid cells by cytotoxic T 
lymphocytes and also extensive non-specific lymphocytolysis and tissue destruction 
(Morrison et al., 1981). Other lesions are evident in the kidney, and frequently, 
haemorrhage in the muscles and sub-cutaneous tissue is also observed. During the 
clinical phase of disease, parasites are evident as macro- and microschizonts in 
lymphoid cell-biopsies of the enlarged lymph nodes. Parallel blood smears may show 
piroplasms. Death can occur within three to four weeks of infection and high levels of 
mortality (>90%) have been seen in fully susceptible stock and calves less than six 
months old. Pulmonary oedema is evident at death.  
1.1.6.2 Diagnosis 
Several approaches to the diagnosis of ECF are routinely applied. Observation 
of the body condition, which progressively deteriorates with disease, coupled with 
knowledge of the disease history and reports of cattle movement or a change of 
management conditions may lead to a provisional diagnosis. In essence, diagnosis is 
dependent on identifying the parasite in the animal by use of Giemsa-stained thin 
blood smears for piroplasms and lymph node biopsy smears for schizonts. In an area 
where ECF is endemic, a blood smear is an essential early test. 
A number of serodiagnostic techniques using schizont and piroplasm antigen 
and nucleic acid-based assays are available. The serodiagnostic tests consist of a 
schizont antigen indirect fluorescent antibody (IFA) test (Burridge and Kimber, 1972; 
Goddeeris et al., 1982), the piroplasm indirect haemagglutination (IHA) (Duffus and 
Wagner, 1984) and an enzyme-linked immunosorbent assay (ELISA) (Katende et al., 
1998). The latter technique has been shown to provide a higher degree of sensitivity 
and specificity than IFA and IHA tests. Serological tests have been used for disease 
surveillance (FAO, 1975; Kiltz, 1985; Flach, 1988; Norval et al., 1985) although they 
are also of restricted value in disease surveys because of several limitations; 
antibodies are usually absent during the early phase of clinical disease and a strong 
antibody response does not persist. None of these serological tests can distinguish 
immunologically distinct strains of T. parva. 
T. parva-specific repetitive DNA probes have been developed and are useful 
for the differentiation of T. parva from other Theileria species and for discrimination 
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of T. parva stocks by detection of restriction fragment length polymorphisms (Conrad 
et al., 1987a; Allsopp and Allsopp, 1988; Morzaria et al., 1990; Bishop et al., 1993; 
1995; Collins, Allsopp and Allsopp, 2002). Newer molecular diagnostic tests 
particularly those based on reverse line blot hybridization (Gubbels et al., 1999) and 
PCR (Skilton et al., 2002) as well as genotyping using mini- and micro-satellite 
markers (Bishop et al., 1996; Oura et al., 2003; 2004; Odongo et al., 2006), are 
proving to be powerful tools for characterising parasite polymorphism, defining 
population genetics and generating epidemiological data.  
1.1.6.3 Control of East Coast fever 
While decimating herds of indigenous cattle, ECF is even a greater threat to 
improved exotic cattle breeds and is therefore limiting development of the livestock 
enterprise which often depends on cross-breed cattle. Control of ECF has depended 
primarily on breaking the transmission cycle between the cattle and the tick vector, R. 
appendiculatus. On the one hand, this has involved short-interval application of 
acaricides by regular dipping or spraying. However this method has major drawbacks 
including the development of resistance in ticks, food safety concerns and 
environmental contamination resulting from toxic residues (George et al., 2004). In 
addition, dipping facilities are frequently not operational because of lack of financial 
resources for maintenance, particularly in pastoral systems, which depend to a 
substantial degree on the informal economy. After nearly a century of acaricide 
utilization, it is widely believed that acaricides alone do not provide a sustainable 
solution to tick and tick-borne disease control (Norval, Perry and Young, 1993). On 
the other hand, treatment of clinically sick animals with antitheilerial drugs has been 
applied. Two theilericidal compounds namely naphthoquinones (Parvaquone 
[Clexon®; Coopers Animal Health] and its analogue Buparvaquone [Butalex®; 
Coopers Animal health]) and febrifugines (Halufuginone [Terti®; Hoechst/Roussel]) 
have been of considerable value in treating clinical theileriosis. However, not only are 
they expensive but their effective use require early diagnosis of the disease. 
Buparvaquone is widely and successfully used to treat early-stage infections of T. 
parva though its cost may be prohibitive for small farms and poor farmers (D’Haese, 
Penne and Elyn, 1999; Muraguri, Kiara and McHardy, 1999; Kivaria, 2006, 2007). 
Recent studies by Lizundia et al., (2009) are targeted at exploiting the T. parva 
apicoplast as a potential target for developing new antitheilerial drugs. Alternatives 
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will be urgently required in the event of buparvaquone resistance. 
An alternative approach to the control of the disease by vaccination led to the 
development of the Infection and Treatment Method (ITM) of immunisation (Radley 
et al., 1975b; Morzaria et al., 1999). This involves the simultaneous administration of 
defined doses of cryopreserved sporozoites and long-acting oxytetracycline. This 
protocol is shown to result in solid immunity to challenge with the homologous 
parasite strain. To overcome the problem of breakthrough infections with 
heterologous strains, currently, the vaccine is administered as a ‘cocktail’ of three 
parasite isolates; Muguga, Kiambu-5 and Serengeti-transformed. In areas of greater 
disease transmission and larger herds, vaccination is the most cost effective strategy 
(Muraguri et al., 1998; D’Haese, Penne and Elyn, 1999).  
However, though ITM was developed over thirty years ago, very little 
progress in the advancement of this technology has been made (Giulio et al., 2009). 
Several pilot trials of ITM have been performed and these have been reviewed 
(Uilenberg, 1999) and despite the effectiveness of the vaccine in inducing protection 
experimentally, until recently, adoption of ITM has been limited. The main practical 
constraints relate to the complex procedure of vaccine production and distribution 
which requires considerable infrastructure and specialized expertise. Each batch of 
sporozoites used in the vaccine needs to be produced by passage through ticks fed on 
infected cattle and the appropriate dose of sporozoites need to be determined by 
titration in cattle (reviewed in Giulio et al., 2009). The latter step is necessary because 
long-acting oxytetracycline fails to control infection initiated with higher doses of 
parasites. The use of an in vivo vaccine production system in cattle also introduces 
significant risk of contamination with extraneous bovine pathogens, necessitating 
rigorous quality control of each vaccine batch. The stocks of parasites are stored as 
cryopreserved stabilates in liquid nitrogen and since the organisms need to be 
administered shortly after thawing, a cold chain is required for distributing vaccine to 
regions distant from the site of production. Ideally, vaccine users should have access 
to therapeutic antitheilerial drugs to allow treatment of any animals in which the 
tetracycline does not effectively control the immunising infection. Related to the 
latter, an additional reason why ITM has not been adopted in some regions is the 
perceived risks associated with establishment of tick-transmissible carrier infections 
(Young et al., 1986, Bishop et al., 1992) with the ‘foreign’ vaccine parasite strains 
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and hence their introduction into local tick populations. Specifically, the main concern 
is that the introduced parasites may be more virulent or differ antigenically from the 
indigenous parasites.  
In spite of all these shortcomings, and given the prevalence and economic 
importance of the disease as well as the lack of more sustainable control options, 
measures are being taken to address some of the limitations in order to allow quality-
controlled bulk production, registration and field delivery of the vaccine. One such 
improvement was the provision of standardised vaccine stabilate (Morzaria et al., 
1999). With an increased acceptance of ITM among livestock owners, the vaccine has 
since been deployed extensively in Tanzania (Melewas, 1999) and Uganda (Nsubuga-
Mutaka, 1999) and to a lesser extent in Malawi and southern Zambia (Lynen et al., 
2006; Homewood et al., 2006). More recently (2006, 2007), the ITM has been 
sanctioned for use in the Maasai ecosystem in Kenya (Personal communication, Dr 
Evans Taracha). The shift in policy on ITM deployment in Kenya was informed by 
the outcome of field trials in the Narok District of Rift Valley Province, which 
generated data on vaccine safety, efficacy and demand. Initiatives are underway to 
roll out the vaccine in other areas including the intensive dairy of central Kenya, 
extensive dairy of North Rift and other pastoral eco-zones of Northern Kenya. Recent 
developments pioneered by the Global Alliance for Livestock Veterinary Medicines 
(GALVMed) and ILRI has seen the production of a new batch of vaccine, the 
successful registration of the vaccine in Kenya, Malawi and Tanzania with Uganda 
expected to follow (DFID Research 2009 – 2010: providing research evidence that 
enables poverty eradication). GALVMed is also working to establish viable 
commercial production and delivery systems adequate for marketing and 
commercialization of the ECF vaccine. 
1.2 Immune responses to Theileria parva 
1.2.1 General features of the immune response 
 A great deal of investment in resources and time has led to the elucidation of 
the nature and specificity of the immune responses underpinning host immunity 
against T. parva. Cattle exposed to a single natural or experimental infection with T. 
parva sporozoites mount diverse immune responses to all the stages of the parasite. 
The role of immune responses against the piroplasm stage of the parasite has been 
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largely ignored because such responses, even if effective, could have little effect in 
preventing disease caused largely by the schizont stage of the parasite. Whereas 
antibody responses against sporozoites, schizonts and piroplasms have been detected 
in recovered cattle, albeit at low levels, such animals exhibited potent cell-mediated 
immune responses directed at schizont-infected cells (reviewed by Morrison et al., 
1989; Morrison and McKeever, 2006). Further, these animals are immune to 
challenge with the same stock of the parasite, but only a proportion will withstand 
heterologous challenge (Neitz, 1957; Barnett, 1957; Wilde, 1967; Radley et al., 
1975b; Radley, 1981; Irvin et al., 1983; Morrison et al., 1986). ). Further in-depth 
studies have been conducted demonstrating an unambiguous role of cell-mediated 
immune responses directed against schizont-infected cells in T. parva immunity 
(Emery, 1981; Morrison et al., 1987; McKeever et al., 1994; Taracha et al., 1995a). It 
has been postulated that the parasite strain specificity of the CD8+ T cell response is 
due to the heterogeneity of parasite antigens recognised by the host immune responses 
(Morrison and Goddeeris, 1990; McKeever and Morrison, 1990). 
 Under experimental conditions, all the methods that have been used to induce 
immunity have utilised infective material such as live sporozoites or schizont-infected 
cells (Brocklesby and Bailey, 1965; Pirie et al., 1970; Radley et al., 1975a and b; 
Schein and Voigt, 1979; Brown et al., 1981; Radley, 1981). Attempts to immunise 
cattle with irradiated non-infective sporozoites or heat-killed schizont-infected cells 
(Cunningham et al., 1973; Wagner et al., 1974; Emery, 1981) were unsuccessful. 
Taken together, these observations have supported the notion that the establishment of 
infection in cells of recipient cattle is necessary for successful development of 
immunity (reviewed by Morrison et al., 1986; 1989; Morrison and Goddeeris, 1990; 
McKeever and Morrison, 1990). Moreover, while the serum from immune cattle 
contains antibody against all stages of the parasite (Burridge and Kimber, 1972), 
antibody was not considered to play a role in the protection seen in recovered animals 
since the transfer of immune serum or concentrated gammaglobulins from immune to 
naïve cattle failed to protect against the disease (Muhammed et al., 1975). By 
contrast, immunity against T. parva was transferred adoptively between chimeric twin 
calves using thoracic duct leucocytes (Emery, 1981). Subsequent studies have 
however provided evidence that antibody responses against sporozoites may play a 
role in immunity, under certain circumstances (Musoke et al., 1992).  
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1.2.2 Immune responses to Theileria parva sporozoites 
 Following immunisation by ITM, low titres of anti-sporozoite antibodies are 
detected in the serum (Musoke et al., 1982). On the other hand, sera from cattle 
exposed to repeated high parasite challenge with large numbers of infected ticks under 
laboratory and field conditions contain high titres of sporozoite-specific antibodies 
(Musoke et al., 1982; 1984). Importantly, these high-titre anti-sporozoite antibodies 
have been demonstrated to neutralise sporozoite infectivity in vitro (Musoke et al., 
1984). Antibodies against T. parva (Muguga) sporozoites neutralise the infectivity of 
homologous sporozoites as well as those of a variety of parasite stocks, some of 
which do not cross-protect following immunisation of cattle by ITM (Musoke et al., 
1984). Hence, it was postulated that sporozoite antigens might be used in vaccination 
initiatives to induce immunity that protects against all parasite strains and prompted a 
search for the antigen(s) targeted by this antibody activity. Monoclonal antibodies 
(mAbs) were raised against purified sporozoites and a number of them exhibited 
neutralising activity in vitro (Musoke et al., 1984; Dobbelaere et al., 1984). One of 
the mAb was shown to recognise a surface coat antigen (p67) with a molecular weight 
of 67 kDa on the sporozoite (Dobbelaere et al., 1985), and furthermore the mAb could 
neutralise sporozoites of other T. parva strains (Musoke et al., 1984). Consequently, 
the gene encoding the p67 sporozoite antigen was cloned and expressed (Nene et al., 
1992). Several recombinant forms of p67 expressed using bacterial or viral vectors 
have been generated and evaluated extensively in laboratory and field immunisation 
and challenge experiments (Musoke et al., 1992; Nene et al., 1995; 1996; Honda et 
al., 1998; Heussler et al., 1998; Bishop et al., 2003; Musoke et al., 2005; Kaba et al., 
2005). Significantly, these experiments have demonstrated that 50% of immunised 
cattle were protected from severe disease following challenge. These findings provide 
a basis for the inclusion of p67 in a multi-component vaccine against T. parva. 
1.2.3 Immune responses to Theileria parva schizont-infected cell 
Schizont-infected cells constitute a critical developmental stage in the life 
cycle of T. parva in terms of pathogenicity and host immunity. Most of the pathology 
observed in ECF is attributed to schizont-parasitized cells. Yet, it is known that 
Theileria parasites have evolved the ability to remain in an intracellular location 
throughout their replication phase within leucocytes, and apparently there is no 
expression of parasite-encoded proteins on the surface of infected cells (reviewed by 
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Morrison et al., 1986; Newson et al., 1986). It is therefore evident that the parasite is 
not accessible to antibodies during this stage of infection, implicating a key role for 
cell-mediated immune responses in protective immunity against T. parva. This notion 
is supported by the intracytoplasmic location of the parasite favouring access of the 
parasite molecules to the class I MHC processing and presentation pathway for 
recognition by CD8+ T cells. 
However, schizont-specific antibodies can be detected using IFA and antigen 
ELISA in cattle following a single T. parva infection (Burridge and Kimber, 1972; 
Katende et al., 1998). Antibodies, most of which are IgG (Duffus and Wagner, 1974; 
Wagner et al., 1975), are first detected after 18-21 days and reach peak levels about 
25-30 days after inoculation of sporozoites (Lohr and Ross, 1969). Antibody 
responses can be detected even in animals that develop only mild infections with T. 
parva (Burridge, 1971). Antibodies last for a variable period of time after recovery, 
depending on factors such as the establishment of a carrier state, chemotherapeutic 
intervention and presence or absence of re-challenge. Following recovery from ECF, 
some animals may have low antibody titres for four to six months but the antibodies 
may persist for more than one year following a single challenge. The presence in 
serum of anti-schizont antibody remains to be the most reliable measure of exposure 
to the parasite and the IFA and antigen-ELISA tests have been applied in national 
disease survey programmes (FAO, 1975; Kiltz, 1985; Flach, 1988; Norval et al., 
1985). 
Studies in immune cattle undergoing challenge have provided a better 
understanding of cell-mediated responses against the schizont-infected cell and their 
role in protective immunity. There is good evidence that protection is mediated by 
parasite-specific MHC class I restricted CD8+ CTL (reviewed in McKeever and 
Morrison, 1990; 1994). CTL are detected transiently in the blood and efferent lymph 
of immune cattle under challenge at the time of parasite clearance (Eugui and Emery, 
1981; Morrison et al., 1987b; McKeever et al., 1994). These are present at moderate 
frequency in immune animals and increase dramatically in number following 
challenge, peaking around the time that parasitosis is controlled, and they have been 
shown to be MHC class I restricted, have a CD2+CD4-CD8+ phenotype (Emery 
Tenywa and Jack., 1981b; McKeever et al., 1994) and, in some instances parasite-
strain specific (Goddeeris et al., 1986; Morrison et al., 1987b). In contrast, PBMCs 
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from naïve cattle undergoing lethal challenge exhibit only non-specific cytolytic 
activity (Emery et al., 1981; Houston et al., 2008). 
Direct evidence indicating that CTL responses mediate immunity has been 
shown in two studies. The first of these studies involved application of a limiting 
dilution assay to analyse the parasite strain specificity of CTL responses in relation to 
cross-protection in individual animals immunised with the Muguga stock of T. parva 
and subsequently challenged with a cloned population of T. parva Marikebuni and 
vice versa (Taracha et al., 1995a). These studies showed that a proportion of animals 
immunised with either parasite exhibited cross-reactive memory CTL, whereas CTL 
detected in the remaining animals were specific for the homologous parasite. On 
challenge with the heterologous stock, those animals with cross-reactive CTL were 
solidly protected while those with strain-specific CTL showed moderate to severe 
reactions. The finding of a close association between parasite strain-specificity of the 
CTL response and protection against challenge provided strong evidence that CTL are 
important in mediating immunity. In the second study, the capacity of CD8+ T cells to 
confer protection was examined by adoptively transferring lymphocytes enriched for 
CD8+ T cells from immune to naïve monozygotic identical twin calves (McKeever et 
al., 1994). Lethally infected naive calves received CD8+ T-cell enriched populations 
of cells or T cells depleted of the CD8+ T cell subset derived from their immune 
monozygous twin partners to coincide with the emergence of patent schizont 
parasitosis. The calves that received cell populations enriched for CD8+ T cells 
controlled the infection whereas the animals that received the population depleted of 
CD8+ T cells underwent severe infection comparable to that in the challenge control. 
These findings indicated that parasite-specific CD8+ T cells play an important role in 
the immunity against T. parva. 
While the experiments described above provided evidence that CD8+ T cells 
are important mediators of immunity, they do not exclude the possibility that other 
cells can also act as immune effectors and/or are required for induction of the CD8+ T 
cell response. Infection with T. parva is known to result in strong CD4+ T cell 
responses against the parasitized lymphoblasts (Baldwin et al., 1987; Brown et al., 
1989). Further to this, in vitro experiments have indicated that CD4+ T-cell derived 
factors are required for induction of CTL (Taracha, Awino and McKeever, 1997). In 
this study, purified populations of bovine immune and naïve CD8+ T cells were co-
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cultured with autologous T. parva-infected lymphoblasts in the presence or absence of 
immune CD4+ T cells. It would be expected that culture of CD8+ T cells from 
immune animals with T. parva-infected lymphoblasts would result in a population 
with detectable CTL activity. However, neither population developed CTL activity 
when cultured with T. parva infected lymphoblasts alone, whereas incorporation of 
immune and not naïve CD4+ T cells in the cultures supported the generation of 
parasite-specific CTL from both immune and naïve CD8+ precursors. This 
observation is consistent with those of previous studies that prolonged maintenance of 
parasite-specific CTL clones (Goddeeris, Morrison and Teale, 1986) required addition 
of exogenous T-cell growth factors or IL2 (Dobbelaere et al., 1988), and hence it is 
likely that these factors are provided in vivo by T. parva-specific CD4+ T cells 
responding to T. parva-infected lymphoblasts. In addition to the release of soluble 
immunomodulatory factors, CD4+ T cells have been shown to play a crucial role in 
the optimal stimulation of CD8+ by activation of antigen presentation. This effect is 
mediated by ligation of CD40 on the surface of antigen presenting cells (APC) by 
CD40L (CD154) expressed on activated CD4+ T cells (Mackey et al., 1998a and b; 
Shoenberger et al., 1998; Toes et al., 1998; Clarke, 2000; Diehl et al., 2000; Ma and 
Clark, 2009). In the context of T. parva infection, the important role of CD4+ T cell 
responses in immunity may further be supported by recent findings from an 
immunogenicity study of potential CTL vaccine antigens in which antigen-specific 
CD4+ T cell responses were undetected, and this appeared to coincide with the 
generally poor CD8+ T cell responses (Graham et al., 2006). 
Previous studies have established that bovine γδ T cells also respond to T. 
parva schizont-infected cells and that this population expands during the course of 
infection (Daubenberger et al., 1999). Findings from this study provided evidence that 
bovine γδ T cells participate in the early phase of an immune response against T. 
parva. These responses are MHC-unrestricted and cross-reactive between different 
parasite stocks. The precise role of these responses is unknown but it is possible that 
they may play a role in the innate arm of immunity to infection. 
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1.3 Molecular mechanism of antigen recognition by T cells 
1.3.1 Mechanism of recognition of antigen by CD4+ and CD8+ T cells 
It is now widely understood that CD8+ and CD4+ T cells recognise antigenic 
peptides bound to major histocompatibility complex (MHC) class I and II proteins, 
respectively, by virtue of their α/β heterodimeric T-cell receptor (TCR) (reviewed by 
Schwartz, 1985; Dembic et al., 1986; Saito et al., 1987). The current accepted model 
of antigen recognition by T cells proposes that an MHC molecule binds a fragment of 
antigen forming an MHC-peptide complex that is recognised by the TCR. 
Direct peptide binding studies have shown that CD4+ T cells of appropriate 
TCR consistently recognised bound peptide suggesting that the TCR recognises 
antigen in the form of processed peptides associated with MHC class II molecules. 
Further studies focusing on the mechanisms of peptide processing demonstrated that 
MHC class II bound peptides are generally derived from exogenous soluble proteins 
(Watts, 1997). Uptake of soluble antigens is achieved through non-specific 
mechanisms such as pinocytosis and phagocytosis or by specific receptor-mediated 
endocytosis by MHC class II-positive antigen-presenting cells (APC). Antigens are 
proteolytically degraded in endosomes into fragments (Shimonkevitz et al., 1983; 
Unanue, 1984; Unanue and Allen, 1987; reviewed in Watts, 1997), although 
unfolding of the intact protein without actual proteolysis has been shown to be 
sufficient to allow presentation of antigen in a number of cases (Streicher et al., 1984; 
Allen and Unanue, 1984; Berzofsky, 1985). The association of antigen and MHC 
class II is thought to take place in the endosome/lysosome system before the 
peptide/class II MHC complex is exported to the cell surface.  
Several studies have also demonstrated that CD8+ T cells recognise antigen in 
the form of processed peptides associated with MHC class I molecules (Townsend et 
al., 1985; Townsend et al., 1986a, b; Maryanski et al., 1986; Bastin et al., 1987; 
Braciale et al., 1987; Bodmer et al., 1988). Studies by Townsend and others working 
on influenza A virus provided the first clues to the nature of epitopes recognised by 
CTL. Mouse L cells transfected with overlapping deletion mutants of the influenza 
virus nucleoprotein gene, were used as targets to map CTL epitopes on the molecule. 
Further experiments using epitope-containing 13–16 mer synthetic peptides to 
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sensitise uninfected targets to lysis by antigen-specific CTL provided more evidence 
of CD8+ TCR recognition of MHC class I -peptide complexes. Maryanski and other 
workers (1986) provided the evidence that this recognition of antigenic fragments by 
MHC class I -restricted CTL is a general feature not limited to antigens of 
intracellular pathogens. They showed that a MHC class I -restricted mouse CTL clone 
could lyse a mouse tumour cell line transfected with class I human leucocyte antigen 
(HLA) gene or pulsed with a 16-amino acid synthetic HLA peptide corresponding in 
sequence to an epitope recognised by a mouse CTL clone. There are several reports 
that the MHC class I -complexed peptides are generated from cytosolic proteins 
degraded in the proteasome and transported to the endoplasmic reticulum where a 
nascent MHC class I heavy and light (β2-microglobulin) chains assemble and bind the 
peptide prior to being exported to the surface of the APC (Townsend et al., 1986; 
Morrison et al., 1986; Germaine, 1986; Yewdell et al., 1988; reviewed in Pamer and 
Cresswell, 1998). 
Although MHC class I molecules primarily present endogenous antigens, 
exogenous antigen can be processed by antigen presenting cells and presented by 
MHC class I molecules to CD8+ T cells (Harding 1996; Cresswell et al., 2005; Rock 
and Shen 2005). This phenomenon was first described in vivo in a mouse model and 
termed cross-priming (Bevan, 1976). MHC class I presentation of exogenous antigens 
is the mechanism enabling professional antigen-presenting cells (APCs), in particular 
dendritic cells, to induce CD8+ T-cell responses against viruses that do not have 
access to the classical pathway for MHC class I presentation in APCs (Arrode et al., 
2000; Herr et al., 2000; Larsson et al., 2001, Tabi et al., 2001). In this process the 
APC acquires antigen through endocytic mechanisms, especially phagocytosis or 
macropinocytosis. MHC class I presentation of exogenous antigens by APCs can 
occur via at least 2 distinct mechanisms (Cresswell et al., 2005; Rock and Shen 2005). 
Antigens can be conveyed from the endocytic compartment into the cytosol in APCs 
(Pfeifer et al., 1993; Harding et al., 1994; Norbury et al., 1995; Kovacsovics-
Bankowski et al., 1995; Reis e Sousa et al., 1995; Li et al., 2001). In the cytosol, 
antigens are degraded into oligopeptides and transported via transporter associated 
with antigen processing (TAP) into the endoplasmic reticulum (ER) for loading onto 
newly synthesized MHC class I molecules (Norbury et al., 1995; Kovacsovics et al., 
1995; Sousa et al., 1995; Sigal and Rock, 2000; Li et al., 2001). Alternatively, 
antigens can be processed in endosomal compartments where peptides are generated, 
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acquired by recycling MHC class I molecules, and transported to the cell surface for 
presentation (Pfeifer et al., 1993; Harding et al., 1994). 
Both MHC class I and II molecules display the capacity to bind stably to many 
different peptides to accommodate the full TCR repertoire of an individual. This is 
consistent with the findings that several peptides could bind to the same molecule 
class II and this binding could be correlated with recognition of the peptides by helper 
T cells in in vitro proliferation assays (Babbit et al., 1985; Buus et al., 1986, 1987; 
Guillet et al., 1986, 1987; Sette et al., 1987). In addition to showing the promiscuity 
of MHC class II molecules in peptide-binding, the findings also showed that most 
peptides competed for binding to the same class II molecule and those that had high 
avidity bound best. Similarly, Chen and Parham (1989) demonstrated direct binding 
of synthetic peptides on purified human leucocyte antigens (HLA) class I molecules. 
The promiscuity of the class I molecules in binding a wide range of peptides has been 
demonstrated in competition studies with synthetic peptides; simultaneous addition of 
competing peptides to an assay system led to inhibition of target cell lysis (Maryanski 
et al., 1988; Pala et al., 1988; Bodmer et al., 1989). The elucidation of the three-
dimensional structure of the human MHC class I molecule, HLA-A2, obtained by X-
ray crystallography revealed a cleft situated between two α-helices derived from the 
α1 and α2 domains of the molecule as described in detail by Bjorkman et al., 
(1987a,b). The cleft, incorporating many of the polymorphic residues of class I has 
been shown to be the binding site for peptides. Indeed, numerous examples of MHC 
class I -peptide complexes have since been successfully crystallised and their three-
dimensional structures determined (Chen and Parham, 1989; Garboczi et al., 1992; 
Jones, 1997). 
The concept that MHC restriction molecules function as receptors of broad 
specificity for a multitude of antigenic fragments was further demonstrated with the 
elucidation of the structure of a second human MHC class I molecule, HLA-Aw68 
that revealed considerable similarity to HLA-A2 except for 11 amino acids 
substitution at polymorphic residues in the antigen-binding cleft. These substitutions 
were shown to alter the detailed shape and electrostatic charge of that binding site 
resulting in localised structural differences that provide the basis for allelic specificity 
in foreign antigen binding and the accompanying responsiveness or lack of it (Garrett 
et al., 1989). Subsequent studies in human and murine models have defined 
 24
polymorphic residues that are critical for the presentation of foreign peptide to CTL 
(McMichael et al., 1988; Nikolic-Zugic and Carbone 1990; Kier-Nielsen et al., 2002) 
and shown that changes at certain residues within the peptide binding cleft can affect 
antigen presentation by either interfering with peptide binding or presumably by 
changing peptide conformation of bound peptide. The structural basis for peptide 
binding to MHC class I molecules has been extensively investigated in humans and 
mice (Wilson et al., 1993; Madden, 1995), less so for other species (Speir et al., 2001; 
Koch et al., 2007). Less is known of the detailed cellular and molecular interactions 
of MHC class I molecules in cattle, an economic important species. In cattle peptide 
binding properties have been investigated for only a small number of MHC class I 
alleles (Hedge et al., 1995; Gaddum, Willis and Ellis, et al., 1996). Several CD8+ T 
cell epitopes in T. parva have been identified recently (Graham et al., 2006, 2007, 
2008). One of these was shown to be presented by the cattle MHC class I allele 
N*01301. Subsequent studies by Macdonald et al. (2010) perhaps present the first 
description of an MHC structure in cattle and the peptide binding properties of the 
cattle MHC class I allele N*01301 to an immunodominant 11mer Theileria parva-
derived peptide. The overall structure of N*01301 is seen to be similar to that of other 
mammalian MHC class I molecules however the peptide is presented in a distinctive 
raised conformation generated by a hydrophobic ridge within the MHC peptide 
binding groove. 
Another factor which may influence antigen recognition is the available T-cell 
antigen receptor repertoire (Deng et al., 1997), and constraints imposed by self 
tolerance (Yewdell and Bennick, 1999). The intrathymic selection events leading to 
the generation of T-cell repertoire involves expression of rearranged T-cell receptor 
genes and selection of T cells based on the avidity of their receptors for self-MHC 
molecules. Current evidence suggests that T cells with medium or high affinity 
receptors for self-MHC molecules are deleted as part of the process of induction of 
self tolerance. In addition, there is positive selection of T cells with low affinity 
receptors for self MHC and these give rise to a repertoire of T cells capable of 
reacting with foreign peptides plus self MHC with relatively high avidity. This is 
manifested by the capacity of the MHC to influence the responsiveness to certain 
antigens. Indeed, it has been shown that the specificity of CTL responses of mice and 
humans to virus-infected cells is influenced by their MHC phenotype (Zinkernagel 
and Doherty, 1979; Vitiello and Sherman, 1983; Townsend and McMichael, 1985). 
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Immunological dominance is a central feature observed particularly in CD8+ T 
cell responses to pathogens most notably HIV-1, influenza and a number of herpes 
viruses (Zinkernagel and Doherty, 1979; Goulder et al., 1997; Butz and Bevan 1998b; 
Yewdell and Bennick, 1999; Crotzer et al., 2000). Few of the enormous number of 
peptides encoded by the pathogen elicit responses, and even among these few, 
responses are often skewed heavily to one or several peptides termed 
immunodominant determinants at the expense of the less preferred sub-dominant 
epitopes (Sercarz et al., 1993). A similar phenomenon has been postulated to exist in 
T. parva infections based on a number of observations. First, a direct role for class I 
MHC molecules in the generation of these responses has been confirmed by the use of 
a monoclonal antibody specific for a monomorphic determinant on bovine MHC class 
I to block the cytolytic activity against infected target cells (Morrison et al., 1987b). 
Second, by examining cytolytic activity of immune peripheral blood mononuclear 
cells against infected target cells derived from animals of various MHC phenotypes it 
was observed that responses appeared to be biased toward one or other of the 
haplotypes in each animal, and that within the group of animals tested, certain bovine 
leucocyte antigen (BoLA) specificities dominated as restricting elements (Morrison et 
al., 1987; Taracha et al., 1995a; Morrison, 1996). These features of the immune 
response were attributed to differences in the frequencies of CTL precursors with 
particular specificities for certain MHC-peptide combinations, and possibly also as a 
reflection of the relative affinities of different epitopes for the MHC binding site. 
Third, while the CTL response is largely parasite strain–specific, some animals can 
make a cross-reactive response to challenge with heterologous parasites (Goddeeris et 
al., 1990; Taracha et al., 1995a). Further, it was observed that the CTL response in 
majority of the animals was restricted by a product of only one of the parental class I 
haplotype indicating that the haplotype was capable of binding and presenting both 
strain-specific and conserved epitopes (Taracha et al., 1995b). In sum, MHC affinity, 
MHC-epitope avidity, T-cell repertoire and immunodominance are key factors that 
influence antigen recognition by T cells. 
1.3.2 Bovine class I major histocompatibility complex genetics 
MHC class I genes are among the most characterised polymorphic gene 
families. In humans, three distinct genomic loci encode class I human leucocyte 
antigens (HLA); HLA-A, HLA-B and HLA-C (Linert and Parham, 1996) allowing 
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individuals to express six different HLA class I molecules. By contrast, current 
evidence from mapping studies as well as haplotype and phylogenetic analyses in 
cattle suggests the number of distinct genomic loci are at least six and the number of 
different class I bovine leucocyte antigens that are expressed in individual animals are 
variable (Ellis et al., 1999; Ellis and Ballingall, 1999; Ellis, 2004; Birch et al., 2006; 
Babiuk et al., 2007). BoLA diversity has primarily been determined using serological 
reagents to analyse haplotypes, and over 50 distinct class I serological specificities 
have been defined (Davies et al., 1994). In contrast to the human MHC, bovine 
haplotypes differ from one another in both the number and composition of expressed 
classical class I genes, bearing one to three gene products (Birch et al., 2006). In 
addition, there are rare cases in which a haplotype expressing two genes may be 
associated with two serological specificities (Bensaid et al., 1991). Currently, there 
are nearly 95 classical class I gene full-length sequences. Most have not been assigned 
to a definitive locus and hence they are currently named in a single series prefixed N* 
(http://www.ebi.ac.uk/ipd/mhc/bola/; Ellis et al., 2005; Robinson et al., 2005).  
Although there are limited functional data on cattle class I loci, peptide 
binding and CTL recognition has been determined for alleles encoded at five of the 
putative six loci, indicating that they can each function as classical class I genes 
(Bamford et al., 1995; Hegde et al., 1995; Gaddum et al., 2003; Graham et al., 2008). 
A very small number of cattle class I MHC haplotypes has been investigated for 
function. Table 2 highlights some of the alleles that are fully characterised. One of the 
functional consequences of cattle class I haplotype diversity is the expression levels of 
the functional products of all or most of the six loci. A number of cattle class I alleles 
have been identified that have significantly lower than usual levels of surface 
expression (Smith and Ellis, 1999). It has also been suggested that for class I 
haplotypes expressing two or three loci, one may have functional dominance over 
others based on criteria such as recognition by alloreactive mAb and CTL. There are 
data indicating that CTL responses to T. parva are often restricted by the products of 
one class I allele. Studies by Morrison et al. (1987), Goddeeris et al. (1990), Taracha 
et al. (1995b) showed that CTL responses to T. parva focused predominantly on one 
of four polymorphic class I products that were expressed in heterozygous animals. 
This is further supported by studies by Graham et al., (2008) and MacHugh et al., 
(2009) which showed that animals heterozygous for A18 consistently respond to a T. 
parva antigen presented by MHC class I allele N*01301 with over 75% of the 
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responding CD8+ T cells being specific for the T. parva antigen in A18 homozygous 
animals (MacHugh et al., 2009). Thus despite its antigenic complexity, CD8+ T cell 
responses induced by infection with the parasite show profound immunodominance of 
restricting haplotypes or class I alleles. Mechanisms underlying this phenomenon are 
unclear but with recent developments in technology more data relating to levels and 
functional role of MHC class I allelic polymorphism can be generated. Recently, it 
has been shown that MHC class I tetramer technology can be adapted for use in 
domestic animals by the successful construction of equine and bovine tetramers 
(Travis McGuire et al.; Shirley Ellis et al.; Didier Colau et al., unpublished data).  
1.3.3 Events leading to activation of T cells 
CD4+ and CD8+ T cells are known to play distinct roles in the function of the adaptive 
immune system. CD4+ T cells are central in the initiation of both antigen-specific B-
cell and CD8+ T-cell responses by providing cognate and non-cognate helper signals 
(Singer and Hodes, 1983; Sprent et al., 1986; Ahmed, Butler and Bhatti, 1988). On 
the other hand, CD8+ T cells are known to mediate immune surveillance against 
autologous cells undergoing malignant transformation or infected with intracellular 
pathogens and also to effect rejection of histo-incompatible tissues (Goddeeris et al., 
1986; Rosenberg and Singer, 1988; Boon et al., 1994). To provide these functions, T 
cells need to differentiate from a resting precursor stage to activated effector cells. 
Robust activation of naïve T cells requires three signals (Bachmann et al., 1999a; 
Andreasen et al., 2000; reviewed by Schwartz, 2003). The first signal is delivered 
through binding of the TCR to peptide/MHC complexes on APCs in which the CD4 
and CD8 surface proteins bind to non-polymorphic domains of MHC class II and I 
molecules, respectively. The second signal is provided by interaction between co-
stimulatory molecules (CD80/86) on the professional APCs and their ligand CD28 on 
the responding T cells. The avidity of the TCR-peptide/MHC interaction coupled with 
the CD80/CD28 and CD86/CD28 engagement is stabilised by cell adhesion molecules 
and their ligands, namely, CD2/LFA-3 and LFA-1/ICAM-1, in a supramolecular 
adhesion cluster (Paul and Seder, 1994; Bromley et al., 2001). The essential role of 
co-stimulatory molecules has been demonstrated in blocking experiments using anti-
CD80/CD86 antibodies or chimeric fusion proteins that recognise both ligands to 
induce T cell unresponsiveness (Bachmann et al., 1999b). Antigen recognition in the 
absence of co-stimulation inactivates naïve T cells thereby inducing a state of anergy 
expressed as the inability to produce IL-2. Anergic T cells fail to proliferate and  
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Table 2: Serologically-defined bovine class I haplotypes and expressed class I alleles.  
Allele name Local names Associated serological 
specificity 
Breed Reference 
N*00101 5.1 A10 Boran Bensaid et al., Immunogenetics (1991) 
N*00102 JSP.2 A10 Boran Ellis et al., Immunogenetics (2005) 
N*00103 JSP.3 A10 N'Dama Ellis et al., Immunogenetics (2005) 
N*00201 JSP.1 A10 Holstein Pichowski et al., Immunogenetics (1996) 
N*00301 KN104 KN104 Boran Bensaid et al., Immunogenetics (1991) 
N*01201 A10.2; T2a A10 Holstein Ellis et al., Immunogenetics (2005) 
N*01301 HD6 A18 (A6) Holstein Ellis et al., Immunogenetics (1996) 
N*01302 HD6.1 A18 Holstein Ellis et al., Immunogenetics (2005) 
N*01701 D18.2, AH11-A A11, Holstein, Ellis et al., Immunogenetics (1999) 
N*01801 D18.3 A11 Holstein Ellis et al., Immunogenetics (1999) 
N*01802 AH11-B A11 Holstein Unpublished 
N*02001 MAN3 A12 (A30) Angus Ellis et al., Immunogenetics (1999) 
N*02101 HD1 A31 (A30) Holstein Ellis et al., Immunogenetics (1996) 
N*02201 HD7 A31 (A30) Holstein Ellis et al., Immunogenetics (1996) 
N*02301 D18.4 A14 Holstein Ellis et al., Immunogenetics (1999) 
N*02401 D18.1 A14, A15 Holstein Ellis et al., Immunogenetics (1999) 
N*02501 D18.5 A14, A15 Holstein Ellis et al., Immunogenetics (1999) 
Haplotypes/alleles indicated in bold were used in the current study  
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differentiate into effector cells when they re-encounter antigen even in the presence of 
co-stimulation (Schwartz, 2003). Inflammatory cytokines, including IL-1, IL-6, IL-12, 
and IFN-γ provide a third signal that acts directly on T cells to optimally activate 
clonal expansion and differentiation (Curtsinger et al., 1999; Curtsinger and Mescher, 
2010). Studies have also demonstrated a requirement for CD4+ T-cell help during the 
generation of primary CD8+ T cell responses, in particular CD40L-CD40 interaction. 
Activated T cells express CD40L that binds to CD40 on APCs to facilitate clonal 
expansion and differentiation (Mackey et al., 1998a and b; Shoenberger et al., 1998; 
Clarke, 2000; Diehl et al., 2000; Ma and Clark, 2009).  In instances where priming of 
CD8+ T cells requires the presence of CD4+ T cells, a three-cell interaction model of 
activation has been proposed (Wagner et al., 1980) which entails that a CD4+ T cell 
and a CD8+ T cell simultaneously recognise their specific antigens on the same APC. 
This ensures that the activated CD4+ T cell apart from providing the cognate (cell-cell 
contact signals) input, delivers the non-cognate (cytokine) signals in the immediate 
micro-environment of CD8+ T cells and APCs. In addition to cytokines such as IL-2 
and IL-7, among others, targeted at the CD8+ T cells, activated CD4+ T cells trigger 
APCs to express higher levels of co-stimulatory molecules (Andreasen et al., 2000; 
Blazevic, Truby and Shearer, 2001; Croft, 2003; Liang and Sha, 2002; Weninger, 
Manjunath and von Adrian, 2002; Seder and Ahmed, 2003). 
Once signals are delivered, the T cells are stimulated to undergo clonal 
proliferation and differentiation into activated cells armed with effector molecules and 
immunological memory. CD4+ T cells divide rapidly and differentiate into one of 
several T-helper (TH) subtypes including TH1, TH2, TH3, TH17 or TFH which secrete 
different cytokines to facilitate a different type of immune response. The mechanism 
by which CD4+ T cells are directed into a particular subtype is poorly understood, 
though signalling patterns from the APC are thought to play an important role 
(Curtsinger 1999; Gutcher and Betcher, 2007). Effector CD8+ T cells exhibit direct ex 
vivo effector function such as cytotoxicity and cytokine production upon TCR 
engagement (Harty, Tvinnereim and White, 2000; Harty and Badovinac, 2002; 
Woodland and Dutton, 2003). Memory T cells exhibit only minimal ex vivo activity if 
compared with effector cells but are able to produce cytokines with equivalent 
kinetics to effector T cells upon reactivation. Memory T cells typically express the 
cell surface protein CD45RO and comprises of two subtypes: central memory T cells 
(TCM) and effector memory T cells (TEM). Central memory T cells express CCR7 and 
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CD62L and preferentially reside in secondary lymphoid organs while effector 
memory T cells are devoid of these cell surface markers and preferentially localise in 
peripheral tissue (Sallusto et al., 1999; Weninger et al., 2001). Both subsets can 
however be found in blood and spleen. These cells display rapid mobilisation of the 
effector molecules upon antigen contact (Lalvani et al., 1997; Bachmann et al., 
1999a; Veiga-Fernandes et al., 2001). Analyses suggest that memory T cells require 
reduced antigen levels and are less dependent on co-stimulation probably due to 
increased expression of adhesion molecules that enhance the TCR avidity, and higher 
precursor frequency of antigen-specific cells (Oehen et al., 1992; Busch et al., 1998; 
Ieezi et al., 1998; Bachmann et al., 1999a; Berard and Tough 2002).  
With regard to stimulation of T cells by T. parva-infected cells, although a 
role for dendritic cells has been proposed in the priming of naïve T cells, parasitized T 
cells have been shown to express co-stimulatory molecules and are therefore capable 
of providing both a priming and recall APC function (Morrison and McKeever, 2006). 
As stated earlier, a requirement for antigen-specific CD4+ T cells in the priming and 
recall of T. parva-specific CD8+ T cell responses has been described in vitro (Taracha, 
Awino and McKeever, 1997). 
1.3.4 Effector mechanisms operative in activated CD8+ T cells 
As aforementioned, CD8+ T cells acquire effector function upon appropriate 
activation with APC-delivered specific antigen and accessory signals. Following 
several rounds (>8-10 cell divisions) of clonal expansion, CD8+ T cells become 
immune effectors by virtue of gaining the capability to induce cytolysis of autologous 
infected cells and/or elaborate cytokines and chemokines that mediate several 
activities (Harty, Tvinnereim and White, 2000; Harty and Badovinac, 2002; 
Woodland and Dutton, 2003). CD8+ T cells are heterogenous in terms of their 
mechanisms of effector function (Harty and Badovinac, 2002; Woodlands and Dutton, 
2003) and other studies (Aandahl et al., 2003) have shown that CD7 expression 
defines CD8+ T cell subpopulations capable of mediating cytolysis or cytokine 
secretion. The highly coordinated expression of both cytolytic and cytokine effector 
activities is tightly regulated through TCR-dependent signals. 
CD8+ T cells secrete cytokines including IFN-γ, TNF-α and TNF-β as well as 
chemokines, which contribute to host defence in several ways. These effector 
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molecules recruit and/or activate the microbicidal activities of effector cells such as 
macrophages and neutrophils. Cytokines also directly interfere with pathogen 
attachment, pathogen gene expression or may limit intracellular replication. For 
instance, IFN-γ inhibits viral replication directly and also induces class I MHC 
expression and macrophage activation. TNF-α and TNF-β can synergize with IFN-γ 
in macrophage activation and in killing some target cells through their interaction 
with TNF receptors on target cells.  
On the other hand, CD8+ T cells are able to induce cytolysis of infected cells 
by two distinct contact-dependent molecular pathways: the granule exocytosis 
pathway or through the interaction of the T-cell Fas-ligand (CD178) with the Fas 
(CD95) molecule on the target cell (Henkart, 1985; Kagi et al., 1994; Kagi et al., 
1996; Zimmermann and Green, 2001; Barry and Beackley, 2002; Russell and Ley, 
2002). A schematic representation of Fas-Fas ligand interaction and the granule 
exocytosis pathway is shown in Figure 2. Both of these pathways, activated in 
response to signals from the TCR stimulate the caspase cascade in the target cell 
leading to apoptotic death. Three distinct classes of cytotoxic proteins including 
perforin, granzymes A and B and granulysin have been identified from natural killer 
cells and cytotoxic CTL (Stenger et al., 1998; Ernst et al., 2000; Krensky et al., 2000; 
Ochoa et al., 2001; Smyth et al., 2001; Lieberman, 2003). Perforin is released on 
contact and polymerises in the presence of calcium to form pores in the target cell 
membrane lysing and killing target cells by necrosis (Voskoboinik, Smyth and 
Trapani, 2006); it also permits delivery of pro-apoptoptic proteases granzymes A and 
B into the target cell (Lowin et al., 1995; Trapani and Smyth, 2002; Trambas et al., 
2003, Bolitho et al., 2007). Two competing models for delivery of granzymes have 
been proposed: diffusion of the granzymes through a plasma membrane perforin 
channel versus coendocytosis of perforin and granzymes with subsequent disruption 
of endosome membrane by perforin to release the granzymes. However, the precise 
molecular mechanism remains to be understood. The molecular mechanism by which 
perforin initiates polymerisation has been reviewed in Baran et al., (2009) and Podack 
(2009). 
The cytotoxic proteins are contained in granules as demonstrated in 
experiments where purified granules from cytotoxic T cells when added to target cells 
in vitro resulted in lysis of the cells by creating pores in the lipid bi-layer. These  
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Figure 2: CD8+ T lymphocyte effector mechanisms 
a) Apoptosis through non-secretory Fas-Fas ligand interaction 
b) Granule exocytosis of an effector cytotoxic CD8+ lymphocyte 
 
Figure sourced from Davidson College: Homepage Template for Biology students 
(http://www.bio.davidson.edu/../perforin.html) 
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proteins are stored in the lytic granules in an active form after post-translational 
modification upon synthesis. Both perforin and granzymes are cleaved by signal 
peptidase to remove the signal peptide. In the case of granzyme, a second enzyme  
(DPPI) cleaves off a short pro-sequence, (Caputo et al., 1993, Mcguire Lipsky and 
Thiele 1993; Smyth, Mcguire and Thia, 1995; Pham et al., 1998; 1999) and it is 
glycosylated in the golgi apparatus (Griffiths and Isaac, 1997). Perforin is synthesised 
as a 70-kDa precursor that is cleaved at the carboxyl terminus to yield the active 60-
kDa form (Uellner et al., 1997). Although stored in an active form, conditions within 
the granules prevent them from functioning until after their release. Other than the 
cytotoxic granules being specialised lysosomes (de Saint Basile and Fischer, 2001), 
Fraser et al., (2000) showed that calreticulin, a chaperone protein of the endoplasmic 
reticulum that is known to exist in CTL granules, inhibits perforin-mediated target 
cell damage raising the possibility that calreticulin acts as a regulatory molecule that 
dampens the effect of perforin by stabilising membranes to prevent excessive damage. 
The highly controlled delivery of effector signals is coordinated by the 
antigen-specific TCR in three ways: firstly, it induces the stable binding of the 
effector cells to the specific target cells to create a tightly held, narrow space in which 
effector molecules can be concentrated; secondly, it focuses the delivery of effector 
molecules at the site of contact by inducing a re-orientation of the secretory apparatus 
of the effector cell; thirdly, it triggers their synthesis and/or release (Montoya et al., 
2002; Dustin, 2003; Trambas and Griffiths, 2003). 
The relative roles of CD8+ T-cell-mediated cytolytic and cytokine effector 
mechanisms in host resistance to viral, bacterial and protozoan intracellular infections 
have been described in mouse experiments and to a lesser extent in humans (Harty, 
Tvinnereim and White, 2000; Nickell and Sharma, 2000). Using perforin-deficient 
mice and antibodies directed at IFN-γ, it has been demonstrated that cytotoxic and 
cytokine responses contribute differentially to host immunity against different 
infections. While lytic CD8+ T cell responses were shown to be the mechanism of 
resistance against the protozoan Encephalitozoon cuniculi, clearance of Trypanosoma 
cruzi infection was dependent on IFN-γ responses (Kumar and Tarleton, 1998; Khan 
et al., 1999). By contrast, immunity against acute and secondary infection with 
Toxoplasma gondii was based on IFN-γ responses whereas clearance of T. gondii 
chronic infections relied on CD8+ T cell lytic activity (Denkers et al., 1997). 
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Similarly, host resistance to Listeria monocytogenes and Chlamydia infections was 
shown to be dependent on lytic and cytokine-mediated CD8+ T-cell responses, 
respectively (Harty and Bevan, 1992; Perry et al., 1999a and b). Concerning viral 
infections, both lytic and cytokine-mediated CD8+ T cell responses appear to 
contribute synergistically to host resistance. 
In the case of T. parva infections, it is likely that CD8+ T-cell-based immunity 
against T. parva might be an interplay of different mechanisms, some of which 
hitherto are unknown. CD8+ CTL directed against the schizont infected cell constitute 
the dominant protective bovine immune response (Morrison et al., 1987; McKeever et 
al., 1994; Taracha et al., 1995a) and antigen-primed CD4+ cells are required for 
effective activation of CD8+ T cells by parasitized cells (Taracha et al., 1997). The 
use of the IFN-γ ELISpot also indicates CD8+ T cell-mediated IFN-γ responses that 
parallel the antigen specificity of the lytic response (Graham et al., 2006). However 
the actual contribution of cytokine-mediated T cell responses in the development of 
immunity to T. parva remains largely unknown. Indeed, there has been inconclusive 
evidence on the activity of IFN-γ against the early or established schizont-infected 
cells. The addition of IFN-γ to cultures of PBMC immediately following infection 
with T. parva sporozoites has no inhibitory effects on the development of the parasite 
or survival of the infected cells. Indeed it was found that many parasitized cell lines 
express IFN-γ (DeMartini and Baldwin, 1991; McKeever et al., 1997; Morrison and 
McKeever, 2006). 
1.3.5 Assays for detection of antigen-specific CD8+ T cells 
Several methods have been developed to analyse CD8+ T cell responses and to 
study their involvement in the immune response to infection under natural infections 
and experimental vaccination. The best-established methods are based on the ability 
of cytotoxic CD8+ T cells to lyse appropriate target cells in vitro. These have been 
performed either under limiting dilution assay (LDA) conditions to provide a 
quantitative measurement of antigen-specific CTL precursors or under bulk culture 
conditions unsuited for quantifying CTL responses (Carmichael et al., 1993; Lau et 
al., 1994; Shaefer-Weaver et al., 2003). Another set of assays has included those that 
measure antigen-stimulated T cell cytokine production, particularly the IFN-γ 
ELISpot (Czerkinsky et al., 1983; Lalvani et al., 1997; Schneider et al., 1999) and 
intracytoplasmic cytokine staining (Suni, Picker and Maino, 1998; Badovinac and 
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Harty, 2000; Ghanekar et al., 2001) techniques. A more recent generation of ELISpot 
assays includes those that are based on human and mouse perforin and granzyme B 
effector molecules (Rininsland et al., 2000; Ewen et al., 2005; Zuber et al., 2005). 
The other distinct set of assays employed in the study of CD8+ T cell responses has 
involved the quantitation of individual TCR transcripts (Kalams et al., 1994; Moss et 
al., 1995) and determination of TCR Vβ chain usage (Walker et al., 1995). 
A long-standing need for appropriate assays to enable accurate measurement 
of the specificity and magnitude of the CD8+ T cell response in infections in general 
has been widely noted. While the LDA has provided useful information on the 
kinetics and duration of antigen-specific effector and memory cytotoxic CD8+ T cells, 
serious concerns that this assay has considerably underestimated the clonal burst size 
have been reported (Altman et al., 1996; Ahmed and Gray, 1996; Busch et al., 1998; 
Murali-Krishna et al., 1998). It has been argued that the LDA, which relies on in vitro 
stimulation of antigen-specific CD8+ T cells for several days prior to measuring 
cytotoxic activity, underestimates the cell numbers as not all potential CD8+ T cell 
responders grow in culture to become effectors. This is particularly evident with 
regard to those cells obtained from animals at the peak of activation that may undergo 
activation-induced cell death in the course of culture (Murali-Krishna et al., 1998; 
Green, Droin and Pinkoski, 2003). In addition, it has been demonstrated that another 
major cause of underestimation of CTL numbers by the LDA is overgrowth of 
specific effectors by other cells, arising from use of high input responder cell numbers 
per well, and that low input cell numbers are less likely to be overgrown thus 
providing a closer estimate of the true CTL frequency (Goulder et al., 2000). A 
technique in which tetramers of fluorochrome bound MHC class I molecules 
assembled with a single antigenic peptide are used to stain CD8+ T cells with 
specificity for the particular peptide- MHC class I complex (Altman et al., 1996) has 
proved a major advance in the study of antigen-specific T cells. Analysis of tetramer 
positive CD8+ T cells by flow cytometry provides a method that reliably quantitates 
the number of specific CD8+ T cells present in peripheral blood (Murali-Krishna et 
al., 1998; Tan et al., 1999; Goulder et al., 2000; Appay et al., 2000; Appay and 
Rowland-Jones, 2002). The combination of tetramer staining and other techniques 
such as CD8 surface marker staining, IFN-γ, perforin or granzyme B ELISpot assays 
that measure responses at the single cell level, has provided a powerful tool to 
generate precise information on phenotype, antigen specificity and function of CD8+ 
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T cell responses. Assays utilising tetramer staining in conjunction with surface 
molecules for naïve (CD45RA+veCD62L+veCCR7+ve), central memory 
(CD45RO+veCD62L+veCCR7+ve) and effector memory (CD45RO+veCD62L-veCCR7-ve) 
T cell phenotypes have been useful in categorising antigen-specific T cells into naïve, 
memory and effector subpopulations, respectively (Callan et al., 1998, 2000; 
Champagne et al., 2001; Aandahl et al., 2003). Combination of tetramer staining with 
measurement of the production of cytokines such as IFN-γ, TNF-α, chemokines 
(RANTES) and cytotoxins (perforin) has provided a means of examining the 
functional phenotype of circulating CD8+ T cells with specificity for a particular 
antigen at a single cell level (Wilson et al., 1998; Pittet et al., 2001a; Appay et al., 
2000; Benito et al., 2004). In addition to this antigen induced cell surface expression 
of CD107a and b has been used as an indicator identifying T cells that had 
degranulated and released effector proteins from their lytic granules (Betts et al., 
2003; Betts and Koup, 2004) and to distinguish effector and memory subsets of CD8+ 
T cells (Wolint et al., 2004). Monoclonal antibodies to TCR Vβ regions used in 
combination with tetramers have further been used to study TCR Vβ usage (Wilson et 
al., 1998; Valmori et al., 2000).  
In the case of evaluation of T. parva-specific CD8+ T cell responses, 
lymphoproliferation, target cell lysis by limiting dilution and bulk cultures of T cells 
as well as surface marker staining of responding cells have been employed (Goddeeris 
and Morrison, 1988; Taracha et al., 1992). While useful information has been derived 
from assays of short-term LDA and bulk cultures as well as long-term T cell lines and 
clones, concerns relating to loss of certain specificities due to skewing of the response 
during prolonged and repeated stimulation have been noted. On the other hand, in 
addition to the shortcomings already associated with the LDA, it is also extremely 
tedious, technically demanding and variable. More recently, a high throughput IFN-γ 
ELISpot assay has been optimised and used in antigen identification and 
immunogenicity studies (Graham et al., 2006). While this assay is more sensitive and 
less variable than LDA, it was found not to be a predictive marker for protection in 
cattle immunised with defined antigens and challenged with T. parva sporozoites and 
did not correlate with cytolytic responses. The prospect of applying bovine tetramers 
and ELISpot and intracellular staining assays based on perforin and granzyme A/B or 
IFN-γ in the study of CD8+ T cell responses following vaccination with candidate 
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antigens or infection with the parasite is compelling.  
1.4 Initiatives in development of improved vaccines against T. parva 
1.4.1  Identification of T. parva antigens 
The practical limitations imposed by using live parasites for vaccination 
against T. parva have justified the research endeavours to develop sub-unit vaccines 
based on defined parasite antigens. As noted earlier, efforts have focused on 
understanding the immune responses that mediate immunity against T. parva and 
using immune probes to identify candidate antigens for vaccination (Musoke et al., 
1984; 1992; Graham et al., 2006; reviewed by Morrison and McKeever, 2006) in line 
with initiatives in other parasite systems (Schofield et al., 1987; Zhang, Lonning and 
McGuire, 1998; Nacer et al., 2001; Gaddum et al., 2003). The discovery of p67 and 
success in induction of antibody responses capable of neutralising the infectivity of 
sporozoites has led to the field testing of a p67-based vaccine with potential to be 
included in a multi-component ECF vaccine. As previously mentioned, many studies 
have provided strong evidence that in animals immunised with live parasites, cellular 
immune responses directed towards parasitized leucocytes play an important role in 
immunity. Considerable effort has therefore been focused on the identification of T. 
parva schizont antigens that provoke protective immune responses, subsequently 
testing these candidate vaccine antigens for immunogenicity and efficacy. Two 
approaches to schizont antigen identification were adopted taking advantage of the 
recent complete T. parva (Muguga) genome sequence and annotation (Gardner et al., 
2005) and optimisation of a high throughput screening system used to identify 
antigens recognised by human tumour cell-specific CD8+ T cells (DePlaen et al., 
1997). Both strategies were dependent on screening APCs transiently transfected with 
parasite cDNA using well characterised bovine CTL in a high throughput IFN-γ 
ELISpot assay (Graham et al., 2006). The two approaches were complementary to 
each other. The first one was based on selecting candidate genes with recognisable 
peptide signal motifs to allow access of the encoded protein to the host cell cytosol 
and class I MHC processing pathway. Since some protein antigens lacking a signal 
peptide are known to access the class I MHC pathway (Nacer et al., 2001), a 
randomly constructed schizont cDNA library was also used to maximise the chances 
of identifying CTL antigens. 
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Applying these methods, six T. parva antigens recognised by CD8+ T cells 
from immune cattle of different MHC genotypes were identified (Graham et al., 2006; 
Graham et al., 2007). Analysis of the predicted amino acid sequences of the genes did 
not reveal any obvious functional relationship between the proteins (Gardner et al., 
2005). Two (Tp1 and Tp2) of these proteins were annotated as hypothetical and four 
(Tp4; elongation translation initiation factor 1A, Tp5; ε-subunit of T complex protein 
1, Tp7; heat shock protein 90, Tp8; cysteine proteinase) were annotated as in other 
systems. Interestingly, three (Tp4, Tp5 and Tp7) of the antigens did not contain 
recognisable signal peptides and would therefore not have been identified by the 
approach using the genome sequence. The identification of Tp9 and Tp10 as a CD8+ 
T cell antigens has recently been described (MacHugh et al., 2011; Graham et al., 
unpublished data). Potential orthologs of these antigens exist in other major protozoan 
parasites including T. annulata, Cryptosporidium parvum and P. falciparum with 
clear implications for wider vaccine application. It is noteworthy that using similar 
strategies (Graham et al., 2006) recent work by MacHugh et al., (2011) has identified 
three T. annulata antigens recognised by CD8+ T cells (Ta5, Ta9 and Ta11), two of 
which represent the orthologs of the T. parva antigens Tp5 and Tp9. 
The relevance of responses to these antigens to the control of infections in vivo 
was examined by analysing CD8+ T-cell responses following sporozoite challenge of 
immune cattle (Graham et al., 2006). The CD8+ T-cell response elicited was shown to 
have memory CD8+ T cells specific for the antigens. The kinetics of these responses 
to four (Tp1, Tp2, Tp5 and Tp8) of the antigens correlated well with those previously 
described for protective schizont-specific CTL in efferent lymph and peripheral blood 
after challenge of immune animals (Morrison et al., 1987; McKeever et al., 1994), 
whereas a delayed response was observed for one antigen (Tp4) and no boosting of 
Tp7-specific CD8+ T cells was observed probably suggesting a delayed expression of 
Tp4 during the parasite development in the host and a low frequency of Tp7-specific 
responder cells. The observation that active CD8+ CTL responses against four of these 
antigens are detected in vivo coinciding with the remission of the challenge infection 
indicates that they are likely to be involved in the protective response and appear to be 
appropriate candidates for use in immunisation. 
While the adoptive cell transfer studies (McKeever et al., 1994) suggested that 
effector CD8+ T cells were, on their own, adequate to resolve a primary T. parva 
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infection, it was not clear whether helper CD4+ T cells were required in the induction 
of the CD8+ CTL. This is an important question in terms of defining strategies for 
identification, formulation and delivery of vaccine candidate antigens. Indeed, 
Taracha and colleagues (1997) demonstrated in in vitro studies that resting CD8+ T 
cells require CD4+ T-cell helper input, in the presence of appropriate antigenic 
stimulation, to acquire effector activity. Further, it was shown that naïve and memory 
CD8+ T cells displayed distinct requirements with the former needing cell-cell 
cognate interactions. The implication of this finding is that vaccine candidate 
antigen(s) targeting naïve CD8+ T cells need to be co-presented with CD4+ T cell-
specific antigen(s) in order to effectively induce antigen-specific CD8+ CTL in 
vaccines. Although the six T. parva antigens identified using defined CD8+ CTL do 
contain MHC class I epitopes, these epitopes do not appear to be expressed by the 
MHC class II molecules on the surface of infected cells (Graham et al., 2006). 
However, it is possible that some of these CD4 epitopes on the Tp antigens are indeed 
presented by other APCs (dendritic cells) after they take up apoptotic TpM (cross-
presentation). This might be more relevant for CD8 T cell induction. Efforts are 
underway to identify further antigens using parasite-specific CD4+ T cells in line with 
previous reports (Baldwin, Goddeeris and Morrison, 1987; Brown et al., 1989). 
1.4.2 Vaccine delivery platforms for evaluating immunogenicity and  efficacy 
A major obstacle in the development of vaccines against diseases such as 
tuberculosis, malaria, theileriosis, leishmaniasis and HIV-AIDS caused by 
intracellular pathogens that require cell-mediated immunity is the lack of an antigen-
delivery strategy to elicit protective antigen-specific CD8+ CTL. In this regard, 
although all currently licensed human and livestock vaccines are efficient at inducing 
antibody responses, only vaccines derived from live attenuated organisms efficiently 
induce cellular immunity. It should be noted, however, that widespread use of live 
attenuated vaccines might be precluded by practical constraints such as manufacturing 
and safety concerns. Different forms of vaccination strategies using bacterial vectors 
such as Listeria monocytogenes, viral vectors e.g., modified vaccinia virus Ankara 
(MVA) strain, canary pox, adenoviruses as well as plasmid DNA vectors have been 
used in vaccine immunogenicity and efficacy studies (Schneider et al., 1998, 1999; 
Degano et al., 1999; McShane et al., 2001; Gilbert et al., 1999, 2002). These prime-
boost regimes have been shown to induce potent CD4+ and CD8+ T cell–mediated 
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IFN-γ and lytic responses in rodents (Schneider et al., 1998, 1999; Degano et al., 
1999; McShane et al., 2001; Gilbert et al., 2002) and, to a lesser extent, in humans 
(McConkey et al., 2003). Testing of such prime/boost regimes in cattle has resulted in 
the induction of T-cell responses to defined antigens (Taracha et al., 2003; 
Vordermeier et al., 2004). 
Genes encoding five (Tp1, Tp2, Tp4, Tp5 and Tp8) of the six CTL target 
antigens were engineered in plasmid DNA, canary pox and MVA viruses and tested in 
BoLA-defined cattle for immunogenicity and efficacy (Graham et al., 2006). Plasmid 
DNA/MVA or canary pox/MVA prime/boost vaccination protocols were used to 
immunise animals simultaneously with the five antigens in separate vaccine 
constructs and challenged, alongside naïve cattle, with a lethal dose of T. parva 
sporozoites. Significantly, cells obtained from 29% of the vaccinates displayed CTL 
activity against parasitized cells. By contrast, 79% of vaccinated cattle mounted 
antigen-specific CD8+ T-cell IFN-γ responses, which were boosted in the majority of 
animals following sporozoite challenge. The significance of the lytic CD8+ T cell 
responses was evident when correlated with the outcome to challenge. While the 
challenge controls suffered clinical ECF, only 9 of 19 IFN-γ responders survived, 
with seven animals having made lytic CD8+ T cell responses. The association between 
the ability to mount a lytic response and survival was highly significant with the mean 
ECF reaction index, a statistical measurement of disease severity, significantly lower 
than that of CTL nonresponders. On the other hand, the high number (10/19) of IFN-γ 
responders that succumbed to challenge would suggest that these responses are not 
predictive of protection against severe ECF or fatality. While the data validated these 
antigens for an in-depth study on effective antigen delivery strategies to induce CD8+ 
T-cell based immunity, the need for assays to detect immune responses that correlate 
with protection is equally of interest.  
1.5 Rationale and objectives of the study 
 The current study aims at developing a platform of immunological assays for 
evaluating different parameters of T. parva antigen-specific CD8+ T cell effectors of 
immunity that would serve as immunological endpoints of protection for application 
in vaccine development. In particular, the study seeks to develop novel assays for 
determining the fine specificity and magnitude of CD8+ T cells with cytolytic activity 
utilizing class I MHC-peptide complexes as well as molecules of the granule 
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exocytosis pathway. The overall objective of this study focuses on establishing a 
bovine tetrameric staining methodology in conjunction with perforin and granzymes 
A/B intracellular staining and release assays as a more sensitive and rapid system for 
quantifying epitope-specific cytotoxic granule-mediated CD8+ T cell responses. The 
specific objectives of the study include:  
1. To clone and express genes encoding bovine perforin, granzymes A 
and B 
2. To generate polyclonal and monoclonal antibodies to bovine perforin 
and granzymes A and B 
3. To develop and optimise perforin and granzyme A and B-based ELISA 
and ELISpot assays 
4. To develop and validate bovine tetramer staining methodology using T. 
parva-specific cytotoxic CD8+ T cell lines and clones of defined 
specificities 
5. To develop and validate flow cytometric assays combining double-
staining with tetramer and antibodies to CD8, perforin and granzymes 
A/B using CD8+ T cells of defined specificities  
6. To detect and enumerate epitope-specific CD8+ T lymphocytes 
expressing perforin, granzymes A and B in peripheral blood 
lymphocytes from live vaccine immunised animals before and after 
challenge. 
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Chapter 2: Cloning, Sequence Analysis and Expression 
of Bovine Perforin, Granzymes A and B 
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2.0 Introduction 
 CTL subsets of PBMC have the ability to recognise bind and lyse specific 
target cells. From morphologic analysis of CTL-target conjugates, it has been 
proposed that the lytic mechanism of CTL resides in their cytoplasmic granules. 
Analysis of the contents of granules from cytotoxic lymphocytes and natural killer 
cells has identified and isolated several proteins including perforin (also referred to as 
cytolysin) and granule specific serine proteases, granzymes A and B. In the case of T. 
parva infections, the actual role of perforin and granzymes is largely unknown 
although it has been demonstrated that cytotoxic CD8+ T cell responses contribute to 
host immunity. The availability of perforin and granzyme A and B will facilitate 
studies on the role of perforin and granzymes in lymphocyte mediated cytotoxicity 
and the subsequent development of alternative assays for CTL. However purification 
of sufficient amounts of granule proteins has been a major obstacle for performing 
extensive analysis of the role of perforin in lysis of target cells as well as granzyme 
pathways for inducing apoptosis. Indeed the isolation of granules from bovine CTL 
has been unsuccessful (Francis Chuma et al., personal communication). Thus 
recombinant DNA approaches have been used to produce perforin and granzyme 
proteins in heterologous systems. Chapter 2 reports on the cloning, sequencing, 
structural analysis and expression of cDNAs that code for bovine perforin, granzyme 
A and B. The data shows that a full-length cDNA encoding bovine perforin and a 
cDNA fragment encoding bovine granzyme A has been cloned and sequenced, 
whereas a full-length cDNA with characteristics resembling those of the granzyme B 
family has been obtained. Further to this, using the baculovirus expression system, 
truncated forms of these bovine proteins have been prepared. 
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2.1 Materials and methods 
2.1.1 Preparation of perforin, granzymes A and B single strand cDNA  
Total RNA was isolated from 1x107  bovine CTLs using the acid guanidinium 
thiocyanate-phenol-chloroform extraction (AGPC) method described by 
Chomczynski and Sacchi (1986). CTLs, generated and maintained as described in 
section 2.1.3.5.2 were harvested on day six post re-stimulation by centrifugation at 
1500 rpm at 4°C for 10 min (Heraeus Megafuge, Model No. 2.0R) and washed twice 
in cold PBS pH 7.4. Cells were lysed by resuspending in 500 μl of denaturing solution 
(4M Guanidine thiocyanate, 25mM sodium citrate-pH 7.0, 0.5% Sarcosyl, 0.1M β-2 
Mercaptoethanol), and RNA extracted by addition of 50 μl of 2 M sodium acetate, 
500 μl of water-saturated phenol and 100 μl of chloroform-isoamyl alcohol mixture 
(49:1), in that order. After vortexing for 10 seconds, the mixture was incubated on ice 
for 15 min followed by centrifugation at 14000 rpm (Bench top Eppendorf centrifuge 
Model No. 5402) for 10 min at 4°C. The aqueous phase (containing the RNA) was 
transferred into a fresh eppendorf tube and mixed with 2.5 volumes of ice-cold 100% 
ethanol, and incubated on dry ice for 30 min to precipitate RNA. After centrifugation 
at 14000 rpm for 10 min at 4°C, the pellet was re-dissolved in 300 μl of denaturing 
solution. RNA was re-precipitated as before by addition of 750 μl of ice-cold 100% 
ethanol followed by incubation on dry ice. After further centrifugation, the pellet was 
washed with ice-cold 70% ethanol, dried overnight at room temperature and re-
dissolved in 30 μl of RNase free water. The yield and integrity of the RNA was 
determined by agarose gel electrophoresis technique described by Pellé and Murphy 
(1993) as follows: 3 μl of the RNA sample was mixed with 7 μl of water (final 
volume 10 μl) to which 2 μl of sterile 6x loading buffer was added. The mixture was 
incubated at 75°C for 5 min to denature the RNA and immediately loaded onto a 
horizontal submarine gel. The gel was prepared by boiling 1.4 g agarose in 100 ml of 
10 mM sodium phosphate buffer, pH 6.8, containing 1 μl of 10 mg/ml ethidium 
bromide. Electrophoresis was carried out at 3 to 7 V/cm in 10 mM sodium phosphate 
buffer containing 0.1 μg/ml ethidium bromide, while constant re-circulation of the 
buffer was maintained to prevent formation of a pH gradient. RNA was visualised on 
a 312 nm ultra-violet transilluminator (UVP Inc.). A digital image of the gel was 
captured with a computerised digital reader (UVP Inc). 
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Single strand-cDNA (ss-cDNA) was synthesised from the total RNA using the 
reverse transcription kit (Superscript™Reverse Transcriptase, Invitrogen) with a 
slight modification of the manufacturer’s protocol as follows: 25 μl of RNA was first 
mixed with 9.5 μl of water and heated at 75°C for 5 min to denature the RNA. After 
chilling on ice for 3 min and brief centrifugation at 10000 rpm (Bench-top Eppendorf 
centrifuge model No.5417) to collect the contents in the bottom of the tube, a master 
mix consisting of 5 μl oligo dT, 5 μl 10x buffer, 2.5 μl 10 mM dNTP mix (dATP, 
dTTP, dGTP, dCTP), 1 μl Ribonuclease inhibitor, 2 μl Reverse Transcriptase was 
then added to a final volume of 50 μl and the mixture incubated at 37°C for 1 hr 
followed by heating at 75°C for 10 min to inactivate the reaction. After synthesis, the 
ss-cDNA was stored at -20°C or diluted in 10mM Tris, pH 8.5, at a 1:10 dilution and 
stored at 4˚C to be used as template in PCR to generate perforin, granzyme A and B 
cDNA. The quality of ss-cDNA was determined by PCR using primers for 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) a constitutively expressed 
gene, as described. Briefly, PCR reagents (Promega Madison, Wisconsin, USA) were 
mixed in a 96-well microtitre plate as follows: 1.5 μl 25 mM Mgcl2, 2.5 μl 10x buffer 
for Taq polymerase, 0.5 μl 10 mM dNTP mix, 0.5 μl 100 ng/μl GAPDH forward 
primer, 0.5 μl 100 ng/μl GAPDH reverse primer, 5 U/ul (∼0.125 μl) Taq DNA 
polymerase, 5 μl of ss-cDNA template and 14.375 μl sterile distilled water to a final 
volume of 25 μl. The PCR reactions were placed in a thermocycler (MinicyclerTM, MJ 
Research) for amplification using the following program: 94°C for 2 min for initial 
denaturation followed by 30 cycles of 94°C for 1 min, 55°C for 1 min, 72°C for 1 min 
and a final extension at 72°C for 5 min. The PCR products alongside DNA size 
markers were resolved and analysed in a 1.2% agarose gel and visualised under UV 
transillumination as previously described. 
2.1.2 Cloning of perforin, granzymes A and B cDNA into pGEM®-T Easy 
Gene-specific primers were designed to obtain the complete coding sequences 
of bovine perforin, granzymes A and B, based on homology to known human, mouse, 
rat and sheep sequences. Sequences encoding human, mouse, rat and sheep molecules 
where available were retrieved from the public database at NCBI 
(http://www.ncbi.nlm.nih.gov/entrez/query). Accession numbers of the retrieved 
sequences are shown in Table 3. The sequence data obtained was submitted for  
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Table 3: Gene accession numbers and sequences for primers used in cloning 
bovine perforin, granzymes A and B 
Perforin, granzymes A and B gene identification 
Accession 
number Size Predicted function Organism Source 
GI:190339 1668 bp pore forming protein - perforin Homo sapiens GenBank 
GI:34808711 1665 bp pore forming protein - perforin Mus musculus GenBank 
GI:59709458 1665 bp pore forming protein - perforin Rattus norvegicus GenBank 
GI:3559947 290 bp pore forming protein - perforin Ovis aries GenBank 
TC135848 1447 bp EST showing significant similarity to perforin Bos taurus TIGRDB 
GI:6996012 878 bp serine esterase 3 – granzyme A Homo sapiens GenBank 
GI:6754101 783 bp granzyme A Mus musculus GenBank 
GI:23618882 786 bp granzyme A Rattus norvegicus GenBank 
TC3999777 1002 bp EST showing significant similarity to granzyme A Bos taurus TIGRDB 
GI:20988817 744 bp serine esterase 1 – granzyme B Homo sapiens GenBank 
GI:7305122 744 bp granzyme B Mus musculus GenBank 
GI:31542925 747 bp granzyme B Rattus norvegicus GenBank 
TC134874 903 bp EST showing significant similarity to granzyme B Bos taurus TIGRDB 
     
 
ILRI 
oligo number 
Primers for cloning cDNA 
Primer sequence 5’ → 3’ end Target 
Primer 
orientation
12782 CGC GGA TCC ATG GCA GCC CGT CTG CT perforin forward 
12071 CAT CAC ATC ACA TTT ATT GGT CAG perforin reverse 
9341 TCC TCA TTC AAG ACC granzyme A forward 
9342 TCC TGG TTT CAC ATC granzyme A reverse 
11848 CCG GAA TTC ATG GTC CTG CTC CTG CTC granzyme B forward 
11849 CCG GCG GCC TCA CAC TGA TCC CTG GCG granzyme B reverse 
Restriction enzyme recognition sequences are shown in bold letters. Several primer 
pairs were used (see Appendix I) but Table 3 shows only those pairs that generated 
the expected sequences. 
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BLASTN search of the TIGR Bos taurus gene index 
http://compbio.dfci.harvard.edu/tgi/cgi-bin/tgi/gimain.pl?gudb=cattle (formerly 
(http://tigrblast.tigr.org/tgi) to search for identical expressed sequence tags (ESTs) 
from available bovine gene sequences. Sequence alignments were done using 
ClustalW (http://www.ebi.ac.uk/Tools/clustalw/index.html) (shown in Appendix I) 
and PCR primers designed based on regions showing close to 100% nucleotide 
identity. Where full-length sequence data was available, primers were designed on the 
flanking 5’ and 3’ ends according to a homology block in the untranslated regions 
upstream of the ATG start codon and/or downstream of the TGA stop codon. Primers 
were obtained from MWG Germany or ILRI SEGOLI unit and the sequences are also 
shown in Table 3 and Appendix I whereas PCR reagents were obtained from Applied 
Biosystems, USA.  
To amplify bovine perforin cDNA, the PCR reaction mixture was set up in a 
total volume of 50 μl as follows: 3.0 μl 25mM MgCl2, 5.0 μl 10x AmpliTaq Gold Taq 
polymerase buffer, 1.0 μl 10mM dNTP mix, 1.0 μl 100 ng/μl forward primer, 1.0 μl 
100 ng/μl reverse primer, 0.25 μl 0.25 U/μl AmpliTaq® DNA polymerase, 10 μl (or 5 
μl) of template ss-cDNA and 28.75 μl (or 33.75 μl) sterile distilled water. PCR was 
carried out in MinicyclerTM, MJ Research thermocycler under the following 
conditions: 94°C for 1 min followed by 35 cycles of 94°C for 1 min, 50°C for 1 min, 
72°C for 1.5 min and a final extension of 1 cycle of 72°C for 10 min. The resulting 
PCR products were analysed by gel electrophoresis using a 1.2% agarose gel stained 
with ethidium bromide and visualised under UV transillumination.  
Bovine granzyme A and B cDNA were amplified essentially as described for 
bovine perforin with minor modifications. A 50-μl PCR reaction mix was set up as 
follows: 3.0 μl 25 mM MgCl2, 5.0 μl 10x buffer for Taq polymerase, 1.0 μl 10 mM 
dNTP mix, 1.0 μl 100 ng/μl forward primer, 1.0 μl 100 ng/μl reverse primer, 0.25 
U/μl (0.25 μl) Taq DNA polymerase, 5 μl of ss-cDNA and 33.75 μl sterile distilled 
water template. PCR reaction conditions for granzyme A were 94°C for 1 min 
followed by 30 cycles of 94°C for 1 min, 40°C for 1 min, 72°C for 1 min and a final 
extension of 1 cycle of 72°C for 5 min. The PCR cycling conditions for granzyme B 
amplification were as follows: 94°C for 1 min followed by 35 cycles of 94°C for 1 
min, 50°C for 1 min, 72°C for 1 min and a final extension of 1 cycle of 72°C for 10 
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min. PCR products were resolved in a 1.2% gel, DNA fragments at expected sizes 
purified from the gel and cloned into pGEM®-T Easy vector for verification.  
The PCR products at the expected molecular size were purified using the 
QIAquick Gel extraction kit (QIAGEN, Germany) as described in the QIAquick® 
Spin Handbook (2001) as follows: 50 μl of the PCR products were resolved in a 1.2% 
(w/v) agarose gel which was subsequently stained with ethidium bromide to visualize 
the DNA under UV transillumination. The DNA fragment band of interest was 
excised from the agarose gel using a scalpel blade under UV light, weighed and 
dissolved in 3 volumes of Buffer QG (contains Guanidine thiocyanate) to 1 volume of 
gel (100 mg of gel is approximately 100 μl) at 50°C for 10 min followed by addition 
of 1 gel volume of isopropanol. The solubilised sample was applied to the QIAquick 
spin column and centrifuged at 10000 rpm (Bench top Eppendorf Centrifuge) for 1 
min. Bound DNA was washed once by adding 0.5 ml of buffer QG, followed by 0.75 
ml of Buffer PE (contains ethanol). Residual wash fluid was removed by spinning the 
column for another 1 min, and DNA eluted with 30 μl of Buffer EB (10 mM Tris.Cl, 
pH 8.5) and quantified by determination of absorbance at 280 nm (Gene Quant II, 
Pharmacia, Biotech). 
Perforin, granzymes A and B PCR products were ligated into the pGEM®-T 
Easy vector in a standard ligation reaction as follows: 5 μl 2x rapid ligation buffer, 1 
μl pGEM®-T Easy vector (approximately 100 ng of vector DNA), 1 μl T4 DNA ligase 
and 3 μl (approximately 50 ng) of purified PCR product (total reaction volume 10 μl). 
The ligation sample was mixed gently, incubated overnight at 4°C and directly used in 
bacteria transformation. Analysis and output of sequence data was performed by 
applying web-based NCBI ORF Finder program 
(www.ncbi.nlm.nih.gov/gorf/gorf.html) using standard genetic codes. Protein analysis 
and alignment of homologous sequences was done using a web based program hosted 
at EMBL-EBI (http://www.ebi.ac.uk/InterProScan/index.html). and BoxShade 
software (http://www.ch.embnet.org/software/BOX.form.html). 
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2.1.3 Transformation of bacteria with plasmid DNA 
2.1.3.1 Preparation of electrocompetent bacterial cells 
Escherichia coli DH10α or JM109 bacteria cells from a frozen glycerol stock 
were recovered by streaking onto a 2xYT plate and grown overnight at 37°C. A start 
culture of the host strain was initiated by inoculating 50 ml of 2xYT medium with a 
single isolated bacterial colony which was then grown overnight at 37°C with shaking 
at 225 rpm in a rotatory shaker (Series 25D, New Brunswick Scientific Co. Inc. NJ, 
USA). A 10-ml aliquot of the overnight culture was then seeded into 500 ml of fresh 
2xYT medium and grown at 37°C with continuous shaking until it reached an 
OD600nm of 0.5-0.7. The culture was then chilled on ice for 30 min in the cold room, 
whose temperature was set at 10˚C, before being transferred into pre-chilled 50ml 
polypropylene tubes (BD Falcon™ USA). In all subsequent steps, the cells were 
maintained and handled on ice in the cold room. The cell pellets were recovered and 
washed 6 times with ice-cold 10% glycerol in sterile distilled water by centrifuging at 
900xg (Model RC-3B, Sorval, Wilmington, DE, USA) for 15 min at 4˚C. Cell pellets 
were pooled gradually at each washing step and resuspended in 2 ml of ice-cold 10% 
glycerol in sterile distilled water after the final wash. Aliquots (100 μl) of the cell 
suspension were then dispensed into pre-chilled 0.5 ml eppendorf tubes and frozen in 
liquid nitrogen (snap freezing) for storage at -80˚C. 
2.1.3.2 Electroporation of bacteria cells 
A 100-μl aliquot of electrocompetent DH10α or JM109 bacteria cells was 
thawed on ice. The respective ligation reaction mix (5 μl) was added directly into the 
cell suspension, stirred gently and transferred into an ice-cold 0.2-cm gap 
electroporation cuvette (Bio-Rad laboratories, CA, USA). The cell suspension was 
then subjected to a high voltage discharge (15kV cm-1) for approximately 5 seconds. 
One ml of chilled LB broth medium was immediately added to the cell suspension 
and mixed gently before being transferred into 10-ml polypropylene tube (Falcon®). 
The cell suspension was incubated for 1 hr at 37°C, with rotatory shaking at 
approximately 255 rpm (Series 25D, New Brunswick Scientific Co. Inc. NJ, USA). 
An aliquot of 100 μl of the transformation mix was plated onto pre-warmed (37°C) 
NZYCM agar plates containing ampicillin (50 μg/ml) and incubated overnight at 
37°C. 
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Bacteria colonies containing the recombinant plasmid were identified by direct 
PCR screening. PCR reagents (Promega Madison, Wisconsin, USA) were mixed in a 
96-well microtitre plate as follows: 1.5 μl 25 mM MgCl2, 2.5 μl 10x Taq polymerase 
buffer, 0.5 μl 10 mM dNTP mix, 0.5 μl 100 ng/μl M13 forward primer, 0.5 μl 100 
ng/μl M13 reverse primer, 0.125 μl 5 U/μl Taq DNA polymerase, and 19.375 μl 
sterile distilled water to a total reaction volume of 25 μl. Single bacterial colonies 
were added to the mix by picking each pre-labelled numbered colony with a sterile tip 
and transferring it into the respective well. Replicate colonies were streaked onto 
fresh NZYCM plates containing ampicillin (50 μg/ml) and incubated at 37°C for 
approximately 6 hr. The PCR reactions were placed in a thermocycler (MinicyclerTM, 
MJ Research, USA) for amplification using the following program: 94°C for 2 min 
for initial denaturation followed by 30 cycles of 94°C for 1 min, 55°C for 1 min, 72°C 
for 1 min and a final extension at 72°C for 5 min. The PCR products were resolved 
and analysed in a 1.2% agarose gel as described before. Bacterial colonies carrying 
the recombinant plasmid were grown overnight with vigorous shaking in 3 ml liquid 
broth medium containing ampicillin (50 μg/ml) for subsequent purification of plasmid 
DNA. 
2.1.3.3 Plasmid DNA purification 
Plasmid DNA was prepared by using the QIAprep® Spin Miniprep kit 
(QIAGEN, Germany) following manufacturer’s instructions. Briefly, PCR positive 
replicate bacterial colonies were pelleted by spinning at 10000 rpm (Bench-top 
Eppendorf centrifuge, Model No. 5417) for 5 min at room temperature (~25˚C). Cell 
pellets were resuspended in 250 μl of Buffer P1 containing RNase A and 
subsequently lysed by addition of 250 μl of Buffer P2 which contains sodium 
hydroxide and sodium dodecyl sulphate (SDS). To avoid shearing of genomic DNA, 
the contents were mixed by inverting the tube 4-6 times. The lysis reaction was 
allowed to proceed at room temperature until the solution became clear and viscous or 
for a period not exceeding a maximum of 5 min. The lysis reaction was stopped by 
addition of 350 μl neutralisation buffer N3 (contains guanidine hydrochloride and 
acetic acid) which was mixed as before. Bacterial debris and precipitated proteins 
were removed by centrifuging at 14000 rpm (Bench-top Eppendorf centrifuge, Model 
No. 5417) at room temperature for 10 min. The supernatant was recovered and 
 52
transferred by decanting into a QIAprep spin column fitted into a 2-ml collection tube. 
The loaded column was then centrifuged at 14000 rpm (Bench-top Eppendorf 
centrifuge, Model No. 5417) for 60 seconds at room temperature and the flow through 
discarded. Column-bound plasmid DNA was washed twice by the addition of 500 μl 
of column wash buffer PB (contains guanidine hydrochloride and isopropanol) and 
once by the addition of 750 μl of buffer PE (contains ethanol) with centrifugation at 
14000 rpm (Bench top Eppendorf centrifuge, model No. 5417) for 60 seconds at room 
temperature. After the final wash, the column was centrifuged for an additional 1 min 
to remove residual wash buffer. The column was transferred to a fresh eppendorf tube 
and bound DNA eluted by adding 50 μl of elution buffer (10 mM Tris.Cl, pH 8.5) to 
the centre of each QIAprep column followed by 1 min centrifugation. Plasmid DNA 
yield was determined by measuring absorbance at 260 nm and was stored at -20°C for 
subsequent use. The DNA insert was further verified by sequencing before use. 
2.1.4 Protein expression in bacteria cells 
2.1.4.1 Sub-cloning bovine perforin and granzyme B cDNA into pGEX-3T  
Full-length cDNA inserts coding for bovine perforin and granzyme B were 
sub-cloned into pGEX-3T (Pharmacia Biotech, NJ, USA) in the appropriate reading 
frame and orientation. To facilitate sub-cloning of the target cDNA, appropriate 
restriction enzyme sites were introduced by PCR using primers flanking the 5’ and 3’ 
ends of the cDNA the resultant cDNA fragment prepared for cloning into pGEX-3T 
by digesting with the appropriate restriction enzyme. 
As shown in Table 3, primer number 12782 was designed to introduce BamHI 
(5’ end) recognition sequence at the N-terminal of perforin cDNA.  The resultant PCR 
product was subcloned into pGEM®-T Easy as previously mentioned in section 2.1.2. 
Consequently the recombinant pGEM®-T Easy/perforin cDNA plasmid was first 
digested with EcoRI restriction enzyme (New England Biolabs, MA, USA) following 
the manufacturer’s guidelines. The perforin cDNA was recovered by resolving the 
reaction mix in a 0.8% agarose gel following which the 2kb-band  was excised and 
purified from the gel essentially as described earlier. In parallel, 5 μg of the pGEX-3T 
plasmid vector was also digested with EcoRI. Digestion of the vector was determined 
by resolving 1 μl of the digest reaction in 1% agarose gel and staining with ethidium 
bromide to visualise plasmid DNA. Complete digestion results in a single band of 
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high molecular weight DNA at approximately 5 kb while incompletely digested 
plasmid DNA is manifested by multiple bands indicating the presence of linear and 
supercoiled plasmids. Linearised pGEX-3T plasmid vector was purified using 
QIAquick PCR purification kit (QIAGEN, Germany) in line with the manufacturer’s 
protocol. Briefly, 5 volumes of Buffer PB were added and mixed with 1 volume of the 
digest reaction. The sample was applied to the QIAquick column and centrifuged at 
14000 rpm (Bench top Eppendorf centrifuge Model No. 5417) for 1 min at room 
temperature. The column-bound plasmid DNA was then washed with 750 μl of Buffer 
PE under similar centrifugation conditions. Residual buffer was removed by an extra 
centrifugation step and bound DNA subsequently eluted with 50 μl of elution buffer 
(10 mM Tris-Cl, pH 8.5). To prevent re-ligation, the vector was further 
dephosphorylated using calf intestinal alkaline phosphatase (CIAP) (Promega USA) 
by adding 10 μl 10x CIAP reaction buffer, 2 μl CIAP and 38 μl sterile distilled water 
directly to the digested plasmid DNA. The dephosphorylation reaction mix was then 
incubated for 30 min at 37°C and the plasmid DNA recovered by purification using 
QIAquick PCR purification kit as described earlier. The EcoRI-digested perforin 
cDNA fragment and linearised plasmid was then digested with BamHI restriction 
enzyme (New England Biolabs, MA, USA) as recommended and recovered as before. 
The perforin cDNA fragment was then ligated to the linearised  pGEX-3T plasmid 
vector in a standard ligation reaction as follows: 1 μl 100 μg/ml vector DNA, 4 μl 10 
μg/ml insert DNA, 1 μl 10x Ligase buffer, 1 μl T4 Ligase (Promega, USA) and 3 μl 
distilled water in total reaction volume of 10 μl in a 200-μl eppendorf tube. The 
contents were mixed and incubated overnight at 16°C. An aliquot of 5 μl of the 
ligation mix was used to transform electrocompetent JM109 bacteria cells as 
described earlier (Section 2.1.3.2). The resultant recombinant pGEX-3T/perforin 
cDNA vector was sequenced to verify the integrity of the open reading frame. 
Granzyme B cDNA was sub-cloned in pGEX-3T vector at the BamHI and SalI 
sites. A set of primers, ILO 647597 and ILO 647598 (Appendix II), were designed 
based on the granzyme B cDNA sequence to generate BamHI/ and SalI restriction 
enzyme recognition sequences at the N- and C terminals of the cDNA, respectively.  
A typical 50-μl PCR reaction mix in a sterile 500 μl eppendorf tube included the 
following reagents: 3.0 μl 25mM Mgcl2, 5.0 μl 10x Taq DNA polymerase buffer, 1.0 
μl 10mM dNTP mix, 1.0 μl 100 ng/μl forward primer, 1.0 μl 100 ng/μl reverse 
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primer, 5 U/μl (∼0.25 μl) AmpliTaq® Gold DNA polymerase, 0.5 μl template (10 
ng/μl recombinant pGEM®-T Easy/granzyme B cDNA plasmid) and 38.25 μl sterile 
distilled water. The reaction mix was overlaid with a drop of mineral oil and 
incubated under the following conditions: 94°C for 2 min followed by 30 cycles of 
94°C for 1 min, 55°C for 1 min, 72°C for 1 min and a final extension of 1 cycle of 
72°C for 5 min (MinicyclerTM, MJ Research). A 5-μl aliquot of the PCR products was 
resolved in a 1.2% w/v TAE agarose gel along side DNA size markers and the DNA 
visualised by staining with ethidium bromide. PCR products were ligated into 
pGEM®-T Easy vector and purified as described previously. The resultant 
recombinant plasmid DNA was sequenced at ILRI (SEGOLI Unit) or Macrogen Inc 
(South Korea) using vector primers to ensure that no cloning artefacts or Taq 
polymerase induced mutations were generated during the amplification process. The 
recombinant plasmid was subsequently digested with BamHI and SalI, the granzyme 
B fragment bearing BamHI and SalI restriction sites recovered from gel as previously 
outlined. Linearised pGEX-3T vector DNA and BamHI/SalI digested granzyme B 
cDNA were ligated using T4 DNA ligase (Promega, USA) essentially as described for 
perforin. 
2.1.4.3 Protein expression in Escherichia coli 
Transformed JM109 cells were used for recombinant protein expression as 
described in QIAexpressionist ™ (A hand-book for high-level expression and 
purification of proteins, 2003). Briefly, start cultures were initiated by inoculating 2 
ml of LB growth medium containing ampicillin (100 μg/ml) with a single colony-
derived cells and grown overnight at 37°C with rotatory shaking at 225 rpm (25D, 
New Brunswick Scientific Co. Inc. NJ, USA). The overnight culture was expanded 
into a larger volume of fresh LB medium containing ampicillin and grown similarly. 
Typically, 500 μl of a 2-ml overnight culture was seeded into 50 ml of LB growth 
medium containing ampicillin. When the culture reached an OD600nm of 0.5-0.7, 
protein expression was induced with the addition of IPTG to a final concentration of 2 
mM or 10 mM and further incubation for 4-5 hr at 37°C with continuous shaking. A 
cell pellet recovered from 10 ml of the cell culture by centrifugation (Bench top 
Heraeus centrifuge) at 3000 rpm at room temperature for 20 min, was prepared for 
protein expression determination by resuspension in 1 ml 8M urea solution (Lysis 
Buffer B) containing a protease inhibitor (1 mM PMSF), lysed by sonication using a 
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micro-tip sonicator (Branson 3328, 50% duty cycle) for 1 min at 4°C and spun as 
before. The total lysate was recovered and analysed for protein content as described in 
Section 2.1.6.  
2.1.5 Protein expression in insect cells using baculovirus 
In order to produce perforin, granzymes A and B in insect cells, the Bac-to-
Bac® expression system (Invitrogen ™ Life Technologies), assembled by first 
cloning the genes into a pFASTBac™HT B vector and then integrating into a 
baculovirus shuttle vector (bacmid), was applied as described in the Bac-to-Bac® 
Baculovirus Expression system manual (Invitrogen ™ Life Technologies). 
2.1.5.1 Sub-cloning bovine perforin, granzymes A and B into pFASTBac™HT B 
Primers were designed to introduce cleavage sites at the 5’ and 3’ ends for 
NcoI and SalI, respectively of cDNA fragments of perforin and granzyme B as well as 
a partial fragment with a predicted coding sequence for granzyme A using primers 
indicated in Appendix II and cloned bovine cDNA (generated in section 2.1.2) as 
template. The amplified fragments were sub-cloned in pGEM®-T Easy vector and 
sequenced for verification. The cDNA fragments were then sub-cloned into 
pFASTBac™HT B at NcoI and SalI sites following recommended protocols (New 
England Biolabs). Briefly, both recombinant pGEM®-T Easy and pFASTBac vectors 
were digested with NcoI and SalI restriction enzymes (NEB). The linearised 
pFASTBac vector and the excised fragment were ligated together in a reaction mix 
containing T4 DNA ligase, and the resulting recombinant pFASTBac™HT B plasmid 
(rec-pFASTBacTMHT.B) used to transform E. coli DH10α by electroporation. A GFP 
gene fragment was also fused in-frame to the C-terminal end of the target cDNA 
using SalI and SphI sites to function as an expression reporter gene. Hence, the 
recombinant pFASTBAC plasmid was isolated and digested with SalI and SphI 
restriction enzymes to allow cloning of the GFP cDNA. A schematic representation of 
the cloning process as well as the primers used is illustrated in Appendix III. The 
resulting GFP-containing recombinant pFASTBac (GFP-rec-pFASTBac™ HT B) was 
further used to transform E. coli DH10α. Plasmid DNA was isolated from ampicillin-
resistant transformants and analysed by enzyme digestion using NcoI, SalI and SphI 
restriction enzymes or by PCR using M13 forward and reverse primers to confirm the 
presence of the insert. Sequencing was performed to verify that the cDNA was cloned 
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in-frame with the N-terminal ATG codon. The recombinant plasmid was then bulked 
and purified and stored at -20˚C until use. 
2.1.5.2 Generation and isolation of recombinant bacmid 
The rec-pFASTBacTMHT.B or GFP-rec-pFASTBac™HTB plasmid DNA was 
used to transform chemically-competent DH10Bac™ E. coli cells (Invitrogen) as 
recommended in the manufacturer’s guidelines. Briefly, 50 μl of competent cells were 
mixed with 1 μl of recombinant plasmid DNA (at a concentration of 1 μg/ml) and 
heat-shocked at 42°C for 45 seconds. The cells were resuspended in 900 μl of LB 
growth medium and plated out in three 10-fold serial dilutions (101, 102, 103) on LB 
agar plates containing 50 μg/ml kanamycin, 7 μg/ml gentamycin, 10 μg/ml 
tetracycline, 100 μg/ml bluo-gal, and 200 mM IPTG. Plates were incubated for 48 hr 
at 37°C. Colonies containing the recombinant bacmids were identified as white 
colonies in a background of blue colonies that harbour the unaltered bacmid. White 
colonies were re-streaked on fresh LB agar plates containing the appropriate 
antibiotics and substrates to confirm the white colour phenotype. 
A single white colony was grown in 2 ml LB growth medium containing 50 
μg/ml kanamycin, 7 μg/ml gentamycin and 10 μg/ml tetracycline at 37°C for 24 hr 
with gentle agitation (Series 25D, New Brunswick Scientific Co. Inc. NJ, USA) for 
aeration. Cells were harvested from 1.5 ml stationary-phase culture by centrifugation 
at 10,000 rpm for 5 min (Bench top Eppendorf centrifuge Model, 5417), recovered in 
300 μl cell resuspension solution (15 mM Tris-HCl, pH 8.0, 10 mM EDTA, 100 
μg/ml RNase A) then lysed by addition of 300 μl of cell lysis solution (0.2 N NaOH, 
1% SDS) and incubation at room temperature for 5 min. Protein and genomic DNA 
was precipitated by addition of 300 μl of cold 3M KOH, pH 5.5 and the sample 
subsequently incubated on ice for 15 min. The white precipitate was removed by 
centrifugation at 14,000 rpm (Bench top Eppendorf centrifuge, Model 5417) for 10 
min at 4°C resulting in a clear supernatant that was transferred into a microcentrifuge 
tube containing 10 μl of endotoxin-removal buffer (QIAGEN, Germany) and 
incubated on ice for 30 min. Endotoxin-free bacmid DNA was precipitated by 
addition of 800 μl of isopropanol with gentle agitation before the tube was placed on 
ice for 10 min. DNA was recovered by centrifugation at 14000 rpm (Bench-top 
Eppendorf centrifuge Model No. 5402) for 15 min at 4°C and the pellet washed by 
 57
further centrifugation as before in 500 μl endotoxin-free 70% ethanol then air-dried at 
room temperature for 15 min prior to dissolving it in 50 μl endotoxin-free TE buffer. 
An aliquot of 1 μl of the DNA was analysed by PCR to verify the presence of the 
target cDNA while 5 μl was used for transfection of insect cells to assess the quality 
of the DNA. Bacmid DNA was stored at 4°C or in 10-μl aliquots at -20°C to avoid 
repeated freeze-thawing.  
2.1.5.3 Analysis of recombinant bacmid by PCR 
PCR amplifications were performed in a total volume of 50 μl containing 1.0 
μl of the purified bacmid DNA, 5.0 μl 10x Taq DNA polymerase PCR buffer, 6.0 μl 
25 mM MgCl2, 1.0 μl 10 mM dNTP mix, 1.0 μl 100 ng/ ml M13 forward, 1.0 μl 100 
ng/μl M13 reverse primer and 0.5 μl 5 units/μl Taq polymerase and 34.5 μl sterile 
double distilled water. The cycling conditions were: initial denaturation at 94°C for 3 
min, 35 cycles of denaturation at 94°C for 45 seconds, primer annealing at 55°C for 
45 seconds and extension at 72°C for 5 min and a final extension cycle at 72°C for 7 
min (GeneAmp, Applied Biosystems). A 5-μl aliquot of the PCR reaction was 
analysed by electrophoresis on a 1.2% agarose gel and DNA bands visualised by 
ethidium bromide staining and UV transillumination of the gel. 
2.1.5.4 Culture and maintenance of insect cell lines 
Spodoptera frugiperda Sf-21 insect cells were used as the host for the 
baculovirus transfer vectors while Trichoplusia ni High-Five™ BTI-TN-5B1-4 cells 
were used for protein expression. Sf-21 cells were maintained in supplemented insect 
cell growth medium (TC-100, Sigma Chemicals, UK) with 5% foetal bovine serum 
(Hyclone, UT, USA) while High-five cells were maintained in Express-Five™ serum-
free growth medium (GIBCO Ltd., UK). Both growth media were supplemented with 
100 U/ml penicillin, 100 μg/ml streptomycin and 100 μg/ml gentamycin to make 
them complete. 
For routine maintenance, cells were seeded and incubated at 2x104- 5x105 
viable cells/cm-2 in 25-cm2 (4-6 ml) or 75-cm2 (15 ml) tissue culture flasks (Costar®). 
Cell culture flasks were kept in an humidified incubator at 27°C with loose caps to 
allow gaseous exchange. The cultures were kept in logarithmic growth phase by 
making sub-cultures when the monolayer reached 80% to 100% confluency; that is 2 
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to 4 days post-seeding. A portion of the cell suspension was removed and replaced 
with an equal volume of fresh growth medium. Cell cultures were discarded after 
approximately 30 passages. For cryopreservation, cells harvested at the peak of 
growth with a viability of >90%, were resuspended to a final cell density of 1x107 – 
2x107 cells/ml in cold incomplete insect cell culture medium containing 7.5% DMSO, 
10% FBS or 10% BSA and stored in 1-ml aliquots in cryotubes (Greiner, Germany) 
as master seed stocks. Vials were chilled at 4°C for 30 min before storage in liquid 
nitrogen. 
To initiate fresh cultures, cells were recovered from the cryopreserved master 
seed stock by rapidly thawing the vials in a 37°C water-bath. The cell suspension was 
quickly transferred into a 10-ml polypropylene tube containing 8 ml of cold 
incomplete insect cell growth medium and washed two times before being transferred 
into pre-warmed complete growth medium at a minimal viable cell density of 3-5x105 
cells/ml. The culture was then maintained at a cell density of 3x105 - 106 cells/ml for 
at least two sub-cultures after recovery then returned to the normal maintenance 
schedule.  
Cell counts were done using a haemocytometer (Neubauer) and trypan blue 
dye exclusion. All operations except centrifugation and counting of cells were 
conducted in a horizontal laminar air flow hood.  
2.1.5.5 Generation and amplification of recombinant baculovirus  
Sf-21 cells were transfected with the recombinant bacmid using Cellfectin 
reagent (Invitrogen) in a 6-well tissue culture plate (Costar®) format according to the 
established protocol (Guide to baculovirus expression vector systems (BEVS) and 
insect cell culture techniques, http://www.invitrogen.com). Briefly, approximately 
9x105 cells in 2 ml of complete growth were seeded in each tissue culture plate well 
and allowed to attach for 1 hr at 27°C in a humidified incubator. An aliquot of 6 μl of 
Cellfectin reagent was diluted in 100 μl of unsupplemented TC-100 medium and 
mixed with 5 μl of purified recombinant bacmid diluted in 100 μl of the same 
medium. The DNA:Cellfectin mix was incubated for 1 hr at room temperature to 
allow the formation of DNA-lipid complexes. A further 800 μl of unsupplemented 
TC-100 medium was added to the tube containing the DNA-lipid complexes and this 
suspension mixed gently and then overlaid onto the Sf-21 cell monolayer. Prior to 
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adding the diluted DNA-lipid mix, the monolayer cells were washed once with 2 ml 
unsupplemented TC-100 medium. The cell culture containing the DNA-lipid 
complexes was then incubated at 27°C in a humidified incubator for 5 hr before the 
complexes were removed by aspiration and replaced with 2 ml of complete TC-100 
medium in each well. The culture was incubated further at 27°C for 72 hr. Budding 
virus released into the growth medium was recovered into 10-ml polysytrene tubes 
(Sterilin, England) and centrifuged (Heraeus Megafuge, Model No. 2.0R) at 1500 rpm 
for 10 min at room temperature to remove cell debris and collect the supernatant in 5-
ml polystyrene tubes (Sterilin, England). This small-scale low titre virus preparation 
termed P1 viral stock, was stored at 4˚C and protected from light until use. 
To generate a high titre virus population, P1 was used to infect more Sf-21 
cells resulting in a P2 viral stock. Briefly, aliquots of 6 ml of cells at a concentration 
of 2x106 cells/ml were seeded in a 25-cm2 tissue culture flask (Costar®) and allowed 
to form an adherent monolayer at room temperature. An aliquot of 500 μl of P1 virus 
stock was added to the cell monolayer and the culture maintained at 27˚C in a 
humidified incubator for 48 hr. The budded virus was recovered and stored as 
described before. All procedures were conducted under laboratory biosafety level 2 
conditions. 
2.1.5.6 Production and purification of recombinant perforin, granzymes A and B 
Approximately 15-ml culture of Trichoplusia ni High Five™ cells at 2-3x106 
cells/ml was transferred into a 75-cm2 tissue culture flask (Costar®) and the cells left 
to attach for at least 30 min at room temperature. The growth medium was removed 
by aspiration, and the cells rinsed once with fresh growth medium before adding a 
further 15 ml of fresh growth medium. The culture was then inoculated with 500 μl of 
the P2 viral stock and incubated at 27°C for 72 hr in a humidified incubator. After 
culture, cells containing the recombinant protein were collected in 10-ml 
polypropylene tubes (Sterilin, England) by centrifugation. The supernatant was 
discarded and the cell pellets washed once in chilled PBS.  
The baculovirus expression vector contained N-terminal 6x-Histidine residues 
that allowed for the expression of the recombinant proteins as His-tag fusion proteins. 
This facilitated the purification of the recombinant fusion proteins using metal-
chelating resin such as Ni-NTA (QIAGEN, Germany) essentially as described in 
 60
‘‘The QIAexpressionist™: A Handbook for High Level Expression and Purification 
of 6xHis-tagged Proteins’’ (2003). Briefly, chilled cell pellets were lysed in 5 ml lysis 
buffer (Lysis buffer A ) containing 1mM PMSF by sonication for 1 min using a 
micro-tip sonicator (Branson 3328, 50% duty cycle) after which cell debri was 
removed by centrifugation (3000 rpm for 20 min at 10˚C; Bench top Heraeus 
centrifuge). His-tagged proteins were purified from the supernate using Ni-NTA resin. 
An aliquot of 200 μl of 50% Ni-NTA slurry was added to the supernate and mixed 
gently on a rolling mixer (Denley Roller Mixer) for 2 hr in the cold room. The Ni-
NTA/sample admixture was then loaded onto a polypropylene column (Pierce 
Chemical Co., Rockford, US). The resin-bound His-tagged protein was washed three 
times with 5 ml of Wash buffer C. The bound protein was eluted sequentially with 
four aliquots of 500 μl Elution buffer E. Immediately after elution, 100 μl of 1M Tris-
Cl, pH 8.0 was added to each of the eluates to neutralise the low pH of the elution 
buffer. An aliquot of the eluates was analysed for protein purity and integrity as 
described in section 2.2.6. The eluates were pooled and their concentration 
determined using the BCA protein assay kit (Pierce Chemical Co., Rockford, US) and 
stored at 4˚C until further use. 
2.1.6 Protein expression analyses 
Expression of recombinant proteins by the E. coli and baculovirus systems 
was assessed by Coomassie staining and Western blotting of sodium dodecyl 
sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) resolved samples. 
Separation of proteins was done based on molecular size in the presence of SDS and 
2-mercaptoethanol (Laemmli et al., 1970; Ausubel et al., 2001). Protein samples were 
resolved in a slab mini-gel (8.0 cm x. 10 cm x 0.5 mm) format. Separating and 
stacking gel solutions were prepared as shown in Appendix IV. The separating gel 
solution was slowly poured into a pre-assembled glass plate sandwich comprising two 
clean glass plates and 0.75 mm spacers (Hoefer Mighty Small SE 250/280) until the 
gels were 6 cm high allowing for 1.5 cm for the stacking gel. The separating gel was 
overlaid gently with distilled water and allowed to polymerise for 1 hr before the 
addition of the stacking gel solution. After pouring off the layer of water, the stacking 
solution was added and gel combs inserted carefully taking care not to trap air 
bubbles. The stacking gel was left to polymerise for 30 min. Once polymerised, the 
combs and spacers were removed and the sample wells rinsed with water followed by 
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the electrophoresis buffer. The assembled gels were then mounted in the 
electrophoresis tank containing electrophoresis buffer. To prepare the protein sample 
(crude E. coli cell lysate or Ni-NTA column eluates) for loading, 10 μl of the sample 
was diluted with 2 μl 6x sample buffer and boiled for 5 min in a microcentrifuge tube. 
The sample was then loaded into one well by carefully applying the sample as a thin 
layer at the bottom of the well. Electrophoresis was done at a constant current of 30 
mA until the dye front reached the bottom of the gel lasting approximately 2 hr. SDS-
PAGE resolved protein bands were visualised by staining with the protein 
precipitating 0.25% Coomassie Brilliant blue R-250 essentially as described 
previously (Wilson, 1983; Sambrook and Russell 2001). Briefly, the staining solution 
was prepared by dissolving the dye in a methanol:acetic acid mixture (500 ml 
methanol, 100 ml water, 100 ml acetic acid). After electrophoresis, the gel was 
immersed in 5 volumes of staining solution at room temperature for 1 hr while 
shaking on a rotating platform. The gel was then destained by soaking it in 30% 
methanol, 10% acetic solution (without the dye) for 2 hr while changing the 
destaining solution three or four times. After destaining, the gels were photographed 
and stored in water containing 20% glycerol. The composition of buffers and reagents 
for polyacrylamide separating and stacking gels is shown in Appendix IV. Prediction 
of the location of a protein band of interest on the gel in relation to a set of protein 
standards was guided by the calculated protein molecular weight of the cloned cDNA 
(http://www.sciencegateway.org/tools/proteinmw.htm). 
For western blotting of SDS-PAGE resolved E. coli expressed proteins, crude 
bacteria cell lysates were separated in 12.5% polyacrylamide gels under reducing 
conditions and the proteins transferred onto a nitrocellulose membrane (PROTRAN, 
0.2μm, Schleicherand Schuell) before addition of relevant antibody as described 
previously (Towbin, Staehelin and Gordon, 1979; Ausubel et al., 2001). The western 
blot sandwich was prepared as follows: the polyacrylamide gel containing the protein 
was laid on a sheet of transfer buffer pre-wetted filter paper. The uncovered side of 
the gel was then overlaid with a sheet of water pre-wetted filter paper. The 
nitrocellulose was then overlaid with another sheet of pre-wetted filter paper. This 
assembly was then sandwiched between two scotch brite pads, secured in a plastic 
support and the entire assembly placed in a tank containing transfer buffer such that 
the nitrocellulose paper faced the anodal (positively charged) side of the tank. 
Proteins were electrophoretically transferred overnight at 4°C using constant voltage 
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(15V) with continuous stirring of the transfer buffer to maintain a constant 
temperature gradient. Protein transfer was confirmed by incubation of the 
nitrocellulose filter in Ponceau S solution for 5 min at room temperature to stain the 
proteins, then visualised by destaining in water for 10 min at room temperature. To 
block non-specific binding sites, the nitrocellulose membrane was pre-incubated in 
5% (w/v) non-fat dry milk in PBS for 30 min while shaking on a rocking platform, 
following which it was incubated with the anti-GST monoclonal antibody diluted 
1:20000 in 0.1% (w/v) non-fat dry milk in PBS for 2 hr at room temperature or 
overnight at 4°C with shaking as before. The blot was then washed three times by 
immersing in PBS containing 0.1 % (w/v) Tween-20 for 10 minutes while shaking as 
before. After the final wash, the filter was incubated in goat anti-mouse 
immunoglobulins (Ig) coupled to alkaline phosphatase (Amersham) diluted 1:30000 
in 0.1% (w/v) non-fat dry milk in PBS for 1 hr at room temperature then washed as 
before. Bound antibody was detected by addition of alkaline phophatase substrate 
buffer (Sigma) for 1-2 min or until a colour signal was observed. To stop the reaction, 
the filter was washed with a copious amount of running tap water and left to dry at 
room temperature. 
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2.2 Results 
2.2.1 Cloning bovine perforin, granzymes A and B 
 Cloning of bovine perforin, granzymes A and B was initiated by 
isolation of total RNA from characterised T. parva stimulated CD8+ CTL, followed 
by synthesis of single strand cDNA (ss-cDNA) from the poly A+ RNA and 
subsequent ligation of PCR amplified gene-specific DNA fragments into the pGEM-T 
vector. As shown in Figure 3, panel A, the yield and quality of the total RNA was 
determined by electrophoresis in a phosphate agarose gel in which it resolved into two 
distinct bands representing the 28S and 18S ribosomal RNA subunits which are 
characteristic eukaryotic total RNA. However the 28S rRNA did not appear 2-fold 
brighter than the 18S rRNA as expected of intact RNA indicating partial degradation 
of RNAs. Synthesis of ss-cDNA was assessed by the inclusion of bovine GAPDH as 
an internal indicator of full-length gene sequences (Figure 3, panel B).  PCR 
amplification of the respective ss-cDNA and subsequent cloning into pGEM-T 
followed by sequencing and in-silico analysis of predicted protein revealed products 
of varying features.  
BLASTN search of the TIGR Bos taurus Gene Index (now DFCI Gene Index) 
identified a 1447-bp Bos taurus EST, TC135848 (TC478084), with significant 
nucleotide similarity to GenBank sequences encoding human (gi:190339; 80%), 
mouse (gi:34808711; 73% ), rat (gi:59709458; 74% ) and sheep (gi:3559947; 96% ) 
perforin. Perforin primers derived from the alignment of these sequences isolated a 
2188 bp cDNA fragment (Figure 3, panel C) that  contained a 1665-bp open reading 
frame with 99% identity to the orf in bovine EST TC135848 and encoding a protein 
of 554 amino acid residues (Figure 4a). Bioinformatic analysis of this polypeptide 
showed presence of conserved regions resembling a calcium-binding motif similar to 
the C2 domain of protein kinase C in the C-terminal region, membrane-attack 
complex components in the central one-third portion, and EGF-like domain and a 
leader (signal) peptide with a likely cleavage site between amino acid residues 20-21 
(APA-PC) as shown in Figure 4b. It is evident that these features are consistent with 
those exhibited by members of the perforin family. BLASTP search of non-redundant 
protein sequences revealed 80%/91% amino acid/homology similarity of the cloned 
bovine sequence to pig perforin (Gene ID: 396575) and 78%/87% 
aminoacid/homology, 74%/85% aminoacid/homology similarity to horse (Gene ID:  
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Figure 3: Generation of bovine cDNA and cloning bovine perforin granzymes A 
and B 
 Bovine total RNA was prepared from 1x107 T. parva stimulated CD8+ T cells 
by the AGPC extraction method. Panel A shows electrophoresis of bovine total RNA. 
RNA preparations (3 μl) were electrophoresed in phosphate agarose (1.4 % w/v) 
minigel and stained with ethidium bromide (Panel A). T .brucei total RNA was used 
as a control to verify the integrity of the bovine RNA preparation. The quality of first 
strand synthesis was assessed by PCR amplification of full length DNA sequence 
encoding bovine GAPDH (expected size 1.0kb). Five μl of the PCR reaction was 
resolved in a 1.2 % w/v agarose gel and the results shown in panel B. The single 
strand DNA was then used as the template in PCR using gene specific primers to 
amplify DNA sequences encoding bovine perforin (Panel C) granzymes A (Panel D) 
and B (Panel E). Panel C, D, E shows PCR products obtained using different gene-
specific-primer pairs. Bands at the expected molecular weight (indicated by arrows) 
were purified from the gel and cloned into pGEM-T Easy for sequence verification as 
detailed in materials and methods. 
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Figure 4a: Nucleotide sequence and predicted amino acid sequence of putative 
bovine perforin 
GenBank accession number FJ176744. 
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      1 atggcagcccgtctgctcctccttggcatcctcctgcttctgccc 
        M  A  A  R  L  L  L  L  G  I  L  L  L  L  P  
     46 acacctgcccctgccccctgctacacagccgcgcgctctgagtgc 
        T  P  A  P  A  P  C  Y  T  A  A  R  S  E  C  
     91 cagcgcgccctcaagtttgtgccaggctcctggctggcaggggag 
        Q  R  A  L  K  F  V  P  G  S  W  L  A  G  E  
    136 ggcgtggatgtgaccagcctccagcgctcaggctcgttcccagtg 
        G  V  D  V  T  S  L  Q  R  S  G  S  F  P  V  
    181 gacacacagcgtttcctgcggcccgacggcacttgcaccctctgc 
        D  T  Q  R  F  L  R  P  D  G  T  C  T  L  C  
    226 cgcaatgccctgcagaaggatgtcctccagcgcctgcccctggca 
        R  N  A  L  Q  K  D  V  L  Q  R  L  P  L  A  
    271 atcaccgactggcgtgcccacggagcgggctgcaagcgcagggtg 
        I  T  D  W  R  A  H  G  A  G  C  K  R  R  V  
    316 gtcaagctagagggccgctccaccgaggatgtggctggggaggcg 
        V  K  L  E  G  R  S  T  E  D  V  A  G  E  A  
    361 gccaacgggatccgcaacgactggcaggtggggctggacgtgtct 
        A  N  G  I  R  N  D  W  Q  V  G  L  D  V  S  
    406 cccaagccaaatgctaatgtccgtgtgacagtggcgggctcccac 
        P  K  P  N  A  N  V  R  V  T  V  A  G  S  H  
    451 tccgaggatgccaacttcgccgcccagaagactcaccaggacaac 
        S  E  D  A  N  F  A  A  Q  K  T  H  Q  D  N  
    496 taccgcttcggcatggacttagtggagtgtcgcttttacagtttt 
        Y  R  F  G  M  D  L  V  E  C  R  F  Y  S  F  
    541 cacctggtgcacactcccccagtacaccctgagttcaagagggcc 
        H  L  V  H  T  P  P  V  H  P  E  F  K  R  A  
    586 ctcaagacactgcccccccacttcaacacctccaccaagcccgac 
        L  K  T  L  P  P  H  F  N  T  S  T  K  P  D  
    631 taccacaggctcatctccagctacggaacccacttcatccggtcc 
        Y  H  R  L  I  S  S  Y  G  T  H  F  I  R  S  
    676 atggagctgggcggncgcatctcggccctcaccgncctgcgnacc 
        M  E  L  G  G  R  I  S  A  L  T  X  L  R  T  
    721 tgcgagctggccctggaggggctcacagccagcgaggtcgaggac 
        C  E  L  A  L  E  G  L  T  A  S  E  V  E  D  
    766 tgcctggctgtcgaggctgaggtcagcataagcgacagggccagt 
        C  L  A  V  E  A  E  V  S  I  S  D  R  A  S  
    811 gcctcgccatcgttcaaggcatgtgaggagaagaagaagaaccac 
        A  S  P  S  F  K  A  C  E  E  K  K  K  N  H  
    856 aaggtggggacctccttccaccaggcctaccgggagcgccattcc 
        K  V  G  T  S  F  H  Q  A  Y  R  E  R  H  S  
    
    901 aatgtcgatggtggccaccactcaaccatgcatgacctgctcttc 
        N  V  D  G  G  H  H  S  T  M  H  D  L  L  F  
    946 gggagccaggctgggcccgagcagttctcagcctgggtggcctca 
        G  S  Q  A  G  P  E  Q  F  S  A  W  V  A  S  
    991 ctgcaggacagccctggcctggtggactacacgctggagcctctg 
        L  Q  D  S  P  G  L  V  D  Y  T  L  E  P  L  
   1036 cacatgcttgtggagagccaggacccgcggcgggaggccctcagg 
        H  M  L  V  E  S  Q  D  P  R  R  E  A  L  R  
   1081 caggccgtgagcaagtacgtgactgacagggcacgctggagggac 
        Q  A  V  S  K  Y  V  T  D  R  A  R  W  R  D  
   1126 tgcaaccgcccgtgccccccggggcaacacaagaacccgaagaac 
        C  N  R  P  C  P  P  G  Q  H  K  N  P  K  N  
   1171 ccatgccagtgcatgtgtcctggttcagcagccaccacccaggac 
        P  C  Q  C  M  C  P  G  S  A  A  T  T  Q  D  
   1216 tgctgtccccggcagaagggactggcccacctggaggtcatgaac 
        C  C  P  R  Q  K  G  L  A  H  L  E  V  M  N  
   1261 ttcaaggcatcaggtctgtggggagactggatcactgccacggac 
        F  K  A  S  G  L  W  G  D  W  I  T  A  T  D  
   1306 gcctatctgaaggtttttttcgccggccaggagcagaggaccgcc 
        A  Y  L  K  V  F  F  A  G  Q  E  Q  R  T  A  
   1351 acagtatggaacgataacaaccccaggtggatgacgcggctggac 
        T  V  W  N  D  N  N  P  R  W  M  T  R  L  D  
   1396 ttcggggatgtgctcctggccaccgggggccccctgagggtgcag 
        F  G  D  V  L  L  A  T  G  G  P  L  R  V  Q  
   1441 gtctgggatgcagactttggctgggacgatgaccttcttggcact 
        V  W  D  A  D  F  G  W  D  D  D  L  L  G  T  
   1486 tgtgaccgcaccccaaagtctggctcacatgaggtgtcatgcccc 
        C  D  R  T  P  K  S  G  S  H  E  V  S  C  P  
   1531 atggaccacggtctcttgaaattctcctaccaggtcaaatgcttg 
        M  D  H  G  L  L  K  F  S  Y  Q  V  K  C  L  
   1576 cctcacctgacgggggagaggtgcctgcagtatgccccccaaggg 
        P  H  L  T  G  E  R  C  L  Q  Y  A  P  Q  G  
   1621 cttctggggaatcctccaggaaaccggagtgggccagtgtggtga   
        L  L  G  N  P  P  G  N  R  S  G  P  V  W  *  
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Figure 4b: In-silico protein analysis of perforin cDNA 
Sequence alignment of perforin proteins  produced by ClustalW. GenBank Accession 
numbers of sequences are as follows NP_035203.2 (mouse perforin), NP_059026.2 
(rat perforin), translated FJ176744 (putative bovine perforin) and AAA60167.1 
(human perforin) 
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MOUSE_PERFORIN     1 MATCLFLLGLFLLLP-RPVPAPCYTATRSECKQKHKFVPGVWMAGEGMDVTTLRRSGSFPVNTQRFLRPDRTCTLCKNSLMRDATQRLPVAITHWRPHSSHCQRNVAAAKVHSTEGVARE 
RAT_PERFORIN       1 MAAYLFLLGLFLLLP-RPVPAPCYTATRSECKQNHKFVPGVWAAGEGVDVTTLRRSSSFPVNTGKFLRPDRTCTLCKNALMNDGIQRLPVAIAHWRPHGSHCQRNVATTKVSSTEGVARE 
BOVINE_PERFORIN    1 MAARLLLLGILLLLP-TPAPAPCYTAARSECQRALKFVPGSWLAGEGVDVTSLQRSGSFPVDTQRFLRPDGTCTLCRNALQKDVLQRLPLAITDWRAHGAGCKRRVVKLEGRSTEDVAGE 
HUMAN_PERFORIN     1 MAARLLLLGILLLLLPLPVPAPCHTAARSECKRSHKFVPGAWLAGEGVDVTSLRRSGSFPVDTQRFLRPDGTCTLCENALQEGTLQRLPLALTNWRAQGSGCQRHVTRAKVSSTEAVARD 
 
 
 
 
 
MOUSE_PERFORIN   120 AAANINNDWRVGLDVNPRPEANMRASVAGSHSKVANFAAEKTYQDQYNFNSDTVECRMYSFRLVQKPPLHLDFKKALRALPRNFNSSTEHAYHRLISSYGTHFITAVDLGGRISVLTALR 
RAT_PERFORIN     120 AAANINNDWRAGLDVNPKPEANVHVSVAGSHSKIANFAAEKAHQDQYNFNTDTVECRMYSFRLAQKPPLHPDFRKALKNLPHNFNSSTEHAYRRLISSYGTHFITAVDLGGRVSVLTALR 
BOVINE_PERFORIN  120 AANGIRNDWQVGLDVSPKPNANVRVTVAGSHSEDANFAAQKTHQDNYRFGMDLVECRFYSFHLVHTPPVHPEFKRALKTLPPHFNTSTKPDYHRLISSYGTHFIRSMELGGRISALTXLR 
HUMAN_PERFORIN   121 AARSIRNDWKVGLDVTPKPTSNVHVSVAGSHSQAANFAAQKTHQDQYSFSTDTVECRFYSFHVVHTPPLHPDFKRALGDLPHHFNASTQPAYLRLISNYGTHFIRAVELGGRISALTALR 
 
 
 
 
 
MOUSE_PERFORIN   240 TCQLTLNGLTADEVGDCLNVEAQVSIGAQASVSSEYKACEEKKKQHKMATSFHQTYRERHVEVLGGPLDSTHDLLFGNQATPEQFSTWTASLPSNPGLVDYSLEPLHTLLEEQNPKREAL 
RAT_PERFORIN     240 TCQLTLDGLTADEVGDCLSVEAQVSIGAQASVSSEYKACEEKKKQHKIATSFHQTYRERHVEVLGGPLDSSNDLLFGNQATPEHFSTWIASLPTRPDVVDYSLEPLHILLEDSDPKREAL 
BOVINE_PERFORIN  240 TCELALEGLTASEVEDCLAVEAEVSISDRASASPSFKACEEKKKNHKVGTSFHQAYRERHSNVDGGHHSTMHDLLFGSQAGPEQFSAWVASLQDSPGLVDYTLEPLHMLVESQDPRREAL 
HUMAN_PERFORIN   241 TCELALEGLTDNEVEDCLTVEAQVNIGIHGSISAEAKACEEKKKKHKMTASFHQTYRERHSEVVGGHHTSINDLLFGIQAGPEQYSAWVNSLPGSPGLVDYTLEPLHVLLDSQDPRREAL 
 
 
 
 
 
MOUSE_PERFORIN   360 RQAISHYIMSRARWQNCSRPCRSGQHKSSHDSCQCECQDSKVTNQDCCPRQRGLAHLVVSNFRAEHLWGDYTTATDAYLKVFFGGQEFRTGVVWNNNNPRWTDKMDFENVLLSTGGPLRV 
RAT_PERFORIN     360 RQAISHYVMSRARWRDCNRPCRAGQHKSSRDSCQCVCQDSNVTNQDCCPRQRGLAKLMVRNFQAKGLWGDYITSTDAYLKVFFGGQEIRTGVVWNNNHPSWSDKMDFGNVLLSTGGPLRV 
BOVINE_PERFORIN  360 RQAVSKYVTDRARWRDCNRPCPPGQHKNPKNPCQCMCPGSAATTQDCCPRQKGLAHLEVMNFKASGLWGDWITATDAYLKVFFAGQEQRTATVWNDNNPRWMTRLDFGDVLLATGGPLRV 
HUMAN_PERFORIN   361 RRALSQYLTDRARWRDCSRPCPPGRQKSPRDPCQCVCHGSAVTTQDCCPRQRGLAQLEVTFIQAWGLWGDWFTATDAYVKLFFGGQELRTSTVWDNNNPIWSVRLDFGDVLLATGGPLRL 
 
 
 
 
 
MOUSE_PERFORIN   480 QVWDADYGWDDDLLGSCDRSPHSGFHEVTCELNHGRVKFSYHAKCLPHLTGGTCLEYAPQGLLGDPPGNRSGAVW* 
RAT_PERFORIN     480 QVWDADNGWDDDLLGTCDKSPKSGFHEVNCPLNHGSIKFIYQANCLPDLTGETCLEYAPQGLLGDPRGNRSGAVW* 
BOVINE_PERFORIN  480 QVWDADFGWDDDLLGTCDRTPKSGSHEVSCPMDHGLLKFSYQVKCLPHLTGERCLQYAPQGLLGNPPGNRSGPVW* 
HUMAN_PERFORIN   481 QVWDQDSGRDDDLLGTCDQAPKSGSHEVRCNLNHGHLKFRYHARCLPHLGGGTCLDYVPQMLLGEPPGNRSGAVW* 
 
 
MACPF - membrane attack components/perforin  
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100072744) and human (Gene ID: 5551) perforin, respectively. 
On the other hand, BLASTN search of the TIGR bovine database identified 
TC399777, a 1002-bp Bos taurus EST with 68% nucleotide identity to human 
granzyme A (GI:6996012), 67% nucleotide identity to mouse granzyme A 
(GI:6754101) and 67% nucleotide identity to rat granzyme A (GI:23618882). 
Granzyme A primers generated a 322 bp cDNA clone (Figure 3, panel D) that 
contained a 303 bp open reading frame with 69% nucleotide identity to TC399777 
and  encoding a 100-amino acid polypeptide as shown in Figure 5a. BLASTP search 
indicated that this polypeptide was an internal coding sequence that mapped onto the 
N-terminal region generally between amino acid residues 40 to 145 of predicted 
granzyme A genes. Over this range the bovine cDNA showed 85%/93% amino 
acid/homology similarity to pig granzyme A (Gene ID: 100526762) as well as 
78%/93% aminoacid/homology similarity and 75%/84% amino acid/homology 
similarity to horse (Gene ID: 100062497) and human (Gene ID: 3001) granzyme A, 
respectively. In silico analysis further showed that the cDNA displayed conserved 
domains that resemble trypsin-like serine protease of the granzyme family with the 
putative active site containing catalytic residues at H25 and D70 of the putative 
bovine granzyme A fragment as shown in Figure 5b. Attempts to clone a full-length 
bovine cDNA encoding granzyme A were however unsuccessful. 
In regard to granzyme B, BLASTN search of  the TIGR database identified 
TC134878, a 903 bp EST with 70% nucleotide similarity to human (GI:20988817),  
70% nucleotide similarity to mouse (GI:7305122) and 68% nucleotide similarity to rat 
(GI:31542925) granzyme B. A 774-bp cDNA was cloned (Figure 3, panel E) and 
sequenced using the granzyme B primers shown in Table 3. Sequence analysis 
identified a coding sequence of 756 bp with a 95% nucleotide identity to TC134878 
with a 251-amino acid long polypeptide reported in Figure 6a. BLASTP search  of  
the protein database identified significant homology of this cDNA to to pig 
(GeneID:100233184; 61%/77% aminoacid/homology), horse (GeneID:10049805; 
59%/76% aminoacid/homology) and human (GeneID:3002; 59%/74% 
aminoacid/homology) granzymes B. The bovine cDNA also showed significant 
homology to sheep mast cell proteinase-3 (Swiss-prot O46683; 90% nucleotide 
identity, 82/87% amino acid/homology) as well as bovine duodenase 
(GeneID:281731; 88/93% amino acid/homology) proteins. Structural analysis of the  
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Figure 5a: Nucleotide sequence and predicted amino acid sequence of putative 
bovine granzyme A  
GenBank accession number FJ176746. 
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      1 atggtgctacttgatgggggaaacatctgtgccggagctttgatt 
        M  V  L  L  D  G  G  N  I  C  A  G  A  L  I  
     46 gccgaagactgggtattgactgcagctcactgttccctgaaccag 
        A  E  D  W  V  L  T  A  A  H  C  S  L  N  Q  
     91 aaatcccagatcattcttggggcccactcaagaaacaaggaagag 
        K  S  Q  I  I  L  G  A  H  S  R  N  K  E  E  
    136 cctgaaaaacagattatgtttgttaagaaagagtttccctatcca 
        P  E  K  Q  I  M  F  V  K  K  E  F  P  Y  P  
    181 tgctatgacccggacacacatgaaggcgatcttaaacttctaaag 
        C  Y  D  P  D  T  H  E  G  D  L  K  L  L  K  
    226 ctgaacaaaaaagcaacacttaataaaaacgtggctatccttcag 
        L  N  K  K  A  T  L  N  K  N  V  A  I  L  Q  
    271 ctcccaaaagagggcgatgatgtgaaaccagga 303     
        L  P  K  E  G  D  D  V  K  P  G  
 
 
 
 73
 
 
 
 
 
 
 
 
 
 
Figure 5b: In-silico protein analysis of granzyme A cDNA   
Sequence alignment of granzyme A proteins  produced by ClustalW. GenBank 
Accession numbers of sequences are as follows NP_034500.1 (mouse granzyme A), 
NP_803198.1 (rat granzyme A), translated FJ176746 (putative bovine granzyme A) 
and NP_006135.1 (human granzyme A) 
 
 74
 
 
 
 
MOUSE_GRZA         1 MRNASGPRGPSLATLLFLLLIPEGGCERIIGGDTVVPHSRPYMALLKLSSNTICAGALIEKNWVLTAAHCNVGKRSKFILGAHSINKE-PEQQILTVKKAFPYPCYDEYTREGDLQLVRL 
RAT_GRZA           1 MRNPCAPWVSSLTTVIFLLLIPEGGCERIIGGDTVVPHSRPYMVLLKLKPDSICAGALIAKNWVLTAAHCIPGKKSEVILGAHSIKKE-PEQQILSVKKAYPYPCFDKHTHEGDLQLLRL 
BOVINE_GRZA        1 ------------------------------------------MVLL--DGGNICAGALIAEDWVLTAAHCSLNQKSQIILGAHSRNKEEPEKQIMFVKKEFPYPCYDPDTHEGDLKLLKL 
HUMAN_GRZA         1 MRNSYRFLASSLSVVVSLLLIPEDVCEKIIGGNEVTPHSRPYMVLLSLDRKTICAGALIAKDWVLTAAHCNLNKRSQVILGAHSITREEPTKQIMLVKKEFPYPCYDPATREGDLKLLQL 
 
 
 
 
 
MOUSE_GRZA       120 KKKATVNRNVAILHLPKKGDDVKPGTRCRVAGWGRFGNKSAPSETLREVNITVIDRKICNDEKHYNFHPVIGLNMICAGDLRGGKDSCNGDSGSPLLCDGILRGITSFGGE-KCGDRRWP 
RAT_GRZA         120 KKKATLNKNVAILHLPKKGDDVKPGTRCHVAGWGRFHNKSPPSDTLREVNITVIDRKICNDEKHYNFNPVIGLNMICAGNLRGGKDSCYGDSGGPLLCEGIFRGITAFGLEGRCGDPKGP 
BOVINE_GRZA       77 NKKATLNKNVAILQLPKEGDDVKPG----------------------------------------------------------------------------------------------- 
HUMAN_GRZA       121 TEKAKINKYVTILHLPKKGDDVKPGTMCQVAGWGRTHNSASWSDTLREVNITIIDRKVCNDRNHYNFNPVIGMNMVCAGSLRGGRDSCNGDSGSPLLCEGVFRGVTSFGLENKCGDPRGP 
 
 
 
 
MOUSE_GRZA       239 GVYTFLSDKHLNWIKKIMKGSV* 
RAT_GRZA         240 GIYTLLSDKHLDWIRKTAKGAV* 
BOVINE_GRZA      102 ----------------------* 
HUMAN_GRZA       241 GVYILLSKKHLNWIIMTIKGAV* 
 
 
A - putative active site amino acid 
D - disulfide bridge 
GRZA - granzyme A 
Conserved regions between proteins are shaded in black 
 
A AD
D
Signal peptide
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Figure 6a: Nucleotide sequence and predicted amino acid sequence of putative 
bovine granzyme B 
   GenBank accession number FJ176745. 
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      1 atggtcctgctcctgctcctggtggcccttctgtcccctaccagg 
        M  V  L  L  L  L  L  V  A  L  L  S  P  T  R  
     46 gaggcagggaaaatcatcgggggccacgaggccaagccacactcc 
        E  A  G  K  I  I  G  G  H  E  A  K  P  H  S  
     91 cgtccctacatggcgtttcttcaggtcaagacttcagggaaatct 
        R  P  Y  M  A  F  L  Q  V  K  T  S  G  K  S  
    136 cacaactgtgggggtttcctcgtgcgtgaggacttcgtgctgaca 
        H  N  C  G  G  F  L  V  R  E  D  F  V  L  T  
    181 gcagctcactgcctgggaagctcaatcagtgtcaccctgggggcc 
        A  A  H  C  L  G  S  S  I  S  V  T  L  G  A  
    226 cacaacatcaaacaacgagagacgacccagcaggtcatcccagtg 
        H  N  I  K  Q  R  E  T  T  Q  Q  V  I  P  V  
    271 agaagacccatcccccacccagactataatgatgagactttggcc 
        R  R  P  I  P  H  P  D  Y  N  D  E  T  L  A  
    316 aacgacatcatgttactgaagctgactaggaaggctgacattacg 
        N  D  I  M  L  L  K  L  T  R  K  A  D  I  T  
    361 gataaagtgagccccatcaatctgcccaggagcttggcgaaggtg 
        D  K  V  S  P  I  N  L  P  R  S  L  A  K  V  
    406 aagacagggatgatgtgcagtgtggccggctgggggcgactgggg 
        K  T  G  M  M  C  S  V  A  G  W  G  R  L  G  
    451 gtaaatatgccctctacagacaaactacaggaggtagatcttgaa 
        V  N  M  P  S  T  D  K  L  Q  E  V  D  L  E  
    496 gtccaaaataagaagaaatgtaaggatcgcttccaagactacaat 
        V  Q  N  K  K  K  C  K  D  R  F  Q  D  Y  N  
    541 gcctccatacagatatgtgctggagatccaagcaagaggaagagt 
        A  S  I  Q  I  C  A  G  D  P  S  K  R  K  S  
    586 tctttcttgggtgactctgggggcccgcttgtgtgtaatggtgtg 
        S  F  L  G  D  S  G  G  P  L  V  C  N  G  V  
    631 gcccagggcattgtgtcctatggaagagatgatgggacacctcca 
        A  Q  G  I  V  S  Y  G  R  D  D  G  T  P  P  
    676 aatgtctacaccagaatctccagctttctgtcctggatccagaca 
        N  V  Y  T  R  I  S  S  F  L  S  W  I  Q  T  
    721 acaatgagacggtacaaacgccagagatcagtgtga 756     
        T  M  R  R  Y  K  R  Q  R  S  V  *  
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Figure 6b: In-silico protein analysis of granzyme B cDNA  
Sequence alignment of granzyme B proteins  produced by ClustalW. GenBank 
Accession numbers of sequences are as follows NP_776721.1 (bovine duodenase), 
NP_001009411.1 (sheep mast cell protease), translated FJ176745 (putative bovine 
granzyme B) and AAHH30195.1 (human granzyme B) 
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BOVINE_DUODENASE       1 M-VLLLLLVALLSPTGEAGKIIGGHEAKPHSRPYMAFLLFKTSGKSHICGGFLVREDFVLTAAHCLGSSINVTLGAHNIMERERTQQVIPVRRPIPHPDY 
SHEEP MCP-3            1 M-VLFLLLVALLSPAGEAGKIIGGHEAKPHSRPYMAFLQFKISGKSYICGGFLVREDFVLTAAHCLGSSINVTLGAHTITDQERTQQVIQVRRAIPHPDY 
BOVINE_GRZB            1 M-VLLLLLVALLSPTREAGKIIGGHEAKPHSRPYMAFLQVKTSGKSHNCGGFLVREDFVLTAAHCLGSSISVTLGAHNIKQRETTQQVIPVRRPIPHPDY 
HUMAN_GRZB             1 MQPILLLLAFLLLPRADAGEIIGGHEAKPHSRPYMAYLMIWDQKSLKRCGGFLIQDDFVLTAAHCWGSSINVTLGAHNIKEQEPTQQFIPVKRPIPHPAY 
 
 
 
BOVINE_DUODENASE     100 NDETLANDIMLLKLTRKADITDKVSPINLPRSLAEVKPGMMCSVAGWGRLGVNMPSTDNLQEVDLEVQSEEKCIARFKNYIP-FTQICAGDPSKRKNSFS 
SHEEP MCP-3          100 NDETCANDIMLLQLTRKAEMTDAVSLINLPRSLEKVKPGMMCSVAGWGQLGVNMPSADKLQEVDLEVQREEKCIARFKDYIP-VTQICAGDPSKRKDSFL 
BOVINE_GRZB          100 NDETLANDIMLLKLTRKADITDKVSPINLPRSLAKVKTGMMCSVAGWGRLGVNMPSTDKLQEVDLEVQNKKKCKDRFQDYNA-SIQICAGDPSKRKSSFL 
HUMAN_GRZB           101 NPKNFSNDIMLLQLERKAKRTRAVQPLRLPSNKAQVKPGQTCSVAGWGQTAPLGKHSHTLQEVKMTVQEDRKCESDLRHYYDSTIELCVGDPEIKKTSFK 
 
 
 
BOVINE_DUODENASE     199 GDSGGPLVCNGVAQGIVSYGRNDGTTPDVYTRISSFLSWIHSTMRRYKRQGSV 
SHEEP MCP-3          199 GDSGGPLVCDGVAQGIVSYGKDDGTTPNVYTRISSFLSWIQRTMRQYKNQGSA 
BOVINE_GRZB          199 GDSGGPLVCNGVAQGIVSYGRDDGTPPNVYTRISSFLSWIQTTMRRYKRQRSV 
HUMAN_GRZB           201 GDSGGPLVCNKVAQGIVSYGRNNGMPPRACTKVSSFVHWIKKTMKRY------ 
 
 
 
DP - activation dipeptide 
A - putative active site amino acid 
C - conserved region (granzymes) 
GRZB - granzyme B 
MCP - mast cell protease 
Conserved regions between proteins are shaded in black 
Signal peptide
DP
A
A 
A 
C
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polypeptide predicted a trypsin- like serine protease showing typical features of 
zymogen activation, catalytic active and substrate-binding sites consisting of His, Asp 
and Serine in conserved domains resembling those of the granzyme subfamily. 
Further sequence analysis as shown in Figure 6b revealed a signal (leader) peptide  
(amino acid 1-17) with a likely cleavage site at positions 17 and 18 (REA-GK), 
followed by an amino-terminal activation dipeptide Glu-Lys (aa 19,20) and three 
highly conserved residues as central elements of the active site (H63, D107, S201). 
However in contrast to other granzymes, the dipeptide appears to be Gly-Lys and not 
Gly-Glu or Glu-Glu that is typically found on rodent and human granzymes. The 
residues at positions 1-4 after the activation dipeptide (typically Ile-Ile-Gly-Gly) and 
9-16 (Pro-Ile-Thr-Ser-Arg-Pro-Tyr-Met-Ala) are similarly conserved.  
Nucleotide and predicted protein sequences of bovine perforin, granzymes A 
and B were submitted (September 2008) to the GenBank sequence database and 
awarded FJ176744, FJ176746, FJ176745 GenBank codes. Amino acid full names and 
abbreviations are shown in Appendix V. 
Recent analyses of the cloned coding sequences indicate that the perforin 
sequence shows 98% identity to the bovine sequence on NCBI accession number 
NM_001143735, (GeneID 369025) in the Bovine Genome Sequencing and Analysis 
Database (BGD) . This sequence is mapped onto chromosome 28.16 of the bovine 
genome and predicted to encode a transcript for perforin pore forming protein gene 
(BGD ID: BT19749). The granzyme A sequence obtained in this study showed 
identity to sequence 98% nucleotide identity to NM_001099095.1 encoding Bos 
taurus cytotoxic T lymphocyte serine esterase 3 or granzyme A (GeneID 539093) and 
mapped onto chromosome 20.18 of the bovine genome, a transcript for bovine 
cytotoxic T lymphocyte associated serine esterase-3 or granzyme A gene (BGD ID: 
BT14165). Unlike perforin and granzyme A, BLASTN search of BGD identified 
nucleotide similarity (E-value 0.0) to transcripts found on four genes- BT23865, 93%; 
BT18850, 93%; BT15925, 92%; BT13165, 92%, all mapped on chromosome 21.28 
except for BT13165 whose genomic location is still unknown. Three of the 
transcripts, BT23865, BT15925 and BT13165  are predicted to encode bovine 
duodenase (NCBI reference 785952, 786126, 782827 respectively), whereas the 
transcript from BT18850  was  identical to sequence in NM_174296.2, predicted to 
encode Bos taurus cytotoxic T lymphocyte associated serine esterase 1 or granzyme B  
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(GeneID 281731).  
2.2.2 Expression of bovine perforin, granzymes A and B 
Full-length cDNA inserts encoding bovine perforin and granzyme B were sub-
cloned in the appropriate reading frame and orientation in the bacterial expression 
vector pGEX-3T. As stated in the Materials and Methods, the 2.1 kb perforin PCR 
fragment was sub-cloned into the BamHI and EcoRI sites of the expression vector 
pGEX-3T to be expressed as glutathione-S-transferase (GST) fusion protein. E. coli 
JM109 was then transformed using the recombinant plasmid and induced to over-
express protein. As shown in Figure 7, panel A, Coomassie staining of SDS-PAGE 
resolved whole cell lysates did not reveal any obvious expression of perforin-GST 
fusion protein, as a band at the expected molecular weight of approximately 81 kDa 
was either too faint or lacking. Similarly, western blot analysis of parallel 
nitrocellulose membranes using anti-GST antibodies failed to show any distinct 
perforin-GST fusion protein band (data not shown). 
To express recombinant granzyme B, the bovine cDNA without its leader 
sequence (generates a 705 bp fragment) was directionally sub-cloned into pGEX-3T 
at the BamHI and SalI sites in-fusion with GST. The As with perforin, no obvious 
expression of granzyme B-GST fusion protein could be detected with Coomassie 
staining (Figure 7, panel B). However, immunoblot analysis of the bacterial cell lysate 
using anti-GST antibodies revealed low level expression of granzyme B-GST fusion 
protein at a predicted size of 52 kDa (Figure 7, panel C). The fusion protein appeared 
to undergo degradation as evidenced by the smears of GST reactive bands of various 
sizes on the western blot. Attempts to improve protein expression of perforin-GST 
and granzyme B-GST fusion proteins by optimisation of several parameters such as 
varying the concentration of IPTG (1-10 mM), the culture temperature (30°C vs. 
37°C) and incubation time after induction (2 hr up to a maximum of 16 hr or 
overnight) or the cell type (expression in E. coli JM109 or BL21 (DE3) were not 
successful. While there was a decrease in expression levels of GST protein 16 hours 
following induction as compared to 6 hours of incubation time after, data obtained 
showed no significant differences in perforin-GST expression after 6 hours or 16 
hours following addition of IPTG (Figure 7, panel A). Similarly there was no 
difference in granzyme B-GST protein expression level in JM109 or BL21 (DE3) or 
by using a different concentration of IPTG in the same cell types (data not shown).
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Figure 7: Expression of GST fusion proteins 
Whole cell lysates were electrophoresed and protein visualized by coomassie staining 
(A & B) or electro-transferred to nitrocellulose membrane and protein detected by 
anti-GST antibodies (C). Panel A shows perforin-GST fusion proteins expressed in 
JM109 cells and induced using IPTG while panel B shows expression of granzyme B-
GST in JM109 or BL21 (DE3). Panel C shows immunoblot analysis of granzyme B-
GST proteins showing various forms of the expressed protein as indicated by the 
arrows. Proteins from 7b (above) were electro-transferred onto nitrocellulose 
membrane and protein detected by anti-GST antibodies. 
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Given the difficulties encountered with attempts to express recombinant 
proteins in bacteria, efforts were made to sub-clone the respective genes in the 
baculovirus expression vector, pFastBac™ HT-B and express the proteins in insect 
cells as overlapping truncated fragments. In the case of perforin, three cDNA 
fragments were generated by PCR consisting of the sequence beginning at 61 through 
to 661 (designated fragment I), 508 to 1107 (fragment II) and 1045 through 1662 
(fragment III) of the open reading frame (shown in Appendix II). Using the cloned 
bovine perforin cDNA as template, cDNA fragments I and II, each sized 600 bp, were 
separately sub-cloned into the donor plasmid in-fusion with an N-terminal His-tag and 
with or without a C-terminal GFP and then incorporated into baculovirus via 
transposition onto a baculovirus shuttle vector as detailed in Materials and Methods. 
Cloning of cDNA fragment III was hindered by the presence of an NcoI recognition 
sequence at position 1529-1534 that generated cDNA fragments with similar ends 
when digested with NcoI restriction enzyme. Although cDNA fragment II also had 
another NcoI recognition sequence at position 674-679, it was possible to clone this 
fragment after partial digestion resulting in the larger sub-fragment (600bp) bearing 
NcoI and SalI digested ends that was separated and purified from the smaller 
fragments (171bp and 429bp) generated from NcoI digestion. In contrast, partial 
digestion of cDNA fragment III generated three fragments of approximately 600bp, 
500bp and 100bp resulting in poor resolution of the 600bp and 500bp fragments on 
agarose gel electrophoresis. Using GFP expression as a ‘shotgun’ approach to 
revealing target cDNA translation, perforin-GFP+ve and perforin-GFP-ve recombinant 
baculovirus-infected cultures were set up in parallel and the GFP+ve culture viewed 
under a U.V. microscope. As shown in Figure 8, panel A, cultures infected with 
perforin-GFP+ve recombinant baculovirus displayed green fluorescence indicating that 
the GFP gene had been successfully cloned in-frame with the perforin gene and that 
both cDNA had translated into protein. The diffuse pattern of GFP staining suggests 
that the proteins are retained in the cytoplasm. To detect individual proteins, the poly-
histidine tagged proteins in perforin-GFP-ve cultures were purified on Ni-NTA resin. 
Coomassie staining of SDS-PAGE resolved samples displayed a single polypeptide of 
approximately 30 kDa encompassing perforin fragment 1 compared to a predicted 
apparent molecular weight of 22 kDa. On the other hand perforin fragment 2 
generated multiple (3) polypeptide products with an apparent molecular size range 
occurring between 21 kDa–30 kDa as compared to a predicted molecular weight of 22  
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Figure 8: Expression and purification of recombinant proteins from insect cells 
Perforin, granzyme A and B were expressed as baculovirus derived proteins in insect 
cells as green fluorescence protein (GFP)-positive or GFPnegative proteins. Column I 
shows typical GFPpositive culture expressing GFP-fusion recombinant proteins when 
viewed under a UV microscope while column II shows Coomassie staining of SDS-
PAGE resolved protein samples purified from GFPnegative cultures. The bands of 
interest are shown by the arrows as follows  
 
A -  Lane 1: Rainbow Protein marker 
 Lane 2-6:  Perforin fragment I;  
 Lane 7-11:  Perforin fragment II 
 
B - Lane 1: Rainbow Protein Marker 
 Lane 2-5: Granzyme A in lanes 2-5 
 
C - Lane 1: Rainbow Protein Marker 
 Lane 2 Granzyme B fragment I and II 
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kDa. (Figure 8, panel A, column II).  
Employing the same strategy the 303-bp granzyme A cDNA PCR fragment 
was sub-cloned into the NcoI and SalI sites of pFastBac in-frame with the N-terminal 
His tag and the C-terminal GFP cDNA. Recombinant baculovirus particles with and 
without GFP were generated and used to infect insect cell cultures in parallel. As in 
the case of perforin, granzyme A-GFP+ve but not granzyme A-GFP-ve recombinant 
baculovirus-infected cultures displayed green fluorescence that was also diffuse in 
nature (Fig 8. panel B, column I). When Ni-NTA-purified SDS-PAGE separated 
granzyme A-GFP-ve protein samples were subjected to Coomassie staining, they 
resolved as a single band of 14 kDa compatible with the molecular weight of 12 kDa, 
respectively (Figure 8, panel B, column II) With regards to granzyme B, a similar 
cloning and expression strategy was adopted. Two overlapping granzyme B cDNA 
fragments sized 450 bp and 321 bp, respectively, were separately sub-cloned into the 
pFastBac™ donor plasmid in-fusion with the N-terminal His tag and C-terminal GFP 
cDNA. It was observed that expression of the recombinant proteins was generally low 
and cultures 72 hours post infection were marked by an increase in cell death while 
the infectivity levels did not differ significantly with the use of a higher dose of virus 
particles. However as observed with the aforementioned polypeptides, the expressed 
granzyme B-GFP fusion protein showed a diffuse fluorescence pattern in the 
cytoplasm. Ni- NTA binding and elution purified proteins at an apparent molecular 
weight approximately 18 kDa which was in line with the predicted molecular weight 
of 17 kDa for granzyme B fragment I. In contrast the predicted molecular weight of 
granzyme B fragment II was shown to be 13 kDa, significantly smaller in size than 
the obtained fragments. 
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2.3 Discussion 
Use of recombinant DNA techniques to select genes expressed preferentially 
in mouse or human CTL has cloned cDNA or RNA encoding perforin and trypsin-like 
serine proteases (Trapani et al., 1988; Liu et al., 1996). cDNA was generated from 
day-three T. parva antigen-stimulated bovine CTL when the mRNA should be 
upregulated. Nucleotide and amino acid sequence comparisons of the three bovine 
cDNAs and available gene sequence data strongly suggested that the cDNAs were the 
bovine homologues of human, mouse, rat perforin and granzymes A and B. Two of 
the cDNAs encoded full-length gene sequences with the third cDNA bearing an 
internal (partial) coding sequence.  
The sequenced cDNA of 2188 base pairs was shown to contain an open 
reading frame of 554 amino acids (Figure 4) whose sequence displayed as expected 
considerable homology with certain functional domains-MACPF, EGF, and Ca2+ 
binding domains, found in the family of pore-forming proteins (Tschopp, Masson and 
Stanley, 1986; Lichtenheld et al., 1988; Ishikawa et al., 1999). These features suggest 
that the protein inserts into the lipid bi-layer of target cell membranes in the presence 
of Ca2+ after polymerization (Blumenthal et al., 1984; Young, Cohn and Podack, 
1986). The amino acid sequence similarity within the conserved domains of the 
bovine cDNA and mouse, rat, and human sequences indicates that it is likely to be of 
the same gene family and hence the bovine homologue is likely to have the same 
functional activity as rat, mouse and human perforin.  
With regard to bovine granzymes, the finding of the typical features of 
zymogen activation, conserved disulfide bridges, catalytic active and substrate 
binding sites consisting of His, Asp and Serine in conserved S1 peptidase domains 
conferring a substrate specificity in two of the cloned bovine cDNAs (322 bp and 774 
bp) is consistent with the predicted activities of mouse and human granzymes A and B 
(Trapani, 2001). Despite the functional similarity between the putative bovine 
granzymes, the two serine proteases are about 36% identical at the amino acid level 
suggesting that they belong to different granzyme sub-families. This observation is 
consistent with what has been observed with murine granzymes (Trapani et al., 1988). 
Mouse, rat and human granzymes B are about 70% identical at the amino acid level, 
by contrast, amino acid sequence identity drops to approximately 30-40% when one 
compares granzymes from different sub-families such as granzyme A and B even 
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within the same species (Trapani, 2001).  
The Bovine Genome Sequencing and Analysis consortium (2009) recently 
released the Bovine Genome Database project (http://BovineGenome.org) (Reese et 
al., 2010; Childers et al., 2011) which was not available at the time of the study. 
Analyses of the cloned bovine sequences showed that the putative bovine perforin, 
granzymes A and B cDNA maps on regions on chromosome 28, chromosome 20 and 
chromosome 21, respectively of the bovine genome. The structural and functional 
annotation of the corresponding genes predict a perforin-pore forming protein, 
cytotoxic T lymphocyte associated serine esterase and a CTL-associated serine 
esterase, respectively. However, the cDNA sequence predicted to encode bovine 
granzyme B also maps on regions encoding transcripts for bovine duodenase. This 
then questions the identity of the cloned cDNA. While it is likely to be a serine 
protease of the granzyme sub-family, there is a need for further functional analysis to 
determine the classification of the cloned cDNA. Work on cloning bovine perforin, 
granzymes A and B for this study was initiated in 2003/2004, a time period when 
bovine genome sequences were available as EST data from few sequencing work 
groups. As such the prevailing situation presented a major challenge with sequence 
data validation relying on sequences derived from other species. 
Attempts to produce recombinant perforin, granzymes A and B in a 
prokaryotic system were not successful (Figure 7). While it is possible to argue that 
cloning of the perforin fragment with its leader sequence contributed to the lack of 
expression, deletion of the leader sequence while cloning granzyme B  had minimal 
effect on successful expression of the protein in bacterial cells. Difficulties in 
expressing these proteins in prokaryotic systems have been reported. Apostolidis et 
al., (1995) reports the formation of an inactive aggregated protein product as a GST-
granzyme B fusion product while Kummer et al., 1993 reports expression of an 
insoluble and inactive enzyme.  
The baculovirus expression system, instead of prokaryotic systems, was hence 
chosen on the basis that recombinant proteins expressed in (eukaryotic) insect cells 
may resemble more closely the natural proteins produced by mammalian cells in 
terms of post-translational modifications (Luckow and Summers, 1988). Results 
obtained showed considerable production of recombinant perforin and granzymes A 
and B in High Five cells infected with recombinant baculovirus. Sufficient amounts of 
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recombinant perforin granzymes A and B, although not secreted into the culture 
medium, were readily purified in soluble form from infected High Five cell 
homogenate. This procedure offers some advantage over conventional purification of 
natural perforin from cultured CTL, as the latter requires expensive culture 
supplements (IL-2) and in our hands did not yield a signficant amount of perforin 
(Chuma, Francis et al., personal communication). Although a detailed qualitative 
analysis is yet to be performed it is possible that differences in the biosynthesis of 
proteins between prokaryotic and eukaryotic cells may contribute to prevent protein 
expression in bacterial cells resulting in an inactive protein product if at all. For 
example Beresford et al., 1997 successfully expressed granzyme A as an inactive 
proenzyme exported to the bacterial periplasm by the replacement of the mammalian 
leader sequence with a bacterial leader sequence. Improved expression may also be 
achieved using mammalian expression vectors and  cells such as pcDNA™ and COS 
cells which could  also ensure generation of functional mammalian proteins. 
 Using the baculovirus expression system, it was possible to express truncated 
forms of perforin and granzyme B protein in addition to a granzyme A polypeptide 
(Figure 8, column II). These polypeptides were however only soluble in urea as 
attempts to re-solubilise the proteins were not successful resulting in insoluble 
precipitate. Whereas the predicted molecular weight of perforin fragments is 22 kDa 
the multiple perforin bands ranging between 21 kDa and 30 kDa seen in Figure 8 
(panel A column I and II), suggest protein products at different levels of glycosylation 
during post-translational modification process. This is further supported by in-silico 
protein structural analysis of bovine perforin cDNA that identifies putative N-linked 
(GlcNAc) glycosylation sites (Figure 4b) a characteristic feature of perforin-like 
molecules (Lowry et al., 1989; Liu et al., 1996; Li et al., 2001). 
 An interesting observation concerning the production of recombinant perforin 
by insect cells is that intracellularly expressed recombinant perforin, although not 
segregated into membrane bound organelles, did not exert any detectable, harmful 
effect on the cells. Using GFP fluorescence as an indicator (Figure 8), it was observed 
that the insect cells remained viable and healthy until the death incurred by 
baculovirus four to five days after infection. Studies have shown significant lytic 
activities in truncated recombinant perforins suggesting that the lytic function in 
perforin lies in both the N-terminal and C terminal portion of the perforin molecule 
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(Liu et al., 1996; Li et al., 2001). It is suggested that mildly acidic pH and low Ca2+ 
concentration in the intracellular environment may prevent the endogenously 
produced recombinant perforin from damaging the host insect cell (Griffiths and 
Argon 1995). The lytic function of perforin is reported to be dependent on Ca2+ and a 
neutral pH while release of perforin from the granules upon granule exocytosis, the 
binding of perforin to the phospholipids bilayers and the homopolymerisation within 
the membranes of target cells are all calcium-dependent processes at a neutral pH 
(Blumenthal et al., 1984; Podack et al., 1985; Masson et al., 1990). As similar 
observations were made with expression of granzyme A and B, the low acidic pH of 
insect cell conditioned medium may contribute to the stability of the proteins allowing 
for the expression of granule proteases and lytic molecules.  
In conclusion, bovine perforin- granzyme A/B- like molecules have been 
cloned sequenced and expressed. Although these molecules were expressed as 
fragments, it provides a basis for which the full-length, biologically active forms of 
the proteins could be cloned and expressed in heterologous systems to facilitate 
further structure and functional analysis of the perforin/granzyme pathways for 
inducing lysis/apoptosis of target cells in bovine CTL.  
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Chapter 3: Generation of Antibodies to Bovine Perforin, 
Granzymes A and B for Assay Development 
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3.0 Introduction 
A body of information on T. parva-specific CD8+ T cell responses has been 
generated by applying a number of immunological readouts. These include 
radioisotope release assays of CTL responses induced in vivo (Morrison, Godderis 
and Teale, 1987; Morrison et al., 1987; McKeever et al., 1994), short- and long-term 
limiting dilution assay (LDA) and bulk culture-generated effectors (Goddeeris, 
Morrison and Teale, 1986; Goddeeris and Morrison, 1988; Taracha et al., 1992; 
1995a and b; McKeever et al., 1994) as well as ex vivo IFN-γ ELISpot analyses of T 
cells following immunisation and challenge (Graham et al., 2006). While assessment 
of T cell responses ex vivo by direct cytotoxicity is informative, this method may not 
detect responses of effector cells present at low frequencies in peripheral blood. On 
the other hand, whereas use of efferent lymph enhanced the detection of CTL in direct 
cytotoxicity assays (McKeever et al., 1994), the method of obtaining it through 
lymphatic duct cannulation is impractical for large-scale studies. Culturing of T cells 
to expand them to detectable frequencies may present an underestimate or highly 
selected specificities not reflecting the in vivo repertoire. Ex vivo IFN-γ ELISpot 
assays are highly sensitive and provide a more representative measure of the in vivo 
situation. However, Graham and co-workers (2006) observed that IFN-γ ELISPOT 
responses are not predictive of protection against T. parva, at least in the context of 
the five candidate antigens and antigen delivery systems tested, suggesting this 
response may not serve as immune correlates.  
There is, therefore, a need for assay systems that are sensitive, rapid and 
relevant to protective immunity permitting the precise evaluation of T. parva-specific 
CD8+ T cell responses in cattle following immunisation with candidate antigens and 
parasite challenge. Chapter 3 seeks to address two of the six objectives of the study 
focusing on the generation of antibodies to bovine perforin, granzymes A and B 
(proteins expressed in Chapter 2) and to evaluate the use of these reagents in 
development and validation of ELISpot, ELISA and intracellular staining assays. 
With the exception of perforin, application of mouse and human standardized assays 
to detect bovine granzymes A/B has not been successful (Simon Graham, personal 
communication). Preliminary studies had identified δG9 (BD Pharmingen), an anti-
human perforin monoclonal antibody that cross reacts with bovine perforin shown by 
intracellular staining of CTL lines and this formed the basis for the generation of 
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additional anti-perforin antibodies for development of ELISpot and ELISA assays. 
3.1 Materials and methods 
3.1.1 Inoculation of laboratory animals with bovine recombinant proteins and 
peptides 
Four- to six-week old male or female Balb/C mice and 6-week old male or 
female rats (Sprague-dawly) and adult New Zealand white male or female rabbits 
were used in the study. All animals were obtained from the ILRI Small Animal Unit, 
and used in accordance with the guidelines of the Institutional Animal Care and Use 
Committee. The animals were kept in a laboratory biosafety level I small animal 
holding facility with regular feeding and watering.  
Bovine recombinant perforin, granzymes A and B as well as synthetic peptides 
(Pepscan Systems BV., Leystad, Netherlands) were formulated in TitreMax® Gold 
adjuvant (CytRx Corporation, Norcross, USA) according to the manufacturer’s 
instructions. The 18-residue synthetic peptides were derived from the predicted amino 
acid sequences of perforin, granzymes A and B (Appendix VI). The antigenic regions 
within the molecules were selected using the Hopp and Woods (1981) algorithm 
which searches and identifies regions displaying properties that define likelihood of 
antigenicity (Appendix VII). The properties including hydrophilicity and accessibility 
to solvent are determined by scoring each amino acid with an antigenicity index. The 
higher the antigenicity index the more likely that antibody would recognise that group 
of amino acid residues. On the basis of this score, particular amino acid residues were 
selected to serve as templates for synthesis of peptides as shown in Table 4. The 
peptides were synthesised, covalently conjugated to keyhole limpet haemocyanin 
(KLH) carrier protein and shipped as lyophilised pellets. These were reconstituted to 
10 mg/ml in sterile PBS and stored at -20°C.  
Unless otherwise specified, relevant antigens in quantities indicated in Table 5 
were emulsified in an equal volume of adjuvant. Water-in-oil emulsions of antigen in 
TiterMax® Gold adjuvant were prepared using the double hub needle method as 
follows: 0.5 volumes of aqueous antigen was added to 1 volume adjuvant oil phase, 
emulsified to a water-in-oil admixture, to which was added the remaining 0.5 volumes 
of aqueous antigen and further mixed to achieve a homogenous emulsion. Stability of 
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Table 4: List of KLH-conjugated peptides 
Protein Amino acid residue Sequence 
Perforin 262-279 EVSISDRASASPSFKACE 
Perforin 446-463 EQRTATVWNDNNPRWMTR 
Granzyme A 38-54 GAHSRNKEEPEKQIMFVK 
Granzyme A 61-78 CYDPDTHEGDLKLLKLNK 
Granzyme B 103-121 LANDIMLLKLTRKADITD 
Granzyme B 149-166 LGVNMPSTDKLQEVDLEV 
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 the water-in-oil emulsions was assessed by placing a drop of the emulsion onto the 
surface of water. The emulsion was ready for use when seen to hold together on the 
surface of water. Various routes of administration of the adjuvant-formulated antigens 
were used according to the manufacturer’s instructions. For mice a total volume of 
200 μl of the formulated antigen was administered subcutaneously in two sites (100 μl 
each) at the base of the tail and in the hind quadriceps. Rats were inoculated 
intramuscularly in the hind quadriceps with a total of 200 μl of formulated antigen. 
Rabbits received a total of 1.0 ml formulated antigen distributed in 6 injection sites as 
follows: four sites (both shoulders and both hind quadriceps) 200 μl each 
subcutaneously and two sites (both hind quadriceps) 100 μl each intramusculary. To 
evaluate the response to immunisation, blood samples were collected from the 
animals in weekly intervals beginning 7 days post-immunisation and serum IgG 
determined using indirect ELISA or immunoblot analysis. Blood for serum IgG 
detection studies was collected by tail vein bleeding for both rats and mice and by ear 
vein bleeding for rabbits. When serum IgG levels declined, usually three to four 
weeks post-inoculation, the animals were boosted in a similar manner. Immunisation 
regimes for the various animals is summarised in Table 5. 
3.1.2 Production of polyclonal antibodies 
Fourteen days after the last booster inoculation, non-heparinised blood was 
collected from the animals to prepare antisera. Rats were sacrificed by CO2 
asphyxiation and blood collected by a cardiac puncture while blood from the rabbits 
was collected by bleeding from the ear vein in accordance with the ILRI IACUC 
standard operating procedures. The blood was incubated at 37°C for 1 hr and 4°C 
overnight for coagulation and separation of serum to take place, respectively. The 
serum samples were transferred into fresh tubes and stored at -20°C for subsequent 
testing.  
Immunoglobulins were purified from the serum samples using a DEAE-52 
cellulose column. Briefly, DEAE-52 (Whatmann International, UK) was equilibrated 
by washing several times in 0.0175 M Phosphate buffer until pH 6.4 was achieved. 
The slurry was used to pack a 10-ml polypropylene column (Pierce Chemical Co., 
Rockford, USA) in order to prepare an 8-ml gel-bed of DEAE-52 per 1 ml of serum 
(in accordance with the Antibody Purification Handbook, Amersham Biosciences).  
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Table 5: Details of immunisation of animals with adjuvant-formulated recombinant proteins and KLH-conjugated peptides 
Antigen Animal species 
(no. of animals/antigen) 
Dosage levels  Week of  booster immunisation 
Recombinant proteins  Primary 
immunisation 
Secondary immunisation 
(no. of inoculations) 
 
   
Recombinant perforin    Mice (2)  50 μg 25 μg (2) 3 6  
       Rats (3) 100 μg 50 μg (2) 3 6  
Recombinant granzyme A     Mice (2)  50 μg 25 μg (2) 3 6  
       Rats (3) 100 μg 50 μg (2) 3 6  
Recombinant granzyme B     Mice (2)  50 μg 25 μg (2) 3 6  
       Rats (3) 100 μg 50 μg (2) 3 6  
KLH conjugated peptides       
Perforin 262-279    Mice (2) 500 μg 250 μg (2) 4 9   
  *Rabbits (2) 500 μg 250 μg (3) 4 9 14 
Perforin446-463     Mice (2) 500 μg 250 μg (2) 4 9   
  *Rabbits (2) 500 μg 250 μg (3) 4 9 14 
Granzyme A38-54     Mice (2) 500 μg 250 μg (2) 4 9   
  ¥Rabbits (2) 500 μg 250 μg (3) 4 9 14 
Granzyme A61-78     Mice (2) 500 μg 250 μg (2) 4 9   
  ¥Rabbits (2) 500 μg 250 μg (3) 4 9 14 
Granzyme B103-121     Mice (2) 500 μg 250 μg (2) 4 9   
  §Rabbits (2) 500 μg 250 μg (3) 4 9 14 
Granzyme B 149-166    Mice (2) 500 μg 250 μg (2) 4 9   
  §Rabbits (2) 500 μg 250 μg (3) 4 9 14 
∗, §, ¥ A total of 6 rabbits were used. Each rabbit within the group was inoculated with both peptides. Antigens were reconstituted at 10mg/ml. 
Total volume of  formulated antigen administered was  200μl for mice and rats and 1.0 ml for rabbits.
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Serum was dialysed (Spectra/Por 4 MWCO 12-14kDa) overnight  in 0.0175M 
Phosphate buffer, pH 6.4 ( 1-2 changes of buffer, volume of dialysis buffer at least 
500-fold greater than than volume of sample) and centrifuged (Heraeus Megafuge 
Model No. 2.0R) at 450xg for 10 min to remove precipitated proteins. One ml of 
clarified serum was applied onto an 8-ml bed volume of DEAE-52 and 1 ml fractions 
of the flow through collected after the column void volume had flowed through the 
column. The absorbance of each fraction was determined at 280 nm. By adding 
phosphate buffer to the column, fractions were collected until the sample approached 
baseline absorbance. Samples showing peak absorbance were pooled and antibody 
concentrated using 10-kDa MWCO Centricon® tubes (Millipore, MA, USA). The 
antibodies were stored in 100 μl aliquots at -20˚C for subsequent evaluation and use. 
3.1.3 Production of monoclonal antibodies 
3.1.3.1 Fusion of myeloma cells with immune splenocytes 
A master seed stock of mouse myeloma cells (X63-Ag) was recovered from 
liquid nitrogen storage by rapid thawing at 37°C before being transferred into a 10-ml 
polypropylene tube containing 5 ml cold complete culture medium comprising RPMI-
1640 with 20 mM HEPES buffer supplemented with 10% (v/v) of gamma-irradiated, 
heat-inactivated FCS 50 μg/ml gentamicin 2mM L-glutamine 5x10-5 M 2-
mercaptoethanol 240 IU/ml penicillin and 100 μg/ml streptomycin. Cells were 
recovered by centrifugation at 180 x g for 10 min at 4°C, the pellet resuspended in 5 
ml culture medium and transferred into a 25-cm2 tissue culture flask which was then 
incubated at 37°C in a humidified 5% CO2 incubator. Cultures were maintained in 
logarithmic phase by sub-culturing every 2-3 days; two-thirds of the cell suspension 
were removed and replaced with an equal volume of fresh culture medium. 
Three days prior to fusion and at least five weeks after the last immunisation, 
mice were subjected to an intraperitoneal inoculation with 25 μg of antigen in PBS. 
Fusion of splenocytes with the mouse X63-Ag myeloma cells was performed 
according to the described procedures (Pearson et al., 1990). Briefly, mice were 
euthanized by CO2 asphyxiation and the spleen surgically removed into a stainless 
steel strainer in a sterile petri dish containing 10 ml complete culture medium where it 
was sliced into small pieces using sterile scissors and forceps. In circular movements, 
the spleen was pressed against the screen of the stainless steel strainer with the plastic 
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syringe plunger of a 3-cc syringe until only the fibrous tissue remained on top of the 
strainer screen. The suspension of spleen cells was then transferred into a sterile 10-
ml polystyrene conical tube and allowed to stand for 3 min at room temperature for 
the large particles to settle. The top 95% of the cell suspension was transferred into a 
50-ml polypropylene tube (Falcon®), centrifuged (Heraeus Megafuge, Model No. 
2.0R) at 1500 rpm for 15 minutes at room temperature and the cell pellet resuspended 
in 10 ml of complete culture medium.  
A cell suspension containing 2x107 viable (determined by trypan blue 
exclusion) myeloma cells in logarithmic phase of growth was harvested and mixed 
with 2x108 splenocytes in a 50-ml polypropylene tube (Falcon®). The cell suspension 
was then centrifuged (Heraeus Megafuge, Model No. 2.0R) at 1500 rpm for 15 
minutes at room temperature, the cell pellet washed once with 10 ml serum-free 
RPMI-1640, recovered by centrifugation as before and drained thoroughly of culture 
medium. Cell fusion was induced by slowly adding 500 μl of 41.6% polyethylene 
glycol/15% dimethylsulfoxide (DMSO) in serum-free RPMI-1640 medium while 
gently swirling the tube for 1 min followed by addition of 500 μl 25% PEG in serum-
free RPMI-1640 medium swirling gently as before for 2 min, and finally 4 ml of 
fusion medium (same as complete culture medium except that it contains 20% FCS) 
with similar agitation. An additional 20 ml of fusion medium was then added, mixed 
gently and the cell suspension dispensed in 1-ml per well aliquots into 24-well tissue 
culture plates which were incubated overnight at 37°C in a humidified 5% CO2 
incubator. After incubation 1-ml aliquots of HAT selective medium (fusion medium 
supplemented with 100 μM hypoxanthine, 100 μM aminopterin and 10 μM 
thymidine) were added into each well and the plate incubated as before. HAT medium 
was renewed every second day for 7 days while screening the well for growth of 
hybrids. This was done by carefully removing 1 ml of the culture medium and 
replacing it with an equal volume of HAT medium. After 7 days or once growth was 
observed, HT medium (fusion medium supplemented with 100 μM hypoxanthine, 10 
μM thymidine) was used. When cell growth covered 10% to 50% of the well surface 
area, the hybridoma cell supernatants were screened for antibody by intracellular 
staining CTLs and those found positive were cloned by limiting dilution. 
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3.1.3.2 Cloning of hybridoma cell lines 
The day prior to cloning, freshly harvested mouse thymocytes resuspended in 
complete culture medium comprising RPMI-1640 with HEPES and supplemented 
with 15% FBS and the same antibiotics as used above, were plated out in 100-μl 
aliquots into a 96-well flat bottom tissue culture plate and incubated overnight at 37°C 
in a humidified 5% CO2 incubator. Cells from each well whose supernatant yielded 
antigen-specific antibody activity were harvested, resuspended at 500 viable cells/ml 
in culture medium, dispensed in 100 μl aliquots into the 96-well tissue culture plate 
containing thymocytes and incubated as before. Wells were screened for growth after 
7 days and those containing single colonies were marked for screening the supernatant 
for specific antibody once cell growth was 10% to 50% confluent. Those found 
positive were expanded first into a separate well of a 24-well tissue culture plate that 
had been pre-incubated with 500 μl of thymocytes in complete culture medium then 
gradually scaled up to maintenance in a 25-cm2 tissue culture flask while reducing the 
15% FBS in the medium to 10%. Once established as stable cell lines, hybridomas 
were maintained and propagated in complete culture medium in a similar manner as 
described for the myeloma cell line. Cells were prepared for liquid nitrogen storage 
while the culture supernatant was harvested for determination of antibody activity, 
isotype and purification. 
3.1.3.3 Monoclonal antibody isotype determination 
Monoclonal antibody in supernatants of hybridoma cultures were assessed for 
class and sub-class type using the ImmunoPure Monoclonal Antibody Isotyping Kit 
(Pierce Chemical Co., Rockford, US). Nunc polysorp 96-well microtitre plates (Nunc, 
Denmark) were coated overnight at 4˚C with 50 μl of goat anti-mouse Ig (G, A and 
M) at a dilution of 1:50 in 0.1 M sodium bicarbonate buffer, pH 9.5. A total of ten 
microtiter wells were used to screen and determine the class/sub-class of one mAb; 
eight served as test and the remaining two being positive and negative controls 
respectively. The plates were washed once by adding and flicking off 200 μl of PBS 
containing 0.05% Tween-20 and blocking with 125 μl of PBS / 0.5% BSA at 37°C for 
1 hr. After discarding the blocking solution, 50 μl of test culture supernatants were 
added to each of nine separate wells (well #1 - #9) of the plate and 50 μl of the 
positive control (mouse IgG1) added to well #10. The plates were kept at 37°C for 1 
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hr. After the culture supernatants were discarded, plates were washed 4 times with 
PBS / 0.05% Tween-20 by adding and flicking off buffer. Aliquots of 50 μl of normal 
rabbit serum and sub-class- specific anti-mouse Ig were added to well #1 (negative 
control) and wells #2 - #9 (test) respectively, while 50 μl of anti-mouse IgG1 was 
added to well #10 (positive control). The sub-class-specific anti-mouse Ig used were 
rabbit anti-mouse IgG1, IgG2a, IgG2b, IgG3, IgA, IgM, Kappa light and Lambda light 
chain. The plates were incubated at 37°C for 1 hr and washed as before. Excess wash 
medium was removed by gently tapping plates on paper towels. An aliquot of 50 μl of 
goat anti-rabbit HRP conjugated-IgG was added and the plated incubated for 1 hr at 
37°C. The plates were further washed as before and developed by adding 100 μl per 
well of ABTS substrate solution and the plates scored by visual inspection. 
3.1.3.4 Monoclonal antibody purification 
Monoclonal antibody were subsequently purified from culture supernatants by 
affinity chromatography essentially as described in the Antibody Purification 
Handbook, Amersham Biosciences (2003). Briefly, 50-ml aliquots of hybridoma 
culture supernatants were centrifuged at 180xg for 15 min to remove cell debri. 
Immunoglobulins in the clarified supernatants were concentrated by ammonium 
sulphate precipitation. Prior to this, 1 part of 1M Tris-HCl, pH 8.0 was added to 10 
parts of the clarified hybridoma supernatant to maintain pH at 8.0. Saturated 
ammonium sulphate solution (100 g ammonium sulphate in 100 ml distilled water) 
was added dropwise up to 50% saturation while stirring gently. The solution was 
incubated at room temperature for 1 hr with continuous stirring and the precipitated Ig 
recovered by centrifuging at 180xg for 20 min at room temperature. The pellet was re-
solubilised in 1 ml PBS, a 1.5-ml aliquot of resolubilised Ig applied on to an 8-ml bed 
volume of Sephadex G-25 column (Amersham Biosciences) and eluted with 1-ml 
fractions of 200 mM sodium phosphate buffer, pH 7.0 for IgG while IgM were eluted 
with 20 mM sodium phosphate and 0.8 M ammonium sulphate solution, pH 7.5. 
A 1-ml HiTrap protein G HP column (Amersham Biosciences) was used for 
the purification of IgG. One-ml aliquots of de-salted antibody preparation were 
applied to the column previously equilibrated with 5 volumes of binding buffer (200 
mM sodium phosphate buffer, pH 7.0). The column was washed with 10-column 
volumes of binding buffer or until no protein was detected in the eluate (determined 
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by UV absorbance at 280 nm). Column-bound antibodies were eluted with 5 column 
volumes of elution buffer (0.01 M glycine-HCl, pH 2.7) directly into a 
microcentrifuge tube containing 100 μl of neutralization buffer (1 M Tris-HCl, pH 
9.0). Protein in eluted fractions was determined by UV absorbance at 280 nm. 
Positive fractions were pooled and stored at -20˚C in 100-μl aliquots. 
Purification of IgM was done essentially as described for IgG but used 1-ml 
HiTrap IgM purification columns (Amersham, Biosciences). Columns were washed 
with 20 mM sodium phosphate, pH 7.5 containing 30% isopropanol and bound 
antibodies eluted with 20 mM sodium phosphate, pH 7.5 with no addition of 
neutralization buffer. 
3.1.4. Evaluation of antibody activity 
3.1.4.1 Testing using Indirect Enzyme Linked Immunosorbent (ELISA) Assay  
Hybridoma and serum samples were evaluated for antigen-specific antibody 
activity using the ELISA technique essentially as described by Sambrook and Russell 
(2001). Nunc® polysorp 96-well microtitre plates (Nunc, Denmark) were coated 
overnight at 4°C with 50 μl or 100 μl of synthetic peptide, KLH, recombinant 
perforin, granzymes A or B (10 μg/ml) or CTL lysate (prepared by rapid freeze-
thawing of bovine CTL re-suspended in serum-free tissue culture medium) in coating 
buffer (bicarbonate buffer, pH 9.6). The plates were washed by washing with 200 μl 
of PBS containing 0.05% Tween-20 (Washing buffer) prior to blocking with 200 μl 
PBS containing 1% casein and 0.05% Tween-20 (Blocking buffer) for 1 hr at room 
temperature. The blocking buffer was discarded, and 50 μl of hybridoma supernatant, 
mouse, rat or rabbit serum added at a 1:100 dilution in PBS containing 0.1% casein 
and 0.05% Tween-20 (antibody dilution buffer) prior to incubation for 2 hr at room 
temperature. After washing four times in washing buffer, 50–100 μl of the anti-mouse 
IgG or IgM-HRP conjugate (Amersham, UK), anti-rat IgG, or anti-rabbit IgG-HRP 
antibody conjugate (Serotec Antibodies Inc., Germany) diluted 1:10000 in antibody 
dilution buffer was added and incubated for 1 hr at room temperature. The plates were 
washed six times and developed by adding 100 μl of tetramethylbenzidine (TMB) 
peroxidase substrate solution (Sigma, UK) to the reaction mix. The intensity of the 
blue product was measured by a spectrophotometer at 405 nm. Alternatively, the 
enzyme-substrate reaction was stopped by the addition of an equal volume of 1N 
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HCL resulting in a yellow product whose intensity was measured at 450 nm.  
3.1.4.2 Immunoblot analysis of antibodies against perforin, granzymes A and B  
This assay was performed essentially as described for western blotting of 
SDS-PAGE resolved His-tagged proteins in section 2.2.6 but with slight 
modifications. After separation of the purified recombinant proteins using a 12.5% 
polyacrylamide gel and transfer onto nitrocellulose filters, blocking of non-specific 
binding sites was performed for 1 hr in 5% non-fat milk in PBS and the membranes 
incubated in 1:100 dilution of polyclonal sera followed by anti-mouse IgG HRP 
conjugate (Amersham) diluted 1:5000 in antibody dilution buffer or anti-rat IgG HRP 
conjugate (SEROTEC Antibodies) diluted 1:10000 in antibody dilution buffer. The 
blots were washed and bound antibody detected using diaminobenzidine (DAB) 
solution containing 0.1% hydrogen peroxide. 
3.1.4.3 Intracellular staining of cytotoxic T cell lines  
 Hybridoma and serum samples were evaluated for antibody activity using the 
procedure described in section 4.1.4.8.2 but with slight modifications. Briefly, 4x105 
cells/well were washed with 200 μl of cold PBS and then fixed by resuspending in 
200 μl 1% paraformaldehyde in PBS for 10 min at room temperature. After washing 
once with PBS, the cells were permeabilised by incubating in 200 μl of a solution 
containing 0.1% (w/v) saponin, 0.1% sodium azide, 10 mM HEPES (PBS-Sap), 
supplemented with 20% heat-inactivated normal goat serum (for Fc receptor 
blocking) for 30 min at room temperature. The cell pellet was recovered by 
centrifuging at 450xg for 5 min resuspended in residual fluid and incubated in 100 μl 
hybridoma supernatant or 100 μl of rabbit or rat serum diluted 1:50 in PBS-Sap for 30 
min at 4°C. Cells were were recovered and washed twice by resuspension in 100 μl 
PBS-Sap by centrifugation as before. After the final wash, the supernatant was 
discarded, the pellet resuspended in residual fluid and incubated in 50 μl PE-
conjugated anti-mouse (whole molecule), rat (anti IgG) or rabbit (IgG) 
immunoglobulins diluted 1:500 in PBS-Sap for for a further 30 min at 4°C. The cells 
were then washed twice with PBS-Sap as before and once with PBS before 
resuspension in 200 μl of FACS fixative (1% paraformaldehyde in PBS). For 
analysis, one colour flow cytometry acquisition was performed on a FACScan ™ flow 
cytometer using Cell Quest software. Viable cells were gated on FSC versus SSC and 
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10,000 – 20,000 events collected within this gate. FACS data was analysed using Cell 
Quest Software or Flow Jo (TreeStar, San Carlos) Software and displayed as dot plots 
of FSC and log fluorescence intensity on FL2. 
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3.2 Results 
3.2.1 Antibodies reactive to perforin and granzymes A and B 
Polyclonal antibody (pAb) was generated by immunisation of rats and mice 
with recombinant protein or KLH-conjugated peptides as indicated in Materials and 
Methods. A list of reagents that were generated from these immunisations is shown in 
Table 6. With the exception of anti-granzyme B, pAb generated by immunisation of 
rats and mice with recombinant proteins recognised the corresponding protein 
fragments expressed by baculovirus in western blot. Data shown in Figure 9a also 
indicates that rat pAb showed reactivity to the four bands of perforin fragments at the 
expected molecular weight ranging from 21 kDa to 30 kDa whereas mouse anti-
perforin recognised only 2 forms of the perforin bands. However the 3rd booster 
immunisation particularly in the rats resulted in boosting of responses to other 
immunogneic insect-cell derived antigens in the protein preparation as shown by the 
smears on the western blot. 
As aforementioned, various peptides predicted by computer analysis to be the 
most hydrophilic and potentially antigenic regions of perforin, granzyme A and B, 
were also injected into mice and rabbits for anti-peptide antibody production. Sera 
was collected during the immunisation protocol and assayed for peptide-specific 
antibody in ELISA. Figure 9b shows the level of antibody generated to individual 
peptides with the rabbit group immunised with a particular peptide combination. All 
peptides induced a reasonable peptide specific antibody response. However sera from 
Rabbit 10 and 12 produced notably a lower level of reactivity to GrzA38-54/GrzA61-78, 
and GrzB103-121/Grz B149-166, respectively. On the other hand all peptides induced a 
significantly lower level of specific antibody response in mice as shown in Figure 9c. 
This immunisation appeared to be unresponsive to subsequent booster inoculations 
with antigen contrary to observations in rabbits. Notably, anti-GrzA38-54/GrzA61-78 
response was slightly elevated compared to the response induced by the other 
peptides.  
As shown in Figure 9d and 9e, sera from rats and rabbits contained a 
significant level of antibody that reacted with the corresponding recombinant protein 
in ELISA. Based on the cut-off value for the lower detection limit it is apparent that  
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Table 6: Characterisation of antibodies against bovine perforin, granzymes A and B 
 
Name Type Species Immunogen Purification Reactivitya 
Antibovine perforin polyclonal rat recombinant perforin serum WB, ELISA 
Antibovine granzyme A polyclonal rat recombinant granzyme A serum WB, ELISA 
Antibovine granzyme B polyclonal rat recombinant granzyme B serum ELISA, FACS
Antibovine perforin polyclonal mouse recombinant perforin serum WB, ELISA 
Antibovine granzyme A polyclonal mouse recombinant granzyme B serum WB, ELISA 
Antibovine granzyme B polyclonal mouse recombinant granzyme B serum ELISA 
Antibovine perforin polyclonal rabbit perforin peptides serum ELISA, FACS
Antibovine granzyme A polyclonal rabbit granzyme aApeptides serum ELISA, FACS
Antibovine granzyme B polyclonal rabbit granzyme B peptides serum ELISA, FACS
b14.F2 IgM mouse perforin peptide hybridoma tissue culture supernatant FACS 
b 36.D3 IgG3 mouse perforin peptide hybridoma tissue culture supernatant FACS 
b 17.H1* IgG1 mouse perforin peptide hybridoma tissue culture supernatant ELISA 
b 18.H3 IgG1 mouse perforin peptide hybridoma tissue culture supernatant ELISA 
44.17 IgM mouse perforin peptide hybridoma tissue culture supernatant FACS 
GA46 IgM mouse granzyme B peptide hybridoma tissue culture supernatant FACS 
c GBA5 IgM mouse granzyme B peptide hybridoma tissue culture supernatant FACS 
c GB29 IgM mouse granzyme B peptide hybridoma tissue culture supernatant FACS 
c GB36 IgG1 mouse granzyme B peptide hybridoma tissue culture supernatant ELISA, FACS
c GB37 IgM mouse granzyme B peptide hybridoma tissue culture supernatant FACS 
 
WB – western blot analysis 
ELISA – enzyme linked immunosorbent assay 
FACS – fluorescent-activated cell sorting (flow cytometry) 
arecombinant proteins used as antigen in ELISA and immunoblotting 
b, c – generated from the same peptide immunogen 
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Figure 9a: Western blot analysis of mouse and rat polyclonal sera 
Mouse polyclonal anti-sera (B) and rat polyclonal antisera (C) were used to detect 
recombinant perforin (21-30 kDa), granzyme A (approximately14 kDa) and granzyme 
B (approximately 17 kDa) antigen transferred onto nitrocellulose membranes as 
indicated by the arrows.  The three strips in panel B and C correspond to the test bleed 
samples collected 7 days following primary immunisation (I), 1st booster 
immunisation (B1; Day 21), and 2nd booster immunisation (B2; Day 42) with 
recombinant antigen.  Panel A shows the coomassie stained gel while panels B and C 
show the corresponding nitrocellulose filters. Blood was collected on day 8 after the 
secondary booster for purification of polyclonal antibody. Reactivity to protein at 
expected sizes is shown by the arrows. 
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Figure 9b: Detecting anti-peptide antibodies in rabbit sera by ELISA 
Un-conjugated peptide was used as the coating antigen and sera used at 1:25 dilution.  
Booster injections were administered on day 28 and 63 and day 98 (indicated by 
arrows). Blood was harvested 14 days (day 112) after the last booster immunisation 
for the purification of polyclonal antibody. 
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Figure 9c: Detecting anti-peptide antibodies in mouse sera by ELISA  
Unconjugated peptide was used as the coating antigen and sera used at 1:25 dilution. 
Booster injections were administered on day 28 and 63 as indicated by the arrows. 
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Figure 9d: Reactivity of rat polyclonal antibodies to recombinant protein 
Perforin, granzyme A and granzyme B recombinant proteins were coated at a 
concentration of 1ug/well and the antibody used titrated in doubling dilution 
beginning at 1:100. The dashed line represents the cut-off for the lower detection limit 
as determined by antibodies binding to irrelevant antigen (mean OD value+2.6SD) as 
indicated below. The values shown are corrected for background staining using 
normal rabbit serum. 
Reactivity of rat anti-perforin 
polyclonal antibodies to perforin II
0.0
0.5
1.0
1.5
2.0
2.5
100 200 400 800 1600 3200 6400 12800
Reactivity of rat anti-perforin 
polyclonal antibodies to perforin I
0.0
0.5
1.0
1.5
2.0
2.5
100 200 400 800 1600 3200 6400 12800
O
.D
. 4
50
 n
m
Reactivity of rat anti-granzyme B 
polyclonal antibodies to granzyme B I
0.0
0.5
1.0
1.5
2.0
2.5
100 200 400 800 1600 3200 6400 12800
O
.D
. 4
50
 n
m
Reactivity of rat anti-granzyme B 
polyclonal antibodies to granzyme B II
0.0
0.5
1.0
1.5
2.0
2.5
100 400 1600 6400
Antibody dilution
Reactivity of rat anti-granzyme A
polyclonal antibodies to granzyme A
0.0
0.5
1.0
1.5
2.0
2.5
100 200 400 800 1600 3200 6400 12800
Antibody dilution
O
.D
. 4
50
 n
m
113
Key
immune rat serum
immune rat serum
immune rat serum
reactivity of immune rat serum to GFP (irrelevant) prote
normal rat serum
cut-off value
 114
 
 
 
 
 
 
 
 
 
 
 
Figure 9e: Reactivity of rabbit polyclonal antibodies to recombinant protein 
Perforin, granzyme A, granzyme B or GFP recombinant protein was coated at a 
concentration of 1 ug/well and rabbit antibodies titrated in doubling dilution 
beginning at 1:25. The dashed line represents the cut-off for the lower detection limit 
as determined by antibody binding to irrelevant antigen (GFP) (mean OD 
value+2.6SD). The values shown are corrected for background staining using normal 
rabbit serum. 
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the level of perforin II reacting antibody in the rat serum samples (1:11000) was 
significantly higher than the level of anti-perforin I specific antibodies (1:6000). 
Similarly the level of rat anti granzyme B I antibodies (1:6000) appeared to be slightly 
higher than granzyme B-II specific antibody (1:4000). Levels of granzyme A specific 
antibody (1:5000) were comparable to levels of perforin I at 1:6000 and granzyme B-I 
specific antibody at 1:4000. In contrast rabbit sera showed significantly lower 
reactivity levels with lower detection limits ranging from 1:50 to 1:200 (except for 
anti-granzyme A antibodies) compared to the rat pAb.  
FACS analysis was done on CTLs to characterise the ability of the pAbs to 
bind native protein. Data shown in Figure 9f indicates that peptide specific rabbit 
antibodies showed marginal staining levels ranging from 4% - 20% positive staining 
CTLs. On the other hand rat anti-perforin pAbs did not bind to intracellular perforin 
and granzyme A whereas staining with rat anti-granzyme B resulted in a slight shift in 
fluorescence intensity of the cells with only 9% of CTLs staining positive above 
background levels.  
Attempts to generate hybridomas using splenocytes obtained from mice 
immunised with recombinant protein were unsuccessful. However screening of 
hybridoma clones and characterisation of anti-peptide monoclonal antibody (mAb) 
was conducted by ELISA and intracellular staining of CTL as described in Materials 
and Methods. Hybridomas that gave positive signals in the primary screening were 
cloned and further screened for reactivity to the recombinant protein by ELISA as 
well as to the native protein by ICS. This data is tabulated in Table 7. Generation of 
mAbs specific to peptides GrzA61-78 and GrzB149-166 were not successful. Out of 182 
hybridoma clones generated, 10 were selected for further evaluation based on their 
peptide specificity, characteristic, staining of CTL (moderate (approximately 60%) or 
>90%), performance in ELISA and the original well that they were cloned from. 
Isotyping results (Figure 10a) showed 6/10 of the mAbs to be of IgM class while 3 
were IgG1 and 1 was of IgG3 sub-type. 
Monoclonal antibodies were tested for reactivity to the corresponding 
recombinant proteins by ELISA and to native protein by staining CTL. Commercially  
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Figure 9f: Reactivity of rabbit and rat polyclonal antibodies to native proteins 
CTLs were stained for the expression of perforin  and granzymes A/B using 
polyclonal antibodies raised in rabbits following immunisation with KLH-conjugated 
peptides (A) and antibodies raised in rats following immunisation with recombinant 
proteins (B). 
Rabbit  3 Rabbit  16 Rabbit  9
Rabbit  10 Rabbit  7 Rabbit  12
Medium control
Medium control
A
B
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Table 7: Screening of hybridomas by intracellular staining of cytotoxic CD8+ T 
cell lines and by indirect ELISA using recombinant protein 
Antigen Peptide Number of positive wells 
(primary screening) 
Number of positive wells 
(secondary screening) 
 
Screening by intracellular staining of CTL 
perforin Perforin262-279 15/48 24/189 
perforin Perforin446-463 8/48 61/171 
granzyme A GranzymeA38-54 10/48 30/247 
granzyme B GranzymeB103-121 6/48 57/288 
    
Screening by indirect ELISA 
perforin Perforin262-279 2/48 9/32 
perforin Perforin446-463 0/48 n/a 
granzyme A GranzymeA38-54 0/48 n/a 
granzyme B GranzymeB103-121 1/48 1/40 
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Figure 10a: Isotyping of monoclonal antibody 
Screening and determination of the class/sub-class of mouse monoclonal antibody 
was done using an ELISA-based antigen-independent technique. Wells of the 
microtiter plates were coated with anti-mouse antibody to immobilise the antibody in 
supernatant samples applied to the antibody well. Captured mouse immunoglobulin 
class, sub-class and light chain was then identified by addition of rabbit anti-mouse 
heavy chain (anti-IgG1, IgG2a, IgG2b, IgG3, IgA and IgM) or anti mouse light chain 
(anti-kappa and lambda) antibodies followed by HRP-conjugated goat anti-rabbit IgG. 
Results were visualised by the addition of TMB substrate and read quantitatively with 
a spectrophotometer at 405nm. 
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available mouse anti-human perforin (δG9; IgG2b; BD Pharmingen), granzyme A 
(GA6; IgG1; Serotec Antibodies, Germany) and granzyme B (2C5/F5; IgG2a; BD 
Pharmingen) mAbs were used in parallel with purified mAbs in various assays. 
Results obtained (Figure 10b) showed that only mAb Perf18.H3, GrzB36.12 and anti-
human perforin (δG9) showed reactivity to the specific recombinant proteins. In 
contrast, GA6 (anti-human granzyme A) and 2C5/F5 (anti-human granzyme B) did 
not cross-react with the bovine molecules. Further analysis of the reactivity of δG9 
showed that the reactivity was specific to perforin fragment 2 (Figure 10c panel A) 
and the binding could be titrated when assayed with limiting antibody (Figure 10c 
panel B) or antigen (Figure 10c panel C). On the other hand, FACS analysis shown in 
Figure 10d, demonstrated variable levels of staining of CTL. This data is summarised 
in Table 8 and indicates the staining with Perf14.F2 (70%) and Perf44.17 (75%) was 
comparable to that of δG9 mAb (90%) whereas granzyme A specific mAb obtained 
80% positive staining CTL and granzyme B specific antibody showed marginal 
staining levels ranging between 30%-50% positive staining of the same CTL. 
Although in limited quantity, sera that were obtained from the mice were also 
included in the assay. Data obtained indicated that immunisation with peptides 
generated anti-peptide antibodies that bind to regions on the corresponding native 
protein by positively staining CTL (Figure 10d). It is also interesting to note that the 
immunisation procedure generated mainly IgM class of antibodies. While these 
antibodies performed fairly well in FACS analysis, they were of limited function in 
ELISA assays. 
3.2.2 Attempts to optimize perforin and granzyme A/B ELISA and ELISpot 
assays 
Polyclonal sera generated by immunisation of rats and mice were used in 
preliminary studies to assess the ability of perforin, granzymes A/B specific antibody 
to function as matched capture and detection pairs in a capture-ELISA with the 
corresponding recombinant protein or CTL lysate (1x107 CTL lysed by freeze 
thawing in 150 μl of PBS) as the source of antigen. Plates were adsorbed overnight 
with 50 μl of crude serum diluted 1:50 in bicarbonate buffer  or 50 μl of affinity 
purified polyclonal and monoclonal antibody (100 μg/ml diluted in bicarbonate 
buffer). Commercial antibodies were diluted at 10 μg/ml. The plates were washed and 
blocked as described in section 3.1.4.1. Purified recombinant proteins or a cell lysate  
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Figure 10b: Reactivity of mAbs to recombinant protein 
Perforin, granzyme A and granzyme B recombinant proteins were coated at a 
concentration of 1 ug/well and the antibody used titrated in doubling dilution 
beginning at 1:100. NMS – normal mouse serum. 
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Figure 10c: Perforin ELISA 
Bovine recombinant perforin purified from insect cells was coated at a 1 µg/well and 
mouse anti human perforin monoclonal antibody (δG9) at 1:400 dilution used to 
detect coated antigen in a direct ELISA (A) . To determine the specificity of the 
reaction antigen was coated at a constant dilution and the antibody used in doubling 
dilution beginning at 1:100 (B) or the coating antibody was titrated in doubling 
dilutions and the antibody used at a constant concentration of 1:400 (C). As shown in 
the figure, the specificity in binding of mAb δG9 to recombinant perforin protein was 
titratable. Concentration of the CTL lysate used was not determined. 100 µl aliquot of 
a total lysate (1x107 CTL lysed in 150 μl of PBS by freeze-thawing) was used to coat 
the plate. rPerforin – recombinant perforin fragment I and II 
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Figure 10d: Reactivity of monoclonal antibodies to native proteins 
CTLs were stained for the expression of perforin  and granzymes A/B using the mAbs 
generated following immunisation of mice with KLH-conjugated peptides in parallel 
with commercially available anti-human perforin and granzyme A/B mAbs (δG9, 
GA6, GB2C5/F59) and anti-peptide polyclonal serum (pAbs) harvested from mice. 
pAb – polyclonal antibody. 
mouse anti-
perforin pAbmedium control 14.F2 17.H1
18.H3 36.D3 44.17 δG9
medium control
mouse anti-
granzyme A pAb GA46 GA6
medium control
mouse anti-
granzyme B pAbGB2C5/F59 GBA5
GB29 GB36 GB37
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Table 8: Characterisation of anti-peptide monoclonal antibody 
Monoclonal antibody Isotype Assay 
  ELISAa ICS (% positive staining) 
14.F2 IgM - 70 
36.D3 IgG3 - 2 
17.H1 IgG1 - 0 
18.H3 IgG1 + 0 
44.17 IgM - 75 
δG9 IgG2b + 90 
GA46 IgM - 85 
GA6 IgG1 - 0 
GBA5 IgM - 50 
GB29 IgM - 53 
GB36 IgG1 + 42 
GB37 IgM - 36 
GB2C5/F59 IgG2a - 0 
Reactivity of the monoclonal antibodies to respective antigens was determined by 
intracellular staining of CTL for native protein and detection of recombinant protein 
by ELISA 
Commercially available anti-human perforin, granzymes A and B are shown in bold. 
aELISA score is shown as positive (+) or negative (-). 
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Figure 11a: Evaluation of rat and mouse sera in sandwich ELISA 
Mouse sera and rat sera were assessed for ability to capture and detect recombinant 
proteins in a sandwich ELISA format. Antigen was diluted serially in doubling 
dilution beginning from 1 μg/well while the detection antibody was used at 1:100 
dilution. Lysate was prepared from 1x107 CTL lysed in 150 μl of PBS. The antigen 
and polyclonal sera is shown in the individual graphs (I-VIII). The antibody 
combinations are as below:  
Panel A:  
Coating antibody -  Mouse sera (generated by immunisation with recombinant 
protein) except in graph I which is coated with δG9 
Detecting antibody - Rat sera (generated by immunisation with recombinant protein) 
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were diluted in antibody dilution buffer and incubated in the plate for 2 hrs hours at 
room temperature. After washing the second antibody was added (working 
concentrations as indicated previously but diluted in antibody dilution buffer) and 
incubated for 2 hrs at room temperature. The plates were washed and the appropriate 
HRP conjugated antibody as described in section 3.1.4.1 was then added and 
incubated for 1 hr. The plate was developed by addition of TMB substrate solution 
and the intensity of the resulting blue product measured at 405nm. 
The use of mouse sera for capture and rat sera for detection resulted in assays 
displaying similar detection capacity as shown in Figure 11a and these antibody 
combinations could detect 500ng – 60ng of recombinant perforin, granzyme A or B 
but could not detect perforin nor granzymes in CTL lysates. As a control, δG9 was 
used in a parallel setup under the same assay conditions with similar results. 
Evaluation of reciprocal combination of pAb resulted in abrogation of the binding of 
mouse antibody to the recombinant granzyme A/B, inhibiting binding by nearly 50%. 
The inhibition of mouse antibody was also observed when rat sera were used as the 
capture antibody and δG9 as the detection mAb further validating observations 
obtained with rat and mouse anti-perforin antibody combination. Following the 
generation of anti-peptide mAb, combinations of mAb for capture or detection of 
recombinant proteins were analysed in a similar set up as that previously described 
(Figure 11b). Two mAbs, 18.H3 and GB36 that demonstrated applicability to an 
ELISA format were combined with corresponding rat or rabbit anti-peptide pAb. The 
use of mAb/rat pAb combination resulted in detection of 1 μg – 250 ng of 
recombinant perforin or granzyme B indicating a decrease in sensitivity of the assay 
compared to use of mouse polyclonal antibodies against the polypeptides. Not 
surprising was that mAb/rabbit (anti-peptide-pAb) combination did not capture 
recombinant protein. This would be expected as the repertoire of antibody is limited 
an 18-mer immunising peptide and it is highly possible that the antibodies are targeted 
to the same antigenic epitope. The intensity of the reaction observed with granzyme B 
antibodies was low as compared to intensities seen with the perforin assays, which 
were performed under identical conditions. Rabbit antibodies did not detect 
recombinant perforin captured by coating with δG9 while similar observations are 
made with anti-perforin antibody 18.H3. In contrast rat antibodies detected 
recombinant perforin using 18.H3 and δG9 as coating antibodies. 
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Figure11b: Evaluation of rat and rabbit sera and anti-peptide monoclonal antibody 
in sandwich ELISA 
Plates were coated with the mAbs as indicated in the individual graphs and bound 
antigen detected using rat (panel A) and rabbit (panel B) polyclonal antibodies as 
indicated below. Recombinant antigen was serially diluted in doubling dilution 
beginning at 1 μg/well. 
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On the basis that some of the perforin specific mAb and rabbit anti- perforin 
peptide antibody generated stained CTL, indicative that the antibodies recognised 
native proteins, ELISpot assays were set up to determine the ability of these 
antibodies to capture and detect perforin released by CTL in response to antigen 
stimulation. CTLs were stimulated in vitro with concanavalin A (con A), TpM or 
peptide pulsed autologous skin fibroblasts. The ELISpot protocol used was similar to 
the IFN-γ ELISpot assay described in materials and methods (Chapter 4) but had 
several modifications outlined in perforin ELISpot assay described by Zuber et al., 
(2005). Briefly, MultiScreen IP 96-well PVDF membrane plates were pre-wetted with 
50 μl of 70% ethanol in distilled water for 2 minutes at room temperature. The plates 
were then washed five times with 200 μl sterile water and coated with the specific 
antibodies (5 μg)  overnight at 4°C. The plates were washed six times with sterile 
PBS and blocked for 1 hour at room temperature with 200 μl RPMI-1640 with 10% 
FCS. Fifty (50) μl of bovine CTL suspension containing 2.5x104 cells, 50 μl of skin 
fibroblasts (2.5x104) and 10 μl of peptide diluted at 10 mg/ml were added in duplicate 
and the cells incubated in the plates overnight at 37°C and 5% CO2. The cell 
suspension was discarded and the plates washed eight times with 200ml PBS. The 
second antibody of the appropriate antibody pair was added diluted in PBS containing 
0.5% FCS was added and incubated at 1 hour at room temperature. After washing, the 
relevant secondary antibody conjugated to alkaline phosphatase was added and 
incubated for 1 hour at room temperature and washed as before. Filtered substrate 
BCIP/NBT plus was added and incubated for up to 30 minutes or until colour 
development was observed. The reaction was stopped by rinsing the plates in tap 
water, dried and analysed by using an automated AID Elispot Reader System (AID, 
Strassberg, Germany). 
 Results obtained showed use of mAbs and rabbit antibody did not detect 
perforin released in response to stimulation by peptide or TpM in spite of adequate 
stimulation of CTL as evidenced by IFN-γ release (Figure 12a). Data obtained was 
inconclusive as there were no significant differences between the background controls 
(unstimulated and con A stimulated CTL) and stimulated CTL samples. Results were 
also irreproducible with different experiments showing no spots to a few diffuse spots 
in repeat experiments using the same CTL cultures. To further evaluate strategies to  
 136
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12a: Optimisation of perforin ELISpot - stimulation protocol 
BV115 CTL were stimulated with Con A, specific peptide (Tp1214-224) or autologous 
TpM (BV115 TpM) in a  perforin ELISpot assay where the plates were coated with 
the 5 anti-bovine perforin mAbs and anti-human perforin mAb (δG9). Rat (Panel A) 
or Rabbit (Panel B) anti-perforin polyclonal serum was used as the detection 
antibody. A standard IFN-γ ELISpot (Panel C) was set up in parallel as a positive 
control. Spot forming units (SFU)/million CTL are shown along the Y-axis and the X-
axis shows the coating antibody. 
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optimise the detection sensitivity the assay was done incorporating several variations 
to the protocol mentioned previously. These included altering the pre-activation 
conditions i.e. with or without ethanol pre-activation, activation with 35% ethanol vs. 
75% ethanol and culturing the ELISpot for 20 hours, 24 hours and 48 hours to 
enhance the signal. Again the results obtained were inconclusive as indicated in 
Figures 12b and 12c that show data obtained from time point experiments and a 
typical image of a bovine perforin ELISpot plate after development. 
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Figure12b: Optimisation of perforin ELISpot - variation of incubation time 
A standard perforin ELISpot assay of BV115 CTL stimulated with Tp1214-224 peptide 
was set up using the anti-perforin mAbs and incubated for 20 hr, 30 hr  and 48 hr 
before detection of bound perforin with Rat (A) or Rabbit (B) anti-perforin polyclonal 
antibodies. Panel C shows an IFN-γ ELISpot assay that was set up in parallel to the 
perforin ELISpot assay. Y-axis shows the SFU/million CTL while the X-axis shows 
the coating antibody used in the assay. 
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Figure 12c: Development of perforin ELISpot - sample photograph  
Typical images of bovine perforin ELISPOT (A & B) and bovine IFN-γ ELISpot (C) 
assay wells following development.  Distinct spots are readily apparent in wells 
containing CTL that were stimulated and cultured overnight with peptide and 
developed for secretion of IFN-γ, whereas no obvious spots are detected in the wells 
containing non-stimulated cells.  In contrast, spots obtained by staining for perforin 
secretion are few and diffuse with no clear difference between stimulated and un-
stimulated wells. 
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3.3 Discussion 
 Perforin and granzymes A/B contained in cytolytic granules, is released by 
antigen-specific CD8+ cytolytic T cells in host defence. Mice deficient in perforin 
display greatly impaired cytotoxicity in vivo (Kagi et al., 1994) as manifested by a 
reduced capacity to clear many viral and intracellular pathogens. The role of CTL in 
protective immunity against T. parva has also been extensively studied and is well 
documented. In-spite of its importance, the understanding of the molecular and 
cellular function of perforin and granzymes contained in CTL is limited. This in part 
is due to a lack of suitable tools for the study of CTL releasing perforin and 
granzymes. This study aimed to generate antibodies against disparate epitopes of 
bovine perforin, granzymes A and B, to allow the development of capture-based 
immunoassays for the same molecules.  
 Immunisation of rats and mice with peptides and recombinant protein induced 
antibody against multiple epitopes of the recombinant proteins (Figure 9, Figure11a). 
However peptide-immunisation induced a significantly lower level of specific 
antibody response as compared to immunisation with recombinant proteins which can 
be attributed to several factors. These include the inherent lack of immunogenicity of 
peptides, the choice of adjuvant and its efficacy in stimulating T-cells  as well as  the 
unresponsiveness of the animal due to tolerance to non-self antigen induced by the 
similarity of the bovine peptide sequence to mouse and rabbit sequences. Whereas an 
antibody response is also targeted to multiple epitopes on the recombinant protein, 
anti-peptide antibodies target epitopes on an 18-mer peptide which may also 
contribute to low levels of antibody. The limited ability of synthetic peptides to 
adhere to assay plates could also cause a poor read out of the assay used in determing 
the effectiveness of immunisation.  
The above not-with-standing, results suggested that the antibody repertoire 
displayed overlapping epitope specificities as seen with the inhibition of mouse 
antibody binding when rat sera are used as the detection antibody for all the proteins 
(Figure 11). This is supported by the observation that mice appeared to generate 
antibodies against 2 of the 4 perforin polypeptides (Figure 9) and hence when the 
antibody combination is reversed in the ELISA assay (Figure 11) the rat pAb saturates 
the epitopes that were predominantly recognised by the mouse pAb. With respect to 
perforin, the cross reactivity of δG9 to bovine perforin not only validates the 
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expression of bovine perforin, it also emphasizes the importance of the region 
presented by the polypeptide in either the structure and/or function of the native 
protein. Given that the bovine perforin cDNA demonstrated on average 80% 
homology to human, mouse and rat perforin homologs (Figure 4b), the region defined 
by δG9 antibody is likely to be conserved across species. In contrast, it appears that 
the anti-human granzyme A and B mAbs used in this study are highly specific to the 
human proteins although human granzymes are about 60% identical at the amino acid 
level. Additionally, although granzyme structure is highly conserved across 
mammalian species, polyclonal antisera raised against purified granzyme B were 
found to be directed almost exclusively against the same region of the molecule 
(Apostolidis et al 1995).  
The inability of the antibodies to bind to native perforin in CTL lysates is 
likely due to degradation of native perforin during cell disruption or perhaps the 
quantity released were below the detection limits of the assay given that the amount of 
protein in the lysate was not quantified. Differential sensitivity of ELISA systems 
have been reported (Tanguan and Killion, 1994; Zuber et al., 2005) moreover, the 
detection of bovine perforin in CTL supernatants using commercially available 
perforin ELISA kits have not been successful and this was attributed partly to the 
detection limits of the available reagents (Bateta, 2004). 
Allowing for differences in antibody preparations (such as integrity of 
antibody after purification procedures) the differences observed between the reactivity 
of anti-perforin peptide and anti-granzyme peptide mAb/pAb combinations in ELISA 
(Figure 11b) is attributable to the resulting competitive binding and inhibition of the 
antibodies generated. These antibodies are likely to display overlapping specificities 
given that they are both generated by peptide immunisation. Further to this, the 
observation that rabbit anti-perforin peptide antibody did not detect recombinant 
perforin captured by δG9 and 18.H3 (Figure 11b) suggests that these two antibodies 
may display similar epitope specificities and by inference are targeted to antigenic 
molecules within if not the same region of the perforin molecule which would be 
defined by peptide Perforin262-279 (Table 8). This may account for the loss of antibody 
binding due to steric hindrance or competitive binding. 
Application of the antibodies that were generated in this study in FACS assays 
gave variable results as shown in Figures 9f and 10d. On one hand it is possible that 
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the rat pAb recognise linear epitopes whose structural presentation is altered or may 
be poorly accessible to antibody in the native molecule and hence their inability to 
bind to native perforin, granzymes A and B. On the other hand, antibodies such as 
δG9, 14.F2, GB36, GA46 and the rabbit anti-peptide antibodies recognise an epitope 
that is preserved and exposed in the recombinant proteins as well as the native form of 
the molecules. With respect to FACS data obtained with mAb (Figure 10d), the 
differences in the cell numbers staining positive for perforin, granzyme A and B, may 
be as a result of different expression levels of the two proteins in activated CTL as the 
assays were carried out using the same CTL population. Differential expression of 
perforin has been reported in several studies (Velotti et al., 1989) Garcia-sanz et al., 
1990). With regard to the granzyme B antibodies, the peptides and consequently the 
recombinant protein used to immunise the animals has been shown in recent analysis 
(Chapter 2, results section) to have poor homology to granzyme B protein and it is 
likely that this contributed to the poor results obtained when staining CTL.  
With regard to generation of monoclonal antibodies, it is of interest to 
determine why the resultant monoclonals were predominantly of IgM subclass. This 
may have been as a result of the adjuvant used or the immunisation procedure and 
therefore calls for testing of different adjuvant and immunisation regimes. The 
observation  may also explain the disparity in the screening of hybridomas by ELISA 
and intracellular staining. While the latter identified hybridomas secreting all class 
types of immunoglobulins, the ELISA technique identified hybridomas secreting IgG 
subclass. Perhaps the same phenomenon occurred following immunisation of rabbits 
whereby the immune response did not mature well enough to generate IgG antibodies. 
This resulted in the poor staining of CTL where the secondary antibody used was anti-
rabbit IgG-PE conjugate. 
Challenges encountered in the development of perforin based ELISA/ELISpot 
assays and by extension granzyme based ELISA/ELISpot assay may be attributed in 
part to the limited functionality and repertoire of the antibodies that were generated. 
Antibodies that were generated were restricted to peptide epitopes while the rat 
polyclonal antibodies generated by immunisation of rats with protein were limited in 
their ability to bind to corresponding epitopes in the native protein. These challenges 
however are not unique to the bovine system. Similar set backs have been reported by 
other groups. For example Zuber et al., (2005) reports generation of perforin-specific 
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mAb that is of limited function in the ELISpot assay while Hameed et al (1992) 
developed an anti-perforin mAb that is restricted for use only in FACS analysis. Of 
the number of anti-human granzyme antibodies that have been generated, only a 
limited selection of 2-3 antibodies are used in ELISA assays while a single pair is 
shown to function in the granzyme ELISpot (Apostolidis et al., 1995). Of specific 
importance is the need for antibodies that recognise at least two distinct determinants 
of the molecule with an ability to recognise native protein as well as to function in 
different assay systems. 
In conclusion, antibodies against bovine perforin, granzymes A and B have 
been generated. Although limited in function the antibodies generated in this study 
can be evaluated further and developed as anti-bovine perforin, granzyme A and B 
reagents. Given appropriate antibodies, the possibility of developing perforin based 
ELISA and ELISpot assays specific for the bovine system still exists as these have 
been successful in human and murine models. Related to this, δG9 antibody has been 
shown to cross-react to bovine perforin and can thus be further analysed and 
incorporated in assays for studies on bovine perforin. 
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Chapter 4: Identification of Theileria parva antigen 
specific CD8+ T cells using peptide-Major 
histocompatibility complex class I tetrameric 
complexes 
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4.0 Introduction  
 Peptide-MHC class I (pMHC) tetrameric complexes are proving invaluable as 
fluorescent reagents for enumeration, characterisation and isolation of peptide-
specific T-cells (Dunbar et al., 1998; Appay et al., 2000; Denkberg et al., 2001; 
Karanikas et al., 2003). Used in combination with functional assays such as cytokine 
secretion or intracellular staining of proteins (Murali Krishna et al., 1998; Callan et 
al., 1998; Wilson et al., 1998; Tan et al., 1999; Appay at al., 2000; Pittet et al., 2001a 
and b) this assay provides additional information on the functional heterogeneity of 
antigen-specific CD8+ T-cells ex vivo. The use of the IFN-γ ELISpot as a means of 
examining the functional phenotype of circulating CD8+ T-cells with specificity for a 
particular T. parva antigen has shown successful induction of IFN-γ antigen specific 
CD8+ T cell responses following vaccination with defined T. parva antigens (Graham 
et al., 2006). However, it does not address their cytolytic function. The analysis of 
tetramer-positive CD8+ T-cells by flow cytometry provides a method that reliably 
quantitates the number of specific CD8+ T-cells present in peripheral blood and 
through co-staining for perforin, can provide additional information about their 
cytolytic potential. 
 Chapter 4 reports on validation of tetramers generated using antigenic peptides 
from T. parva by staining established T-cell lines and clones. It also describes a 
method that combines the use of tetramers and intracellular staining to examine the 
expression of perforin. The pMHC tetramers and intracellular staining for perforin has 
further been used to assess the T-cell response to specific antigens in animals 
following live vaccine immunisation and subsequent challenge with parasites. The 
functional relevance of tetramer staining is suggested by the correlation with other 
assays of CTL function, including 111Indium-release assays and IFN-γ ELISpot. 
Tetramer staining is also used to examine antigen-specific T cells in cryopreserved 
samples obtained from animals vaccinated with defined T. parva antigens and 
challenged with live parasites (Graham et al., 2006, unpublished results). 
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4.1 Materials and methods 
4.1.1 Cattle 
A total of 10 cattle born and bred at ILRI and free from T. parva, were used in 
the study. The animals used in the study were selected on the basis of their bovine 
MHC phenotype by typing for bovine leucocyte antigens. Four of the 10 animals 
(BX063, BX064, BV115 and BZ144) had previously been immunised against T. 
parva by the infection and treatment method (ITM) conducted as part of another study 
(Graham et al., personal communication). At the outset of the experiments all animals 
were clinically normal. A detailed animal list is shown in Table 9.  
4.1.2 Bovine leucocyte antigen typing 
The bovine leucocyte antigen (BoLA) class I phenotypes were determined 
using a combination of immunofluorescence staining with anti-BoLA monoclonal 
antibodies followed by flow cytometry as described in section 4.1.4.8 (Goddeeris and 
Morrison, 1988) and allele-specific PCR (Ellis et al., 1998). The expression of 
specific class I alleles was also confirmed functionally by testing the ability of cells 
from individual typed animals to present relevant peptide to CD8 T-cell lines of the 
appropriate BoLA restriction specificity. Lymphoblasts obtained by the stimulation of 
peripheral blood mononuclear cells with Con A (Sigma, Poole, United Kingdom) as 
described in section 4.1.4.4 were pulsed with serially titrated preparations of antigenic 
peptides for 1 hr at 37°C and then fixed in 0.1% glutaraldehyde (McKeever et al., 
1992). Pulsed lymphoblasts (2.5x104 cells/well) were co-cultured with antigen-
specific CD8 T cells (2.5x105 cells/well), and recognition was assessed by IFN-γ 
ELISpot assay (Graham et al., 2006) as described in section 4.1.4.7. 
4.1.3 Immunisation and challenge 
Five cattle (BB001, BB006, BB007, BB069, BB169) were immunised by  
ITM using cryopreserved viable T. parva (Muguga) (TpM) sporozoites and a slow-
release formulation of antibiotic essentially as described previously (Radley et al., 
1975a). The cryopreserved ILRI stabilate No. 4133 was pooled from plastic straws 
after rapid thawing in a water-bath at 37°C and a final dilution of 1:20 achieved using 
stabilate diluent (3.5% BSA, 7.5% glycerol 1ml/100ml Pen-Strep in D-MEM).  
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Table 9: Details of experimental cattle 
Animal MHC class I 
serotypeb 
Class I  MHC 
restricting allele 
Aged 
(months) 
Breed 
BB001 A10-KN104/A18 N*00101 17 Friesian-Boran cross 
    N*01301     
BB006 A10/- N*01201 17 Friesian-Boran cross 
BB007 A18/- N*01301 17 Friesian-Boran cross 
BB069 A10-KN104c N*00101 19 Boran 
BB070 A10-KN104c N*00101 17 Boran 
BB0169 A10-KN104c N*00101 15 Boran 
BX063a A10-KN104c N*00101 74 Boran 
BX063a A10-KN104c N*00101 74 Boran 
 BV115a  A10/A18 N*01301 unknown   Friesian 
  N*01201 unknown   
BZ144a A10-KN104/- N*00101 37 Boran 
a T. parva immune cattle – cattle previously immunised by ITM. BX063 and BX064 
are identical twins 
b a minus sign indicates that the MHC haplotype is unknown 
c homozygous for MHC serotype 
d age at time of experiment 
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A lethal dose of 1 ml of diluted stabilate was administered sub-cutaneously 
below the right ear. Long-acting oxytetracycline hydrochloride (Alamycine LA 300, 
Norbrook Pharmaceuticals) was inoculated deep in the gluteal muscles at 20 mg/kg 
body weight immediately after administration of the stabilate. Following inoculation 
with sporozoites, cattle were monitored clinically for temperature and parasitosis by 
microscopic examination of giemsa-stained smears of needle aspirates of local lymph 
nodes. Examination for parasitosis and measurement of rectal temperature were 
performed daily starting from 5 days after inoculation with sporozoites until recovery. 
A rectal temperature of 39.5ºC or higher, associated with schizont parasitosis, was 
considered a pyrexic response and treatment using an antitheilerial drug Butalex® 
(Coopers Animal health) administered at 2.5mg/kg body weight. Recovery of animals 
was defined as disappearance of schizonts from lymph nodes, a rectal temperature 
below 39.5ºC, and a clinically healthy appearance. 
Homologous challenge infections were achieved by a lethal dose of 1 ml 
(1:20) of Stabilate No. 4133 administered as described. Examination for parasitosis 
and measurement of rectal temperature was also performed daily starting from 5 days 
to day 15 after challenge. 
4.1.4 Generation, cloning and characterisation of bovine cytotoxic T cells 
specific for Theileria parva 
4.1.4.1 Media 
Tissue culture media used for growth and maintenance of T. parva-infected 
cell lines and Theileria-specific short-term T cell cultures or established polyclonal 
and clonal T cell lines were prepared as described by Goddeeris and Morrison (1988). 
Complete culture medium for growth of parasitized cells consisted of RPMI-1640 
with 20 mM HEPES buffer (Flow laboratories, Ltd., Irvine Scotland) supplemented 
with 10% (v/v) of gamma-irradiated, heat-inactivated (56˚C, 35 min then stored at 
4˚C) foetal calf serum (FCS) (Hyclone, Logan, UT), 50 μg/ml gentamicin (Flow 
Laboratories, Irvine Scotland), 2mM L-glutamine (GIBCO, Paisley Scotland), 5x10-5 
M 2-mercaptoethanol (Merck, Darmstadt, Germany) 240 IU/ml penicillin and 100 
μg/ml streptomycin. Culture medium used in Theileria-specific T cell cultures was as 
described above but without HEPES buffer. Culture medium used in cytotoxicity 
assays comprised of RPMI-1640 medium with HEPES buffer supplemented with 5% 
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(v/v) of heat-inactivated FCS.  
4.1.4.2 Preparation of bovine peripheral blood mononuclear cells  
Peripheral blood mononuclear cells (PBMC) were isolated from blood 
collected in Alsever’s solution by density gradient centrifugation on Ficoll-paque® 
(Pharmacia, Uppsala, Sweden) essentially as described by Goddeeris and Morrison 
(1988). Briefly, blood was aseptically collected from the jugular vein into a syringe 
containing an equal volume of Alsever’s solution to form a mixture that was then 
layered onto Ficoll-paque solution and centrifuged (Model RC 3B, Sorval, DE) at 
900xg for 30 min at room temperature with the brakes off. Cells at the interface 
between the plasma phase and the Ficoll-paque® were collected and transferred into a 
50-ml polypropylene tube (Falcon®) and pelleted by centrifugation at 450xg for 10 
min at room temperature. Residual red blood cells were lysed by incubating the cell 
pellet in Tris-ammonium chloride buffer pre-warmed at 37°C for 10 min. The cells 
were then washed three times with Alsever’s solution by centrifuging at 180xg for 10 
min at room temperature before being resuspended in the appropriate cell culture 
medium or buffer. Viable cell count was determined by trypan blue dye-exclusion 
using a haemocytometer. All operations except centrifugation and counting of cells 
were conducted in a horizontal laminar flow hood. 
4.1.4.3 Establishment and maintenance of Theileria parva-infected cell lines 
Parasitized cell lines were established by infection of PBMC in vitro with T. 
parva sporozoites. An aliquot of sporozoite suspension derived by homogenizing 
dissected tick salivary glands in HEPES buffered-culture medium was added to a cell 
pellet containing 2x107 PBMC in a 10-ml polycarbonate tube (Nunc) to give a final 
volume of 200 μl. The sporozoite-cell mixture was incubated at 37˚C in a humidified 
5% CO2 incubator for 1.5 hr while mixing the contents every 30 min. The volume was 
then made up to 10 ml with the culture medium and centrifuged at 180xg for 10 min 
at room temperature. The pelleted cells were resuspended in 5 ml of the culture 
medium and transferred into a 25 cm2-tissue culture flask (Costar®, Cambridge, MA) 
which was then incubated in a humidified 5% CO2 incubator at 37°C. From about 2-3 
days cultures were observed under an inverted microscope for appearance of 
lymphoblasts. Cytospin smears were also made and stained with Giemsa (Merck, 
Darmstadt, Germany) to confirm the presence of Theileria schizonts in the 
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lymphoblasts. The cultures were maintained in logarithmic growth phase by making 
sub-cultures when cell numbers reached 1x106 cells/ml; that is, every 2 days, two-
thirds of the cell suspension was removed and replaced with an equal volume of fresh 
culture medium. 
Once cell lines were established, stabilates were prepared and frozen in liquid 
nitrogen. A cell suspension containing 5x106 infected cells was spun at 180xg for 10 
min at room temperature and the pellet resuspended gently in 1 ml of pre-chilled 
(4˚C) culture medium (without HEPES). An aliquot of 1 ml of pre-chilled FCS 
containing 20% dimethylsulfoxide (DMSO) (Merck, Germany) was added gently to 
the cell suspension. Aliquots of 1 ml were distributed in cryogenic vials (Nunc), 
suspended overnight in the vapour phase of liquid nitrogen and subsequently 
immersed in liquid nitrogen for storage. 
In order to recover the stabilate from liquid nitrogen, the cryogenic vial was 
quickly thawed by immersing in a water-bath at 37°C and subsequently placed on ice. 
The cells were then gently transferred into a 10-ml centrifuge tube containing 5 ml 
pre-chilled complete culture medium. The cell suspension was centrifuged at 180xg 
for 10 min at 4°C. After discarding the supernatant, the cell pellet was resuspensed in 
5 ml of complete culture medium and transferred into a 25-cm2 tissue culture flask. 
The flask was incubated at 37°C in a humidified CO2 incubator and the cell line was 
maintained in logarithmic growth phase as described before. 
4.1.4.4 Establishment of uninfected lymphoblastoid cell lines 
Uninfected lymphoblasts for use as control target cells in cytotoxicity assays 
were obtained from PBMC as described by Goddeeris and Morrison (1988). A 
suspension of PBMC containing 2x106 cells/ml of complete culture medium without 
HEPES buffer was distributed in 1-ml aliquots into a 24-well culture plate. Aliquots 
of 1 ml complete culture medium containing 5 μg/ml Con A was added to each well 
and the cultures incubated at 37°C in a humidified incubator for 5 days. The cultured 
cells were harvested and resuspended at 5x105 viable cells/ml of culture medium 
containing 10U/ml human recombinant IL2 (Sigma) or 1% bovine recombinant IL2 
(ILRI in-house reagent) and 5 ml transferred into a 25-cm2 tissue culture flask. The 
cell culture was maintained by making sub-cultures every 3 to 4 days; three-quarters 
of the cell suspension was removed and replaced with fresh complete culture medium 
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containing IL2. One day before use of uninfected lymphoblasts as target cells, 
complete culture medium containing IL2 and 0.1M alpha-methyl-D-mannoside was 
added to neutralise any residual Con A present. 
4.1.4.5 Generation Theileria parva-specific CD8+ T cells 
4.1.4.5.1 Generation of polyclonal T-cell lines 
The methodology applied was essentially as described by Goddeeris and 
Morrison (1988). Briefly, aliquots of 4x106 PBMC and 2x105 irradiated autologous T. 
parva-infected cells were added in a total volume of 2 ml complete culture medium 
(without HEPES) to the wells of a 24-well tissue culture plate (Costar®). The 
parasitized stimulator cells were irradiated by exposure to 50 Gy of gamma irradiation 
from a 137Cesium source. Cultures were then incubated at 37°C in a humidified 5% 
CO2 incubator. After incubation for 7 days, viable cells were recovered from the 
cultures by centrifugation (450xg, 20 min at room temperature) over Ficoll-paque® 
remove dead cells. Viable cells were then resuspended at 4x106 cells/ml in complete 
culture medium and re-stimulated with irradiated autologous infected cells as 
described before. After 7 days incubation, viable cells were separated and 
restimulated a third time as before; using aliquots of 2x106 restimulated cells/well 
with 4x105 irradiated (50 Gy) autologous infected cells and 2x106 irradiated (50 Gy) 
autologous PBMC as filler cells. Cytotoxicity assays (51Chromium-release assays) 
were conducted on effector cells after each stimulation. The cells were cloned after 
the third stimulation, when maximal levels of killing had been achieved. Alongside 
the cloning, the remaining cells were maintained in culture by periodic re-stimulation 
to generate established polyclonal CTL lines. 
4.1.4.5.2 Generation of cloned T-cell lines 
 The procedures followed for cloning were as previously described by 
Goddeeris and Morrison (1988). Prior to cloning, CD4+ T cells were depleted from re-
stimulated cultures by complement-mediated lysis with mAb IL-A12 (Baldwin et al., 
1986) to enrich for the CD8+ T cells known to mediate CTL activity. Briefly, 1x107 
viable cells in 1 ml of complete culture medium were incubated with 500 μl of sterile 
mAb (at 1:250 dilution of murine ascetic fluid in complete culture medium) for 40 
min at 4°C. An aliquot of 500 μl of sterile rabbit complement solution was added to 
the mixture which was further incubated for 40 min at 37°C before adding 8 ml of 
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culture medium and centrifuging at 180xg for 10 min at room temperature. The cell 
pellet was washed twice by adding 10 ml culture medium and centrifuging as before 
then resuspended in 2 ml culture medium containing 1% bovine recombinant IL-2 
(ILRI in-house reagent) and transferred into a well of a 24-well culture plate and 
incubated overnight at 37°C in a humidified 5% CO2 incubator.  
 Following the overnight incubation, the cells were recovered by 
centrifugation, counted and adjusted to concentrations of 30, 10 and 3 cells/ml in 
culture medium. Aliquots of 100 μl of each dilution were dispensed into the wells of 
96-well micro-titre round-bottom tissue culture plates (Costar®); 5 plates of each 
dilution at 0.3 cells/well and 1 cell/well and 2 plates at 3 cells/well were prepared. 
Aliquots of 100 μl of a cell suspension containing 5x104 irradiated autologous 
infected cells/ml, 2x105 irradiated autologous PBMC/ml and 1% IL-2 in complete 
culture medium was added to each well. The culture plates were incubated at 37°C in 
a humidified 5% CO2 incubator. After about two weeks of incubation, wells were 
screened for cell growth and those wells with obvious cell pellets were selected and 
half of the cells in each well analysed for cytotoxicity on infected target cells in an 
111Indium oxine-release assay. 
 Wells that exhibited cytotoxic activity and originated from a cell concentration 
that gave rise to cell growth in less than 30% of the wells were selected for further 
study. These cloned cells were resuspended in culture medium at concentrations 
estimated to be between 500 and 5000 cells/ml; aliquots of 100 μl of cloned cells were 
distributed in the wells of 96-well round bottom tissue culture plates. Into each well, 
was added 100 μl of stimulator cell suspension containing 5x103 – 1x104 autologous 
irradiated infected cells and 1% IL-2 in culture medium. The plates were incubated as 
described before for 10 – 14 days. After this period of incubation, cloned cells were 
further sub-cultured as described above but at a responder-to-stimulator ratio of 1:10. 
Expanded cloned cells were analysed for cytotoxicity using 51Cr-release assay. 
Aliquots of the cloned cells were also cryopreserved in liquid nitrogen. 
4.1.4.6 Cytotoxicity assays 
4.1.4.6.1 [51Cr] Chromium-release assay 
The 51Cr-release assay was used to determine cytotoxicity of short-term 
cultures of PBMC, polyclonal T cell lines or CTL clones against T. parva-infected 
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lymphoblasts or Con-A induced lymphoblasts (peptide-pulsed or unpulsed) used as 
target cells essentially as described previously (Goddeeris, Morrison and Teale, 1986; 
Goddeeris and Morrison, 1988; Graham et al., 2006; 2008). Briefly, 2x106 target cells 
were radio-labelled at 37°C for 1 hr with 100 μl containing 100 μCi of [51Cr] sodium 
chromate (Amersham, UK). Target cells were then washed four times in 5ml of 
cytoxicity medium (HEPES-buffered RPMI-1640 supplemented with 5% FCS) and 
resuspended in 2 ml of the cytotoxicity medium to give a final concentration of 1x106 
cells/ml. For assays utilising short-term bulk PBMC cultures, viable effector cells 
were resuspended at 1x107 cells/ml in cytotoxicity medium. Aliquots of 200 μl of 
two-fold dilutions of the effector cell suspension were plated in duplicate into the 
wells of a 96-well flat-bottom culture plate (Costar®). Radiolabelled target cells were 
added in each well in aliquots of 50 μl containing 5x104 cells to give an effector-to-
target cell ratio ranging from 40:1 to 1.25:1. Assays of cytotoxicity with polyclonal 
CD8+ T cell lines and cloned T cells utilised 96-well V-bottom tissue culture plates 
(Costar®). Aliquots of 50 μl of radiolabelled target cell suspensions containing 
2.5x104 cells were added to each well. The effector cells were suspended at 1x106 
cells/ml and aliquots of 100 μl were added to duplicate wells giving effector target 
ratios ranging from 4:1 to 0.125:1. To determine the spontaneous release of 
radioisotope, aliquots of 50 μl of each target cell suspension were added in triplicate 
wells containing 200 μl (or 100 μl) of cytotoxicity medium only. Maximum release of 
the radiolabel was determined by adding in triplicate wells, 50 μl of the labelled target 
cell suspension to 200 μl (or 100 μl) of 1% (v/v) Tween-20 in water.  
After 4 hr incubation at 37°C in a humidified 5% CO2 incubator, cells in each 
well were resuspended and spun at 450xg for 5 min at room temperature to separate 
the cells from the released radio-label. Aliquots of 75 μl or 125 μl were harvested 
from each well and transferred into sample vials for assessing gamma emission using 
a gamma counter (Gamma Counter, Gamma 5500, Beckman, Geneva, Switzerland). 
Percent-specific cytotoxic release of 51Cr (hereafter referred to as % cytotoxicity) was 
calculated from the formula: (ER – SR)/(MR - SR) x 100, where ER is the mean 
experimental release, SR is the mean spontaneous release and MR is the mean 
maximum release. 
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4.1.4.6.2 [111In] Indium oxine-release assay 
The 111In-release assay was used to screen for cytotoxic activity in T cell 
clones during and after the cloning process as well as assessing cytotoxicity in ex vivo 
PBMC essentially, as described previously (Goddeeris, Morrison and Teale, 1986; 
Goddeeris and Morrison, 1988). To assay for cytotoxic activity in T cell clones, 1x106 
target cells were radio-labelled in 50 μl of cytotoxicity medium with 5 μCi of [111In] 
indium oxine (Amersham, UK) by incubating for 15 min at 37°C. The required 
volume of radiolabel was calculated for each occasion based on the reference date as 
111In has a half-life of 2.8 days. The labelled cells were washed six times with 
cytotoxicity medium essentially as described for the 51Cr-labelled cells, and 
resuspended in 10 ml of cytotoxicity medium to give a concentration of 1x105 
cells/ml. Target cells were autologous Theileria-infected lymphoblasts, peptide-
pulsed Con A-stimulated lymphoblasts and unpulsed Con A lymphoblasts which 
served as the negative control (Goddeeris and Morrison, 1988).  
Ex vivo PBMC were resuspended at 4x106 cells/ml while established T-cell 
clones at 4x105 cells/ml and aliquots of 100 μl of two-fold dilutions of the effector 
cells were plated in duplicate in 96-well V-bottom microtitre plates (Costar®), 
followed by 50 μl containing 5x103 radio-labelled target cells resulting in effector-to-
target cell ratio ranging from 80:1 to 10:1 and 8:1 to 1:1 for PBMC and T-cell clones, 
respectively. For assays utilising T-cell clones in a cloning process an aliquot of 100 
μl was transferred directly from the selected wells into single wells of 96-well, V-
bottom plates containing 5x103 radiolabelled target cells. The cells were pelleted and 
incubated for 4 hr at 37°C in a humidified 5% CO2 incubator. The remaining aspects 
of the assay, including determination of spontaneous release and maximum release 
and harvesting of the supernatants was carried out as described for the 51Cr-release 
assay. 
4.1.4.7 Interferon-γ Enzyme Linked Immunospot Assay  
The IFN-γ ELISpot assay was applied to quantify the frequency of peptide-
specific IFN-γ secreting CD8+ T cells and assess the kinetics of the response in cattle 
undergoing immunisation and challenge with T. parva, essentially as described 
previously (Taracha et al., 2003; Graham et al., 2006). Briefly, sterile 96-well 
microtitre plates (MAIPS4510, Millipore, MA, USA) were pre-coated overnight at 
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4°C with 50 μl-aliquots of mouse anti-bovine IFN-γ mAb (CC302; IgG1; Serotec 
Antibodies, UK) diluted at 1 μg/ml in coating carbonate buffer, pH 9.6. Plates were 
washed twice with unsupplemented RPMI-1640 medium and blocked with 50 μl/well 
of RPMI-1640 supplemented with 10% FCS for 2 hr at 37°C. Aliquots of 50 μl 
containing 2.5x105 responder PBMC were added per well followed by peptides in 50 
μl-aliquots at a final concentration of 1 μg/ml. A control well with responder cells in 
medium alone and another well with responder cells with Con A at a final 
concentration of 5 μg/ml were included as background and positive controls. All 
samples were plated out in duplicate. The plates were kept for 20 hr at 37°C in a 
humidified 5% CO2 incubator.  
After the cells were discarded, the plates were washed four times with distilled 
water containing 0.05% Tween-20 and then four times with PBS-0.05% Tween-20, 
each time with gently shaking of the plates for 20 seconds before the wash fluid was 
flicked off. Excess wash buffer was removed by gently tapping plates on paper 
towels. A second rabbit anti-bovine IFN-γ antibody (ILRI in-house reagent) diluted at 
1:1500 in PBS-0.05% Tween-20/ 0.1% BSA was added in 50-μl aliquots, and the 
plates incubated for 1 hr at room temperature. A further four washes with PBS-0.05% 
Tween-20 were performed without shaking the plates. Fifty-microlitre aliquots of an 
anti-rabbit IgG (α-chain specific)-alkaline phosphatase conjugate (RG-96; Sigma 
Chemicals, UK) diluted at 1:2000 in PBS- 0.05% Tween-20/ 0.1% BSA were added 
to the plates and incubated for 1 hr at room temperature. Plates were further washed 
six times with PBS-0.05% Tween-20 and developed with 50 μl/well of SigmaFast™ 
BCIP/NBT substrate (Sigma Chemicals, UK) solution at room temperature for 10 min 
in the dark to allow for spot development. The reaction was stopped by rinsing the 
plates with copious amounts of water. The plates were air-dried and spots counted in 
each well using an automated ELISPOT plate reader (AID ELISpot Reader system, 
Germany). After the ELISpot reader count, spots were manually edited to ensure that 
only “true” positive spots were included. After correction for background signals as 
determined in the absence of any antigen, results were expressed as spot-forming cells 
(SFC)/million PBMC. 
 159
4.1.4.8 Immunofluorescent staining and flow cytometry 
4.1.4.8.1 Immunofluorescence surface staining 
 Suspensions of PBMC were stained with mAb specific for BoLA class I 
antigens (see Appendix VIII) using the indirect immunofluorescence technique and 
analysed using a fluorescence-activated cell sorter (FACScan™, Beckton Dickinson, 
USA). To stain the cells, aliquots of 50 μl of FACS medium (RPMI-1640 medium 
with HEPES and supplemented with 5% heat-inactivated horse serum [Sigma]) 
containing approximately 4x105 cells, were added to 50 μl of mAb diluted at 1:500 in 
FACS medium in a 96-well round-bottom tissue culture plate (Costar®) and 
incubated for 30 min at 4°C, essentially as described previously (Lalor et al., 1986; 
Goddeeris et al., 1988) cells were then washed three times, by resuspension in 100 μl 
of FACS medium and centrifugation (Heraeus Megafuge, Model No. 2.0R) at 1500 
rpm for 2 min at room temperature. After the final wash, the supernatant was 
discarded, the pellet resuspended in residual fluid by vortexing, 50 μl of a 1:200 final 
concentration of FITC-conjugated or PE-conjugated goat anti-mouse Ig added and 
incubated for a further 30 min at 4°C. The cells were then washed three times as 
before. The cell samples were finally resuspended in 200 μl of FACS fixative (1% 
paraformaldehyde in PBS) and analysed on the FACS machine. 
 One colour flow cytometry acquisition was performed on a FACScan ™ flow 
cytometer using Cell Quest software. Viable cells were gated on FSC versus SSC and 
10,000 – 20,000 events collected within this gate. FACS data was analysed using Cell 
Quest Software or Flow Jo (TreeStar, San Carlos) Software and displayed as dot plots 
of FSC and log fluorescence intensity on FL1 or FL2. 
4.1.4.8.2 Intracytoplasmic staining for perforin  
This procedure was based on methods described previously by Jung et al., 
(1993). Briefly, 4x105 cells/well were washed with 200 μl of cold PBS and then fixed 
by resuspending in 200 μl 1% paraformaldehyde in PBS for 10 min at room 
temperature. After washing once with PBS, the cells were permeabilised by 
incubating in 200 μl of a solution containing 0.1% (w/v) saponin, 0.1% sodium azide, 
10 mM HEPES (PBS-Sap), supplemented with 20% heat-inactivated normal goat 
serum (for Fc receptor blocking) for 30 min at room temperature. The cell pellet was 
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recovered by centrifuging at 450xg for 2 min and the cell sample stained for 
expression of perforin by incubating in 25 μl of mouse anti-human perforin 
monoclonal antibody δG9 (BD Pharmingen), diluted 1:250 in PBS-Sap, for 30 min at 
4°C. Cells were washed twice by resuspension in 100 μl PBS-Sap and centrifugation 
as before. After the final wash, the supernatant was discarded, the pellet was 
resuspended in residual fluid and incubated in 25 μl FITC-conjugated or PE-
conjugated anti-mouse Ig diluted 1:200 or 1:500, respectively, for 30 min at 4°C. The 
cells were washed as before then washed once with PBS and finally resuspended in 
200 μl FACS fixative (1% paraformaldehyde) for FACS analysis as described in 
Section 4.1.4.8.1. 
4.1.4.8.3 BoLA class I-peptide tetramer staining 
BoLA class I-peptide complexes were synthesised and tetramerised by 
collaborators (Didier Colau et al.) at the Ludwig Institute for Cancer Research, 
Brussels, Belgium and shipped as PE conjugated tetramers for use at ILRI. Four 
BoLA class I-peptide tetrameric complexes were constructed in accordance with 
established protocols (http://research.yerkes.emory.edu/tetramer_core/protocol.html). 
Details of synthetic peptides and BoLA class I restricting elements are described in 
Table 10. Briefly, the assembly of the bovine tetramers first involved the cloning and 
expression of the BoLA heavy and light chains. BoLA N*00101, N*01301 and 
N*01201 cDNA clones were used as a templates to amplify the sequence coding for 
the extracellular domains (amino acid 1–279 of the mature protein) of the heavy 
chains. The PCR products were cloned into a vector derived from pET3D (Stratagene) 
and containing a BirA biotinylation site in-frame with the 3'-end of the BoLA 
sequences. A cDNA clone containing the bovine beta-2 (β-2m) microglobulin gene 
was used to amplify the sequence coding for the mature β-2m protein (amino acid 21-
118). The PCR product was cloned into a derivative of plasmid pET9A (Novagen). 
Recombinant proteins were expressed in E. coli strain BL21 (DE3) (Stratagene). 
Recombinant BoLA/peptide molecules were folded in vitro as previously described 
(Altman et al., 1996). Soluble complexes were purified by gel filtration and 
biotinylated using the BirA enzyme (Avidity LCC, Denver, CO). PE-labelled 
tetramers were produced by mixing the biotinylated complexes with streptavidin-PE 
(BD Pharmingen) (Dr. Didier Colau, LICR, personal communication). 
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Table 10: Cytotoxic CD8+ T cell epitopes and bovine tetramers 
BoLA class I peptide complex Peptide sequence Peptide size 
BoLA-N*01301-Tp1214-224 VGYPKVKEEML 11-mer 
BoLA-N*01201-Tp298-106 QSLVCVLMK 9-mer 
BoLA-N*00101-Tp4328-336 TGASIQTTL 9-mer 
BoLA-N*00101-Tp8379-387 CGAELNHFL 9-mer 
Four peptides corresponding to antigenic epitopes on four T. parva antigens, Tp1, 
Tp2, Tp4 and Tp8, previously identified to be the targets of CD8 T cell responses of 
T. parva immune cattle (Graham et al., 2006; 2008) were used in this study. The 
epitopes, as defined by the minimal peptide length that induced maximal T cell 
activity and their restricting MHC class I alleles are shown above. Tp4328-336 and 
Tp8379-387 are restricted by the same class I allele (N*00101; A10-KN104+ haplotype), 
Tp1214-224 is restricted by (N*01301; A18+ haplotype) while Tp298-106 is shown to be 
restricted by N*01201 associated with A10+ MHC class I haplotype. Peptides were 
synthesised by Mimotopes (Clayton, Australia; Tp1214-224) and PepScan Systems 
(Netherlands; Tp4328-336, Tp8379-387, Tp298-106) and shipped as lyophilised pellets which 
were reconstituted by resuspending in a solution of 50% (v/v) DNA synthesis grade 
acetonitrile-water (Applied Biosystems, UK), aliquoted and stored at -20°C and 
subsequently diluted in sterile RPMI-1640 for use in IFN-γ ELISpot, CTL lytic 
activity assays as described. 
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Tetramers obtained from LICR were used to stain CTL prepared from cattle 
bearing the relevant MHC (Graham et al.). Briefly, 4x105 CTL/well were washed 
twice by resuspension in 100 μl-aliquots of PBS-0.5% BSA, 0.1% sodium azide 
(PBS-BSA) and centrifugation at 450xg at room temperature for 2 min to recover the 
sample. After the final wash, the cell pellet was resuspended in residual fluid and 
incubated in 25 μl of tetramer at the appropriate dilution at room temperature for 30 
min in the dark. The cells were washed twice as before and resuspended in 200 μl of 
PBS-BSA for FACS analysis. 
4.1.4.8.4 Immunofluorescence double staining technique 
Tetramer/CD8 and perforin/CD8 double staining was conducted on cell 
samples essentially as described previously (Appay et al., 2000; Meidenbauer et al., 
2001; Denkberg et al., 2001). Briefly 4x105/well of PBMC or CTL was centrifuged at 
450xg for 2 min and washed twice with cold PBS-BSA. To avoid blocking of 
tetramer binding by anti-CD8 antibody, the cells were first incubated with 25μl of 
40nm of tetramer in PBS containing 0.5% BSA and 0.1% sodium azide (PBS-BSA) 
for 10 min at room temperature in the dark followed by addition of 25 μl anti-CD8 
(IL-A51; IgG1) mAb at 1:250 dilution in PBS-BSA and incubated for a further 20 min 
in the dark, at room temperature. Cells were then washed twice by the addition of 150 
μl aliquots of PBS-BSA and centrifugation as before. After the final wash, the cell 
pellet was resuspended in residual fluid and 25 μl of FITC conjugated anti-mouse 
IgG1 (Southern Biotech) diluted 1:200 in PBS-BSA or 1 μl of anti-mouse IgG1 PerCP 
reagent (X56; IgG1; BD Immunocytometry Systems) added and incubated for a further 
30 min. The cells were then washed twice as before and resuspended in 200 μl of 
FACS. 
Two colour flow cytometric acquisition was performed on a FACScan™ flow 
cytometer (Beckton Dickinson) using CellQuest software (BD Biosciences, 
Immunocytometry Systems) or FACSCanto II using FACS Diva software as 
described previously in section 4.1.4.8. 
For perforin/CD8 staining, 4x105cells/well were fixed and permeabilised as 
previously described in Section 4.1.4.8.2. After permeabilisation the cell pellet was 
recovered by centrifugation and incubated in 25 μl of anti-human perforin monoclonal 
antibody δG9 (IgG2b) diluted 1:250 in PBS-Saponin and 25 μl of IL-A105 (IgG2a) 
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diluted 1:250 in PBS-Sap at 4°C for 30 min. Cells were washed twice with PBS-Sap 
as described previously and incubated in 50 μl of a 1:200 final concentration of FITC-
conjugated anti-mouse IgG2a and PE-conjugated anti-mouse IgG2b for 30 min at room 
temperature. The cells were washed two times with PBS-Sap and once with PBS by 
centrifugation and resuspended in 200 μl FACS fixative for two-colour flow 
cytometric acquisition and analysis as described before. IL-A105 (IgG2b) was used in 
place of IL-A51 (IgG1) because when used with the  anti-IgG2a FITC reagent it 
showed better discrimination of double positive staining cells in FACS profile 
analysis as compared to profiles obtained using the anti-IgG1 FITC reagent. 
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4.2 Results 
4.2.1 Studies with defined polyclonal and cloned CTL lines 
4.2.1.1 T cell receptor staining using BoLA class I-peptide complexes 
 BoLA class I-peptide complexes were synthesised and tetramers prepared at 
the Ludwig Institute for Cancer Research, Brussels, Belgium and shipped as PE 
conjugates for use at ILRI. Tetramer binding to antigen-specific TCRs was examined 
by staining CTL lines and clones showing the appropriate specificity as indicated in 
Table 11 and titrated to determine the optimum concentration for use in staining. 
These CTL lines and clones generated after TpM restimulation of PBMC from T. 
parva immune animals, had shown specificity for Tp1 (VGYPKVKEEML), Tp2 
(QSLVCVLMK), or Tp8 (CGAELNHFL) peptides using the IFN-γ ELISpot assay 
and exhibited specific lytic activity against autologous immortalised skin fibroblasts 
(iSF) transfected with the appropriate T. parva cDNA or COS-7 cells transfected with 
the restricting BoLA and peptide (Graham et al., 2006). CTL specific for Tp4 had not 
been successfully generated at the time of the study.  
Cell staining was carried out 14 days after the last restimulation. As shown in 
Figure 13, over 80% staining of BV115 clone 27, BV115 clone 20 and BX064 clone 5 
was observed with the Tp1, Tp2 and Tp8 tetramers, respectively, in comparison with 
a less than 1% background non-specific staining observed with an irrelevant CTL 
clone which was used as the negative control. The relevant tetramers were also able to 
discriminate and identify antigen-specific T cells in CTL lines. Additionally, the 
binding was titrated and covered a similar concentration range. Optimal staining was 
achieved at a tetramer dilution of 1/500 – 1/1000 corresponding to a final 
concentration of 20-10nm of tetramer, respectively. This was the lowest concentration 
of tetramer that yielded the highest percentage of tetramer positive events. These 
experiments demonstrate the specificity and potential usefulness of tetrameric class I-
peptide complexes in the identification of antigen-specific T cells.   
 Further analysis of the Tp1214-224, Tp298-106 and Tp8379-387 specific CTL clones 
stained with tetramers revealed the presence of two distinct T cell sub-sets in the flow 
cytometry dot plots corresponding to tetramer ‘high’ and tetramer ‘low’ staining T 
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Table 11: Cytotoxic CD8+ T cells used in determining specificity of tetramers 
Animal source CD8+ CTL Specificity 
    Tp1214-224 Tp298-106 Tp8379-387 Restricting class I BoLA
BV115 A10/A18 restricted polyclonal line  
+ 
+  N*01201 
N*01301 
BZ144 A10/KN104 restricted polyclonal line   + N*00101 
BV115 A10/A18 restricted clone 27 +   N*01301 
BV115 A10/A18 restricted clone 20  +  N*01201 
BX064 A10/KN104 specific clone 5   + N*00101 
Specificity of the CTL is denoted by (+).  
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Figure 13: Validation of bovine tetramers 
Specific cytotoxic CD8+ T cell lines and clones were stained with BoLA-N*01301-
Tp1214-224 tetramer (A) BoLA-N*1201-Tp249-59 tetramer (B) and BoLA-N*00101-
Tp8379-387 tetramer (C) and analysed by flow cytometry. The data is displayed as dot 
plots showing forward scatter (FSC) versus tetramer positive cells on FL2 
phycoethrin (PE). 
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cells. Dilution of tetramers gave progressively lower percentage values for the 
tetramer+ T cell sets with nearly 1.5-fold difference between percent epitope specific 
T cell population recovered at saturating tetramer (40nm) staining conditions and 
limiting tetramer (2.5nm) dilution conditions. This observation suggests that the cell 
lines were not clonal but epitope-specific T cell sub-sets within  the Tp1, Tp2, and 
Tp8 epitope-specific response with differing degress of expression of the particular 
TCR as defined by the interaction of TCR and pMHC complex.  
4.2.1.2 Double staining with CD8 monoclonal antibody and peptide MHC class I 
tetramers 
 To phenotype the tetramer positive population, BV115 A10/A18 restricted- 
and BZ144 A10-KN104 restricted polyclonal T cell lines were stained with tetramer 
followed by anti-CD8 antibody (IL-A51). Results obtained showed that tetramer 
positive cells are CD8 positive and the proportions of tetramer+CD8+ T cells were 
comparable to tetramer+ T cells. The dot blots also showed two distinct populations of 
the tetramer+CD8+ T cells corresponding to tetramerhighCD8+ and tetramerlowCD8+ 
staining T cell populations (Figure 14). Further to this, data obtained using Tp1 and 
Tp2 tetramers to stain BV115 polyclonal CTL line, also indicates that the CTL line 
comprises of CTL of other peptide specificities with Tp1 and Tp2 antigen-specific T 
cells accounting for nearly 50% or more of the CTL population. The same argument 
may be proposed for the composition the BZ144 CTL line, with Tp8-specific CTL 
accounting for 18% of the CTL population with the remainder being CTL of other 
peptide specificities. 
4.2.1.3 Combination of tetramer staining and intracellular staining for perforin 
 Tetramer positive populations were stained for the expression of perforin 
using anti-human perforin antibody (δG9). A potential hindrance to intracellular 
staining of perforin in tetramer positive cells is the need for fixation and 
permeabilisation of the cells whose effect on the TCR and subsequently tetramer 
binding had not been established. Figure 15a shows staining of the BV115 polyclonal 
T cell line with Tp1- and Tp2- tetramers before or after fixation with 1% PFA and 
permeabilisation with 0.1% saponin in PBS solution. A near complete loss of tetramer 
binding was seen in cells pre-treated with PFA and saponin. However, cells stained 
with tetramers before fixation/permeabilisation maintained comparable levels of 
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Figure 14: Immunofluorescence double staining of cytotoxic CD8+ T cell lines 
with tetramer and anti-CD8 antibody 
BV115 polyclonal CTL and BZ144 polyclonal CTL were double stained with 20 nm 
of BoLA-N*01301 Tp1-tetramer, BoLA N*01301 Tp2-tetramer, 5 nm of BoLA-
N*00101-Tp8 tetramer respectively and anti CD8 antibody (IL-A51; IgG1). Dot plots 
are shown as log fluorescence intensity of CD8:FITC versus Tetramer:PE 
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Figure 15: Double immunofluorescence staining for tetramer and intracellular 
perforin 
To assess the effect of fixation and permeabilisation BV115 polyclonal CTL lines 
(columnsI II and III) were fixed and permeabilised as required for intracellular 
staining before or after staining with Tp1- or Tp2-tetramers (A). Panel B shows 
BV115 polyclonal CTL shown in column III stained for intracellular perforin using 
titrating amounts of mouse anti-perforin antibody (δG9, IgG2b) and 20 nm Tp1- or 
Tp2-tetramer.  PFA – paraformaldehyde 
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staining although a slight increase in tetramer+ populations was noted. An optimised 
protocol for combined tetramer and intracellular perforin staining was used to stain 
the polyclonal T cell lines for expression of perforin. Results obtained showed that 
tetramer+ cells expressed perforin and the level of Tp1 and Tp2 tetramer+perforin+ T 
cells was comparable to tetramer+ cells (Figure 15b). The proportion of Tp1 and Tp2-
antigen specific CTL expressing perforin in the BV115 CTL line was additionally 
comparable to that obtained by costaining tetramer with CD8 antibody as shown in 
Figure 14. 
4.2.2 Studies with ex vivo T cells 
4.2.2.1 Elimination of non-specific tetramer binding events 
 To analyse Tp1, Tp2, Tp4 and Tp8 specific T cell responses in animals 
following immunisation and challenge, PBMC were collected on alternate days and 
stained with tetramer and anti-CD8 monoclonal antibody. One of the early 
observations in analysis of the results was high background staining obtained when 
staining PBMC as compared to staining T cell lines and clones. This required a gating 
strategy to minimise non-specific tetramer binding events. The logic of the selection 
of tetramer-labelled cells is shown in Figure 16. Live cells were first gated based on 
scatter light distribution in an SSC vs FSC dot plot. For each sample approximately 
100,000 events were acquired within this gate (G1), with the appropriate 
compensation (spectral overlap) adjustment for fluorescein on FL1, phycoerythrin on 
FL2 and PerCP on FL3. Events within G1 were next gated with an additional region 
in an SSC vs FL-3 (CD8) dot plot (G2). To improve specificity, cells emitting high 
autofluorescence were gated out by displaying the cells in the FL-1 “empty channel” 
vs CD8 (FL-3) (G3) using a regional gate. A final region was placed around tetramer 
positive events that emerged as a discernible cluster of tetramer+ T above the negative 
population in a tetramer (FL-2) vs CD8 (FL-3) dot plot (G4). Assay validation was 
further improved by staining samples with irrelevant tetramers. Tetramer positive 
cells were expressed as frequencies of parent CD8+ population and lymphocyte (live 
gate) population as percentages as well reciprocal frequencies. Precursor frequencies 
were determined as a function of staining 4x105 cells/well.  
Using this strategy sources of non-specific binding were eliminated and 
compound gating also permitted the use of a liberal lymphocyte scatter panel that  
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Figure 16: Compound gating used to identify tetramer+CD8+ T cells 
Peripheral blood mononucleated cells (PBMC) from respective animals were stained 
with tetramer followed by anti-CD8 monoclonal antibody using two-colour flow 
cytometry. To obtain a clearly discernible cluster of tetramer+ cells (G4) gates within 
an extended live lymphocyte light scatter (G1), CD8+ gate (G2) and selection of cells 
without autofluorescence (G3) were used. Results are shown for six independent 
PBMC samples from BB001, BB006, BB007, BB069, BB070 and BB169 (A-F) 
stained with BoLA N*00101-Tp8-tetramer and ILA-51. 
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does not exclude large activated T cells. However, a ‘smear’ of tetramer+CD8+ cells 
was often detected, which included a significant number of cells with ‘low’ and ‘high’ 
and low tetramer staining intensity. Generally better compensation was seen using PE 
and PerCP fluorochromes visualised by a large separation between positive and 
negative populations as compared to FITC and PE double stains. 
Using the above strategy a distinct population of Tp1 tetramer+CD8+ T and 
Tp8 tetramer+CD8+ T cells was repeatedly stained in PBMC samples from A18 and 
A10-KN104 animals, respectively. However, it was not possible to demonstrate a 
clearly discernable cluster of Tp2 and Tp4 tetramer+CD8+ T cells which were at least 
one log above the mean fluorescence intensity of the negative population in PBMC 
samples from the respective BoLA matched animals. For all tetramers, low levels of 
tetramer+CD8+ T cells were detected in PBMC of BoLA-mismatched donors. As 
these events were non-specific by definition, this data set was used to empirically 
determine the lower limit of detection of the assay as reported in section 4.2.2.3. 
4.2.2.2 Log transformation of data and the use of geometric mean 
 Examination of the raw data using normal probability plots showed that the 
raw data, expressed as reciprocal frequencies, was left skewed and did not conform to 
a normal distribution invalidating the use of parametric tests for data analysis and 
interpretation. For the four tetramers used in this study, taking the log of the 
reciprocal frequency was seen to bring data into conformation with a normal 
distribution with the mode and median values closer to the mean (Figure 17). Log-
transformation of the reciprocal frequencies resulted in more symmetric data 
distribution with the mode and median values closer to the mean. Accordingly, 
descriptive statistics (means, standard deviation (SD), confidence intervals (CI) and 
statistical analyses (Student’s t-test) were performed on log-transformed reciprocal 
frequencies. 
4.2.2.3 Definition of the lower limit of detection of tetramer positive cells 
 Despite application of the gating strategy described in section 4.2.2.1, low 
levels of tetramer+CD8+ T cells were detected in PBMC of BoLA-mismatched 
donors. As these events were considered non-specific, a cut-off for the lower 
detection limit of each of the tetramers was established at the upper 99th percentile of 
geometric mean frequency of tetramer+CD8+ T cells in BoLA mismatched samples 
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Figure 17: Tetramer frequency data are log normally distributed 
Reciprocal frequency data (left) and log-transformed reciprocal frequency data (right) 
from the analysis using the four tetramers are displayed as frequency histograms.  
Without log-transformation, the data are poorly represented by the normal 
distribution.  This invalidates the use of parametric tests and renders the mean and 
standard deviation (SD) poor descriptors of the data set. 
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(geometric mean + 2.6SD). The limit of detection of BoLA-N*01301-Tp1 tetramer 
was determined to be 1/7440, and 1/3768, 1/4068 and 1/12287 for BoLA-N*01201-
Tp2, BoLA-N*00101-Tp4 and BoLA-N*00101-Tp8 tetramers,respectively (Table 
12a). 
 These cut offs were then applied to data obtained from testing BoLA matched 
animals to determine differences between positive and negative events (Table 12b). 
For Tp1 and Tp8 tetramers, the detectable frequencies of Tp1-tetramer+CD8+ and 
Tp8-tetramer+CD8+ events were significantly higher than the established cut-off 
(p<0.001) with a mean of 1/862 and 1/6931 for Tp1-tetramer+CD8+ and Tp8-
tetramer+CD8+ events, respectively. However the difference between most Tp2-
tetramer+CD8+ (mean=1/2861), Tp4-tetramer+CD8+ (mean=1/5712) and negative 
events was not statistically significant with less than 50% of Tp2-tetramer+CD8+ and 
Tp4-tetramer+CD8+ events above the cut-off values. These two tetramers were 
characterised by non-specific binding and ambiguous staining of CD8+ populations 
making it difficult to clearly determine tetramer positive events suggesting that the 
sensitivity of staining with these tetramers may be just below threshold levels.  
4.2.3 Evaluation of antigen-specific CD8+ T cells in cattle after live vaccine 
immunisation and challenge with T. parva sporozoites 
 Five animals, BB001, BB006, BB007, BB069 and BB169 were immunised by 
ITM and challenged in this study whereas BB070, BV115 and BX063, (the latter two 
already ITM immunised in earlier studies) were challenged with sporozoites. All 
seven ITM immunised animals survived as expected whereas BB070, an animal not 
previously exposed to T. parva nor ITM vaccinated, succumbed to ECF 21 days  
following challenge with T. parva.  Five of the ITM animals, BB001, BB006, BB007, 
BB069 and BB169 were protected against secondary infection with T. parva while 
BV115 and BX063 remained immune to infection after repeated challenge. As 
mentioned in materials and methods, BV115 and BX063 had previously been 
immunised by ITM and challenged for use in other studies. Experimental animal 
records are shown in Appendix IX. Of the five animals immunised during the study 
two animals, BB001 and BB006, were characterised by a a vaccine break-through 
infection during the course of immunisation which necessitated treatment with 
Butalex.  
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Table 12a: Summary statistics of background levels 
Tetramer Geometric mean 
P<0.001 
Std error of means Cut-off  
(geometric mean+2.6SD)
BoLA-N*01301-Tp1 3.872 (7438) 0.07 7440 
BoLA-N*01201-Tp2 3.577 (3766) 0.06 3768 
BoLA-N*00101-Tp4 3.610 (4063) 0.06 4064 
BoLA-N*00101-Tp8 4.090 (12286) 0.04 12287 
Reciprocal frequencies of the geometric mean are shown in parentheses 
 
 
Table 12b: Means of tetramer+CD8+ events 
Tetramer Reciprocal 
frequency 
Geometric  mean 
P<0.01 
Std error of 
means 
P-probability 
BoLA-N*01301-Tp1 862 2.940 0.115 <0.001 
BoLA-N*01201-Tp2 2861 3.4580 0.078 NS 
BoLA-N*00101-Tp4 5712 3.757 0.05 NS 
BoLA-N*00101-Tp8 6931 3.841 0.06 <0.001 
P-probability is derived from general linear regression to determine differences 
between positive events and negative events. 
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Tetrameric complexes were used for a quantitative analysis of the intensity and 
kinetics of T. parva specific CD8+ T cell response in relation to T. parva infection 
following ITM vaccination as well as after a subsequent challenge infection.  
The results obtained showed that the epitopes on T. parva antigens Tp1, Tp2, 
Tp4 and Tp8 are recognised by animals expressing the relevant MHC class I 
restricting genotype. The data obtained and presented hereafter also shows that T. 
parva specific CD8+ T cells are circulating following vaccination as well as challenge 
infection and the appearance of tetramer+CD8+ T cells coincided with the 
demonstration of schizont parasitosis in lymph node biopsies shown in Appendix IX. 
Additionally the antigen-specific CD8+ T-cells were shown to express perforin and 
correlated with peptide-specific cytotoxic activity in bulk cultures, a described below. 
4.2.3.1 Intensity and kinetics of T. parva antigen specific CD8+ T cell activity in 
 PBMC 
 Almost all animals generated significant CD8 T cell responses to antigens for 
which they expressed the restricting class I molecule. The average frequencies of 
Tp1-, Tp2-, Tp4- and Tp8- specific CD8+ T cells are reflected and summarised in 
Table 13a and Table 13b  as well as Figure 18a. FACs dot-plot profiles are shown in 
Appendix X. The responses to Tp2 and Tp4 were generally poor with the significant 
values being close to the mean threshold value. T cells reactive with the BoLA-
N*01301 restricted (VGYPKVKEEML) peptide from Tp1 antigen were detected in 
PBMC ranging between 0.12% and 8.76% of CD8+ T cells from the two A18+ 
animals before challenge and in all 3 animals after challenge. T cells reactive with the 
BoLA N*00101 restricted (CGAELNHFL) peptide from Tp8 antigen was detected in 
all four A10-KN104+ cattle before and after challenge and ranged from 0.04% to 
6.76% of circulating CD8+ T cells. The results obtained above indicate that in 
peripheral blood a frequency of T cells specific for a single T. parva epitope to be 
estimated at a range between 1:2876 to as high as 1:36 (for the Tp1 specific T cells) 
or 1:12518-1:68 (for Tp8 specific T cells) of the total lymphocyte population. The 
frequency of T cells specific for the BoLA-N*00101 restricted Tp4 peptide 
(TGASIQTTL) was significantly lower ranging from at 0.11% - 1.74% of circulating 
CD8+ T cells (1:3964-1:280) and was detected in all four A10-KN104+ animals after 
immunisation. However significant levels of Tp4 specific CD8 T cells were observed 
after challenge in only three of the four A10-KN104+ cattle and even in these cattle,  
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Table 13a: Average frequency of Tp1- Tp2- Tp4 and Tp8 specific CD8+ T cells in peripheral blood in individual animals after ITM vaccination and 
  sporozoite challenge 
 
Average frequencies are given as reciprocal frequencies 
n-samples collected over a 2-3 week period following immunization or sporozoite challenge 
s.e.-  standard error of means  
p - probability 
ND not determined.  
*Animals were not immunised because they were already T. parva immune having been immunised by ITM in previous studies. However these two 
animals were subjected to sporozoite challenge 
Average statistics of antigen specific CD8+ T cell responses in individual animals 
after post live-vaccine immunisation and sporozoite challenge. (confidence level 95%) 
Post live vaccine immunisastion Post sporozoite challenge 
 Tp1 Tp2 Tp4 Tp8 Tp1 Tp2 Tp4 Tp8 
BB001 ND  1 :3280 s.e. 0.12 P=0.002 n=18 
1:1644 s.e. 0.21 
P=0.025 n=18 
1:1810 s.e 0.15 
P=0.003 n=13  
1:9166 s.e. 0.18 
P= 0.004 n=14 
1:6296 s.e. 0.06 
P=0.001 n=14 
BB006  1 :2610 s.e. 0.10 P=0.002 n=14    
1:3136 s.e. 0.12 
P=0.003 n=14   
BB007 1 :249 s.e. 0.16 P=0.004 n=14    
1:997 s.e. 0.17 
P=0.004 n=12    
BB069   1:3845 s.e. 0.13 P=0.003 n=18 
1:1487 s.e. 0.18 
P=0.004 n=19   
1:8887 s.e 0.15 
P=0.003 n=14 
1:10162 s.e 0.01 
P=0.002 n=14 
BB070   1:5965 s.e. 0.11 P=0.002 n=19 
1:17700 s.e 0.01 
P=0.002 n=19   
1:10427 s.e. 0.139 
P=0.003 n=14 
1:16218 s.e 0.08 
P=0.002 n=14 
BB169   1 :3038 s.e. 0.12 P=0.0025 n=19 
1:10798 s.e. 0.11 
P=0.002 n=18   
1:10149 s.e. 0.13 
P=0.003 n=14 
1;18064 s.e. 0.11 
P=0..002 n=14 
BV115* ND ND   1:1663 s.e. 0.21 P=0.001 n=5 
1:7580 s.e. 0.12 
P=0.003 n=5   
BX063*   ND ND   1:2430 s.e. 0.3 P=0.001 n=14 
1:2656 s.e 0.008 
P=0.002 n=12 
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Table 13b: Antigen specificity of CD8+ T cells in animals after live-vaccine  
  immunisation and challenge 
 
Responses are scored as positive, weak or below detection limits by comparing the 
average post-immunisation and post challenge frequencies in each individual animal 
to the threshold determined for the tetramer shown in Table 12a. 
aT. parva-immune animals 
bCD8+ T cells detected by tetramer staining indicated as positive (+) or negative (-) 
cnon-immunised control animal challenged with sporozoites 
Ф responses were present but weak nearing threshold values 
ND – not determined 
BDL – below detection limit 
 
Class I BoLA restricting 
allele 
(associated serotype) 
Animal Antigen specific CD8+ T cells in PBMCb 
  Post-immunisation Post-challenge 
  Tp1 Tp2 Tp4 Tp8 Tp1 Tp2 Tp4 Tp8 
 
N*01301 (A18) BB001 ND    +    
 BB007 +    +    
 BV115a ND    +    
N*01201 (T2a) BB006  Ф    Ф   
                (A10) BV115a  ND    BDL   
N*00101 (A10-KN104) BB001   Ф +   BDL + 
 BB069   Ф +   BDL Ф 
 BB070c   BDL BDL   BDL BDL
 BB169   Ф Ф   BDL BDL
 BX063a   ND ND   + + 
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the responses appeared to be poor with frequencies observed being close to cut-off 
values. Tp2 specific responses appeared to be short lived with BoLA-N*01201 
restricted Tp2 (QSLVCVLMK) peptide reactive cells when detected at significant 
levels, were at a range between 0.14%-0.75% of circulating CD8+ T cells (1:2648-
1:750) in the two expressing N*01201 class I restricting genotype. No antigen 
specific CD8+ T cells were detected in BB070, a non-immune animal that was used as 
a negative control in the study. 
The onset, duration, magnitude and peaking of the CD8+ T cell response 
following ITM immunisation differed from animal to animal as well as the antigen. 
Tp1 specific T-cells were first detected 12 days after immunisation and increased 
significantly peaking by day 19 to constitute 8.76% of circulating CD8 T cells in 
BB007, while Tp2 responses were in most instances undetectable in the two animals 
expressing BoLA N*1201 although in BB006 significant levels were detected from 
day 17, albeit at a low frequency of approximately 1:1000 lymphocytes. Tp4 and Tp8 
specific CD8 T cell responses were detected between days 9-12. Significant responses 
to Tp4 were observed at frequencies between 1:2000-1:5000 lymphocytes on average 
while Tp8 responses were most significant in two animals, BB001 and BB069, and 
were observed to peak at 1:223 (1.73% of CD8+ T cells) and 1:68 (6.76% of CD8+ T 
cells), on days 20 and 17 respectively. Tp8 responses in BB169 remained on average 
at 1:5500 lymphocytes after immunisation. After challenge infection the magnitudes 
of the responses were variable with the three animals expressing BoLA N*01301, 
(BB001, BV115 and BB007) showing a clear recall of Tp1 responses. Tp1-specific 
responses increased from pre-challenge levels by day 7/9 although the magnitude of 
the responses was below that observed after immunisation. Tp2– and Tp4– specific 
responses remained below detection limits at most sampling time points while there 
was no significant increase in Tp8-specific T cells from pre-challenge levels although 
frequencies remained just above threshold values.  
4.2.3.2 Immunodominance hierarchy of CD8+ T cell responses after live vaccine 
immunisation and parasite challenge 
 In animals that responded to more than one antigen, comparing the relative 
numbers of T cells in response to Tp1, Tp2, Tp4 and Tp8 was used to determine the 
immunodominance hierarchy of the CD8+ T cell responses directed against multiple 
pathogen-derived epitopes. Figure 18b shows the relative numbers of Tp1, Tp2, Tp4  
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Figure 18a: Antigen-specific CD8+ T cell responses in animals after live vaccine 
immunisation and subsequent challenge with sporozoites 
Peripheral blood mononucleated cells (PBMC) harvested from animals after live 
vaccine immunisation (panel A) and subsequent challenge with T. parva sporozoites 
(panel B) were stained with Tp1- Tp2- Tp4- or Tp8- tetramers followed by anti-CD8 
antibody (ILA-51).  Antigen-specific CD8+ T cell frequencies are determined per 
4x105 cells that were stained in a well. FACS dot plots are shown in Appendix X. 
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Figure 18b: Immunodominance hierarchy of antigen-specific CD8+ T cell 
responses in animals expressing more than one defined class I BoLA 
allele 
Peripheral blood mononucleated cells (PBMC) harvested from animals after live-
vaccine immunisation (panel A) and subsequent challenge with T. parva sporozoites 
(panel B) were stained with Tp1- Tp2- Tp4- or Tp8- tetramers followed by anti-CD8 
antibody (ILA-51).  Antigen-specific CD8+ T cell frequencies are determined per 4 x 
105 PBMC that were stained in a well. 
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and Tp8 epitope-specific CD8+tetramer+ cells T cells in individual animals after live 
vaccine immunisation and secondary challenge with parasite. BoLA N*00101-
restricted Tp8 responses are shown to dominate over BoLA N*00101-restricted Tp4 
responses during priming as shown in A10-KN104+ animals except in BB169 where 
Tp4 epitope-specific CD8+ T cell responses appear to dominate. Data comparing 
BoLA N*01301-restricted Tp1, BoLA N*01201-restricted Tp2, and BoLA N*00101-
restricted Tp4 and Tp8 responses after immunisation was not available for analysis in 
this experiment. 
Comparison of the CD8+ T cell response after secondary challenge showed 
that memory T cells recognising epitopes derived from Tp4 and Tp8 did not expand 
as vigorously compared to the primary response and the levels remained just within or 
below the threshold detection limits. In contrast, BoLA N*01301-restricted Tp1 
specific T cells expanded during the secondary challenge and were the dominant T 
cell population among the tested epitope specificities. This is well illustrated in 
BB001 whose MHC serotype A18+/A10-KN104+ is associated with the restricting 
alleles BoLA N*01301, BoLA N*00101. If precursor frequency is merely the critical 
factor in determination of immunodominance of the Tp1-specific recall response then 
it is possible to hypothesise that BoLA N*01301-restricted Tp1 response also 
dominates during the primary challenge. This dominance of the Tp1-specific response 
also appears to be maintained after multiple challenge events as illustrated in BV115 
whose MHC serotype A18+/A10+ is associated with the restricting alleles BoLA 
N*01301 and BoLA N*01201. 
4.2.3.3 T. parva tetramer+ CD8+ T cells express perforin and are cytolytic 
The optimized protocol for combined tetramer and intracellular staining was 
used to examine the phenotype of circulating CD8+ T-cells specific for Tp1, Tp2, Tp4 
and Tp8 in PBMC collected on days 19, 20 and 21 post vaccination were stained with 
tetramer and anti-perforin antibodies as well as anti-CD8 and anti-perforin antibodies. 
Results obtained and shown in Figure 19 demonstrated Tp1- and Tp8-tetramer+ 
perforin expressing T cells. The frequencies of tetramer+perforin+ T-cells were 
comparable to the frequency of tetramer+CD8+ T-cells. Perforin staining levels in 
PBMC were however noted to be significantly reduced as compared to that stained in 
CTL lines and clones (Figure 15a, Section 4.2.1.3). 
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Figure 19: Staining of peripheral blood mononucleated cells with tetramer and 
anti-perforin antibodies 
Peripheral blood mononucleated cells harvested on  days 19, 20 and 21 post live 
vaccine immunisation were stained with IL-A105 (anti-CD8 monoclonal antibody; 
IgG2a) , Tp1- Tp2- Tp4- or Tp8- tetramers and anti-perforin antibody (δG9; 
IgG2b).Dot plots show log flourescence intensity of perforin-FITC:FL1 and tetramer 
or CD8-PE:FL2 
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The functional relevance of tetramer+ CD8+ T cells was determined by 
antigen-specific CTL activity against peptide-pulsed lymphoblasts. Bulk cultures 
assayed for cytotoxic activity against autologous T. parva infected cells (TpM) and 
peptide-pulsed targets after one round of restimulation with TpM of PBMC harvested 
12 days post-ITM and 14 days post-challenge. The data obtained is summarised in 
Table 14. Whereas TpM-specific killing activity was observed in PBMC post-ITM 
and challenge, cytotoxicity on peptide-pulsed targets was observed in all seven 
animals after the challenge infection. Only post-ITM PBMC from BB069 showed 
peptide-specific cytotoxic activity albeit at a low level (0.1%). Examination of FACS 
data obtained from staining the PBMC samples from the two time points (Appendix 
X) showed no or very low frequencies of tetramer staining cells on day 12 post-
immunisation and a significant number of tetramer positive cells on day 14 post-
challenge. Coupled with the low sensitivity associated with bulk cultures, it is likely 
that peptide-specific T-cells in PBMC sampled day 12 post-immunisation failed to 
proliferate sufficently relative to other cell types. Peptide-specific cytotoxic activity 
ranged from 1%-15% specific lysis and was observed in PBMC sampled on day 14 
after challenge. Specifically, BoLA-N*01301 restricted Tp1 peptide specific 
cytotoxicity was detected at 15% specific lysis in BB007 (E: T ratio 40:1) whereas 
BoLA-N*00101 restricted Tp4 and Tp8 peptide specific cytolytic activity in the 
relevant animals was comparatively low at <6% specific lysis but nonetheless 
suggesting lytic activity from antigen-specific CTL in the bulk culture. BoLA-
N*01201 restricted Tp2 peptide-specific cytolysis was observed to be at 13% E: T 
ratio 40:1. Given that Tp2 specific CD8+ T cells were undetectable, it’s likely that this 
cytotoxic activity may be due to non-specific killing of peptide-loaded targets. The 
bulk culture from BB006 showed a high level of non-specific killing of Con A 
activated lymphoblasts (9% E:T ratio 40:1) (Appendix XI). Similarly, peptide-specific 
cytotoxic activity in PBMC from BB070 (11%), a non-immunised animal, is likely 
due to non-specific killing of peptide-loaded targets. Cytotoxic activity of the bulk 
cultures is shown in Appendix IX. 
4.2.3.4 Comparison of ELISpot assay and peptide-MHC tetrameric complexes in 
 detection and enumeration of T. parva antigen-specific T-cells 
Antigen-specific CD8+ T cell-mediated IFN-γ responses were measured in 
PBMC obtained at selected time points in the course of the experiment. With the  
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Table 14: Cytotoxic activity of short-term (primary) T cell cultures and corresponding tetramer+CD8+ T cell frequencies after live 
vaccine immunisation and sporozoite challenge 
BoLA class I restricting allele 
 (associated serotype) 
Animal c,dPeptide-specific CD8+ T cell cytotoxic activity after 
 live vaccine immunisation (Frequency of tetramer+CD8+ T cells) 
  TpM Tp1214-224 Tp298-106 Tp4328-336 Tp8379-387 
N*01301 (A18) BB001 72% (2.6x105) 0%(ND)    
 BB007 85% (4.3x105) 0% (568)    
 BV115 ND ND    
N*01201 (T2a) BB006 90% (5.6x105) 0% (BDL)   
               (A10) BV115a ND  ND   
N*00101 (A10-KN104) BB001 72% (2.6x105)  0% (BDL) 0% (563) 
 BB069 90% (3.7x105)  0% (2x103) 0.1% (8.2x103) 
 BB070b 0% (2.7x105)  0% (BDL) 0% (BDL) 
 BB169 0% (4.0x105)  0% (2x103) 0% (396) 
 BX063a 3% (5.59x105)  0% (1.0x103) 0% (800) 
  c,eAntigen-specific CD8+ T cell cytotoxic activity after sporozoite challenge 
(Frequency of tetramer+CD8+ T cells) 
  TpM Tp1214-224 Tp298-106 Tp4328-336 Tp8379-387 
N*01301 (A18) BB001 21% (3.5x105) 1%(2.2x103)   
 BB007 40% (4.3x105) 15%(4.8x103)   
 BV115a ND ND    
N*01201 (T2a) BB006 0% (5.1x105) 13% (BDL)  
                (A10) BV115 ND  ND   
N*00101 (A10-KN104) BB001 72% (2.6x105)  5% (BDL) 0% (214) 
 BB069 16% (4.1x105)  0% (922) 6% (565) 
 BB070b 8% (9.6x104)  4% (BDL) 11% (BDL) 
 BB169 14% (1.6x105)  6% (BDL) 1% (BDL) 
 BX063a 73% (6.6x105)  5% (1.0x103) 1% (300) 
a T. parva immune animals 
b non-immunised control animal infected with sporozoites 
c peptide-specific cytotoxic activity is determined from short-term (primary) bulk cultures expressed as % cytotoxic activity at effector:target ratio of 40:1. 
Frequencies of tetramer+CD8+ is shown in parentheses and expressed per 2x106 PBMC except when using TpM as the target where the frequencies correspond to 
CD8+ T cells 
d primary cultures were set up with PBMC harvested on day 12 post-immunisation 
e primary cultures were set up with PBMC harvested on day 14 post challenge 
TpM - T. parva (Muguga) schizont-infected cells 
ND - not determined 
BDL - below detection limit 
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Table 15a: Antigen-specific IFN-γ responses following live-vaccine immunisation and challenge 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a T. parva immune animals 
b non-immunised control animal infected with sporozoites 
c ‘post-immunisation’ data is based on pre-challenge data as animal was already T. parva immune 
d IFN-γ response determined by ELISpot assay is shown as positive (+) or negative (-) 
IFN- interferon  
ND – not determined 
 
Class I BoLA restricting allele 
(associated serotype) 
Animal dIFN-γ responses to epitope 
  Post-immunisation Post-challenge 
  Tp1214-224 Tp298-106 Tp4328-336 Tp8379-387 Tp1214-224 Tp298-106 Tp4328-336 Tp8379-387 
N*01301 (A18) BB001 +    +    
 BB007 +    +    
 BV115a ND    ND    
N*01201 (T2a) BB006  -    -   
                (A10) BV115a  ND    +   
N*00101 (A10-KN104) BB001   + +   + + 
 BB069   + +   + + 
 BB070b   - -   - - 
 BB169   + +   + + 
 BX063a,c   + +   + + 
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exception of Tp2, responses to Tp1, Tp4, and Tp8 epitopes were detected before and 
after challenge as shown in Table 15a. Responses to Tp2 epitope appeared to be weak 
and below the assay detection limits. The Tp1-specific response was not detected until 
day 23 contrary to results obtained with tetramer staining which detected Tp1 specific 
T cells from around day 12 post immunisation. Tp4 and Tp8 specific T cells were 
detected by ELISpot on day 9/10 post-immunisation comparable to the results 
obtained by staining with Tp4 and Tp8 tetramers. Also in line with previous 
observations using tetramers, only the Tp1-specific response appeared to significantly 
increase from pre-challenge levels of 149 SFC/million PBMC to nearly 1000 
SFC/million PBMC by day 15 after challenge while there appeared to be no 
significant change in the response to Tp4 and Tp8 epitopes over the 15 day period 
after challenge. 
The frequencies of T cells reactive with Tp1, Tp4, and Tp8 epitopes were 
compared to the data obtained by parallel staining of the PBMC samples with the 
relevant tetrameric complex. As shown in Table 15b and c, ELISpot assays using T. 
parva antigen peptides indicated frequencies of Tp1-epitope specific T cells ranging 
from approximately 36-1400/106 PBMC, while Tp4 and Tp8 specific T cells ranged 
from 32-766/106 PBMC and 46-446/106 PBMC. Estimated frequencies of tetramer 
positive cells in corresponding samples were generally seen to be higher than those 
obtained by ELISpot assays. The frequency of BoLA N*01301 restricted Tp1 epitope 
ranged from 262-1986/106 PBMC while the frequencies of BoLA N*00101 restricted 
Tp4- and Tp8-epitopes ranged from 100-706/106 PBMC and 100-2500/106 PBMC, 
respectively. While the low frequencies obtained by the ELISpot may suggest sub-
optimal performance of the assay in using PBMC as the responder population, it is 
also likely that the tetramers could be binding to T-cells that may not secrete IFN-γ 
upon stimulation. 
4.2.4 Evaluation of responses induced by immunisation of cattle with T. parva 
antigens expressed individually in vaccine constructs 
 Access to cryopreserved PBMC from animals subjected to heterologous 
prime-boost immunisation regimes with three of the T. parva antigens (Graham et al., 
2006, unpublished data) by using separate vaccine constructs for each antigen 
provided an opportunity to use tetramers to assess CD8+ T cells induced in response  
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Table 15b: Frequencies of Tp1-, Tp2-, Tp4- and Tp8-antigen specific IFN-γ secreting T cells and tetramer+CD8+ T cells after 
immunisation 
Epitope Class I restricting 
element 
(associated serotype) 
Animal Day post-immunisation 
   8 9 10 11 23 43 
Tp1214-224- VGYPKVKEEML N*01301 (A18) BB001 ND ND ND ND 274 (ND) 250 (504) 
  BB007 0 (BDL) 0 (BDL) 0 (BDL) 0 (BDL) 374 (8476) 48 (360) 
  BV115 ND ND ND ND ND ND 
 
Tp298-106 - QSLVCVLMK N*01201 (T2a) BB006 BDL BDL BDL BDL BDL BDL 
                 (A10) BV115 ND ND ND ND ND ND 
 
Tp4328-336 - TGASIQTTL N*00101 (A10-KN104) BB001 28 (584) 196 (706) 22 (270) 0 (362) 0 (173) 66 (446) 
  BB069 0 (BDL) 50 (BDL) 0 (BDL) 482 (553) 0 (BDL) 32 (BDL) 
  BB169 8 (BDL) 0 (BDL) 2 (BDL) 480 (379) 0 (349) 6 (724) 
  BX063 ND ND ND ND ND 6 (615) 
 
Tp8379-387 - CGAELNHFL N*00101 (A10-KN104) BB001 0 (BDL) 0 (BDL) 0 (BDL) 78 (214) 322 (2516) 50 (148) 
 BB069 0 (BDL) 14 (292) 58 (239) 446 (239) 50 (632) 0 (BDL) 
 BB169 0 (BDL) 2 (BDL) 292 (110) 158 (BDL) 4 (141) 0 (113) 
 BX063 ND ND ND ND ND 2 (400) 
Values from IFN-γ ELISpot and staining with tetramers (shown in parentheses) are given per 106 PBMC 
ND – not determined 
BDL – below detection limit 
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Table 15c: Frequencies of Tp1-, Tp2-, Tp4- and Tp8-antigen specific IFN-γ secreting T cells and tetramer+CD8+ T cells after sporozoite             
  challenge 
Values from IFN-γ ELISpot and staining with tetramers (shown in parentheses) are given per 106 PBMC 
ND – not determined 
BDL – below detection limit 
 
Epitope Class I restricting 
element (associated 
serotype) 
Animal Day post-challenge 
   5 6 7 8 9 13 15 
Tp1214-224- VGYPKVKEEML N*01301 (A18) BB001 314 (477) 14 (522) 568 (1161) 68 (1105) 60 (1105) 316 (1611) 476 (1986) 
  BB007 70 (262) 70 (282) 72 (310) 0 (276) 36 (328) 1316 (5445)  1420 (5934) 
  BV115 ND ND ND ND ND ND ND 
 
Tp298-106 - QSLVCVLMK N*01201 (T2a) BB006 BDL BDL BDL BDL BDL BDL BDL 
                 (A10) BV115 ND ND ND ND ND ND ND 
 
Tp4328-336 - TGASIQTTL N*00101 (A10-KN104) BB001 152(BDL) 0 (388) 108 (BDL) 174 (246) 34 (BDL) 0 (BDL) 0 (BDL) 
  BB069 162(BDL) 0 (BDL) 0 (BDL) 0 (BDL) 10 (BDL) 0 (BDL) 162 (B) 
  BB169 0 (BDL) 362 (BDL) 208 (BDL) 34 (118) 28 (BDL) 766 (BDL) 88 (BDL) 
  BX063 72 (115) 80 (137) 10 (BDL) 100 (110) 44 (49) 0 (222) 44 (183) 
 
Tp8379-387 - CGAELNHFL N*00101 (A10-KN104) BB001 286 (254) 0 (235) 138 (216) 248 (192) 56 (172) 100 (116) 100 (329) 
 BB069 164 (134) 0 (132) 0 (BDL) 0 (BDL) 72 (109) 0 (202) 16 (122) 
 BB169 0 (355) 0 (126) 74 (BDL) 16 (BDL) 0 (BDL) 30 (BDL) 180 (147) 
 BX063 28 (1000) 118 (1100) 0 (100) 182 (500) 28 (300) 0 (500) 106 (700) 
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to immunisation with defined antigens. Animals were immunised with recombinant 
canary pox viruses expressing Tp2, Tp4 and Tp8. After 4 weeks the animals received 
a booster dose of recombinant modified vaccinia virus (Ankara strain) (MVA) 
expressing the same antigens and were then challenged with T. parva sporozoites 
after 3 weeks (Graham et al., 2006, unpublished data). Specific CD8 T cell responses 
to the three antigens were examined every seven days by using peptides in an IFN- 
ELISpot and by CTL activity against peptide-pulsed lymphoblasts (Graham et al., 
unpublished data) and the summary are presented in Table 16a. Tetrameric complexes 
were used to stain cryopreserved PBMC after immunisation with MVA and challenge. 
 Results obtained using tetramers showed that with the exception of three 
animals (BA021, BA031 and BZ188-refer to Table 16a), 10 other animals generated 
responses to antigens for which the animal expressed the corresponding class I 
restriction genotype (Table 16b). Responses to Tp2 were generally poor with only 
three of six BoLA T2a+ animals giving significant responses. T cells reactive to the 
BoLA-N*01201 Tp2 restricted epitope ranged from 0.02%-0.79% of circulating CD8+ 
T cells corresponding to a frequency of 1:5108-1:126 lymphocytes. Frequencies of 
BoLA-N*00101 restricted Tp4 epitope restricted CD8 T cells were detected above 
threshold level in four of the seven A10-KN104+ animals ranging from 0.02%-0.14% 
of circulating CD8+ T cells (1:4900-1:733 lymphocytes) while significant BoLA 
N*00101 restricted Tp8 epitope restricted CD8 T cells were detected in all seven 
animals and ranged from 0.06%-0.09% of CD8 T cells (1:17000-1:1066 lymphocytes) 
above the cut-off value. This data is summarised in Table 16c. Following challenge 
infection, the majority of the animals (6/10) showed a clear recall of the responses 
with seven of the animals having higher frequencies of antigen-specific T cells than 
the frequencies observed after the MVA booster immunisation and two (BA091 and 
BA048) having comparable levels of antigen-specific T cells after MVA 
immunisation as well as challenge. Significant Tp4 and Tp8 specific responses could 
not be detected in BA064 and BA066 after challenge. The magnitude of responses 
varied between animals and antigens but it was observed that in animals that 
responded to Tp4 and Tp8 both restricted by BoLA N*00101, Tp8 responses 
appeared to dominate over Tp4 responses in most instances. It was however noted that 
in some animals (BA064, BA067, BA093-refer to table 16a) at time points where 
levels of Tp4-tetramer+ T cells were above cut-off values, the magnitude of Tp4 
specific T cells were significantly higher than Tp8 specific T cells. CD8+ T cell  
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Table 16a: Summary details of cattle and their Tp2-, Tp4- and Tp8- antigen specific CD8+ T cell responses  
Animal class I BoLA serotype CD8+ T cell IFN-γ responses Peptide specific CTL activity 
   
Status 
(outcome to challenge)
    post-immunisation post-challenge post-immunisation post-challenge   
BA091 A10-KN104 + + + +      non-survivor 
BA063 A10-KN104 - + - -      Survivor 
BA064 A10-KN104 + + + -      Survivor 
BA066 A10-KN104 + + + +      Survivor 
BA067 A10-KN104 + + - -      Survivor 
BA075 A10-KN104 - + - -      Survivor 
BA093 A10-KN104 + + + -      Survivor 
BA021 A18/T2a - - - -      non-survivor 
BA024 T2a - - - -      non-survivor 
BA048 T2a + - - -      non-survivor 
BZ188 T2a - + - -      non-survivor 
BA031 T2a - - - -      Survivor 
BZ015 T2a - - - -      Survivor 
 
Animals were immunised with canary pox and modified vaccinia virus (Ankara strain) expressing Tp1, Tp2 and Tp8 antigens and challenged 
with sporozoites. Data is compiled from Graham et al., 2005, unpublished results. 
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Table 16b: Characterisation of the CD8+ T cell response in animals after prime-
boost immunisation with Tp2, Tp4 and Tp8 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
adetection of antigen specific CD8+ T cell response was determined by staining 
PBMC with Tp2- Tp4- or Tp8-specific tetramers. 
Class I restricting allele  
(associated serotype) 
Animal aAntigen specificity of  
CD8+ T cells in PBMC 
 
   Tp298-106 Tp4328-336 Tp8379-387 
N*00101 (A10-KN104) BA091  + + 
 BA063  - + 
 BA064  + + 
 BA066  - + 
 BA067  + + 
 BA075  - + 
 BA093  + + 
 
N*01201 (T2a) BA021 -   
 BA024 +   
 BA048 +   
 BZ188 -   
 BA031 -   
 BZ015 +   
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Table 16c: Summary statistics of Tp2- Tp4- and Tp8- specific CD8+ T cells in 
peripheral blood following vaccination with Tp2, Tp4 and Tp8  
 
 
 
 
 
 
avalues are given as reciprocal frequencies and % CD8+ T cell in PBMC and were 
determined by tetramer staining 
cthreshold value of individual tetramers is shown as reciprocal frequency and is 
calculated from the geometric mean + 2.6 standard deviation units of tetramer+CD8+ 
T cells from BoLA mis-matched PBMC samples. The standard error of means (s.e.) is 
shown in parentheses 
Tetramer aFrequency bCut-off values 
   
BoLA N*01201-Tp298-106 1:5108 – 1:126 1:6600 (s.e. 0.156) 
 0.02% - 0.79%  
BoLA N*00101-Tp4328-336 1:4900 – 1:733 1:4998 (s.e. 0.19) 
 0.02% - 0.14%  
BoLA N*00101-Tp8379-387 1:17000 – 1:1066 1:18117 (s.e. 0.204) 
 0.06% - 0.09%  
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responses in the animals are depicted in Figure 20 a and b.The identification of 
tetramer positive cells was correlated to cytotoxic activity detected in four of the 
vaccinates and the IFN-γ responses determined by ELISpot assay (Table 17a and b). 
The data obtained showed that with few exceptions, antigen-specific lytic activity 
paralleled the detection of peptide-specific CD8+ T cells as shown by tetramer 
staining. Expression of perforin by tetramer+ population was inconclusive as analysis 
of live gate events showed that the staining intensity of perforin was very low 
compared to the negative (unstained) control. In addition to high background levels, 
increased autofluorescence due to fixation and permeabilisation coupled with low 
frequencies of tetramer+ population also presented a challenge in differentiating 
positive and negative events. There was good correlation between results obtained 
from ELISpot assays and those obtained by direct staining with tetrameric complexes. 
However it was noted that tetramer positive cells were on the average four-fold lower 
than ELISpot estimates.  
 205
 
 
 
 
 
 
 
 
 
 
 
 
Figure 20a: Tp4- and Tp8-specific CD8+ T cell responses in A10-KN104+ animals 
Animals were immunised with Tp2, Tp4 and Tp8 expressed individually in canary 
pox virus and modified vaccinia virus-Ankara strain. Cattle were primed with canary 
pox virus (data not shown) and boosted with MVA viruses expressing the same 
antigens after four weeks. Data shows tetramer+CD8+ T cell responses detected after 
the MVA booster immunisation following which they were challenged with T. parva 
sporozoites after three weeks on Day 21.  
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Figure 20b: Tp2-specific CD8+ T cell responses in T2a+ animals 
Animals were immunised with Tp2, Tp4 and Tp8 expressed individually in canary 
pox virus and modified vaccinia virus-Ankara strain. Cattle were primed with canary 
pox virus (data not shown) and boosted with MVA viruses expressing the same 
antigens after four weeks. Data shows tetramer+CD8+ T cell responses detected after 
the MVA booster immunisation following which they were challenged with T. parva 
sporozoites after three weeks on Day 21 indicated by the arrow. 
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Table 17a: Peptide-specific cytotoxic activity of short-term (primary) T cell cultures and corresponding frequencies of tetramer+CD8+ T cells 
in peripheral blood 
 
 
 
 
 
 
 
 
 
apeptide-specific cytotoxic activity was determined from short-term (primary) T cell cultures and expressed as % cytotoxic activity at an effector 
ratio of 40:1. Frequencies of tetramer+CD8+ T cells in PBMC on the day that the primary culture was set up is shown in parentheses and 
expressed per 2x106 PBMC except when using TpM as the target where the frequencies correspond to the CD8+ T cell population. Cytotoxic 
activity data is obtained from a previous experiment by Graham et al., 2006, unpublished data.  
BDL - below detection limit.. 
TpM - T. parva (Muguga) schizont-infected cell 
 
Class I BoLA restricting allele 
(associated serotype) 
Animal aPeptide-specific CD8+ T cell 
cytotoxic activity 
  post- immunisation post-challenge 
  TpM Tp4328-336 Tp8379-387 
 
TpM Tp4328-336 Tp8379-387 
 
N*00101 (A10-KN104) BA064 17% (1.22x105) 52% (236) 8% (183) 0% (4.2x104) 0% (52) 8% (46) 
 BA066 3% (1.24x105) 34% (176) 6% (87) 4% (6.9x104) 41% (20) 2% (BDL)
 BA091 20% (1.35x105) 60% (448) 20% (759) 5% (1.04x105) 55% (562) 36% (780)
 BA093 0% (1.28x105) 41% (242) 3% (76) 0% (8.82x104) 0% (230) 0% (657) 
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Table 17b: Frequencies of Tp2-, Tp4- and Tp8-antigen specific IFN-γ secreting CD8+ T cells and tetramer+CD8+ T cells in 
peripheral blood 
Epitope Class I restricting element 
(associated serotype) 
Animal aFrequencies of  
epitope-specific CD8+ T cells 
    
Post-immunisation
 
Post-challenge 
 
Tp298-106 - QSLVCVLMK N*01201 (T2a) BA031 118 (BDL) 10 (BDL) 
  BZ188 106 (102) 16 (BDL) 
  BA021 0 (93) BDL 
  BZ015 22 (BDL) 40 (BDL) 
  BA024 BDL BDL 
  BA048 10 (301) 0 (343) 
 
Tp4328-336 - TGASIQTTL N*00101 (A10-KN104) BA067 0 (507) 0 (101) 
  BA091 1184 (448) 1454 (562) 
  BA064 1778 (236) 1288 (BDL) 
  BA093 1704 (242) 258 (230) 
  BA075 10 (BDL) BDL 
  BA063 26 (BDL) 184 (BDL) 
  BA066 BDL BDL 
 
Tp8379-387 - CGAELNHFL N*00101 (A10-KN104) BA067 4 (197) 0 (31) 
 BA091 0 (759) 0 (780) 
 BA064 1942 (183) 1762 (46) 
 BA093 2000 (76) 0 (652) 
 BA075 0 (48) 0 (561) 
 BA063 4 (45) 302 (143) 
 BA066 0 (87) 12 (0) 
 
aValues from IFN-γ ELISpot and staining with tetramers (shown in parentheses) are given per 106 PBMC harvested from animals after immunisation with 
Tp2, Tp4 and Tp8 antigens. ELISpot data is obtained from a previous experiment by Graham et al., 2006, unpublished data. 
ND – not determined 
BDL – below detection limit 
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4.3 Discussion 
Bovine MHC class I molecules, N*01301, N*01201 and N*00101, β2-
microglobulin and a peptide epitope derived from T. parva antigens Tp1, Tp2, and 
Tp4 or Tp8, (Graham et al., 2006, 2007, 2008) were used to construct soluble peptide-
MHC complexes (tetramers) at LICR. These MHC class I tetramers were able to 
detect antigen specific T cells in cell lines expanded from PBMC in vitro and the 
specificity of the tetramers was also demonstrated. Tetramer staining of CTL lines 
and clones derived from PBMC from immune cattle identified what appeared to be 
two distinct sub-sets of CD8+ T cells specific for Tp1214-224, Tp298-106 and Tp8379-387 
epitopes. The differential binding of the MHC class I-peptide complexes to CD8+ T 
cells resulting in tetramerhigh and tetramerlow T cell populations, showed that a 
tetramer dilution assay provides a potential mechanism for analysis of TCR diversity 
within within a defined antigen-specific CD8+ T cell pool. Few articles describe the 
construction of bovine tetramers (Norimine, Han and Brown, 2006; Han et al., 2008; 
Guzman, Birch and Ellis, 2010) and tetramers generated in this study would be the 
first successful construction of bovine MHC class I-peptide complexes that can be 
used to analyse CD8+ T cell responses in cattle following immunisation or infection 
with T. parva. Some of these tetramers have since been used to study immunological 
dominance of the CD8 T cell response in cattle (MacHugh et al., 2009) as well as to 
define peptide binding to bovine MHC class I molecules (Macdonald et al., 2010). By 
directly binding the TCR the tetramers generated further presents reagents with a 
potential of being used as a tools for the analyses of TCR diversity. 
Cattle can be immunised against T. parva by inoculation of live sporozoites 
and simultaneous treatment with a long-acting formulation of oxytetracycline (Radley 
et al., 1975a and b). One mechanism of protection induced by ITM is based on MHC 
class I-restricted cytotoxic CD8+ T cell which target the schizont-infected 
lymphoblast (Morrison et al., 1987; McKeever et al., 1994). These previous studies 
demonstrated CTL in PBMC and efferent lymph from T. parva-immunised cattle 
following homologous or heterologous parasite challenge. In this study, MHC class I-
peptide complexes were used to demonstrate primary T. parva antigen-specific T cell 
responses following infection during immunisation and the recall of memory T cells 
with subsequent challenge. Based on tetramer binding of CD8+ T cells specific for 
epitopes on Tp1, Tp2 and Tp4 and Tp8 data obtained demonstrated a range of 0.75% - 
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8.76% of the activated CD8 T cells being specific for a single epitope at the peak of 
the primary response. As data obtained with Tp2 epitope- and Tp4 epitope-specific 
tetramers was statistically insignificant the functional relevance of the responses 
observed using these tetramers at specific time points is unclear nearly 50% of the 
animals survived and yet they did not exhibit a detectable CTL response as 
determined by cytotoxic activity. Several reasons may be advanced and this may 
include but not be limited to prior exposure to T. parva. Nonetheless, the detection of 
responses to Tp1 and Tp8 supports previous evidence that infection with T. parva 
induces a CD8+ T cell response and that these antigens are immunodominant in line 
with previous observations (Graham et al., 2006, 2008).  
The kinetics of the responses correlated well with those previously described 
for protective schizont-specific CTL in efferent lymph and peripheral blood after 
challenge of immune animals (Morrison et al., 1987; Taracha et al., 1992, 1995a; 
McKeever et al., 1994). Antigen specific CD8+ T cell numbers dropped over time to 
below assay detection limits and upon challenge with T. parva sporozoites there was a 
substantial increase in the number of antigen-specific CD8+ T cells from pre-
challenge levels in most of the animals. Allowing for variation between epitopes and 
animal responses, and given that tetramer staining has not yet been tested vigorously, 
the frequency of antigen-specific CD8+ T cells by tetramer staining were comparable 
to that obtained by limiting dilution analysis while Tp1 specific responses 
significantly increased from pre-challenge levels by day 9 after challenge as 
previously reported (Graham et al., 2006). Of significant interest however is the 
observation that the frequencies in the recall response were lower than post 
immunisation. The differences in the kinetics of the response may reflect different life 
spans of memory T cells, influences of immunodominance of restricting alleles or 
epitopes (other specificities), as well as being as a result of the biological function of 
the target proteins among others. Previous killing data in responding immune lymph 
showed a dramatic increase in frequency in the recall response over pre-challenge 
levels and as such use of a single epitope (tetramer) as a tracker may not reflect the 
true effector  response in the animal unless the entire CD8+ T cell response is directed 
against a single epitope. 
The functional activity of tetramer positive cells was shown to be secretion of 
IFN-γ and T. parva-antigen specific cytotoxicity, possibly through perforin-mediated 
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cytolytic activity. By use of IFN-γ ELISpot assay and intracellular staining of PBMC 
for perforin, tetramer+ T cells were shown to secrete IFN-γ and express perforin. 
Although T. parva-specific cytototoxic activity was demonstrated in PBMC obtained 
both post-immunisation and post-challenge, peptide-specific cytotoxic activity was 
observed in PBMC 14 days after challenge and this corelated with the demonstration 
of peptide-specific CD8+ T cells in the total CD8 T cell population. Tetramer+ cells in 
PBMC obtained post-immunisation were observed at significant levels on average 
after 15 days while the cytototoxicity assay was performed using PBMC from day 12 
post-ITM. IFN-γ ELISpot assays with freshly isolated PBMC from donor animals in 
most instances detected effector CD8+ T cells specific for Tp1, Tp2 and Tp8. In some 
samples the frequency obtained by tetramer analysis were in the same range as those 
determined by IFN-γ ELISpot. However it was also noted that in some samples, the 
estimates of T cell frequencies using tetramer staining was higher than those obtained 
by ELISpot assay. While the low frequencies obtained by the ELISpot may suggest 
sub-optimal performance of the assay in using PBMC as the responder population, it 
is also likely that the tetramers could be binding to T-cells that may not secrete IFN-γ 
upon stimulation accounting for differences observed between the two assays. Based 
on intracellular staining data, the expression of perforin in tetramer+ populations in 
PBMC was significantly reduced as compared to staining CTL lines and clones 
possibly due to the release of pre-formed perforin through degranulation in response 
to activation through TCR recognition of its specific ligand on the infected cell, 
interaction of co-stimulatory molecules and other accesory activation signals. In 
determining cytotoxic activity of peptide-specific CD8+ T cells, the assay required 
culturing PBMC with T. parva infected lymphoblasts for 7 days. At the end of the 
culture period the culture was tested for presence of peptide-specific cytotoxic T cells. 
Nagata and Golstein (1995) and Janssen et al., (2005) show that activated T cells are 
prone to apoptosis upon restimulation. At day 12 post-primary infection it is likely 
that a substantial fraction of effector CD8+ T cells are prone to activation induced cell 
death or fail to divide to a sufficient extent to demonstrate detectable cytotoxic 
activity in vitro explaining why cytotoxic activity was not detected post-primary 
infection. It is also possible that not all of the antigen specific CD8+ T cells 
differentiate into cytolytic CD8+ T cells. 
Immunodominance hierarchies are a substantial characteristic of CD8 T cell 
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mediated immunity (Yewdell and Bennick, 1999), however the underlying 
mechanisms are unclear. The size of both primary and secondary response is likely to 
be influenced by relative epitope levels and at least after secondary challenge, the 
magnitude is also determined by CD8 T cell precursor frequency. Recognising that 
the number of cattle used in this study is not sufficiently robust to draw a strong 
conclusion, comparison of frequencies of CD8 T cells directed against epitopes on 
Tp1, Tp2, Tp4 and Tp8 provided quantitative data on the extent to which these 
antigens dominate the response depending on their relative contribution to the total 
CD8+ T cell response. Data obtained showed that the Tp1 response restricted by 
BoLA N*01301 dominated over the Tp2 and Tp4/Tp8 response restricted by BoLA 
N*01201 and BoLA N*00101 respectively. It thus appears that BoLA-N*01301 
haplotype dominates as the restricting element in line with previous observations that 
the MHC influences the antigenic specificity of the T. parva-specific CD8+ T cell 
response (Morrison, 1996; Machugh et al., 2009). The pattern of immunodominance 
hierarchy was maintained during primary and secondary immune responses although 
the magnitude of tetramer+CD8+ T cells detected after secondary challenge was lower. 
The observation that Tp8 is consistently characterised by a poor recall response as 
compared to Tp1 further suggests that differential antigen presentation may regulate 
CD8 T cell immunodominance in primary and secondary T. parva infections. Studies 
in mice have shown that T-cell immunodominance can differ substantially between 
primary and secondary responses to infections (Selin et al., 1999; Belz et al., 2000; 
2001). The specificity of the CD8+ T cell responses has been shown to be due to due 
to differences in antigen presentation (Nugent et al., 1995; Butz and Bevan, 1998a; 
Crowe et al., 2003). With regard to the epitope on Tp4 and Tp8, the differential 
prominence of the CD8 T cell response suggests that the response is likely to be 
influenced by T cell receptor affinity/avidity and competition for presentation of these 
epitopes within antigen-presenting cells or these epitopes are restricted by closely 
related MHC class I elements. Immunodominance hierarchy is a well-described 
phenomenon for CD8 T-cell responses to viruses with several important features for 
the development of immunological hierarchies of T cells having been described (Chen 
et al., 2002, 2004; Yang et al., 2006; Kastenmuller et al., 2007; La Gruta et al., 2006, 
2010). 
With the identification of T. parva CTL target antigens, heterologous prime 
boost protocols involving injections of different vectors encoding the same 
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recombinant antigen have been used to focus the CTL response towards peptides with 
the recombinant antigen, which are the only CTL epitopes shared by the different 
agents. Studies by Graham et al., (2006) have demonstrated that priming with plasmid 
DNA or canary pox virus and boosting with recombinant modified vaccinia Ankara 
(MVA) generate significant levels of specific CD8+ T cells. In these studies ELISpot 
and peptide-specific cytotoxic assays were used to measure animal responses to 
vaccination. Tetramer binding was used to determine the frequency of CD8+ T cells in 
one such vaccine trial (Graham et al., unpublished data) in which animals were 
immunised with Tp2, Tp4 and Tp8. Using PBMC harvested after the MVA booster 
immunisation results obtained demonstrated a vaccine induced CD8+ T cell response 
but no significant changes in the number of tetramer+CD8+ T cells specific for any of 
the epitopes was observed after parasite challenge. Due to low frequencies of epitope 
specific T-cells in the peripheral circulation, tetramer staining measured values 
largely at the lower limit of detection and the true meaning of these results obtained 
by tetramer staining cannot be appropriately evaluated working at the lower limit of 
the assay sensitivity. It will be necessary to re-evaluate the staining with improved 
protocols incorporating staining with monoclonal antibodies against CD4, CD14 or 
CD3 in combination with anti-CD8 and tetramer to help eliminate CD4+, monocytes 
and CD3- cells which may be sources of non-specific binding of tetramer. 
Comparison of tetramer binding and data obtained by ELISpot and 
cytotoxicity assays yielded results that varied considerably for the same sample. The 
ELISpot assay in most instances detected the highest numbers of peptide-specific 
CD8+ T cells while there no significant concordance between the demonstration of 
tetramer+CD8+ and cytolytic activity. Both the IFN-γ ELISpot and peptide-specific 
cytotoxic assay have been evaluated extensively and performance described 
previously (Graham et al., 2006). The reproducibility of ELISpot is a function of the 
interassay variability and the necessity for enrichment of CD8+ T cells by positive 
selection on immunobeads in the experimental format used in the vaccine trial. The 
cytotoxicity assay is on the other hand dependent on proliferation of antigen-specific 
T cells and differentiation into effector T cells following in vitro restimulation. 
Although requiring minimal manipulation, the reproducibility of the flow-cytometry 
based tetramer staining assay is governed by the operator’s skills of setting the gates 
and excluding non-specific events, and is, therefore open to considerable subjectivity. 
It cannot however be assumed or expected that the three assay will yield comparable 
 216
results. On this basis, it can be hypothesised that the differences on frequencies of 
IFN-γ secreting CD8+ T cells and tetramer+CD8+ T cells was probably due to down 
regulation of TCR following activation of T cell by MHC class I bound peptide 
antigen which consequently prevents tetramer binding. TCRs may be down regulated 
following stimulation (Appay et al., 2000) and thus some acutely stimulated T cells 
may not be detected using tetramers but will be detected by the IFN-γ ELISpot. The 
peptide specific CD8+ T cells may also have failed to proliferate in vitro or are 
sensitive to activation induced cell death. 
In the context of induction of immune responses and outcome to challenge, T. 
parva antigen vaccinated animals showed significantly lower frequencies of antigen 
specific CD8+ T cells as compared to that observed in animals immunised using live 
vaccine. This finding can be extended to have implications for developing strategies 
of T. parva sub-unit vaccines in the choice of delivery systems and protocols. While 
the vaccination protocol did generate antigen-specific T cells, the generation of a 
strong and consequently effector response may be determined by the magnitude of the 
initial priming as seen in live vaccine immunised animals. 
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An ideal vaccine should contain relevant antigens formulated in an appropriate 
vehicle and be capable of inducing desirable and measurable immune responses that 
result in durable protection of all members of an out-bred population. The success of 
developing an effective vaccine is therefore dependent on identifying appropriate 
antigens, availability of a suitable vaccine platform and capacity to monitor 
immunogenicity and efficacy of the vaccine candidate(s). Correlates of protective 
immunity are desirable for identifying protective antigens, demonstrating the 
immunogenicity of a vaccine candidate and its potential efficacy, and permitting 
optimization of the dose, vehicle, adjuvant, and schedule of immunisation. In 
addition, defining and understanding correlates of immunity would enable the 
targeting of vaccine candidates towards a particular response known to mediate 
protection, and in cases where such correlates are fully validated, help minimise the 
conduct of expensive challenge trials as well as being applied to monitor vaccine 
failures. Aside from lack of effective antigen delivery technologies for induction of 
CD8+ T cell-based immunity, correlates of immunity as immunological endpoints 
aimed at predicting protection, which depend on availability of reliable assays, remain 
a major challenge in many vaccine development initiatives. 
With regard to T. parva, findings from a preliminary vaccine trial of five 
schizont-derived CD8+ T cell antigen-coding genes engineered in plasmid DNA and 
viral vectors demonstrated induction of antigen-specific IFN-γ and cytolytic CD8+ T 
cell responses (Graham et al., 2006). Their potential as vaccine candidates will rely on 
the demonstration of their immunogenicity and efficacy following immunisation 
using an effective antigen delivery system that induces an appropriate memory CTL 
response. While the majority of animals that exhibited CD8+ T cell secreting IFN-γ 
ELISpot responses succumbed to challenge infection cytolytic CD8+ T cells were 
detected only after several rounds of re-stimulation in vitro suggesting low precursor 
frequencies that pose a major challenge for bulk culture cytotoxicity assays to detect. 
Subsequent characterisation of the epitopes recognised in the T. parva antigens 
together with their MHC class I restriction elements (Graham et al., 2008) allowed the 
development of the MHC class I tetramers evaluated in this study as tools for 
monitoring the responses. Four bovine MHC class I molecules loaded with the 
corresponding peptide epitopes on T. parva antigens Tp1, Tp2, Tp4 and Tp8 were 
successfully synthesised at the Ludwig Institute of Cancer Research, Brussels and 
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validated in this study using established CD8+ T cell lines and clones. These four 
peptide-MHC complexes (tetramers) were used to define specific CD8+ T cell 
populations in animals following live vaccine immunisation and subsequent challenge 
with live sporozoites. Results of this study showed that tetramers can be used for the 
detection and analysis of the kinetics and intensity of T. parva antigen-specific CD8+ 
T cell responses more directly in PBMC populations. Previous studies of the kinetics 
and intensity of T. parva-specific CD8+ T cell responses in cattle were based on 
assays of direct killing activity in PBMC and efferent lymph and the IFN-γ ELISpot 
assay (Morrison et al., 1987; Taracha et al., 1992; McKeever et al., 1994; Graham et 
al., 2006) all of which require in vitro stimulation and in some instances fractionation 
of the CD8+ T cell population. In this study the data obtained demonstrated that T. 
parva antigens Tp1, Tp2, Tp4 and Tp8 are recognised by MHC class I restricted 
CD8+ T cells with frequencies of antigen specific CD8+ T cells as high as 1:36 for 
Tp1, 1:750 for Tp2, 1:280 for Tp4 and 1:68 for Tp8 at the peak of the response with 
CD8+ T cell activity. Results obtained also indicated that Tp2, Tp4 and Tp8 are 
targets of CD8+ T cell responses.  The kinetics of T. parva antigen specific CD8+ T 
cell responses have shown that activity appears between day 9 and 12 after live 
vaccine immunisation consistent with the appearance of schizont parasitosis in the 
draining lymph node. Immunised animals usually undergo an asymptomatic or mild 
ECF reaction (Brocklesby and Bailey 1965; Radley et al., 1975 a,b). The mechanism 
by which the oxytetracycline works to control infection and enhance immunity is not 
fully understood, but the drug seems to affect the degree of maturation of sporozoites 
to schizonts after infection of lymphocytes (Spooner, 1990). The mild transient 
infection thus allows for parasite molecules to access the host cell MHC class I 
antigen processing and presentation pathway. By use of peptide specific IFN-γ 
ELISpot assay, the results showed that Tp1, Tp2, Tp4 and Tp8 induce MHC class I 
restricted IFN-γ secreting CD8+ T cells suggesting that the tetramer staining CD8+ T 
cell population was functionally active. Additionally intracellular staining of tetramer+ 
T cells for expression of perforin suggested lytic ability of the antigen specific CD8+ 
T cells. Post-challenge analysis of the CD8+ T cell response using tetramers, IFN-γ 
ELISpot and cytotoxic assays demonstrated that the four antigens are targets of MHC 
class I restricted IFN-γ secreting and lytic CD8+ T cells further indicating that the live 
vaccine primes a CD8+ T cell response against the T. parva antigens in line with 
previous observations (Graham et al., 2006). The response after challenge was of 
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lesser magnitude as compared to that obtained after immunisation suggesting a 
change in specificity of CD8+ T cell responses between primary and secondary T. 
parva infections. Tetramer staining of T cell populations was used to examine the 
immunogenicity of Tp2, Tp4 and Tp8 in cattle following immunisation of cattle with 
a canary pox/MVA prime boost vaccination strategy (Graham et al., 2005, 
unpublished data). Responding CD8+ T cells were identified in cryopreserved PBMC 
samples collected during the experiment using BoLA-N*01201 restricted Tp298-106 
tetramer, and BoLA-N*00101-Tp4328-387 tetramer or BoLA-N*00101-Tp8379-387 
tetramer. Generally the estimates of antigen-specific T cells correlated well with those 
obtained by IFN-γ ELISpot and demonstration of peptide-specific cytotoxic activity 
as reported but the intensity of the response appeared to be nearly 10 times lower than 
that observed in ITM immunised animals. The functional relevance of the induced 
CD8 T cell response however remained unclear as the animals were not protected 
following a challenge infection suggesting that the response did not develop into a 
sustained and efficient memory although it recognised schizont antigen. Although 
Tp2, Tp4 and Tp8 antigens may be characterised by low immunogenicity, a limitation 
of the vaccine delivery strategy in eliciting protective antigen specific CD8+ cytotoxic 
T cells cannot be ruled out. 
Research on the development of a T. parva sub-unit vaccine has focused on 
designing a vaccine that will stimulate the cellular arm of the immune system, in 
particular cytotoxic CD8+ T cells. Among the scientific hurdles that need to be 
addressed include  understanding of the mechanisms that will induce a CD8+ T cell 
immune reponse that is of significant magnitude and appropriate functional 
differentiation and sustained memory, a choice of parasite antigens that will confer 
broad protection  against T. parva strains by generating protective responses in 
animals of diverse MHC types and vaccine formulation. By use of Tp1- Tp2- Tp4- 
and Tp8-tetramers, this study identified antigen-specific, perforin expressing CD8+ T 
cells. That T. parva-specific killing activity was demonstrated at the same time point 
(day 12 post-immunisation) when peptide-specific cytotoxic activity was not observed 
possibly due to the low frequency of appropriate cytotoxic CD8 T cells raises the 
question of the role of the Tp1, Tp2, Tp4 and Tp8 as potential vaccine candidates in 
induction and development of a protective immune response. Clearly other CD8 T 
cell specificities are present at early time points perhaps in the form of early schizont 
antigens that can be exploited to stimulate an early recall response. Taking into 
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consideration that in vitro restimulation of PBMC from immune cattle may create a 
bias in the specificites that are amplified and that a T cell response is directed to a few 
antigenic determinants tetramers can be used by negative selection to isolate CD8 T 
cells of unknown specificities from a responding PBMC population which can then be 
used to screen a T. parva antigen library to identify other potential CD8 T cell 
antigens.  
In the context of the choice of antigens for potential sub-unit vaccines, 
tetramer staining revealed differences in the kinetics and frequencies of antigen-
specific CD8+ T cells suggesting a differences and a change in the specificity of 
responses between primary and secondary T. parva infections. This may be attributed 
to differential antigen processing and presentation which in turn may impact on the 
priming, induction and specificity of the CD8 T cell responses. Studies in the 
induction of CD8 T cell against Plasmodium in mice show that sporozoites need to be 
alive (attenuated or irradiated) and not heat killed, parasite replication is not essential 
and systemic or prior activation of dendritic cells (for cross-presentation) inhibits 
priming of the CD8 T cells (Jung et al., 2002). This is similar to observations done in 
earlier studies with T. parva.  The hypothesis being dead parasites to not move and 
this mobility is essential for the parasites to get to the lymph nodes. In addition to this, 
during this migration parasites may shed particulate proteins which are then 
endocytosed by dendritic cells. Antigen processing, presentation and induction CTL 
responses in the mouse model is well characterised (Boscardin et al., 2006) unlike in 
the case of T. parva schizont infected cell which is a potential research area. To what 
role cross-presenting/priming plays in generation of CTL has not been demonstrated 
for ECF. Studies in Anaplasma suggest linked-recognition in the development of 
protective immunity (Morse et al., 2011). Whereas CD4+ T cells have been isolated in 
the context of T. parva, the role of CD4 T cell response in driving the induction, 
maturation and generation of an effective CD8 memory is not determined. It is 
proposed that the relative processing efficiency of different epitopes determines the 
hierarchy of T cell responses following immunisation (Vijh et al., 1998), but this 
hypothesis has not been rigorously tested. In T. parva it is likely that although there is 
proposed a limited number of immunodominant antigens, it is also likely that they are 
processed differently with respect to the MHC expressed. With regard to sub-unit 
vaccines, then differential antigen presentation will impact on the choice of antigens 
and efficacy of peptide-based vaccination strategies. Antigens through direct or cross-
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presentation should induce a CD8 T cell response against schizont antigen to 
stimulate a quick recall response. Currently there is no consistent and robust 
vaccination system to induce CTL in cattle. As mentioned previously, tetramer 
staining of PBMC samples from a  T. parva vaccine trial that used an endogenous 
antigen delivery strategy using replication defective viruses showed priming of a 
CD8+ T cell response but it was of low magnitude as compared to ITM vaccination 
and it was unclear if the response was capable of stimulating an efficient response 
against schizont antigen.  However emerging technologies for inducing CD4 and CD8 
T cell responses can now be explored using the available tetramers and T. parva 
antigens. This could include alternatives such as the use of particulate antigen as 
opposed to peptides and nano-bead based adjuvants in the induction of cellular 
immune responses. The identification of a vaccination strategy that induces CTL 
responses in cattle will be crucial in future efforts to develop a sub-unit vaccine. New 
approaches to cattle vaccination--parasite based vaccine vehicle for cattle pathogens 
have been described. Trypanosoma theileri has been tranformed to deliver a babesia 
antigen and it been shown to have generated specific immune responses (Mott et al., 
2011) while genetically modifed babesia expressing protective tick antigen Bm86 for 
tick control  (Suarez and Noh, 2011) have also been developed. Can a similar 
approach be used to deliver T. parva T cell antigens? 
Previous investigations on the specificity of the cytotoxic T cell response of 
cattle to T. parva have shown that the CD8+ T cell response is restricted to a limited 
number of immunodominant antigens with certain BoLA specifities dominating as 
restricting elements (Goodeeris et al., 1990; Taracha et al., 1995b Graham et al., 
2008; MacHugh et al., 2009). Though assesed in a limited number of samples, 
animals heterozygous for A18 haplotype consistently responded to the Tp1 epitope 
presented by BoLA N*01301. This study with tetramers has extended the previous 
observation that Tp1, and Tp8 and to some extent Tp2 and Tp4 are dominant in 
animals with the corresponding MHC genotypes. Dominant CD8+ T cell responses 
restricted by BoLA N*01301 allele have in addition been reported for respiratory 
syncytial virus (Morrison et al., 1999) and foot and mouth disease virus (Guzman et 
al., 2008). While differential antigen processing and presentation may regulate 
dominance hierarchies of CD8 T cell responses to infections (Crowe et al., 2003) of 
importance too is if immunodominance can be broken in vaccine strategies. Peptide 
immunisation is only useful in animals with appropriate BoLA molecules capable of 
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presenting that peptide. Due to the complexity of the host immune response against T. 
parva and the genetic restriction imposed by MHC molecules, an effective sub-unit 
vaccine containing multiple epitopes may be required to ensure a broad coverage of 
genetically heterogenous population similar to what has been attempted in malaria 
vaccine strategies (Joshi et al., 2001). A potential area for research would be the role 
of heat shock proteins in adaptive and innate immunity. Heat shock proteins have the 
ability to interact with a wide range of proteins and peptides - a property that is shared 
by major histocompatibility complex molecules- and this makes the HSPs uniquely 
suited to an important role in organismal survival by their participation in innate and 
adaptive immune responses (Srivastava, 2002a, b). The immunological properties of 
HSPs enable them to be used as antigen delivery vehicles with a potential of breaking 
MHC-restriction. 
Although tetramer staining has been shown to be sensitive and specific in 
detection and quantitative analysis of T. parva antigen specific T cells, there are 
limitations inherent in this assay system. One, it is restricted to few epitopes and 
secondly, it is not applicable when the MHC class I and the T cell epitope is not 
known, therefore it may have limited application in out-bred animals. Another 
limitation is the inability to quantify functional T cells. In view of this latter 
disadvantage, concurrent with the development and evaluation of bovine tetramers 
was the cloning, expression and generation of antibodies to bovine perforin, 
granzymes A and B as potential markers of cytolytic lymphocytes. The significance 
of perforin and granzyme proteins in vivo through intracellular staining of T cell 
populations or detection of perforin secreting T cells by the perforin ELISpot or 
ELISA assays would support the idea that expression of the proteins is linked to 
cytotoxicity. Although a number of anti-perforin and anti-granzyme A and B 
antibodies were available when this study was initiated, only δG9 monoclonal 
antibody to human perforin (Hameed et al., 1992) showed recognition of the bovine 
native perforin molecule by immunofluorescence staining of bovine CTL. Further  
δG9 was only suitable for use in flow cytometry and consequently was used as a co-
staining reagent to phenotype tetramer positive cells. Some of the constraints related 
to priming and assessment of CTL responses is inadequate tools and reagents. Most 
tools and methods being used in similar studies are optimised for the mouse system 
and this does not always work in larger mammals. There is thus a general need in the 
scientific community to develop tools and reagents for use in cattle models. The T. 
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parva/cattle ITM model provided such an opportunity to develop protocols that work 
in large animals with potential application to other diseases such as TB, HIV and 
malaria. There has been atempts to identify and characterise identification of a 
biologically active bovine homologue to granulysin - antimicrobial proteins found in 
the granules of human and swine cytotoxic lymphocytes. Intracellular flow cytometry 
and immunoblotting confirmed the presence of protein corresponding to the bovine 
granulysin homologue in activated bovine T lymphocytes and PBMC (Endsley et al., 
2004). From this study the nucleotide sequence coding for bovine perforin, granzymes 
A and a granzyme B-like serine protease has been determined from cDNA generated 
from bovine CTL. The protein sequence derived from the 1665-bp bovine perforin 
cDNA is shown to contain 554 amino acid residues and displays, as expected, 
considerable homology with functional domains such as MACPF, EGF and Ca2+ 
binding domains, found in the family pore-forming proteins (Lichtenheld et al., 1988; 
Lowrey et al., 1989; Ishikawa et al., 1999). Two clones of cDNA of 303-bp and 756-
bp, encoding two serine proteases, were also isolated. The deduced amino acid 
residues from the two cDNA possessed a high level of homology to sequences of 
human, rat and mouse granzymes, bovine duodenase and mast-cell proteases. 
Analysis of the enzyme structures allowed the identification of the catalytic amino 
acid triad and prediction of substrate specificity. Based on this homology data, the 
303-bp cDNA, consisting of 101 amino acid residues DNA was concluded to be a 
member of granzyme A family, mapping to the N-terminus of human, mouse and rat 
granzyme A while the 756-bp cDNA consisting of 251 amino acid residues belonged 
to the bovine granzyme B family. Two overlapping fragments of bovine perforin and 
granzyme B and a  fragment of granzyme A, were expressed in Trichoplusia ni insect 
cells using recombinant baculovirus as the expression of full length cDNA was not 
successful. The expressed fragments encoded the full-length coding sequence for 
bovine perforin,  granzyme B-like serine protease and a partial coding sequence for 
bovine grazyme A. Analyses of the expressed proteins obtained showed that bovine 
perforin is recognised by δG9 whose epitope maps to the N-terminal region of the 
recombinant perforin while none of the human anti-granzyme A or B monoclonal 
antibodies tested in this study bound the respective bovine recombinant protein. 
Although generation of monoclonal antibody to recombinant perforin, granzymes A 
and B was not successful polyclonal antibodies to the recombinant proteins were 
generated in rats. However results obtained indicated that the immunogenic epitopes 
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were not accessible in the native form of the proteins reflected by lack of intracellular 
staining of bovine CTLs by rat polyclonal antibodies. Given this limitation, antibodies 
to 18-mer antigenic epitopes determined by Hopp and Woods (1981) algorithm from 
amino acid sequences of the recombinant proteins were generated in rabbits and mice. 
Antibodies generated showed variable intracellular staining of bovine CTL with four 
of five anti perforin monoclonal antibodies that were generated not binding to the 
native molecule. Given that these anti-perforin peptide monoclonal antibodies can be 
assumed to display similar epitope specificities it was concluded that these 
monoclonals were limited functionality in the ‘capture-detection’ based immuno-
assays. Of the range of antibodies generated, only the perforin antibodies could be 
tested in capture-based perforin ELISA or ELISpot assay as they were raised against 
disparate perforin epitopes. However results obtained indicated that the assays were 
negative or unsuccessful.  
The development and optimisation of capture-immunoassay for bovine 
perforin, granzymes A or B is still compelling as the use of perforin or granzyme 
ELISpot provides an attractive alternative to the use of radioactive-labelled target 
cells as a read out assay of cytotoxic CD8+ T cells with the added advantage of 
eliminating the need of amplifying the frequency of precursor CTL prior to analysis. 
Monoclonal antibody 18.H3 (anti-bovine perforin) would be a potential antibody for 
further quality control because not only does it recognise bovine perforin, it also 
appears to have overlapping specifity with δG (anti-human perforin) and can be 
adapted for use in an ELISA based assay or an alternative ‘capture-based’ assays with  
appropriate polyclonal antibodies. With respect to granzyme A and B, monoclonal 
antibody GB36 also provides a potential reagent for development as it can be 
optimised for use in an ELISA assay as well as FACS staining. Similarly GA46 can 
be optimised for granzyme A specific assays. However the latter two antibodies will 
depend on verification of the expressed proteins. 
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Appendix I: GenBank sequences for perforin, granzyme A and B 
Sequence alignments produced by ClustalW for perforin, granzyme A and B 
homologs identified by the TIGR database or Genbank accession numbers and 
primers used for cloning bovine cDNA 
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Perforin 
 
 
 
Accession 
number Size Predicted function Organism Source 
GI:190339 1668 bp pore forming protein - perforin Homo sapiens GenBank 
GI:34808711 1665 bp pore forming protein - perforin Mus musculus GenBank 
GI:59709458 1665 bp pore forming protein - perforin Rattus norvegicus GenBank 
GI:3559947 290 bp pore forming protein - perforin Ovis aries GenBank 
TC135848 1447 bp EST showing significant similarity to perforin Bos taurus TIGRDB 
 
 
ILRI oligo 
number 
Primer sequence 5'-3' Name Primer binding site Orientation 
9229 CCA GGA CTG CTG TCC Perf-Fwd2 486-500 forward 
9338 CTG TTC CTC CTG GGC Perf-Fwd1 13-27 (rat seq) forward 
9340 GGA CAG CAG TCC TGG Perf-Rev1 486-500 reverse 
12046 GCC TCT GCA CAT GCT TGT GGA GAG BOV_PERF1 306-329 forward 
12047 CCT TCA GAT AGG CGT CCG TGG CAG BOV_PERF2 572-595 reverse 
12067 GCA CGA GCC CTG GAG GGG CTC ACA BOV_PERF3  1-24  forward 
12068 CTG CCT GAG GGC CTC CCG CCG CGG BOV_PERF4 337-360 reverse 
12069 GGT CTG TGG GGA GAC TGG ATC ACA BOV_PERF5 245-268 (sheep seq) forward 
12070 CTT TCC AGT TTG GCA CAG AGG TCC BOV_PERF6 961-984 reverse 
12071 CAT CAC ATC ACA TTT ATT GGT CAG BOV_PERF8 1424-1447 reverse 
12780 CGC GGA TCC GCC TCT GCA CAT GCT TG BOV_PERF1BAMH1 similar to 12046 forward 
12781 GCG GTC GAC CAT CAC ATC ACA TTT AT BOV_PERF8SAL1 similar to 12071 reverse 
12782 CGC GGA TCC ATG GCA GCC CGT CTG CT BOV_PERF7BAMH1 1-17 (human seq) forward 
 
- Primer binding site is shown for bovine EST sequence or other sequences (indicated in parentheses) 
and marked in bold in the alignment file  
-Restriction enzyme recognition sequences are shown in bold 
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TC135848        ------------------------------------------------------------ 
GI3559947       ------------------------------------------------------------ 
GI190339        ATGGCAGCCCGTCTGCTCCTCCTGGGCATCCTTCTCCTGCTGCTGCCCCTGCCCGTCCCT 60 
GI59709458      ATGGCC---GCGTACCTGTTCCTCCTGGGCCTTTTCCTGCTGCTGCCACGACCTGTCCCT 57 
GI34808711      ATGGCC---ACGTGCCTGTTCCTCCTGGGCCTTTTCCTGCTGCTGCCACGACCTGTCCCT 
                                                                             
 
TC135848        ------------------------------------------------------------ 
GI3559947       ------------------------------------------------------------ 
GI190339         GCCCCGTGCCACACAGCCGCACGCTCAGAGTGCAAGCGCAGCCACAAGTTCGTGCCTGGT 120 
GI59709458      GCTCCCTGCTACACTGCCACTCGGTCAGAATGCAAGCAGAAGCACAAATTCGTGCCTGGT 
GI34808711      GCTCCCTGCTACACTGCCACTCGGTCAGAATGCAAGCAGAAGCACAAGTTCGTGCCAGGT 
                                                                             
 
TC135848        ------------------------------------------------------------ 
GI3559947       ------------------------------------------------------------ 
GI190339        GCATGGCTGGCCGGGGAGGGTGTGGACGTGACCAGCCTCCGCCGCTCGGGCTCCTTCCCA 180 
GI59709458      GTGTGGGCGGCTGGGGAAGGTGTGGATGTGACCACCCTCCGCCGCTCCAGCTCCTTCCCA 
GI34808711      GTATGGATGGCTGGGGAAGGCATGGATGTGACTACCCTCCGCCGCTCCGGCTCCTTCCCA 
                                                                             
 
TC135848        ------------------------------------------------------------ 
GI3559947       ------------------------------------------------------------ 
GI190339        GTGGACACACAAAGGTTCCTGCGGCCCGACGGCACCTGCACCCTCTGTGAAAATGCCCTA 
GI59709458      GTGAACACAGGGAAGTTCCTGAGGCCTGACCGCACCTGCACCCTCTGTAAAAACGCCCTG 
GI34808711      GTGAACACACAGAGGTTCCTGAGGCCTGACCGCACCTGCACCCTCTGTAAAAACTCCCTA 
                                                                             
 
TC135848        ------------------------------------------------------------ 
GI3559947       ------------------------------------------------------------ 
GI190339        CAGGAGGGCACCCTCCAGCGCCTGCCTCTGGCGCTCACCAACTGGCGGGCCCAGGGCTCT 
GI59709458      ATGAATGACGCTATACAGCGCCTACCCGTGGCAATCGCCCACTGGCGGCCTCACGGCTCA 
GI34808711      ATGAGAGACGCCACACAGCGCCTACCTGTGGCAATCACCCACTGGCGGCCTCACAGCTCA 
                                                                             
 
TC135848        ------------------------------------------------------------ 
GI3559947       ------------------------------------------------------------ 
GI190339        GGCTGCCAGCGCCATGTAACCAGGGCCAAAGTCAGCTCCACTGAAGCTGTGGCCCGGGAT 
GI59709458      CACTGCCAGCGTAATGTGGCCACAACCAAGGTCAGCTCCACGGAGGGTGTGGCGCGGGAG 
GI34808711      CACTGCCAGCGTAATGTGGCCGCAGCCAAGGTCCACTCCACGGAGGGTGTGGCCCGGGAG 
                                                                             
 
TC135848        ------------------------------------------------------------ 
GI3559947       ------------------------------------------------------------ 
GI190339        GCGGCTCGTAGCATCCGCAACGACTGGAAGGTCGGGCTGGACGTGACTCCTAAGCCCACC 
GI59709458      GCGGCTGCTAATATCAATAACGACTGGCGTGCGGGGCTGGATGTGAACCCTAAACCGGAA 
GI34808711      GCAGCTGCTAATATCAATAACGACTGGCGTGTGGGGCTGGATGTGAACCCTAGGCCAGAG 
                                                                             
 
TC135848        ------------------------------------------------------------ 
GI3559947       ------------------------------------------------------------ 
GI190339        AGCAATGTGCATGTGTCTGTGGCCGGCTCACACTCACAGGCAGCCAACTTTGCAGCCCAG 
GI59709458      GCAAACGTGCATGTGTCCGTGGCTGGCTCCCATTCCAAGATAGCCAATTTTGCAGCCGAG 
GI34808711      GCAAACATGCGCGCCTCCGTGGCTGGCTCCCACTCCAAGGTAGCCAATTTTGCAGCTGAG 
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TC135848        ------------------------------------------------------------ 
GI3559947       ------------------------------------------------------------ 
GI190339        AAGACCCACCAGGACCAGTACAGCTTCAGCACTGACACGGTGGAGTGCCGCTTCTACAGT 
GI59709458      AAGGCCCATCAGGACCAATACAACTTTAATACTGACACAGTGGAGTGTCGCATGTACAGT 
GI34808711      AAGACCTATCAGGACCAGTACAACTTTAATAGCGACACAGTAGAGTGTCGCATGTACAGT 
                                                                             
 
TC135848        ------------------------------------------------------------ 
GI3559947       ------------------------------------------------------------ 
GI190339        TTCCATGTGGTACACACTCCCCCGCTGCACCCTGACTTCAAGAGGGCCCTCGGGGACCTG 
GI59709458      TTTCGCCTGGCACAAAAGCCTCCACTCCACCCTGACTTCAGAAAGGCACTCAAGAACCTT 
GI34808711      TTTCGCCTGGTACAAAAACCTCCACTCCACCTTGACTTCAAAAAGGCGCTCAGAGCCCTC 
                                                                             
 
TC135848        ------------------------------------------------------------ 
GI3559947       ------------------------------------------------------------ 
GI190339        CCCCACCACTTCAACGCCTCCACCCAGCCCGCCTACCTCAGGCTTATCTCCAACTACGGC 
GI59709458      CCCCACAACTTTAACAGCTCCACAGAGCATGCTTACCGTAGACTCATCTCTTCCTATGGG 
GI34808711      CCCCGCAACTTTAACAGCTCCACAGAGCATGCTTACCACAGGCTCATCTCCTCCTATGGC 
                                                                             
 
TC135848        ------------------------------------------------------------ 
GI3559947       ------------------------------------------------------------ 
GI190339        ACCCACTTCATCCGGGCTGTGGAGCTGGGTGGCCGCATATCGGCCCTCACTGCCCTGCGC 
GI59709458      ACTCATTTTATTACGGCTGTGGACCTAGGTGGCCGCGTCTCGGTCCTCACGGCTCTGCGT 
GI34808711      ACGCACTTTATCACGGCTGTGGACCTCGCTGGCCGCATCTCGGTCCTTACAGCCCTGCGT 
                                                                             
 
TC135848        ------GCACGAGCCCTGGAGGGGCTCACAGCCAGCGAGGTCGAGGACTGCCTGGCTGTC 54 
GI3559947       ------------------------------------------------------------ 
GI190339        ACCTGCGAGCTGGCCCTGGAAGGGCTCACGGACAACGAGGTGGAGGACTGCCTGACTGTC 
GI59709458      ACCTGTCAGCTGACCCTGGATGGGCTCACAGCTGATGAGGTAGGAGACTGCTTGAGCGTG 
GI34808711      ACCTGTCAGCTGACCCTGAATGGGCTCACAGCTGATGAGGTAGGAGACTGCCTGAACGTG 
                                                                             
 
TC135848        GAGGCTGAGGTCAGCATAAGCGACAGGGCCAGTGCCTCGCCATCGTTCAAGGCATGTGAG 114 
GI3559947       ------------------------------------------------------------ 
GI190339        GAGGCCCAGGTCAACATAGGCATCCACGGCAGCATCTCTGCCGAAGCCAAGGCCTGTGAG 
GI59709458      GAAGCCCAGGTCAGCATCGGTGCCCAAGCCAGTGTCTCAAGCGAATACAAAGCTTGCGAG 
GI34808711      GAGGCCCAGGTCAGCATCGGTGCCCAAGCCAGCGTCTCCAGTGAATACAAAGCTTGTGAG 
                                                                             
 
TC135848        GAGAAGAAGAAGAACCACAAGGTGGGGACCTCCTTCCACCAGGCCTACCGGGAGCGCCAT 174 
GI3559947       ------------------------------------------------------------ 
GI190339        GAGAAGAAGAAGAAGCACAAGATGACGGCCTCCTTCCACCAAACCTACCGGGAGCGCCAC 
GI59709458      GAGAAGAAGAAACAACACAAAATCGCCACCTCTTTCCACCAGACCTACCGTGAGCGTCAT 
GI34808711      GAGAAGAAGAAACAGCACAAAATGGCCACCTCTTTCCACCAGACCTACCGTGAGCGTCAC 
                                                                             
 
TC135848        TCCAATGTCGATGGTGGCCACCACTCAACCATGCATGACCTGCTCTTCGGGAGCCAGGCT 234 
GI3559947       ------------------------------------------------------------ 
GI190339        TCGGAAGTGGTTGGCGGCCATCACACCTCCATTAACGACCTGCTGTTCGGGATCCAGGCC 
GI59709458      GTCGAAGTGCTCGGTGGCCCCCTTGACTCCTCGAATGACCTGCTCTTCGGGAACCAAGCT 
GI34808711      GTCGAAGTACTTGGTGGCCCTCTGGACTCCACGCATGATCTGCTCTTCGGGAACCAAGCT 
                                                                             
 
TC135848        GGGCCCGAGCAGTTCTCAGCCTGGGTGGCCTCACTGCAGGACAGCCCTGGCCTGGTGGAC 294 
GI3559947       ------------------------------------------------------------ 
GI190339        GGGCCCGAGCAGTACTCAGCCTGGGTAAACTCGCTGCCCGGCAGCCCTGGCCTGGTGGAC 
GI59709458      ACCCCTGAGCACTTCTCTACCTGGATAGCCTCATTGCCCACCAGGCCTGATGTGGTGGAC 
GI34808711      ACACCAGAGCAGTTCTCAACCTGGACAGCCTCACTGCCCAGCAACCCTGGTCTGGTGGAC 
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TC135848        TACACGCTGGAGCCTCTGCACATGCTTGTGGAGAGCCAGGACCCGCGGCGGGAGGCCCTC 354 
GI3559947       -----------GCCTCTGCACATTCTTGTGGAGAGCCAGGACCCGCGGCGGGAGGCCCTC 49 
GI190339        TACACCCTGGAACCCCTGCACGTGCTGCTGGACAGCCAGGACCCGCGGCGGGAGGCACTG 
GI59709458      TACAGCCTGGAGCCCCTGCACATACTACTGGAAGACTCGGACCCGAAGCGAGAGGCACTG 
GI34808711      TACAGCCTGGAGCCCCTGCACACATTACTGGAAGAACAGAACCCGAAGCGGGAGGCTCTG 
                           .** ******.   *  **** ... .*.*****..***.***** **  
 
TC135848        AGGCAGGCCGTGAGCAAGTACGTGACTGACAGGGCACGCTGGAGGGACTGCAACCGCCCG 414 
GI3559947       AGGCGGGCCGTGAGTAAGTATGTGACTGACAGGGCGCGCTGGAGGGACTGCAACCGCCCA 109 
GI190339        AGGAGGGCCCTGAGTCAGTACCTGACGGACAGGGCTCGCTGGAGGGACTGCAGCCGGCCG 
GI59709458      AGACAGGCTATCAGCCATTATGTGATGAGCAGGGCTCGCTGGCGAGACTGTAACCGGCCC 
GI34808711      AGACAGGCTATCAGCCATTATATAATGAGCAGAGCCCGGTGGCAGAACTGTAGCAGGCCC 
                **...***  * ** .* **  *.*  ..***.** ** ***....**** *.*.* **  
 
TC135848        TGCCCCCCGGGGCAACACAAGAACCCGAAGAACCCATGCCAGTGCATGTGTCCTGGTTCA 474 
GI3559947       TGCCCCCCGGGGCAACACAAGAACCCGAAGAACCCATGCCAATGCATGTGTCCTGGCTCA 169 
GI190339        TGCCCACCAGGGCGGCAGAAGAGCCCCCGAGACCCATGCCAGTGTGTGTGCCATGGCTCA 
GI59709458      TGCAGGGCAGGCCAGCATAAGAGTAGTCGTGATTCATGCCAGTGTGTGTGCCAGGATTCG 
GI34808711      TGCAGGTCAGGCCAGCATAAGAGTAGCCATGATTCATGCCAGTGTGAGTGCCAGGATTCA 
                ***.   *.** *..** ****. .  .. .*  *******.** .:*** *. *. **. 
 
TC135848        GCAGCCACCACCCAGGACTGCTGTCCCCGGCAGAAGGGACTGGCCCACCTGGAGGTCATG 534 
GI3559947       GCAGCCACCACCCAGGACTGCTGTCCCCGGCAGAGGGGCCTGGCCCACCTGGAGGTCATG 229 
GI190339        GCGGTCACCACCCAGGACTGCTGCCCTCGGCAGAGGGGCCTGGCCCAGCTGGAGGTGACC 
GI59709458      AAGGTCACCAACCAGGACTGCTGCCCACGCCAGAGGGGCTTGGCCAAGTTGATGGTAAGG 
GI34808711      AAGGTCACCAACCAGGACTGCTGCCCACGACAGAGGGGCTTGGCCCATTTGGTGGTAAGC 
                ...* *****.************ ** ** ****.***. *****.*  **.:*** *   
 
TC135848        AACTTCAAGGCATCAGGTCTGTGGGGAGACTGGATCACTGCCACGGACGCCTATCTGAAG 594 
GI3559947       AACTTCAAGGCATCGGGTCTGTGGGGAGACTGGATCACAGCCACAGACGCCTATCTGAAG 289 
GI190339        TTCATCCAAGCATGGGGCCTGTGGGGGGACTGGTTCACTGCCACGGATGCCTATGTGAAG 
GI59709458      AATTTCCAGGCCAAGGGTCTGTGGGGGGACTACATCACATCTACGGATGCTTATCTGAAG 
GI34808711      AATTTCCGGGCAGAACATCTGTGGGGAGACTACACCACAGCTACTGATGCCTACCTAAAG 
                :: :**...**.  . . ********.****. : ***: * ** ** ** **  *.*** 
 
TC135848        GTCTTCTTCGCCGGCCAGGAGCAGAGGACCGCCACAGTATGGAACGATAACAACCCCACG 654 
GI3559947       G----------------------------------------------------------- 
GI190339        CTCTTCTTTGGTGGCCAGGAGCTGAGGACGAGCACCGTGTGGGACAATAACAACCCCATC 
GI59709458      GTCTTCTTTGGTGGCCAGGAGATCAGGACCGGTGTAGTGTGGAACAATAACCATCCCTCG 
GI34808711      GTCTTCTTTGGTGGCCAGGAGTTCAGGACCGGTGTCGTGTGGAACAATAACAATCCCCGG 
                                                                             
 
TC135848        TGGATGACGCGGCTGGACTTCGGGGATGTGCTCCTGGCCACCGGGGGCCCCCTGAGGGTG 714 
GI3559947       ------------------------------------------------------------ 
GI190339        TGGTCAGTGCGGCTGGATTTTGGGGATGTGCTCCTGGCCACAGGGGGGCCCCTGAGGTTG 
GI59709458      TGGAGTGACAAGATGGACTTTGGGAATGTGCTCCTGTCCACAGGGGGACCCCTCAGGGTG 
GI34808711      TGGACTGACAAGATGGACTTTGAGAATGTGCTCCTGTCCACAGGGGGACCCCTCAGGGTG 
                                                                             
 
TC135848        CAGGTCTGGGATGCAAACTTTGGCTGGGACGATGACCTTCTTGGCACTTGTGACCGCACC 774 
GI3559947       ------------------------------------------------------------ 
GI190339        CAGGTCTGGGATCAGGACTCTGGCAGGGACGATGACCTCCTTGGCACCTGTGATCAGGCT 
GI59709458      CAGGTCTGGGATGCTGACAATGGCTGGGATGATGACCTTCTTGGTACTTGTGACAAGTCT 
GI34808711      CAGGTCTGGGATGCCGACTACGGCTGGGATGATGACCTTCTTGGTTCTTGTGACAGGTCT 
                                                                             
 
TC135848        CCAAAGTCTGGCTCACATGAGGTGTCATGCCCCATGGACCACGGTCTCCTGAAATTCTCC 834 
GI3559947       ------------------------------------------------------------ 
GI190339        CCCAAGTCTGGTTCCCATGAGGTGAGATGCAACCTGAATCATGGCCACCTAAAATTCCGC 
GI59709458      CCCAAGTCTGGTTTCCATGAGGTGAATTGTCCCCTGAACCACGGCAGTATAAAATTCATC 
GI34808711      CCCCACTCTGGTTTCCATGAGGTGACATGTGAGCTAAACCACGGCAGGGTGAAATTCTCC 
 269
                                                                             
 
TC135848        TACCAGGTCAAATGCTTGCCTCACCTGACGGGGGAGAGGTGCCTGCAGTATGCCCCCCAA 894 
GI3559947       ------------------------------------------------------------ 
GI190339        TATCATGCCAGGTGCTTGCCCCACCTGGGAGGAGGCACCTGCCTGGACTATGTCCCCCAA 
GI59709458      TACCAGGCCAATTGCTTGCCCCATCTCACTGGAGAGACCTGCCTGGAGTATGCCCCCCAG 
GI34808711      TACCATGCCAAGTGTCTGCCCCATCTCACTGGAGGGACCTGCCTGGAGTATGCCCCCCAG 
                                                                             
 
TC135848        GGGCTTCTGGGGAATCCTCCAGGAAACCGGAGTGGGCCAGTGTGGTGAGAGAAGTGGGTC 954 
GI3559947       ------------------------------------------------------------ 
GI190339        ATGCTTCTGGGGGAGCCTCCAGGAAACCGGAGTGGGGCCGTGTGGTGA------------ 
GI59709458      GGGCTTCTAGGAGATCCACCAGGAAACCGCAGTGGGGCTGTGTGGTAA------------ 
GI34808711      GGGCTTCTGGGAGATCCTCCAGGAAACCGCAGTGGGGCTGTGTGGTAA------------ 
                                                                             
 
TC135848        CTGAGAGGACCTCTGTGCCAAACTGGAAAGGAACCCAGTGCAGGAACCCAGAGGGCCTAT 1014 
GI3559947       ------------------------------------------------------------ 
GI190339        ------------------------------------------------------------ 
GI59709458      ------------------------------------------------------------ 
GI34808711      ------------------------------------------------------------ 
                                                                             
 
TC135848        ATCTCCATATCTCCATTAGACAGACAGAAAACTGAGACTTCTTTTTTTCTTCCAATGAGG 1074 
GI3559947       ------------------------------------------------------------ 
GI190339        ------------------------------------------------------------ 
GI59709458      ------------------------------------------------------------ 
GI34808711      ------------------------------------------------------------ 
                                                                             
 
TC135848        TGGCTGGATTTACAGGCCAGCCCTCAGCCCTGTCCAAACTGCCTTAGCTCTTCAATATTC 1134 
GI3559947       ------------------------------------------------------------ 
GI190339        ------------------------------------------------------------ 
GI59709458      ------------------------------------------------------------ 
GI34808711      ------------------------------------------------------------ 
                                                                             
 
TC135848        TCGAGCCCAGGAACGTAGGTGGAGCTGGGTCAGGCCCTGCAGCCAGTGCTTCACTGCCCT 1194 
GI3559947       ------------------------------------------------------------ 
GI190339        ------------------------------------------------------------ 
GI59709458      ------------------------------------------------------------ 
GI34808711      ------------------------------------------------------------ 
                                                                             
 
TC135848        ACAGGTCAGGGACAGGGCAGAAAGCCCGGACGCTGTGCCCGCCAGGCTGCCTGGTGTCAC 1254 
GI3559947       ------------------------------------------------------------ 
GI190339        ------------------------------------------------------------ 
GI59709458      ------------------------------------------------------------ 
GI34808711      ------------------------------------------------------------ 
                                                                             
 
TC135848        TTACACCATTCCCTCGCAGCCCCGCTTCTAGCGTGGTGAATTCTTCATCATATTAGACCT 1314 
GI3559947       ------------------------------------------------------------ 
GI190339        ------------------------------------------------------------ 
GI59709458      ------------------------------------------------------------ 
GI34808711      ------------------------------------------------------------ 
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TC135848        AACGTCTTTGGCCCCAGCTGCTCCGGTTACTCTGTTTTCTTGGCCCACCAAGCTTTGCCT 1374 
GI3559947       ------------------------------------------------------------ 
GI190339        ------------------------------------------------------------ 
GI59709458      ------------------------------------------------------------ 
GI34808711      ------------------------------------------------------------ 
                                                                             
 
TC135848        CTCAGCCAAAATCCAGGACTGTCTTGACTTGTCTCATTGTGTACACAGTCTGACCAATAA 1434 
GI3559947       ------------------------------------------------------------ 
GI190339        ------------------------------------------------------------ 
GI59709458      ------------------------------------------------------------ 
GI34808711      ------------------------------------------------------------ 
                                                                             
 
TC135848        ATGTGATGTGATG 1447 
GI3559947       ------------- 
GI190339        ------------- 
GI59709458      ------------- 
GI34808711      ------------- 
                              
 
Key: 
Single letters nucleotides 
* identical nucleotides 
: conserved nucleotide substitutions 
. semi-conserved nucleotide substitutions  
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Granzyme A 
 
 
Accession 
number Size Predicted function Organism Source 
GI:6996012 878 bp serine esterase 3 – granzyme A Homo sapiens GenBank 
GI:6754101 783 bp granzyme A Mus musculus GenBank 
GI:23618882 786 bp granzyme A Rattus norvegicus GenBank 
TC399777 1002 bp EST showing significant similarity to granzyme A Bos taurus TIGRDB 
 
 
 
 
ILRI oligo 
number 
Primer sequence 5'-3' Name primer binding 
site 
Orientation 
9341 TCC TCA TTC AAG ACC grzA-FWD 146-160 forward 
9342 TCC TGG TTT CAC ATC grzA-REV 459-473 reverse 
13767 CGC GCC ATG GTG CTA CTT GAT GGG Bov_GRZA3-Nco1 See Appendix II pg 
279 
forward 
13768 CGC CTA CGT CGA CGT TCC TGG TTT CAC Bov_GRZA4-Sal1 See Appendix II pg 
279 
reverse 
 272
TC399777        --GAAACTAGTCTCCATATGTGAATAAC---AGGAGCCATGAA---------TATTCCTT 
GI6996012       CAGATTTTCAGGTTGATTGATGTGGGACAGCAGCCACAATGAGGAACTCCTATAGATTTC 60 
GI6754101       --------------------------------------ATGAGGAACGCCTCTGGTCCCC 
GI23618882      --------------------------------------ATGAGGAACCCCTGTGCTCCCT 
                                                      ****.         *. :     
 
TC399777        TTCCTTTCTCTTTTCCTCCTGCCATTTGTCTCCTTCTAATTCCTGGAGTTTTTCCAGTAT 
GI6996012       TGGCATCCTCTCTCTCAGTTGTCGTTTCTCTCCTGC---------TAATTCCTGAAGATG 111 
GI6754101       GGGGGCCATCTCTTGCTACTCTCCTTTTTCTTCTGC---------TTATTCCTGAAGGAG 
GI23618882      GGGTGTCCTCTCTTACTACTGTCATTTTTCTTCTGC---------TAATTCCTGAAGGTG 
                       .*** *  *:  *  * *** *** ** *          :.**  * .** :  
 
TC399777        CCTGCGAGGGAATTATAGGAGGAAATGAAGTGGCCCCTCACACAAGACGCTACATGGCTC 
GI6996012       TCTGTGAAAAAATTATTGGAGGAAATGAAGTAACTCCTCATTCAAGACCCTACATGGTCC 171 
GI6754101       GCTGTGAAAGAATCATTGGAGGAGACACGGTTGTTCCTCACTCAAGACCGTATATGGCTC 
GI23618882      GCTGTGAAAGAATCATTGGAGGAGACACAGTAGTTCCTCACTCAAGGCCATACATGGTTC 
                 *** **...*** **:******.* ...** .  ***** :****.*  ** ****  * 
 
TC399777        TAATCA------AAGGGCTGAAACTCTGTGCAGGGGCTTTAATCAAAGAAAACTGGGTGT 
GI6996012       TACTTAGTCTTGACAGAAAAACCATCTGTGCTGGGGCTTTGATTGCAAAAGACTGGGTGT 231 
GI6754101       TACTTAAACTTAGTTCAAATACCATCTGTGCTGGCGCTTTGATTGAAAAGAACTGGGTGT 
GI23618882      TACTTAAACTTAAACCAGACAGCATCTGTGCTGGCGCTTTGATTGCAAAAAACTGGGTGT 
                **.* *      .   . : * ..*******:** *****.** ..*.*..********* 
 
TC399777        TGACAGCCGCTCATTGTGACCTGAAGGGCAATCCTCAAGTTATTCTTGGGGCCCACTCTA 
GI6996012       TGACTGCAGCTCACTGTAACTTGAACAAAAGGTCCCAGGTCATTCTTGGGGCTCACTCAA 291 
GI6754101       TGACTGCTGCCCACTGTAACGTGGGAAAGAGATCTAAGTTCATTCTTGGGGCTCACTCAA 
GI23618882      TGACCGCTGCACATTGTATCCCGGGAAAGAAATCTGAGGTCATTCTTGGGGCTCACTCAA 
                **** ** ** ** ***.:*  *.. .. *.  *  *. * *********** *****:* 
 
TC399777        CATCCCATAAAGAGAAACTTGACCAAGTATTTTCCATTAAAAAGGCAATTCCCTACCCAT 
GI6996012       TAACCAGGGAAGAGCCAACAAAACAGATAATGCTTGTTAAGAAAGAGTTTCCCTATCCAT 351 
GI6754101       TCAATAAGG---AGCCAGAACAACAGATATTGACTGTTAAGAAAGCATTTCCCTATCCAT 
GI23618882      TAAAAAAAG---AGCCGGAACAACAGATATTATCTGTTAAGAAAGCATATCCCTATCCTT 
                 .:. .. .   **...  : *.**..**:*    .****.**.*..::****** **:* 
 
TC399777        GCTTTGATCCACAGACATTTGAAGGGGATCTTCAACTACTTCAGCTGGAAGGTAAAGCAA 
GI6996012       GCTATGACCCAGCCACACGCGAAGGTGACCTTAAACTTTTACAGCTGACGGAAAAAGCAA 411 
GI6754101       GCTATGATGAATATACACGTGAGGGGGATCTACAACTTGTACGGCTAAAGAAAAAAGCAA 
GI23618882      GCTTTGACAAACACACACATGAGGGTGATCTACAACTTCTACGGCTAAAGAAAAAAGCAA 
                ***:***  .* . ***   **.** ** **:.****: *:*.***......:******* 
 
TC399777        CTATGACCAAAGCTGTAGGAATACTTCAGCTACCAAGAACAGAAGACGATGTCAAACCCC 
GI6996012       AAATTAACAAATATGTGACTATCCTTCATCTACCTAAAAAGGGGGATGATGTGAAACCAG 471 
GI6754101       CAGTTAACAGAAATGTGGCTATCCTTCACCTACCTAAAAAGGGAGATGATGTGAAACCAG 
GI23618882      CACTTAACAAAAACGTGGCTATCCTTCATCTACCTAAAAAGGGGGATGATGTGAAACCAG 
                .: * *.**.* . **.. :**.***** *****:*.**..*..** ***** *****.  
 
TC399777        ACACCAAGTGTCATGTGGCAGGATGGGGAAGCACCAAAAAAGACGCATGTCAAATGTCTA 
GI6996012       GAACCATGTGCCAAGTTGCAGGGTGGGGGAGGACTCACAATAGTGCA---TCTTGGTCCG 
GI6754101       GAACCAGATGCCGAGTAGCAGGATGGGGGAGATTTGGCAATAAGTCA---GCTCCCTCTG 
GI23618882      GAACCAGATGTCATGTAGCAGGGTGGGGGCGTTTTCACAATAAGTCA---CCTCCCTCTG 
                ..**** .** *.:** *****.*****..* :   ..**:..  **    .:   ** . 
 
TC399777        ATGCCTTGAGAGAAGCCAACGTTACAGTGATAGATAGGAAAATATGCAATGATGCCCAGC 
GI6996012       ATACTCTGAGAGAAGTCAATATCACCATCATAGACAGAAAAGTCTGCAATGATCGAAATC 
GI6754101       AAACTCTGAGAGAAGTCAACATCACTGTCATAGACAGAAAAATCTGCAATGATGAAAAAC 
GI23618882      ATACTCTGAGAGAAGTCAACATCACTGTCATAGACAGAAAAATCTGCAATGATGAAAAAC 
                *:.*  ********* *** .* ** .* ***** **.***.*.*********  ..* * 
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TC399777        ACTATAATTTTAATCCAGTTATTGATCTCAGTATGATCTGTGCTGGTGGTAGAAAAGGTG 
GI6996012       ACTATAATTTTAACCCTGTGATTGGAATGAATATGGTTTGTGCTGGAAGCCTCCGAGGTG 
GI6754101       ACTATAATTTTCATCCTGTAATTGGACTAAACATGATTTGTGCAGGGGACCTCCGTGGTG 
GI23618882      ACTATAATTTTAACCCTGTAATTGGACTAAATATGATTTGTGCCGGAAACCTCCGTGGTG 
                ***********.* **:** ****.:.* *. ***.* ***** ** .. . ...:**** 
 
TC399777        AAGATGATTCATGTGAAGGGGATTCTGGAAGTCCTCTGATATGTGATAATGTTTTCAGAG 
GI6996012       GAAGAGACTCGTGCAATGGAGATTCTGGAAGCCCTTTGTTGTGCGAGGGTGTTTTCCGAG 
GI6754101       GAAAGGACTCCTGCAATGGGGATTCTGGCAGCCCTCTGCTATGTGATGGTATTTTGCGAG 
GI23618882      GGAAGGACTCATGCTACGGAGATTCTGGAGGCCCTCTGCTATGTGAGGGTATTTTCCGAG 
                .... ** ** **  * **.********..* *** ** *.** ** ..*.**** .*** 
 
TC399777        GTGTCACTTCCTTTGGCAAGTGTGGTA---------ATCCCCAGAAGCCTGGCATCTACA 
GI6996012       GGGTCACTTCCTTTGGCCTTGAAAATAAATGCGGAGACCCTCGTGGGCCTGGTGTCTATA 
GI6754101       GCATCACCTCTTTTGGTGGAGA---GAAGTGTGGAGATCGCCGATGGCCTGGTGTCTATA 
GI23618882      GCATCACAGCTTTTGGCCTTGAGGGAAGGTGTGGAGACCCCAAAGGGCCTGGCATCTATA 
                * .****  * *****     .    *         * *  ..  .****** .**** * 
 
TC399777        TCCTCCTTACCAAAAAACACCTCAACTGGATAAAGAAAACCATTGCAGGAGCCATATAAC 
GI6996012       TTCTTCTCTCAAAGAAACACCTCAACTGGATAATTATGACTATCAAGGGAGCAGTTTAAA 
GI6754101       CTTTCCTCTCAGATAAACACCTCAATTGGATAAAGAAGATTATGAAGGGTTCTGTGTAA- 
GI23618882      CTTTACTCTCAGACAAACACCTCGATTGGATAAGGAAGACTGCGAAGGGCGCTGTTTAA- 
                   * ** :*..* *********.* *******  *:.*  .  ...**  * .* ***  
 
TC399777        ATTTCTACTTCAAAGTAGAAAATCGAAGTAACCAAGTGAAAGGGTCTTAAACTTGACCTG 
GI6996012       TAACCGTTTCCTTTCATTTACTGTG----------------GCTTCTTAATCTTTTCACA 
GI6754101       ------------------------------------------------------------ 
GI23618882      ------------------------------------------------------------ 
                                                                             
 
TC399777        TCCGAAGAAGCATCTTGCAGCCCTTTGAACTTCACATACAAAATGCCGCCTGTCTAAAAT 
GI6996012       AATAAA------------------------------------------------------ 
GI6754101       ------------------------------------------------------------ 
GI23618882      ------------------------------------------------------------ 
                                                                             
 
TC399777        AAATTCAGCAATGAAAGAAATGACCTCCTGCTGTCACTCTTCCCCGATCAGCAAAGACTG 
GI6996012       ------------------------------------------------------------ 
GI6754101       ------------------------------------------------------------ 
GI23618882      ------------------------------------------------------------ 
                                                                             
 
TC399777        AGTCATCACAT 
GI6996012       ----------- 
GI6754101       ----------- 
GI23618882      ----------- 
 
Key: 
Single letters nucleotides 
* identical nucleotides 
: conserved nucleotide substitutions 
. semi-conserved nucleotide substitutions  
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Granzyme B 
 
 
 
Accession number Size Predicted function Organism Source 
GI:20988817 744 bp serine esterase 1 – granzyme B Homo sapiens GenBank 
GI:7305122 744 bp granzyme B Mus musculus GenBank 
GI:31542925 747 bp granzyme B Rattus norvegicus GenBank 
TC134874 903 bp EST showing significant similarity to granzyme B Bos taurus TIGRDB 
 
 
 
 
 
 
ILRI 
Oligo 
Number 
Primer sequence 5'-3' Name primer binding 
position 
Orientati
on 
9343 TCC CGC CCC TAC ATG GC grzB-FWD 91-107 (human) forward 
9344 ACA CAC AAG GCC TCC AG grzB-REV   
11848 CCG GAA TTC ATG GTC CTG CTC CTG CTC Bov_GRAB1 
EcoRI 
47-64 forward 
11849 CCG GCG GCC TCA CAC TGA TCC CTG GCG Bov_GRAB2  785-802 reverse 
11850 CTG GGA AGC TCA ATC AAT GTC ACC CTG Bov_GRAB3 239-265 forward 
11851 CTT GCT TGG ATC TCC AGC ACA TAT CTG Bov_GRAB4 596-622 reverse 
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TC134874        GCATGAAAGTAGCAGCTGCTCAGATCTGGGCAGCTTTCCTGCAGAGATGGTCCTGCTCCT 60 
GI20988817      -------------------------------------------ATGCAACCAATCCTGCT 17 
GI7305122       -------------------------------------------ATGAAGATCCTCCTGCT 
GI31542925      -------------------------------------------ATGAAGCTCCTCTTGCT 
                                                           .:*.:.  ..*  * ** 
 
TC134874        GCTCCTGGTGGCCCTTCTGTCCCCTACTGGGGAGGCAGGGAAAATCATCGGGGGTCACGA 120 
GI20988817      TCTGCTGGCCTTCCTCCTGCTGCCCAGGGCAGATGCAGGGGAGATCATCGGGGGACATGA 77 
GI7305122       ACTGCTGACCTTGTCTCTGGCCTCCAGGACAAAGGCAGGGGAGATCATCGGGGGACATGA 
GI31542925      CCTGCTGAGCTTCTCTCTGGCCCCCAAGACAGAGGCAGGGGAGATCATCGGGGGACATGA 
                 ** ***.        ***    * *  . ..* ******.*.***********:** ** 
 
TC134874        GGCCAAGCCACACTCCCGTCCCTACATGGCGTTTCTTCTGTTCAAGACTTCAGGGAAATC 180 
GI20988817      GGCCAAGCCCCACTCCCGCCCCTACATGGCTTATCTTATGATCTGGGATCAGAAGTCTCT 137 
GI7305122       AGTCAAGCCCCACTCTCGACCCTACATGGCCTTACTTTCGATCAAGGATCAGCAGCCTGA 
GI31542925      AGCCAAGCCCCACTCTCGACCCTACATGGCCTATCTTCAGATCATGGATGAGTATTCTGG 
                .* ******.***** ** *********** *::***  *:**: *..* .. .  .:   
 
TC134874        T---CACATATGTGGGGGTTTCCTTGTGCGTGAGGACTTCGTGCTGACAGCAGCTCACTG 237 
GI20988817      G---AAGAGGTGCGGTGGCTTCCTGATACAAGACGACTTCGTGCTGACAGCTGCTCACTG 
GI7305122       G---GCGATATGTGGGGGCTTCCTTATTCGAGAGGACTTTGTGCTGACTGCTGCTCACTG 
GI31542925      GAGTAAGAAGTGTGGCGGCTTCCTTATACGAGAAGACTTTGTGCTGACTGCTGCTCACTG 
                     . * .** ** ** ***** .* *.:** ***** ********:**:******** 
 
TC134874        CCTGGGAAGCTCAATCAATGTCACCCTGGGGGCCCATAACATCATGGAACGAGAGAGGAC 297 
GI20988817      TTGGGGAAGCTCCATAAATGTCACCTTGGGGGCCCACAATATCAAAGAACAGGAGCCGAC 
GI7305122       TGAAGGAAGTATAATAAATGTCACTTTGGGGGCCCACAACATCAAAGAACAGGAGAAGAC 
GI31542925      TTCGGGAAGCAAAATAAATGTCACGTTGGGGGCCCACAACATCAAAGAACAGGAGAAGAT 
                   .***** : .**.********  ********** ** ****:.****..***. **  
 
TC134874        CCAGCAGGTCATCCCAGTGAGAAGACCCATCCCCCACCCAGACTATAATGATGAGACTTT 357 
GI20988817      CCAGCAGTTTATCCCTGTGAAAAGACCCATCCCCCATCCAGCCTATAATCCTAAGAACTT 
GI7305122       CCAGCAAGTCATCCCTATGGTAAAATGCATTCCCCACCCAGACTATAATCCTAAGACATT 
GI31542925      GCAACAAATCATCCCTGTGGTGAAAATCATTCCCCACCCAGCGTATAATTCTAAGACAAT 
                 **.**. * *****:.**. .*.*  *** ***** ****. ****** .*.***. :* 
 
TC134874        GGCCAACGACATCATGTTACTGAAGCTGACTAGGAAGGCTGACATTACGGATAAAGTGAG 417 
GI20988817      CTCCAACGACATCATGCTACTGCAGCTGGAGAGAAAGGCCAAGCGGACCAGAGCTGTGCA 
GI7305122       CTCCAATGACATCATGCTGCTAAAGCTGAAGAGTAAGGCCAAGAGGACTAGAGCTGTGAG 
GI31542925      CTCCAATGACATCATGCTGTTAAAGCTGAAGAGTAAGGCCAAGAGGTCTAGCGCTGTGAA 
                  **** ********* *. *..*****.. ** ***** .* .  :* .. ..:***.. 
 
TC134874        CCCCATCAATCTGCCCAGGAGCTTGGCGGAGGTGAAGCCAGGGATGATGTGCAGTGTGGC 477 
GI20988817      GCCCCTCAGGCTACCTAGCAACAAGGCCCAGGTGAAGCCAGGGCAGACATGCAGTGTGGC 
GI7305122       GCCCCTCAACCTGCCCAGGCGCAATGTCAATGTGAAGCCAGGAGATGTGTGCTATGTGGC 
GI31542925      GCCTCTCAATCTGCCCAGACGCAACGTCAAAGTGAAACCAGGAGATGTGTGCTATGTGGC 
                 ** .***. **.** ** ..*:: *   * *****.*****. : . .***:.****** 
 
TC134874        CGGCTGGGGGCGACTGGGGGTAAATATGCCCTCTACAGACAAACTACAGGAGGTAGATCT 537 
GI20988817      CGGCTGGGGGCAGACGGCCCCCCTGGGAAAACACTCACACACACTACAAGAGGTGAAGAT 
GI7305122       TGGTTGGGGAAGGATGGCCCCAATGGGCAAATACTCAAACACGCTACAAGAGGTTGAGCT 
GI31542925      TGGTTGGGGAAAGCTGGGCCCAATGGGCAAATACTCAGACACACTACAAGAGGTTGAGCT 
                 ** *****..... **    ..: .  ... . :** ***..*****.***** .* .* 
 
TC134874        TGAAGTCCAAAGTGAGGAGAAATGTATCGCTCGCTTCAAAAAC---TACATCCCCTTCAC 594 
GI20988817      GACAGTGCAGGAAGATCGAAAGTGCGAATCTGACTTACGCCATTATTACGACAGTACCAT 
GI7305122       GACAGTACAGAAGGATCGGGAGTGTGAGTCCTACTTTAAAAATCGTTACAACAAAACCAA 
GI31542925      AACAGTACAGGAGGATCAGAAGTGTGAGTCCTACTTAAAAAATTATTTCGACAAAGCCAA 
                 ..*** **... **  ...*.** .:  *  .*** ....*    *:*.:*.    **  
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TC134874        ACAGATATGTGCTGGAGATCCAAGCAAGAGGAAGAATTCTTTCTCGGGTGACTCTGGGGG 654 
GI20988817      TGAGTTGTGCGTGGGGGACCCAGAGATTAAAAAGACTTCCTTTAAGGGGGACTCTGGAGG 
GI7305122       TCAGATATGTGCGGGGGACCCAAAGACCAAACGTGCTTCCTTTCGGGGGGATTCTGGAGG 
GI31542925      TGAGATATGTGCAGGGGACCCAAAGATCAAACGTGCTTCCTTTCGGGGGGACTCTGGAGG 
                : **:*.** *  **.** ***.. *  *.... ..*** **   *** ** *****.** 
 
TC134874        CCCGCTTGTGTGTAATGGTGTGGCCCAGGGCATTGTGTCCTATGGAAGAAATGATGGGAC 714 
GI20988817      CCCTCTTGTGTGTAACAAGGTGGCCCAGGGCATTGTCTCCTATGGACGAAACAATGGCAT 
GI7305122       CCCGCTTGTGTGTAAAAAAGTGGCTGCAGGCATAGTTTCCTATGGATATAAGGATGGTTC 
GI31542925      GCCTCTTGTGTGTAAAAAAGTGGCCGCGGGCATCGTCTCCTATGGACAAAATGATGGTTC 
                 ** *********** .. *****  ..***** ** ********* .:** .**** :  
 
TC134874        AACTCCAGATGTCTACACCAGAATCTCCAGCTTTCTGTCCTGGATCCATTCAACAATGAG 774 
GI20988817      GCCTCCACGAGCCTGCACCAAAGTCTCAAGCTTTGTACACTGGATAAAGAAAACCATGAA 
GI7305122       ACCTCCACGTGCTTTCACCAAAGTCTCGAGTTTCTTATCCTGGATAAAGAAAACAATGAA 
GI31542925      AACTCCACGGGCATTCACCAAAGTCTCGACTTTCCTATCATGGATAAAGAAAACTATGAA 
                ..***** . *  * *****.*.**** *  **  *. ..*****..* :.*** ****. 
 
TC134874        ACGGTACAAACGCCAGGGATCAGTGTGATGTGTGCTCAAGGTGGACCCCTCCATGTTCCC 834 
GI20988817      ACGCCACTAA-------------------------------------------------- 
GI7305122       AAGCAGCTAA-------------------------------------------------- 
GI31542925      AAAGAGCTAA-------------------------------------------------- 
                *..  .*:**                                                   
 
TC134874        TGGGATTGGAAGCATTGATCAAAGTGTGTGAAGGAAGGTTGCCTGGAACTTAATAAACAT 894 
GI20988817      ------------------------------------------------------------ 
GI7305122       ------------------------------------------------------------ 
GI31542925      ------------------------------------------------------------ 
                                                                             
 
TC134874        TCATCTCTT 903 
GI20988817      --------- 
GI7305122       --------- 
GI31542925      --------- 
                          
 
Key: 
Single letters nucleotides 
* identical nucleotides 
: conserved nucleotide substitutions 
. semi-conserved nucleotide substitutions  
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Appendix II: Gene sequences for cloned bovine perforin, granzymes A and B 
Bovine perforin, granzymes A and B was cloned from TpM stimulated CTL as 
described in materials and methods. The cloned sequences were subcloned into 
bacterial and insect cell vectors for protein expression. Primer binding sites are shown 
on the specific sequences 
 278
DEFINITION:  Perforin  2188 bp  linear 
ORF:         +1  10-1674  length 1665 bp 
ACCESSION:   FJ176744 
SOURCE:      CDNA 
ORGANISM:    BOVINE 
BASE COUNT      434 a    701 c    633 g    417 t      3 others 
ORIGIN       
        1 cgcggatcca tggcagcccg tctgctcctc cttggcatcc tcctgcttct gcccacacct 
       61 gcccctgccc cctgctacac agccgcgcgc tctgagtgcc agcgcgccct caagtttgtg 
      121 ccaggctcct ggctggcagg ggagggcgtg gatgtgacca gcctccagcg ctcaggctcg 
      181 ttcccagtgg acacacagcg tttcctgcgg cccgacggca cttgcaccct ctgccgcaat 
      241 gccctgcaga aggatgtcct ccagcgcctg cccctggcaa tcaccgactg gcgtgcccac 
      301 ggagcgggct gcaagcgcag ggtggtcaag ctagagggcc gctccaccga ggatgtggct 
      361 ggggaggcgg ccaacgggat ccgcaacgac tggcaggtgg ggctggacgt gtctcccaag 
      421 ccaaatgcta atgtccgtgt gacagtggcg ggctcccact ccgaggatgc caacttcgcc 
      481 gcccagaaga ctcaccagga caactaccgc ttcggcatgg acttagtgga gtgtcgcttt 
      541 tacagttttc acctggtgca cactccccca gtacaccctg agttcaagag ggccctcaag 
      601 acactgcccc cccacttcaa cacctccacc aagcccgact accacaggct catctccagc 
      661 tacggaaccc acttcatccg gtccatggag ctgggcggnc gcatctcggc cctcaccgnc 
      721 ctgcgnacct gcgagctggc cctggagggg ctcacagcca gcgaggtcga ggactgcctg 
      781 gctgtcgagg ctgaggtcag cataagcgac agggccagtg cctcgccatc gttcaaggca 
      841 tgtgaggaga agaagaagaa ccacaaggtg gggacctcct tccaccaggc ctaccgggag 
      901 cgccattcca atgtcgatgg tggccaccac tcaaccatgc atgacctgct cttcgggagc 
      961 caggctgggc ccgagcagtt ctcagcctgg gtggcctcac tgcaggacag ccctggcctg 
     1021 gtggactaca cgctggagcc tctgcacatg cttgtggaga gccaggaccc gcggcgggag 
     1081 gccctcaggc aggccgtgag caagtacgtg actgacaggg cacgctggag ggactgcaac 
     1141 cgcccgtgcc ccccggggca acacaagaac ccgaagaacc catgccagtg catgtgtcct 
     1201 ggttcagcag ccaccaccca ggactgctgt ccccggcaga agggactggc ccacctggag 
     1261 gtcatgaact tcaaggcatc aggtctgtgg ggagactgga tcactgccac ggacgcctat 
     1321 ctgaaggttt ttttcgccgg ccaggagcag aggaccgcca cagtatggaa cgataacaac 
     1381 cccaggtgga tgacgcggct ggacttcggg gatgtgctcc tggccaccgg gggccccctg 
     1441 agggtgcagg tctgggatgc agactttggc tgggacgatg accttcttgg cacttgtgac 
     1501 cgcaccccaa agtctggctc acatgaggtg tcatgcccca tggaccacgg tctcttgaaa 
     1561 ttctcctacc aggtcaaatg cttgcctcac ctgacggggg agaggtgcct gcagtatgcc 
     1621 ccccaagggc ttctggggaa tcctccagga aaccggagtg ggccagtgtg gtgagagaag 
     1681 tgggtcctga gaggacctct gtgccaaact ggaaaggaac ccagtgcagg aacccagagg 
     1741 gcctatatct ccatatctcc attagacaga cagaaaactg agacttcttt ttttcttcca 
     1801 atgaggtggc tggatttaca ggccagccct cagccctgtc caaactgcct tagctcttca 
     1861 atattctcga gcccaggaac gtaggtggag ctgggtcagg ccctgcagcc agtgcttcac 
     1921 tgccctacag gtcagggaca gggcagaaag cccggacgct gtgcccgcca ggctgcctgg 
     1981 tgtcacttac accattccct cgcagccccg cttctagcgt ggtgaattct tcatcatatt 
     2041 agacctaacg tctttggccc cagctgctcc ggttactctg ttttcttggc ccaccaagct 
     2101 ttgcctctca gccaaaatcc aggactgtct tgacttgtct cattgtgtac acagtctgac 
     2161 caataaatgt gatgtgatgg tcgaccgc 
 
 
ILRI oligo  
number 
Primers for cloning perforin into pFASTBac HTB 
Primer sequence 5’ → 3’ end 
Restriction enzyme and primer 
binding site 
Primer 
orientation 
13841 CGC GCC ATG GTG CCC TGC TAC ACA NcoI  (70-81) forward 
13842 CGC GCT CGT CGA CGT GGT TCC GTA GCT SalI  (658 -669) reverse 
13843 CGC GCC ATG GAC TTA GTG GAG TGT NcoI (521 -534) forward 
13844 CGC GCT CGT CGA CGT GTC AGT CAC GTA SalI (1105-1117) reverse 
13845 CGC GCC ATG GTG GAG AGC CAG GAC NcoI  (1055-1068) forward 
13846 CGC GCT CGT CGA CGT CCA CAC TGG CCC SalI (1660-1671) reverse 
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DEFINITION Granzyme A  322 bp  linear 
ORF  -2   1-303  length 303 
ACCESSION FJ176746 
SOURCE  CDNA 
ORGANISM BOVINE 
 
FEATURES 
BASE COUNT       73 a     70 c     75 g    104 t 
ORIGIN       
        1 tcctggtttc acatcatcgc cctcttttgg gagctgaagg atagccacgt ttttattaag 
       61 tgttgctttt ttgttcagct ttagaagttt aagatcgcct tcatgtgtgt ccgggtcata 
      121 gcatggatag ggaaactctt tcttaacaaa cataatctgt ttttcaggct cttccttgtt 
      181 tcttgagtgg gccccaagaa tgatctggga tttctggttc agggaacagt gagctgcagt 
      241 caatacccag tcttcggcaa tcaaagctcc ggcacagatg tttcccccat caagtagcac 
      301 catgtagggt cttgaatgag ga 
 
 
ILRI oligo  
number 
Primers for cloning granzyme A in to pFASTBac 
HTB Primer sequence 5’ → 3’ end 
Restriction enzyme and primer 
binding site 
Primer orientation 
13768 CGC CTA CGT CGA CGT TCC TGG TTT CAC SalI (1-12) reverse 
13767 CGC GCC ATG GTG CTA CTT GAT GGG NcoI (286-299) forward 
 
Forward primer is derived from the reverse complement of the DNA sequence because the open reading 
frame is on the reverse strand 
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DEFINITION Granzyme B  774 bp  linear 
ORF  +1   10-765  length 756  
ACCESSION FJ176745 
SOURCE  CDNA 
ORGANISM BOVINE 
 
FEATURES 
BASE COUNT      200 a    196 c    216 g    162 t 
ORIGIN       
        1 ccggaattca tggtcctgct cctgctcctg gtggcccttc tgtcccctac cagggaggca 
       61 gggaaaatca tcgggggcca cgaggccaag ccacactccc gtccctacat ggcgtttctt 
      121 caggtcaaga cttcagggaa atctcacaac tgtgggggtt tcctcgtgcg tgaggacttc 
      181 gtgctgacag cagctcactg cctgggaagc tcaatcagtg tcaccctggg ggcccacaac 
      241 atcaaacaac gagagacgac ccagcaggtc atcccagtga gaagacccat cccccaccca 
      301 gactataatg atgagacttt ggccaacgac atcatgttac tgaagctgac taggaaggct 
      361 gacattacgg ataaagtgag ccccatcaat ctgcccagga gcttggcgaa ggtgaagaca 
      421 gggatgatgt gcagtgtggc cggctggggg cgactggggg taaatatgcc ctctacagac 
      481 aaactacagg aggtagatct tgaagtccaa aataagaaga aatgtaagga tcgcttccaa 
      541 gattacaatg cctccataca gatatgtgct ggagatccaa gcaagaggaa gagttttttt 
      601 ttgggtgatt ctgggggccc gcttgtgtgt aatggtgtgg cccagggcat tgtgtcctat 
      661 ggaagagatg atgggacacc tccaaatgtc tacaccagaa tctccagctt tctgtcctgg 
      721 atccagacaa caatgagacg gtacaaacgc cagggatcag tgtgaggccg ccgg 
 
 
 
 
 
 
 
 
 
 
 
ILRI oligo  
number 
Primers for cloning granzyme B into pGEX 3T. 
Primer sequence 5’ → 3’ end 
Restriction enzyme 
and primer binding site 
Primer orientation 
647597 CGC GGA TCC ATG GGG AAA ATC ATC GGG BamHI (61-75) forward 
647598 GCG GTC GAC TCA CAC TGA TCC CTG GCG SalI (748-765) reverse 
ILRI oligo  
number 
Primers for cloning granzyme B into pFASTBac HTB. 
Primer sequence 5’ → 3’ end 
Restriction enzyme 
and primer binding site 
Primer orientation 
13847 CGC GCC ATG GCG TTT CTT CAG GTC NcoI (112-126) forward 
13848 GCG GCT CGT CGA CGT TAT GGA GGC ATT SalI (547-558) reverse 
13849 CGC GCC ATG GGC TGG GGG CGA CTG NcoI (443-456) forward 
13850 GCG GCT CGT CGA CGT CAC TGA TCC CTG SalI (751-762) reverse 
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DEFINITION enhanced GFP  729 bp  linear 
ACCESSION 
FEATURES 
ORF  +1   1-720  720bp 
BASE COUNT      175 a    243 c    207 g    104 t 
ORIGIN       
        1 atggtgagca agggcgagga gctgttcacc ggggtggtgc ccatcctggt cgagctggac 
       61 ggcgacgtaa acggccacaa gttcagcgtg tccggcgagg gcgagggcga tgccacctac 
      121 ggcaagctga ccctgaagtt catctgcacc accggcaagc tgcccgtgcc ctggcccacc 
      181 ctcgtgacca ccctgaccta cggcgtgcag tgcttcagcc gctaccccga ccacatgaag 
      241 cagcacgact tcttcaagtc cgccatgccc gaaggctacg tccaggagcg caccatcttc 
      301 ttcaaggacg acggcaacta caagacccgc gccgaggtga agttcgaggg cgacaccctg 
      361 gtgaaccgca tcgagctgaa gggcatcgac ttcaaggagg acggcaacat cctggggcac 
      421 aagctggagt acaactacaa cagccacaac gtctatatca tggccgacaa gcagaagaac 
      481 ggcatcaagg tgaacttcaa gatccgccac aacatcgagg acggcagcgt gcagctcgcc 
      541 gaccactacc agcagaacac ccccatcggc gacggccccg tgctgctgcc cgacaaccac 
      601 tacctgagca cccagtccgc cctgagcaaa gaccccaacg agaagcgcga tcacatggtc 
      661 ctgctggagt tcgtgaccgc cgccgggatc actctcggca tggacgagct gtacaagtaa 
      721 ggatccgcg 
 
 
ILRI oligo  
number 
Primers for cloning GFP into pFASTBac HTB 
Primer sequence 5’ → 3’ end 
Restriction enzyme and 
primer binding site 
Primer 
orientation 
13769 CGC ACG TCG ACG ATG GTG AGC AAG SalI (1-12) forward 
13770 CGC GCA TGC TTA CTT GTA CAG CTC GTC SphI (703-720) reverse 
 
 282
 
 
 
 
 
 
 
 
 
 
 
Appendix III: Cloning bovine perforin, granzymes A and B cDNA in pFASTBac 
Gene fragments were cloned in-frame to the initiating ATG and N-terminal His-tag.  
GFP was clone fused to the C-terminal of the cDNA as shown in panel A. Cloning 
was verified by restriction digest of the recombinant pFastBacHT as shown in panel B 
– restriction digest of perforin (fragment I)-GFP construct. 
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Appendix IV: Buffers and solutions 
 285
Buffers and solutions for DNA analysis 
50x TAE buffer 
242 g Tris base, 57.1 ml glacial acetic acid, 100ml EDTA (0.5M, pH 8.0) dissolved in 
a total volume of 1000ml 
Ethidium bromide (10mg/ml) 
1g Ethidium bromide dissolved in 100ml distilled water 
 
Bacteria growth medium  
2xYT medium 
16g bacto-trypton, 5g bacto-yeast extract, 10g NaCl dissolved in 1L of distilled water 
NZYCM medium for plates (per litre) 
10g NZ amine, 5g NaCl, 1g casamino acids, 5g bacto-yeast extract, 2g MgSO4, 15g 
agar dissolved in 1L of distilled water. Sterilise by autoclaving and cool to 55°C 
before adding ampicillin to a final concentration of 50μg/ml. Pour solution onto 
plastic petridishes. Driyplates at 37°C and store the plates at 4°C 
 
Reagents for SDS-PAGE and western blotting 
30 % acrylamide/ 0.8 % bisacrylamide  
30.0 g acrylamide and 0.8 g N, N’-methylene-bisacrylamide dissolved in a total 
volume of 100 ml deionised distilled water. Filter solution through a 0.45-μm filter 
and store at 4˚C in the dark 
0.5 M Tris-HCl/SDS, pH 6.8  
6.05 g Tris base in 40 ml dissolved in distilled and deionised water. Adjust pH to 6.8 
with 1N HCl. Add deionised distilled water to 100 ml total volume. Filter the solution 
through a 0.45-μm filter, added 0.4 g SDS and store at 4˚C 
1.5 M Tris-HCl/SDS, pH 8.8 
91g Tris base in 300 ml dissolved distilled and deionised water. Adjust pH to 8.8 with 
1N HCl. Add deionised distilled water to 500 ml total volume. Filter the solution 
through a 0.45-μm filter, add 2g SDS and store at 4˚C 
Preparation of polyacrylamide separating and stacking gels 
12.5% separating gel 
5.0 ml 30% acrylamide/bis, 3.0 ml 1.5 M Tris-cl, pH 8.8, 5.0 ml water, 45 μl 10% 
APS, 10 μl TEMED 
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5% stacking gel 
700 μl 30% acrylamide/bis, 1.0 ml 0.5 M Tris-cl, pH 6.8, 2.3 ml water, 30 μl 10% 
APS, 10 μl TEMED 
10X electrophoresis buffer 
30 g Tris base, 144.1 glycine, 10 g SDS dissolved in a total volume of 1000 ml 
deionised distilled water. To make 1X running buffer dilute 1:10 in distilled and 
deionised water 
6x SDS sample buffer 
7 ml 0.5 M Tris-HCl/SDS, pH 6.8, 3.6 ml glycerol, 0.93 g DTT, 1g SDS, 1.2 mg 
Bromophenol blue. Store in 0.5-ml aliquots at -70˚C 
10 % SDS 
10 g SDS in total volume of 100 ml dissolved in deionised distilled water 
1X protein transfer buffer (20mM Tris/150mM glycine, pH 8.0) 
9.7 g Tris base, 44.7 g glycine in 3000 ml dissolved in deionised distilled water, 
adjuste pH to 8.0 with 6N HCl, add 800 ml methanol, 4 ml 10% and deionised 
distilled water to make a total volume of 4 liters. Store in the cold room 
Lysis buffer A (100 mM NaH2PO4, 10 mM Tris-Cl, 6 M GuHCl, pH 8.0) 
13.8 g NaH2PO4, 1.2 g Tris base, 573 g guanidine hydrochloride dissolved in 1000 ml 
distilled water. Adjust pH to 8.0 using NaOH 
Lysis buffer B* (100 mM NaH2PO4, 10 mM Tris-Cl, 8 M Urea, pH 8.0) 
13.8 g NaH2PO4, 1.2 g Tris base, 480.5 g Urea dissolved in 1000 ml distilled water. 
Adjust pH to 8.0 using NaOH 
Wash buffer C* (100 mM NaH2PO4, 10 mM Tris-Cl, 8 M Urea, pH 6.3) 
13.8 g NaH2PO4, 1.2 g Tris base, 480.5 g Urea dissolved in 1000 ml distilled water. 
Adjust pH to 6.3 using HCl 
Elution buffer E* (100 mM NaH2PO4, 10 mM Tris-Cl, 8 M Urea, pH 4.5) 
13.8 g NaH2PO4, 1.2 g Tris base, 480.5 g Urea dissolved in 1000 ml distilled water. 
Adjust pH to 4.5 using HCl 
1 M Tris-Cl, pH 8.0 
121.1 g Tris base dissolved in 800 ml of distilled water. Adjust pH to 8.0 by adding 
42 ml concentrated HCl. Adjust volume of the solution to 1 L with distilled water 
                                                          
*Due to dissociation of urea, the pH of buffers B, C, E were adjusted immediately prior to use 
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Buffers for ELISA 
Bicarbonate buffer pH 9.6 
STOCK A: 0.2 M Na2CO3 
21.2g Na2CO3 dissolved in 1L distilled water 
 
STOCK B: 0.2 M NaHCO3 
16.8 g NaHCO3 dissolved in I L distilled water 
 
For bicarbonate coating buffer 
Mix 80 ml A + 170 ml B + 250 ml distilled water 
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Appendix V: Amino acid residues  
 289
 
 
Amino Acid Short abbreviation
Alanine A Ala 
Cysteine C Cys 
Aspartic acid D Asp 
Glutamic acid E Glu 
Phenylalanine F Phe 
Glycine G Gly 
Histidine H His 
Isoleucine I Ile 
Lysine K Lys 
Leucine L Leu 
Methionine M Met 
Asparagine N Asn 
Pyrrolysine O Pyl 
Proline P Pro 
Glutamine Q Gln 
Arginine R Arg 
Serine S Ser 
Threonine T Thr 
Selenocysteine U Sec 
Valine V Val 
Tryptophan W Trp 
Tyrosine Y Tyr 
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Appendix VI: Peptides derived from predicted amino-acid sequences of 
perforin, granzymes A and B 
 291
 
Perforin 
perf_mouse      240 TCQLTLNGLTADEVGDCLNVEAQVSIGAQASVSSEYKACEEKKKQHKMATSFHQTYRERHVEVLGGPLDSTHDLLFGNQATPEQFSTWTASLPSNPGLVDYSLEPLHTLLEEQNPKREAL 
perf_rat        240 TCQLTLDGLTADEVGDCLSVEAQVSIGAQASVSSEYKACEEKKKQHKIATSFHQTYRERHVEVLGGPLDSSNDLLFGNQATPEHFSTWIASLPTRPDVVDYSLEPLHILLEDSDPKREAL 
Bovine_cDNA     240 TCELALEGLTASEVEDCLAVEAEVSISDRASASPSFKACEEKKKNHKVGTSFHQAYRERHSNVDGGHHSTMHDLLFGSQAGPEQFSAWVASLQDSPGLVDYTLEPLHMLVESQDPRREAL 
perf_human      241 TCELALEGLTDNEVEDCLTVEAQVNIGIHGSISAEAKACEEKKKKHKMTASFHQTYRERHSEVVGGHHTSINDLLFGIQAGPEQYSAWVNSLPGSPGLVDYTLEPLHVLLDSQDPRREAL 
 
perf_mouse      360 RQAISHYIMSRARWQNCSRPCRSGQHKSSHDSCQCECQDSKVTNQDCCPRQRGLAHLVVSNFRAEHLWGDYTTATDAYLKVFFGGQEFRTGVVWNNNNPRWTDKMDFENVLLSTGGPLRV 
perf_rat        360 RQAISHYVMSRARWRDCNRPCRAGQHKSSRDSCQCVCQDSNVTNQDCCPRQRGLAKLMVRNFQAKGLWGDYITSTDAYLKVFFGGQEIRTGVVWNNNHPSWSDKMDFGNVLLSTGGPLRV 
Bovine_cDNA     360 RQAVSKYVTDRARWRDCNRPCPPGQHKNPKNPCQCMCPGSAATTQDCCPRQKGLAHLEVMNFKASGLWGDWITATDAYLKVFFAGQEQRTATVWNDNNPRWMTRLDFGDVLLATGGPLRV 
perf_human      361 RRALSQYLTDRARWRDCSRPCPPGRQKSPRDPCQCVCHGSAVTTQDCCPRQRGLAQLEVTFIQAWGLWGDWFTATDAYVKLFFGGQELRTSTVWDNNNPIWSVRLDFGDVLLATGGPLRL 
 
Granzyme A 
GrzA_mouse        1 MRNASGPRGPSLATLLFLLLIPEGGCERIIGGDTVVPHSRPYMALLKLSSNTICAGALIEKNWVLTAAHCNVGKRSKFILGAHSINKE-PEQQILTVKKAFPYPCYDEYTREGDLQLVRL 
GrzA_rat          1 MRNPCAPWVSSLTTVIFLLLIPEGGCERIIGGDTVVPHSRPYMVLLKLKPDSICAGALIAKNWVLTAAHCIPGKKSEVILGAHSIKKE-PEQQILSVKKAYPYPCFDKHTHEGDLQLLRL 
Bovine_cDNA       1 ------------------------------------------MVLL--DGGNICAGALIAEDWVLTAAHCSLNQKSQIILGAHSRNKEEPEKQIMFVKKEFPYPCYDPDTHEGDLKLLKL 
GrzA_human        1 MRNSYRFLASSLSVVVSLLLIPEDVCEKIIGGNEVTPHSRPYMVLLSLDRKTICAGALIAKDWVLTAAHCNLNKRSQVILGAHSITREEPTKQIMLVKKEFPYPCYDPATREGDLKLLQL 
 
GRAA_mouse      120 KKKATVNRNVAILHLPKKGDDVKPGTRCRVAGWGRFGNKSAPSETLREVNITVIDRKICNDEKHYNFHPVIGLNMICAGDLRGGKDSCNGDSGSPLLCDGILRGITSFGGE-KCGDRRWP 
GrzA_rat        120 KKKATLNKNVAILHLPKKGDDVKPGTRCHVAGWGRFHNKSPPSDTLREVNITVIDRKICNDEKHYNFNPVIGLNMICAGNLRGGKDSCYGDSGGPLLCEGIFRGITAFGLEGRCGDPKGP 
Bovine_cDNA      77 NKKATLNKNVAILQLPKEGDDVKPG----------------------------------------------------------------------------------------------- 
GRAA_human      121 TEKAKINKYVTILHLPKKGDDVKPGTMCQVAGWGRTHNSASWSDTLREVNITIIDRKVCNDRNHYNFNPVIGMNMVCAGSLRGGRDSCNGDSGSPLLCEGVFRGVTSFGLENKCGDPRGP 
 
Granzyme B 
Bovineduodenase       100 NDETLANDIMLLKLTRKADITDKVSPINLPRSLAEVKPGMMCSVAGWGRLGVNMPSTDNLQEVDLEVQSEEKCIARFKNYIP-FTQICAGDPSKRKNSFS 
sheepMCP-3            100 NDETCANDIMLLQLTRKAEMTDAVSLINLPRSLEKVKPGMMCSVAGWGQLGVNMPSADKLQEVDLEVQREEKCIARFKDYIP-VTQICAGDPSKRKDSFL 
Bovine_cDNA           100 NDETLANDIMLLKLTRKADITDKVSPINLPRSLAKVKTGMMCSVAGWGRLGVNMPSTDKLQEVDLEVQNKKKCKDRFQDYNA-SIQICAGDPSKRKSSFL 
GrzB_human            101 NPKNFSNDIMLLQLERKAKRTRAVQPLRLPSNKAQVKPGQTCSVAGWGQTAPLGKHSHTLQEVKMTVQEDRKCESDLRHYYDSTIELCVGDPEIKKTSFK 
Regions selected using by Hopp and Woods (1981) algorithm for antigenicity.  Peptides are highlighted as follows; Yellow, perforin peptide 264 
and 260; Blue, granzyme A peptides 258 and 263; Red, granzyme B peptide 265 and 259 
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Appendix VII: Hopp and Woods (1981) antigenicity plots of bovine perforin 
granzyme A and granzyme B 
Regions of antigenicity are identified by assigning each amino acid in an amino acid 
sequence an antigenicity index based on hydrophilicity and accessibility to solvent. 
The higher the antigenicity the more likely that antibody will bind to the region. 
Antigenic regions are identified as those regions above a set threshold shown by the 
dotted line  
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Appendix VIII: Class I BoLA specific monoclonal antibodies matched with 
their respective specificities 
 295
 
Monoclonal 
antibody Isotype BoLA class I specificity Reference 
P3 IgG2a Class I KN18 and others Lalor et al., 1986 
FJ101 - Class I Subgroups of w6 Taracha et al., 1995b 
B4/18 IgM Class I Polymorphic (w6,2) Goddeeris and Morrison, 
1988 
IL-A4 IgM Class I KN104 Toye et al., 1990 
IL-A7 IgG2a Class I w10 and others Bensaid et al., 1988 
IL-A9 IgM Class I w4 ,w7 and others - 
IL-A10 IgM Class I w10 and T7 associated Toye et al., 1990 
IL-A13 IgG1 Class I w4 and w7 - 
IL-A31 IgG3 Class I w10 - associated - 
IL-A34 IgG2a Class I w10 - associated Toye et al., 1990 
IL-A35 IgG2a Class I w10 - associated Toye et al., 1990 
IL-A36 IgM Class I KN18-associated - 
IL-A38 IgG2a Class I w10 - associated Toye et al., 1990 
IL-A88 IgG2a Monomorphic class I Toye et al., 1990 
IL-A89 IgG2a Class I w25 Gwakisa, 1992 
IL-A120 IgM Polymorphic w1 - 
IL-A121 IgG3 Polymorphic KN8 - 
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Appendix IX: Experimental animal records 
Cattle were immunised by the Infection and Treatment method (ITM). One ml of 
stabilate diluted 1:20 was administered sub-cutaneously below the right ear using 
cryopreserved viable T. parva (Muguga) sporozoites ILRI stabilate No. 4133 and a 
slow-release formulation of antibiotic, Alamycine 300 LA, at 20 mg/kg body weight. 
Homologous challenge infections were achieved by a lethal dose of 1 ml (1:20 
dilution) of stabilate No. 4133. Following inoculation with sporozoites, cattle were 
monitored clinically for temperature and parasitosis by microscopic examination of 
giemsa-stained smears of needle aspirates of local lymph nodes and observations 
scored as H for hyperplasia or Ma for macroshizonts. Examination for parasitosis and 
measurement of rectal temperature were performed daily starting 5 days after 
inoculation with sporozoites until recovery. A rectal temperature of 39.5ºC or higher, 
associated with schizont parasitosis, was considered a pyrexic response and treatment 
done using an anti-theileriacidal drug Butalex® (Coopers Animal health). 
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Appendix X: Tetramer+CD8+ T cells in animals immunised by ITM and challenged 
with T. parva sporozoites 
Peripheral blood mononucleated cells were stained with corresponding tetramer 
followed by anti CD8-antibody.  Dot plot profile shows log fluorescence intensity of 
CD8 staining (FL1) versus Tetramer staining (FL3) on specific days indicated (in red) 
after immunisation and challenge 
 311
 312
 313
 314
 315
 316
 317
 318
 319
 320
 321
 
 322
 
 
 
 
 
 
 
 
Appendix XI: Cytotoxic activity against Theileria parva infected cells and peptide-
pulsed lymphoblasts following immunisation and challenge 
Cytotoxic activity was determined in primary bulk cultures derived from PBMC 
harvested on day 12 post-immunisation and day 14 post-challenge. No lytic activity 
was detected in PBMC cultures of BB169 hence data is not shown. BB070 is T. parva 
non-immune and data was based on PBMC collected post-challenge infection. BX064 
is T. parva immune and was used as a post-challenge positive control. 
BB001: Cytotoxic activity against Theileria parva infected cells 
and peptide pulsed lymphoblasts post-immunisation
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BB001: Cytotoxic activity against Theileria parva  infected cells 
and peptide pulsed lymphoblasts post-challenge
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BB006: Cytotoxic activity against Theileria parva  infected cells 
and peptide pulsed lymphoblasts post-immunisation
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BB006: Cytotoxic activity against Theileria parva  infected cells 
and peptide pulsed lymphoblasts post-challenge
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BB007: Cytotoxic activity against Theileria parva  infected cells 
and peptide pulsed lymphoblasts post-immunisation 
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BB007: Cytotoxic activity against Theileria parva  infected cells 
and peptide pulsed lymphoblasts post-challenge 
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BB069: Cytotoxic activity against Theileria parva  infected cells 
and peptide pulsed lymphoblasts post-immunisation 
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BB069: Cytotoxic activity against Theileria parva  infected cells 
and peptide pulsed lymphoblasts post-challenge
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BB070: Cytotoxic activity against Theileria parva  infected cells 
and peptide pulsed lymphoblasts post-challenge
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BB169: Cytotoxic activity against Theileria parva  infected cells 
and peptide pulsed lymphoblasts post-challenge
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BX064: Cytotoxic activity against Theileria parva  infected cells 
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